

NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF SODIUM NITRITE (CAS NO. 7632-00-0) IN F344/N RATS AND B6C3F₁ MICE (DRINKING WATER STUDIES)

NTP TR 495

MAY 2001

NTP TECHNICAL REPORT

ON THE

TOXICOLOGY AND CARCINOGENESIS

STUDIES OF

SODIUM NITRITE

(CAS NO. 7632-00-0)

IN F344/N RATS AND B6C3F₁ MICE

(DRINKING WATER STUDIES)

NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709

May 2001

NTP TR 495

NIH Publication No. 01-3954

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health

FOREWORD

The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation.

The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease.

The studies described in this Technical Report were performed under the direction of the NIEHS and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals. The prechronic and chronic studies were conducted in compliance with Food and Drug Administration (FDA) Good Laboratory Practice Regulations, and all aspects of the chronic studies were subjected to retrospective quality assurance audits before being presented for public review.

These studies are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected chemicals in laboratory animals (usually two species, rats and mice). Chemicals selected for NTP toxicology and carcinogenesis studies are chosen primarily on the bases of human exposure, level of production, and chemical structure. The interpretive conclusions presented in this Technical Report are based only on the results of these NTP studies. Extrapolation of these results to other species and quantitative risk analyses for humans require wider analyses beyond the purview of these studies. Selection *per se* is not an indicator of a chemical's carcinogenic potential.

Details about ongoing and completed NTP studies are available at the NTP's World Wide Web site: http://ntp-server.niehs.nih.gov. Abstracts of all NTP Technical Reports and full versions of the most recent reports and other publications are available from the NIEHS' Environmental Health Information Service (EHIS) http://ehis.niehs.nih.gov (800-315-3010 or 919-541-3841). In addition, printed copies of these reports are available from EHIS as supplies last. A listing of all the NTP reports printed since 1982 appears on the inside back cover. NTP TECHNICAL REPORT

ON THE

TOXICOLOGY AND CARCINOGENESIS

STUDIES OF

SODIUM NITRITE

(CAS NO. 7632-00-0)

IN F344/N RATS AND B6C3F₁ MICE

(DRINKING WATER STUDIES)

NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709

May 2001

NTP TR 495

NIH Publication No. 01-3954

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health

CONTRIBUTORS

National Toxicology Program

Evaluated and interpreted results and reported findings

P.C. Chan, Ph.D., Study Scientist
D.W. Bristol, Ph.D.
J.R. Bucher, Ph.D.
R.E. Chapin, Ph.D.
J.R. Hailey, D.V.M.
J.K. Haseman, Ph.D.
R.R. Maronpot, D.V.M.
D.P. Orzech, M.S.
G.N. Rao, D.V.M., Ph.D.
J.H. Roycroft, Ph.D.
R.C. Sills, D.V.M., Ph.D.
C.S. Smith, Ph.D.
G.S. Travlos, D.V.M.
K.L. Witt, M.S., Integrated Laboratory Systems, Inc.

Microbiological Associates, Inc.

Conducted 14-week studies and evaluated pathology findings

M.L. Wenk, Ph.D., Principal Investigator L.H. Brennecke, D.V.M.

Battelle Columbus Operations

Conducted 2-year studies and evaluated pathology findings

M.R. Hejtmancik, Ph.D., Principal Investigator J.D. Toft, II, D.V.M., M.S. J.T. Yarrington, D.V.M., Ph.D.

Experimental Pathology Laboratories, Inc.

Provided pathology quality assurance

J.F. Hardisty, D.V.M., Principal Investigator A. Brix, D.V.M., Ph.D. E.T. Gaillard, M.S., D.V.M. C.C. Shackelford, D.V.M., M.S., Ph.D.

Dynamac Corporation

Prepared quality assurance audits

S. Brecher, Ph.D., Principal Investigator

NTP Pathology Working Group

Evaluated slides and prepared pathology report on rats (13 May 1999)

M.P. Jokinen, D.V.M., Chairperson Pathology Associates International A. Brix, D.V.M., Ph.D. Experimental Pathology Laboratories, Inc. E.T. Gaillard, M.S., D.V.M. Experimental Pathology Laboratories, Inc. J.R. Hailey, D.V.M. National Toxicology Program R.A. Herbert, D.V.M., Ph.D. National Toxicology Program A. Nyska, D.V.M. National Toxicology Program J.C. Seely, D.V.M. PATHCO, Inc. R.C. Sills, D.V.M., Ph.D. National Toxicology Program

Evaluated slides and prepared pathology report on mice (1 December 1998)

M.T. Butt, D.V.M., Chairperson Pathology Associates International
J.R. Hailey, D.V.M. National Toxicology Program
R.A. Herbert, D.V.M., Ph.D. National Toxicology Program
A. Nyska, D.V.M. National Toxicology Program
J.C. Seely, D.V.M. PATHCO, Inc.
C.C. Shackelford, D.V.M., M.S., Ph.D. Experimental Pathology Laboratories, Inc.
R.C. Sills, D.V.M., Ph.D. National Toxicology Program

Analytical Sciences, Inc. Provided statistical analyses

R.W. Morris, M.S., Principal Investigator L.J. Betz, M.S. K.P. McGowan, M.B.A. J.T. Scott, M.S.

Biotechnical Services, Inc.

Prepared Technical Report


S.R. Gunnels, M.A., Principal Investigator S.B. Dass, Ph.D. L.M. Harper, B.S. S.L. Kilgroe, B.A., B.A. E.S. Paal, M.S.J. D.C. Serbus, Ph.D.

CONTENTS

ABSTRACT .		. 7
EXPLANATIO	ON OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY	. 11
TECHNICAL	REPORTS REVIEW SUBCOMMITTEE	. 12
SUMMARY O	OF TECHNICAL REPORTS REVIEW SUBCOMMITTEE COMMENTS	. 13
INTRODUCT	ION	. 15
MATERIALS	AND METHODS	. 25
RESULTS		. 37
DISCUSSION	AND CONCLUSIONS	. 63
REFERENCE	S	. 69
Appendix A	Summary of Lesions in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite	. 81
Appendix B	Summary of Lesions in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite	115
Appendix C	Summary of Lesions in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite	145
APPENDIX D	Summary of Lesions in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite	179
Appendix E	Genetic Toxicology	213
Appendix F	Clinical Pathology Results	221
Appendix G	Organ Weights and Organ-Weight-to-Body-Weight Ratios	229
Appendix H	Reproductive Tissue Evaluations and Estrous Cycle Characterization	233
Appendix I	Determinations of Plasma Nitrite and Blood Methemoglobin Concentrations	237
Appendix J	Chemical Characterization and Dose Formulation Studies	249
APPENDIX K	Water and Compound Consumption in the 2-Year Drinking Water Studies of Sodium Nitrite	261

APPENDIX L	Ingredients, Nutrient Composition, and Contaminant Levels in NTP-2000 Rat and Mouse Ration	267
APPENDIX M	Sentinel Animal Program	271

ABSTRACT



SODIUM NITRITE

CAS No. 7632-00-0

Chemical Formula: NaNO₂ Molecular Weight: 69.00

Synonyms: Diazotizing salts; nitrous acid, sodium salt Trade names: Anti-Rust, Erinitrit, Filmerine

Sodium nitrite is used as a color fixative and preservative in meats and fish. It is also used in manufacturing diazo dyes, nitroso compounds, and other organic compounds; in dyeing and printing textile fabrics and bleaching fibers; in photography; as a laboratory reagent and a corrosion inhibitor; in metal coatings for phosphatizing and detinning; and in the manufacture of rubber chemicals. Sodium nitrite also has been used in human and veterinary medicine as a vasodilator, a bronchial dilator, an intestinal relaxant, and an antidote for cyanide poisoning. Sodium nitrite was nominated by the FDA for toxicity and carcinogenesis studies based on its widespread use in foods. Male and female F344/N rats and B6C3F1 mice were exposed to sodium nitrite (99% pure) in drinking water for 14 weeks or 2 years. Genetic toxicology studies were conducted in Salmonella typhimurium, rat and mouse bone marrow, and mouse peripheral blood.

14-WEEK STUDY IN RATS

Groups of 10 male and 10 female rats were exposed to 0, 375, 750, 1,500, 3,000, or 5,000 ppm sodium nitrite (equivalent to average daily doses of approximately 30, 55, 115, 200, or 310 mg sodium nitrite/kg body weight to males and 40, 80, 130, 225, or 345 mg/kg to

females) in drinking water for 14 weeks. Clinical pathology study groups of 15 male and 15 female rats were exposed to the same concentrations for 70 or 71 days. One female exposed to 3,000 ppm died before the end of the study. Body weights of males exposed to 3,000 or 5,000 ppm and females exposed to 5,000 ppm were significantly less than those of the controls. Water consumption by 5,000 ppm males and 3,000 and 5,000 ppm females was less than that by the controls at weeks 2 and 14. Clinical findings related sodium nitrite exposure included brown to discoloration in the eyes and cyanosis of the mouth, tongue, ears, and feet of males exposed to 3,000 or 5,000 ppm and of females exposed to 1,500 ppm or greater. Reticulocyte counts were increased in males and females exposed to 3,000 or 5,000 ppm. The erythron was decreased on day 19 but increased by week 14 in males and females exposed to 5,000 ppm. Methemoglobin concentrations were elevated in almost all exposed groups throughout the 14 week study; a no-observed-adverse-effect level was not achieved. The relative kidney and spleen weights of males and females exposed to 3,000 or 5,000 ppm were significantly greater than those of the controls. Sperm motility in 1,500 and 5,000 ppm males was significantly decreased. Increased erythropoietic activity in the bone marrow of exposed males and females was observed. The incidences of squamous cell hyperplasia of the forestomach in 5,000 ppm males and females were significantly increased.

14-WEEK STUDY IN MICE

Groups of 10 male and 10 female B6C3F₁ mice were exposed to 0, 375, 750, 1,500, 3,000, or 5,000 ppm sodium nitrite (equivalent to average daily doses of approximately 90, 190, 345, 750, or 990 mg/kg to males and 120, 240, 445, 840, or 1,230 mg/kg to females) in drinking water for 14 weeks. Body weights of males exposed to 5,000 ppm were significantly less than those of the controls. Water consumption by males exposed to 1,500 ppm or greater was slightly less than that by the controls at week 13. Relative spleen weights of 3,000 and 5,000 ppm males and absolute and relative heart, kidney, liver, and spleen weights of females exposed to 3,000 or 5,000 ppm were greater than those of the control groups. Sperm motility was decreased in 5,000 ppm males, and the estrous cycles of 1,500 and 5,000 ppm females were significantly longer than in the controls. There were increased incidences of squamous cell hyperplasia of the forestomach in 5,000 ppm males and females, extramedullary hematopoiesis of the spleen in 3,000 and 5,000 ppm males and 1,500 ppm or greater females, and degeneration of the testis in 3,000 and 5,000 ppm males.

2-YEAR STUDY IN RATS

Groups of 50 male and 50 female rats were exposed to 0, 750, 1,500, or 3,000 ppm sodium nitrite (equivalent to average daily doses of approximately 35, 70, or 130 mg/kg to males and 40, 80, or 150 mg/kg to females) in drinking water for 2 years. For toxicokinetic studies of plasma nitrite and blood methemoglobin, 10 male and 10 female special study rats were exposed to the same concentrations for 12 months. Survival of exposed groups was similar to that of the controls. Mean body weights of males and females exposed to 3,000 ppm were less than those of the controls throughout the study. Water consumption by males and females exposed to 3,000 ppm was less than that by the controls throughout the study, and that by the other exposed groups was generally less after week 14.

The incidences of hyperplasia of the forestomach epithelium in males and females exposed to 3,000 ppm were significantly greater than those in the control groups. The incidence of fibroadenoma of the mammary gland was significantly increased in females exposed to 1,500 ppm, and the incidences of multiple fibroadenoma were increased in 750 ppm and 1,500 ppm females; however, these neoplasms occur with a high background incidence, and no increase was seen in the 3,000 ppm group. The incidences of mononuclear cell leukemia were significantly decreased in males and females exposed to 1,500 or 3,000 ppm.

2-YEAR STUDY IN MICE

Groups of 50 male and 50 female $B6C3F_1$ mice were exposed to 0, 750, 1,500, or 3,000 ppm sodium nitrite (equivalent to average daily doses of approximately 60, 120, or 220 mg/kg to males and 45, 90, or 165 mg/kg to females) in drinking water for 2 years. Survival of exposed groups was similar to that of the controls; mean body weights of 3,000 ppm females were less than those of the controls throughout the study. Exposed groups generally consumed less water than the control groups.

The incidences of squamous cell papilloma or carcinoma (combined) in the forestomach of female mice occurred with a positive trend. The incidence of hyperplasia of the glandular stomach epithelium was significantly greater in 3,000 ppm males than in the controls.

GENETIC TOXICOLOGY

Sodium nitrite was mutagenic in *Salmonella typhimurium* strain TA100, with and without Aroclor 1254-induced hamster and rat liver S9 enzymes; no mutagenicity was observed in strain TA98. Results of acute bone marrow micronucleus tests with sodium nitrite in male rats and mice by intraperitoneal injection were negative. In addition, a peripheral blood micro nucleus assay conducted with mice from the 14-week study gave negative results.

CONCLUSIONS

Under the conditions of this 2-year drinking water study, there was *no evidence of carcinogenic activity** of sodium nitrite in male or female F344/N rats

exposed to 750, 1,500, or 3,000 ppm. There was *no* evidence of carcinogenic activity of sodium nitrite in male $B6C3F_1$ mice exposed to 750, 1,500, or 3,000 ppm. There was equivocal evidence of carcinogenic activity of sodium nitrite in female $B6C3F_1$ mice based on the positive trend in the incidences of squamous cell papilloma or carcinoma (combined) of the forestomach.

Exposure to sodium nitrite in drinking water resulted in increased incidences of epithelial hyperplasia in the forestomach of male and female rats and in the glandular stomach of male mice.

Decreased incidences of mononuclear cell leukemia occurred in male and female rats.

^{*} Explanation of Levels of Evidence of Carcinogenic Activity is on page 11. A summary of the Technical Reports Review Subcommittee comments and the public discussion on this Technical Report is on page 13.

-	5	0.		
	Male F344/N Rats	Female F344/N Rats	Male B6C3F ₁ Mice	Female B6C3F ₁ Mice
Concentrations in drinking water	0, 750, 1,500, or 3,000 ppm	0, 750, 1,500, or 3,000 ppm	0, 750, 1,500, or 3,000 ppm	0, 750, 1,500, or 3,000 ppm
Body weights	3,000 ppm group less than the control group	3,000 ppm group less than the control group	Exposed groups similar to the control group	3,000 ppm group less than the control group
Survival rates	29/50, 38/50, 36/50, 36/50	33/50, 31/50, 36/50, 33/50	39/50, 45/50, 42/50, 39/50	40/50, 34/50, 37/50, 41/50
Nonneoplastic effects	<u>Forestomach</u> : epithelial hyperplasia (12/50, 9/50, 10/50, 44/50)	<u>Forestomach</u> : epithelial hyperplasia (8/50, 6/50, 8/50, 40/50)	<u>Glandular stomach:</u> epithelial hyperplasia (0/50, 0/50, 2/50, 10/50)	None
Neoplastic effects	None	None	None	None
Uncertain findings	None	None	None	<u>Forestomach</u> : squamous cell papilloma or carcinoma (1/50, 0/50, 1/50, 5/50)
Decreased incidences	<u>Mononuclear cell</u> <u>leukemia</u> : (17/50, 12/50, 7/50, 3/50)	<u>Mononuclear cell</u> <u>leukemia</u> : (15/50, 10/50, 1/50, 1/50)	None	None
Level of evidence of carcinogenic activity	No evidence	No evidence	No evidence	Equivocal evidence
Genetic toxicology Salmonella typhimurium gene mutations: Micronucleated erythrocytes Male rat bone marrow <i>in vivo</i> : Male mouse bone marrow <i>in vivo</i> : Male and female mouse peripheral blood <i>in vivo</i> :		Positive in strain TA100 with and without S9; negative in strain TA98 Negative Negative Negative		

Summary of the 2-Year Carcinogenesis and Genetic Toxicology Studies of Sodium Nitrite

EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY

The National Toxicology Program describes the results of individual experiments on a chemical agent and notes the strength of the evidence for conclusions regarding each study. Negative results, in which the study animals do not have a greater incidence of neoplasia than control animals, do not necessarily mean that a chemical is not a carcinogen, inasmuch as the experiments are conducted under a limited set of conditions. Positive results demonstrate that a chemical is carcinogenic for laboratory animals under the conditions of the study and indicate that exposure to the chemical has the potential for hazard to humans. Other organizations, such as the International Agency for Research on Cancer, assign a strength of evidence for conclusions based on an examination of all available evidence, including animal studies such as those conducted by the NTP, epidemiologic studies, and estimates of exposure. Thus, the actual determination of risk to humans from chemicals found to be carcinogenic in laboratory animals requires a wider analysis that extends beyond the purview of these studies.

Five categories of evidence of carcinogenic activity are used in the Technical Report series to summarize the strength of the evidence observed in each experiment: two categories for positive results (clear evidence and some evidence); one category for uncertain findings (equivocal evidence); one category for no observable effects (no evidence); and one category for experiments that cannot be evaluated because of major flaws (inadequate study). These categories of interpretative conclusions were first adopted in June 1983 and then revised in March 1986 for use in the Technical Report series to incorporate more specifically the concept of actual weight of evidence of carcinogenic activity. For each separate experiment (male rats, female rats, male mice, female mice), one of the following five categories is selected to describe the findings. These categories refer to the strength of the experimental evidence and not to potency or mechanism.

- Clear evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing a dose-related (i) increase of malignant neoplasms, (ii) increase of a combination of malignant and benign neoplasms, or (iii) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy.
- Some evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing a chemical-related increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence.
- Equivocal evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing a marginal increase of neoplasms that may be chemical related.
- No evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing no chemical-related increases in malignant or benign neoplasms.
- Inadequate study of carcinogenic activity is demonstrated by studies that, because of major qualitative or quantitative limitations, cannot be interpreted as valid for showing either the presence or absence of carcinogenic activity.

When a conclusion statement for a particular experiment is selected, consideration must be given to key factors that would extend the actual boundary of an individual category of evidence. Such consideration should allow for incorporation of scientific experience and current understanding of long-term carcinogenesis studies in laboratory animals, especially for those evaluations that may be on the borderline between two adjacent levels. These considerations should include:

- · adequacy of the experimental design and conduct;
- · occurrence of common versus uncommon neoplasia;
- progression (or lack thereof) from benign to malignant neoplasia as well as from preneoplastic to neoplastic lesions;
- some benign neoplasms have the capacity to regress but others (of the same morphologic type) progress. At present, it is
 impossible to identify the difference. Therefore, where progression is known to be a possibility, the most prudent course is to
 assume that benign neoplasms of those types have the potential to become malignant;
- combining benign and malignant tumor incidence known or thought to represent stages of progression in the same organ or tissue;
- latency in tumor induction;
- multiplicity in site-specific neoplasia;
- · metastases;
- supporting information from proliferative lesions (hyperplasia) in the same site of neoplasia or in other experiments (same lesion in another sex or species);
- presence or absence of dose relationships;
- statistical significance of the observed tumor increase;
- concurrent control tumor incidence as well as the historical control rate and variability for a specific neoplasm;
- · survival-adjusted analyses and false positive or false negative concerns;
- · structure-activity correlations; and
- in some cases, genetic toxicology.

NATIONAL TOXICOLOGY PROGRAM BOARD OF SCIENTIFIC COUNSELORS TECHNICAL REPORTS REVIEW SUBCOMMITTEE

The members of the Technical Reports Review Subcommittee who evaluated the draft NTP Technical Report on sodium nitrite on 18 May 2000 are listed below. Subcommittee members serve as independent scientists, not as representatives of any institution, company, or governmental agency. In this capacity, subcommittee members have five major responsibilities in reviewing the NTP studies:

- · to ascertain that all relevant literature data have been adequately cited and interpreted,
- · to determine if the design and conditions of the NTP studies were appropriate,
- · to ensure that the Technical Report presents the experimental results and conclusions fully and clearly,
- · to judge the significance of the experimental results by scientific criteria, and
- · to assess the evaluation of the evidence of carcinogenic activity and other observed toxic responses.

A. John Bailer, Ph.D., Chairperson Department of Mathematics and Statistics Miami University Oxford, OH

James S. Bus, Ph.D., Principal Reviewer Health and Environmental Sciences Dow Chemical Company Midland, MI

Linda A. Chatman, D.V.M., Principal Reviewer Pfizer, Inc. Groton, CT

John M. Cullen, V.M.D., Ph.D. Department of Microbiology, Parasitology, and Pathology College of Veterinary Medicine North Carolina State University Raleigh, NC

Harold Davis, D.V.M., Ph.D.* Director of Toxicology Amgen, Inc. Thousand Oaks, CA

* Did not attend

Norman R. Drinkwater, Ph.D. McArdle Laboratory for Cancer Research University of Wisconsin-Madison Madison, WI

Susan M. Fischer, Ph.D.* M.D. Anderson Cancer Center The University of Texas Smithville, TX

Stephen S. Hecht, Ph.D., Principal Reviewer University of Minnesota Cancer Centers Minneapolis, MN

Michele Medinsky, Ph.D. Durham, NC

Jose Russo, M.D.* Fox Chase Cancer Center Philadelphia, PA

SUMMARY OF TECHNICAL REPORTS REVIEW SUBCOMMITTEE COMMENTS

On 18 May 2000, the draft Technical Report on the toxicology and carcinogenesis studies of sodium nitrite received public review by the National Toxicology Program's Board of Scientific Counselors' Technical Reports Review Subcommittee. The review meeting was held at the National Institute of Environmental Health Sciences, Research Triangle Park, NC.

Dr. P.C. Chan, NIEHS, introduced the toxicology and carcinogenesis studies of sodium nitrite by describing the experimental design, reporting on survival and body weight effects, and commenting on compound-related neoplastic lesions in female mice, possible compound-related neoplastic lesions in female rats, and compound-related nonneoplastic lesions in male and female rats and male mice. The proposed conclusions were *no evidence of carcinogenic activity* in male F344/N rats or male B6C3F₁ mice, *equivocal evidence of carcinogenic activity* in female B6C3F₁ mice.

Dr. F. Ye, NIEHS, presented statistical analyses and information on the toxicokinetic modeling of nitrite absorption and elimination and methemoglobinemia in rats and mice. The objectives of the analyses were to study the relationship between nitrite and methemoglobinemia by developing a toxicokinetic model to characterize the nitrite-induced methemoglobin process and to compare net absorption and elimination rates of nitrite from plasma. The studies found that nitrite is rapidly absorbed after oral exposure and may depend on dose level. The studies also found that overall clearance of nitrite may depend on species, route, and dose, and nitrite is rapidly cleared from plasma because it causes oxidation to methemoglobin by binding to hemoglobin. Dr. Ye further concluded that reduction of hemoglobin to its ferrous form is sensitive to basal methemoglobin reductase activity, strong binding of nitrite to methemoglobin, and the autocatalytic cycle.

Dr. Hecht, a principal reviewer, agreed with the proposed conclusions in regard to male rats but disagreed with the proposed conclusions in regard to female mice, for which he stated the data only supported equivocal evidence of carcinogenic activity. Dr. Hecht also stated that the NTP had ignored literature on endogenous formation of nitrosamines and that the literature should be updated and expanded.

Dr. Bus, the second principal reviewer, agreed with the proposed conclusions for male rats and mice but disagreed with the proposed conclusions for female rats and mice. For female rats, he argued that the response in the mammary glands was not exposure concentration dependent, occurred in the presence of high concurrent and historical control incidences of fibroadema, and was not accompanied by increased incidences of carcinomas, thus supporting no evidence of carcinogenic activity. Dr. J.R. Bucher, NIEHS, stated the incidence in the mid-exposure group was the highest seen, and the finding could not be dismissed. Dr. Bus emphasized that the increased incidence of forestomach squamous cell papilloma or carcinoma (combined) in 3.000 ppm female mice was not significantly different from that in the controls, and that only the trend test showed statistical significance, thus supporting equivocal evidence of carcinogenic activity. Dr. Chan agreed that the level of evidence in female mice could be debated. Due to the positive trend in the incidences of squamous cell papillomas and carcinomas (combined) and because the incidence in the 3,000 ppm females exceeded the historical range for NTP controls on NTP-2000 diet, he concluded the evidence supported some evidence of carcinogenic activity. Also, he found the two carcinomas hard to ignore.

Dr. Chatman, the third principal reviewer, disagreed with the proposed conclusions for female rats and mice. Dr. Chatman agreed with Dr. Bus that the level of evidence should be no evidence of carcinogenic activity in female rats and equivocal evidence of carcinogenic activity in female mice. Dr. Chatman questioned the use of drinking water rather than dosed feed as the route of administration.

Dr. J.R. Hailey, NIEHS, addressed a comment by Dr. Bus and by Dr. G. Williams, New York Medical College, concerning incidences of gastrointestinal neoplasms in mice on the NTP-2000 diet compared with the NIH-07 diet. Dr. Hailey stated there was an increase noted in the incidences of intestinal neoplasms but not in forestomach neoplasms. Dr. Bailer suggested that significant negative trends in the incidences of neoplasms such as mononuclear cell leukemia in male and female rats warranted more attention than given in the report.


Dr. L.L. Borchert, Director of Research (Retired), Oscar Mayer Foods Corporation and Adjunct Professor, Meat Science and Muscle Biology, University of Wisconsin-Madison, representing the American Meat Science Association, provided historical background on the food industry's need to use sodium nitrite and the safety of sodium nitrite as a food additive. He stated the United States Department of Agriculture and its predecessors have permitted the use of sodium nitrite in processed meat products since 1925, when it was proven safe for human consumption. He said the industry welcomed the use of sodium nitrite because it accelerated the curing process from days and weeks to hours. He stated that in order to meet safety concerns arising in the 1970s, the food industry eliminated sodium nitrate, reduced usage levels of sodium nitrite, incorporated sodium ascorbate into all processed meat products, and monitored nitrosamine formation in fried bacon. He noted a national survey from 1996 which showed that processed meats in the United States contain about 10 ppm of sodium nitrite and no sodium nitrate.

Dr. D. Archer, Food Science and Human Nutrition Department, University of Florida, representing the Food Safety Advisory Committee of the American Meat Institute Foundation, noted some of the positive aspects of having sodium nitrite in the food supply. First, he stressed the positive physiologic role of nitric oxide and its metabolites, including nitrite. Second, he noted that nitrite is a physiologically endogenous compound. Third, he emphasized the profound effect of sodium nitrite in preventing growth of and toxin production by *Clostridium botulinum*. Fourth, he remarked on the growth retardant role that sodium nitrite plays on food pathogens as a bactericidal agent in conjunction with stomach acid.

Dr. G. Williams, New York Medical College, representing the American Meat Institute Foundation, asserted that due to several reasons, the small incidence of forestomach neoplasms seen in 3,000 ppm female mice at the end of the study is not attributable to sodium nitrite. He commented that the high pH of the female mouse forestomach and sodium nitrite solutions used were not conducive to formation of DNAdeaminating nitrous acid or of carcinogenic N-nitroso compounds, and there was no evidence for this reaction. Also, he noted that the genetic toxicology database for sodium nitrite supports the view that it is not an in vivo genotoxic agent. Dr. Williams further stated that the new NTP-2000 diet appears to facilitate the development of more spontaneous gastrointestinal neoplasms than the NIH-07 diet, and sodium nitrite has not been shown to be a forestomach carcinogen in rats in this bioassay or in the scientific literature.

Dr. Hecht moved that the Technical Report on sodium nitrite be accepted with revisions discussed including changes in the conclusions for female rats and mice. The proposed revised conclusions were, for male and female rats and male mice, *no evidence of carcinogenic activity* and for female mice, *equivocal evidence of carcinogenic activity*. Dr. Bus seconded the motion. The motion was accepted unanimously with six yes votes.

INTRODUCTION



SODIUM NITRITE

CAS No. 7632-00-0

Chemical Formula: NaNO₂ Molecular Weight: 69.00

Synonyms: Diazotizing salts; nitrous acid, sodium salt Trade names: Anti-Rust, Erinitrit, Filmerine

CHEMICAL

AND PHYSICAL PROPERTIES

Sodium nitrite is a white solid. It has a melting point of 271° C and decomposes at 320° C; its specific gravity is 2.17 at 0° C; it is very soluble in water and ammonia and soluble in methanol, ethanol, ether, and pyridine; and it slowly oxidizes to nitrate in air (*Kirk-Othmer*, 1985; *Merck Index*, 1996).

PRODUCTION, USE, AND HUMAN EXPOSURE

Industrially, sodium nitrite is produced by mixing 1 to 10 parts oxygen, 2 to 12 parts nitrogen oxide, 15 to 20 parts water, and 58 to 83 parts inert gas. The mixture is cooled from 900° C to between 300° and 350° C and then dispersed under the surface of an aqueous sodium hydroxide solution at 30° to 120° C. A 99% pure product is obtained by evaporating the solution and drying the residue.

Sodium nitrite can also be prepared by reducing sodium nitrate with lead, heat, light, or ionizing radiation (*Kirk-Othmer*, 1985). Approximately 61 million pounds of sodium nitrite were produced in

the United States. More recent production information was not located.

Sodium nitrite inhibits the formation of a toxin by the anaerobic spore-forming bacteria, *Clostridium botulinum*. It imparts a pink color to nitrite-cured meats and stabilizes the flavors of stored meats. Therefore, it is used as a color fixative and preservative in meats and fish. It is also used in manufacturing diazo dyes, nitroso compounds, and other organic compounds; in dyeing and printing textile fabrics; in bleaching fibers; in photography; as a laboratory reagent and a corrosion inhibitor; in metal coatings for phosphatizing and detinning; and in the manufacture of rubber chemicals. Sodium nitrite also has been used in human and veterinary medicine as a vasodilator, a bronchial dilator, an intestinal relaxant, and an antidote for cyanide poisoning.

Humans are constantly exposed to sodium nitrite through the oral route because it is used as a food additive (21 CFR §§ 172.175, 172.177, 181.34, and 573.700). Some vegetables, such as spinach and beets, and some well water contain high concentrations of nitrates, which may be reduced to nitrites by the action of microorganisms before and after ingestion (Wolff and Wasserman, 1972; Heisler *et al.*, 1974; Ishiwata

et al., 1975; White, 1975; Tannenbaum *et al.*, 1978a,b; Archer, 1982). White (1976) estimated that a United States resident ingests 99.8 mg per day of nitrates and nitrites, Phillips (1968) estimated that Canadians consume 313 mg nitrate per meal (4.5 mg/kg), Stephany and Schuller (1980) estimated nitrate ingestion in the Netherlands as 100 mg per person per day, and Knight *et al.* (1987) reported daily intake of 95 mg nitrate and 1.4 mg nitrite from food and 13.5 mg nitrate from water per person in Britain.

Sodium nitrite is also found in human saliva. Tannenbaum *et al.* (1974, 1976) estimated that human saliva contains 6 to 10 mg/L, and the amount is directly related to nitrate intake. Nitrate and nitrite are also formed *de novo* in the intestines of humans, possibly by heterotrophic nitrification of microorganisms (Tannenbaum *et al.*, 1978a).

Nitrite exposure may occur as a result of inhaling nitrogen oxide and nitrogen dioxide, which are converted to nitrate and nitrite *in vivo*, from the polluted atmosphere (Imaizumi *et al.*, 1980; Mirvish, 1995). The National Occupational Health Survey conducted from 1972 to 1974 estimated that 69,341 workers in 1,008 plants were potentially exposed to sodium nitrite annually (NIOSH, 1976). Another survey conducted from 1981 to 1983 indicated that 54,179 workers at 2,530 sites were potentially exposed to sodium nitrite (NIOSH, 1990).

The main concern regarding sodium nitrite exposure is that the chemical reacts readily with secondary amines and amides present in food or drugs to form carcinogenic N-nitroso compounds in vivo in the stomach under low pH conditions (Mirvish, 1975; Maekawa et al., 1982). Nitrosation of amines also occurs in the presence of saliva (Ishiwata et al., 1975; Tannenbaum et al., 1978b), in the intestine (Tannenbaum et al., 1978a), in the urinary bladder (Hill et al., 1973), and via nitric oxide formation during inflammation (Mirvish, 1995). In the early 1960s, incidences of poisoning in mink and ruminants fed herring meal were traced to the formation of nitrosamine in the meal from sodium nitrite used as a preservative (Archer, 1982). Maekawa et al. (1982) reported that CRF-1 rat diet contained 7.5 ppb N-nitrosodimethylamine. Newly formed N-nitrosodimethylamine was found in the stomach of male (18.0-36.8 ppb) and female (13.5-15.2 ppb) F344 rats fed CRF-1 diet and given

water containing 0.25% sodium nitrite. Fine *et al.* (1977) reported that 0.35 μ g/L nitrosodimethylamine and 0.09 μ g/L nitrosodiethylamine were present in the blood of humans. After a meal of raw spinach and tomatoes, cooked bacon, bread, and beer, the nitrosodimethylamine concentration had increased to 0.76 μ g/L and the nitrosodiethylamine concentration to 0.46 μ g/L. The total nitrosamine concentration in the blood was higher than that present in the food consumed and was considered to have been formed *in vivo*. Carcinogenic tobacco-specific nitrosamines are formed endogenously in rats treated with tobacco alkaloids and sodium nitrite (Carmella *et al.*, 1997).

Sodium nitrite can also act with secondary amines and amides in *in vitro* conditions, forming *N*-nitroso compounds (Aoyagi *et al.*, 1980; Maekawa *et al.*, 1982; Chen *et al.*, 1996). Approximately 300 nitrosamines and nitrosoamides have been shown to be carcinogenic in experimental animals (Hecht, 1997).

Furthermore, sodium nitrite may react with phenolic antioxidants (e.g., phenol, 3-methoxycatechol, catechol, vanillin, and butylated hydroxyanisole) under acidic conditions to form compounds with cell proliferative, hyperplastic, genotoxic, and carcinogenic activities (Kawabe *et al.*, 1994). For example, incidences of forestomach hyperplasia and papilloma in rats were significantly greater when sodium nitrite was given with catechol or 3-methoxycatechol than when catechol or 3-methoxycatechol was given alone (Kawabe *et al.*, 1994).

REGULATORY STATUS

The FDA approves the use of sodium nitrite as a color fixative and preservative in smoked, cured sablefish, salmon, and shad and in meat products including poultry and wild game at concentrations not to exceed 200 ppm (21 CFR §§ 172.175, 172.177, 181.34, and 573.700). The Safe Drinking Water Act (43 USC 300f) established a maximum contaminant concentration for nitrate of 10 mg/L. The World Health Organization (1974) set the acceptable daily intake for nitrate at 3.67 mg/kg body weight and nitrite at 0.13 mg/kg body weight (expressed as nitrate and nitrite ion). The Joint FAO/WHO Expert Committee on Food Additives established an accepted daily nitrite intake of 0 to 0.06 mg/kg body weight (Speijers, 1996). The U.S. Environmental Protection Agency has

designated sodium nitrite as a hazardous substance and requires that it be notified if 100 pounds or more is released in water or on land (40 CFR Part 302). Under the Hazardous Materials Transportation Act (49 CFR §172.101), the Department of Transportation regulates sodium nitrite as an oxidizer that is subject to certain labeling and packaging requirements. Neither the American Conference of Governmental Industrial Hygienists (1999) nor the Occupational Safety and Health Administration (NIOSH, 1997) has established a workplace or permissible exposure limit for sodium nitrite.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION Experimental Animals

Ingested nitrate is absorbed from the small intestine into the circulatory system. Blood nitrate is either concentrated in the salivary glands where it is reduced to nitrite by bacteria or removed by the kidney and excreted in the urine. Sodium nitrite is absorbed unchanged from the stomach of rats and mice. In blood, nitrite is rapidly and irreversibly oxidized to nitrate (Vleeming *et al.*, 1997), which is then eliminated by excretion.

Following gavage administration of 150 µg sodium nitrite in an aqueous solution, 85% of the dose disappeared from the stomach of ICR/Ha mice in 10 minutes, and 95% disappeared in 30 minutes (Friedman et al., 1972). In Wistar rats, 154 µg/g sodium nitrite mixed in 5 g of food persisted in the stomach for up to 5 hours with a half-life of 1.4 hours (Mirvish et al., 1975). Sodium nitrate or nitrite injected intraperitoneally or intravenously showed a mean plasma half-life of 1.54 hours in mice (Veszelovsky et al., 1995). Nitrite is unstable in acid and spontaneously decomposes to nitrate and nitrogen dioxide. Under acidic conditions and in the presence of food, nitrite disappeared with a half-life of 2.2 hours at pH 4.5, 0.93 hours at pH 3.5, and 0.42 hours at pH 2.5 (Mirvish et al., 1975).

Humans

No information on the absorption, distribution, metabolism, or excretion of sodium nitrite in humans was found in a review of the literature.

BIOLOGIC EFFECTS

Nitrite in blood is highly reactive with hemoglobin and causes methemoglobinemia. Ferrous iron associated with hemoglobin is oxidized by nitrite to ferric iron, leading to the formation of methemoglobin. The oxygen-carrying capacity of methemoglobin is much less than that of hemoglobin (NAS, 1981).

Following a single oral dose of $0.15 \,\text{g/kg}$ sodium nitrite to Sprague-Dawley rats, maximum methemoglobin concentrations (45%-80%) occurred within 60 minutes; the concentration returned to normal after 24 hours if the animal survived (Imaizumi et al., 1980). The production of methemoglobin was preceded by the formation of nitrosyl hemoglobin. Blood concentrations of nitrate and nitrite reached a maximum 20 to 30 minutes after dosing; nitrite had a half-life of about 70 minutes while nitrate concentrations remained high for more than 5 hours. After 6 months of exposure to 0.5% sodium nitrite in drinking water, methemoglobin concentration peaked between 6:00 and 9:00 p.m. and was at a minimum around 9:00 a.m. Increased methemoglobin concentration was accompanied by marked increases in Heinz body formation in erythrocytes, anisocytosis, and hypohemoglobinemia. This study also showed that the minimum lethal concentration of methemoglobin is about 80% to 85%. The lowest concentration of methemoglobin occurred at 9:00 a.m. because of its short half-life and because 80% of a rat's daily intake of water is at night (Shuval and Gruener, 1972). Blood methemoglobin concentrations correlate positively with plasma sodium nitrite concentrations in rats (Hirneth and Classen, 1984).

The enzyme methemoglobin reductase catalyzes the reduction of methemoglobin to hemoglobin and protects red cells against oxidative damage. Along with methemoglobin concentrations, methemoglobin reductase activities increased after nitrite administration to rats (Pankow *et al.*, 1975). Calabrese *et al.* (1983) showed that 50% methemoglobin was formed when 1 mL of human whole blood was mixed with 10 μ L of a 3 mM solution of sodium nitrite, whereas the same concentration of sodium nitrite induced only 14% methemoglobin formation with rat blood. The difference in sensitivity is probably due to the fivefold difference in erythrocyte methemoglobin reductase activity between the two species (Smith and Beutler, 1966).

Nitrite reacts readily with secondary amines and amides to produce carcinogenic *N*-nitroso compounds. The reaction proceeds when the pH in the stomach is acidic and at near-neutral pH in the presence of enteric bacteria in the small intestine of rats. The nitrosation rate for secondary amines is proportional to the square of the nitrite concentration (Mirvish, 1975). Nitrosation also occurs with tertiary amines and quaternary ammonium compounds.

ΤΟΧΙCITY

Experimental Animals

The primary acute effect of sodium nitrite in rats and mice is methemoglobinemia. Smith and Layne (1969) reported methemoglobin concentrations ranging from 9.5% to 72.1% in female CD-1 mice following intraperitoneal injection of 0.5 to 2.8 nmol/kg (35 to 193 mg/kg). Methemoglobin concentrations in Sprague-Dawley rats increased to 45% to 80% 1 hour after an oral dose of 150 mg/kg and returned to normal within 24 hours in surviving rats (Imaizumi *et al.*, 1980). Sodium nitrite administered in drinking water at 1,000 to 3,000 mg/L (1,000 to 3,000 ppm) for 2 years elevated methemoglobin concentrations in male rats (unspecified strain) throughout the 2-year period (Shuval and Gruener, 1972).

The secondary effects of acute nitrite intoxication in animals are vasodilation, relaxation of smooth muscle, and lowering of blood pressure (Gangolli *et al.*, 1994) and a decrease in D-xylose absorption in the intestinal mucosa (Grudzinski and Szymanski, 1991a,b; Grudzinski *et al.*, 1991). Other nitrite-induced toxic effects include abdominal pain, diarrhea, atrophied intestinal villi, and apoptotic cell death in the intestinal crypts (Grudzinski and Szymanski, 1991a,b; Grudzinski *et al.*, 1991; Grudzinski and Law, 1998a,b). The LD₅₀ values for experimental animals are given in Table 1.

Sodium nitrite administered in drinking water at 0.06%, 0.125%, 0.25%, 0.5%, or 1% (600, 1250, 2500, 5,000, or 10,000 ppm) to male and female ICR mice for 6 weeks caused slight degeneration and spotty necrosis of hepatocytes and hemosiderin deposition in the liver, spleen, and lymph nodes, indicating hemolysis. At 2% and 4% (20,000 and 40,000 ppm), mice died within 3 weeks (Inai *et al.*, 1979). In F344 rats subjected to the same exposure regimen as the ICR mice, abnormal blood and spleen colors due to methemoglobin were observed in the 0.5% and 1.0% groups (Maekawa *et al.*, 1982).

TABLE 1		
LD ₅₀ Values of Sodium	Nitrite in Ex	perimental Animals

Strain	Route	LD ₅₀ (mg/kg)	Reference
BD	gavage	130 77 (fasted)	Druckery et al., 1963
	intravenous	65	
Sprague-Dawley	oral	150 (fasted)	Imaizumi et al., 1980
White	oral	214 (male) 216 (female)	Riemann, 1950
CD-1	intraperitoneal	158 (female)	Smith and Layne, 1969
New Zealand	oral	124	Dollahite and Rowe, 1974
	BD Sprague-Dawley White CD-1	BD gavage intravenous Sprague-Dawley oral White oral CD-1 intraperitoneal	BDgavage130 77 (fasted) 65BDgavage130 77 (fasted) 65Sprague-Dawleyoral150 (fasted)Whiteoral214 (male) 216 (female)CD-1intraperitoneal158 (female)

Darad *et al.* (1983) reported that hepatic microsomal lipoperoxidation activity, as measured by malondialdehyde formation, was increased in male Wistar rats given 0.2% sodium nitrite in drinking water. Liver lysosomal enzyme (acid phosphatase and cathepsin) and superoxide dismutase activities were increased compared to the controls. The data suggest that sodium nitrite stimulates generation of superoxide radicals in the liver and causes damage to the cellular and subcellular membranes. Decreased plasma vitamin E and greater reduced glutathione-per-erythrocyte values were reported in male rats receiving sodium nitrite in drinking water (Chow *et al.*, 1980).

Sodium nitrite administered in feed at 10 or 25 mg/kg (10,000 or 25,000 ppm) to unilaterally ovariectomized Long-Evans rats for 21 days inhibited body weight gain and caused a decrease in the compensatory ovarian hypertrophy that follows hemicastration. Decreased uterine, liver, and kidney weights and increased spleen weights were also observed (Noel *et al.*, 1974). Hsu *et al.* (1997) demonstrated that feeding sodium nitrite to male Wistar rats at 0.3% (3,000 ppm) for 3 months did not affect relative liver weights or the expression of hepatic c-*Jun*, c-*Fos*, or c-*Myc* oncogenes.

Humans

In humans, sodium nitrite causes smooth muscle relaxation, methemoglobinemia, and cyanosis. Fatal poisonings of infants resulting from ingestion of nitrates in water or spinach have been recorded (Shuval and Gruener, 1972; Knobeloch et al., 2000). Longterm ingestion of water containing high levels of nitrate may increase the risk of gastric cancer (Xu et al., 1992; Morales-Suarez-Varela et al., 1995; Yang et al., 1998). However, prospective cohort study did not support an association between the intake of nitrate and nitrite and gastric cancer risk (Van Loon et al., 1998). The LD₅₀ value for sodium nitrite has been estimated to be about 1 g in adults (Archer, 1982); a 17-year-old woman died after taking a single 1-g tablet (Gowans, 1990). Fatal methemoglobinemia was reported after ingestion of a laxative solution contaminated with 15 g/L sodium nitrite (Ellis et al., 1992).

REPRODUCTIVE TOXICITY

There is evidence for placental transfer of sodium nitrite to rat and mouse fetuses. Sodium nitrite admin-

istered by oral intubation to pregnant mice (0.5 mg/mouse per day) did not cause fetal mortality or resorption or changes in embryo weight or incidence of skeletal malformation. The treatment did stimulate fetal hepatic erythropoiesis, probably related to fetal methemoglobinemia (Globus and Samuel, 1978). Nitrite and methemoglobin were detected in fetal blood after pregnant rats were given a single dose of 2.5 to 5.0 mg sodium nitrite/kg body weight (Shuval and Gruener, 1972).

Sodium nitrite (60 mg/kg) administered in drinking water to pregnant guinea pigs produced maternal anemia and increased the incidences of abortion and fetal mortality (Sinha and Sleight, 1971). At 0.31 g/kg in drinking water, sodium nitrite did not affect reproductive parameters of female C57BL/6 mice (Anderson *et al.*, 1985). Pregnant Swiss CD-1 mice given up to 0.24% sodium nitrite in drinking water had reduced water consumption, but body weight was not affected (Chapin and Sloane, 1997). The treatment did not affect the mean number of litters per pair, the number of pups per litter, or the pup viability or weight. Reproductive success in the F_1 generation was not affected.

Administration of 2,000 or 3,000 mg/L of sodium nitrite in drinking water to pregnant rats (exposure period and rat strain not specified) caused 30% or 53% fetal mortality, respectively; fetal mortality in the controls was 6% (Shuval and Gruener, 1972). In rat dams given 0.025% to 0.5% in feed, sodium nitrite caused increases in fetal and pup mortality and decreases in preweanling body weights (Vorhees *et al.*, 1984). However, oral intubation of up to 120 mg/kg on gestation day 13 had no effect on dams or pups (Khera, 1982). Reproductive performance was not affected in male or female rats given up to 0.05% in feed before and during breeding (Vorhees *et al.*, 1984).

NEUROTOXICITY

After a single subcutaneous dose of 55 mg sodium nitrite/kg body weight, locomotor, exploratory, and grooming activities were suppressed in 3-month-old male rats; complete recovery was observed after 24 hours (Hlinak *et al.*, 1990). Exposure of rats to sodium nitrite at 100 to 2,000 mg/L in drinking water for 2 months produced changes in the pattern of brain electrical activity (Shuval and Gruener, 1972, 1977).

The electroencephalogram pattern of four dosed rats differed from those for controls and remained different after sodium nitrite withdrawal (Behroozi *et al.*, 1972).

CARCINOGENICITY

Experimental Animals

Conflicting results were reported in sodium nitrite studies with rats. Rats exposed to sodium nitrite in drinking water at 2 g/L (Taylor and Lijinsky, 1975), 3 g/L (Shuval and Gruener, 1972), or 0.25% (2.5 g/L) (Maekawa et al., 1982) for 2 years did not have increased tumor incidences compared to the controls. Rats given 390 mg/kg sodium nitrite in feed for life (2.5 years) had tumor incidences (incidences not given) similar to those in the controls (cited in Rubenchik et al., 1990); however, liver tumors (incidences 5/19 or 26%) were induced in Wistar rats given 1,600 ppm in pelleted feed (Aoyagi et al., 1980). Mirvish et al. (1980) administered 3 g/L in drinking water to Wistar rats for life and reported increased incidences (18% versus 2% in controls) of forestomach squamous papilloma in males and females. Lijinsky (1984a) reported that 2,000 ppm administered in drinking water to F344 rats increased the incidences of liver tumors in females but not males. Newberne (1979) gave Sprague-Dawley rats 250 to 2,000 ppm in an agar diet, 1,000 to 2,000 ppm in a commercial diet, 1,000 ppm in a casein diet, or 1,000 to 2,000 ppm (20-30 mg/day) in drinking water; exposure began during pregnancy and continued for life (up to 26 months) for dams and pups. Incidences of malignant lymphoma were significantly increased in all exposed groups compared to the controls, and immunoblastic cell proliferation was observed in some animals in each exposed group. However, these results were not confirmed by a committee specially formed to review the data (FDA, 1980). In an earlier study, Shank and Newberne (1976) reported that Sprague-Dawley rats fed 1 g sodium nitrite/kg body weight in feed developed a higher incidence (27%) of lymphoreticular tumors than did the controls (6%).

Sodium nitrite may react *in vivo* with secondary amines to form carcinogenic nitrosamines in the stomach. In a number of interaction studies, concurrent administration of sodium nitrite in drinking water and secondary amines in feed induced a variety of tumors in rats and mice. Sodium nitrite was given in water and the amines in feed in order to avoid any chemical reaction before ingestion (Table 2); the studies demonstrated that carcinogenic *N*-nitroso compounds are formed *in vivo* as a result of sodium nitrite reacting with secondary amines. Carcinogenesis studies have also been conducted by exposing animals to sodium nitrite and amines together in feed or in drinking water (Table 3).

Sodium nitrite in drinking water appears to be nontumorigenic in mice. Male and female outbred ICR mice administered 7 mg/kg daily by gavage for 10 weeks and allowed to live without treatment for up to 18 months did not have increased tumor incidences (Yoshida et al., 1993). Inai et al. (1979) reported that tumor incidence, latency period, and tumor type were not different between exposed and control groups of male and female ICR mice exposed to 0%, 0.125%, 0.25%, or 0.5% sodium nitrite in drinking water for 109 weeks. Sodium nitrite in drinking water at 1.0 g/L for 20 to 34 weeks did not induce lung tumors in Swiss or A-strain mice (Greenblatt et al., 1971; Greenblatt and Lijinsky, 1972; Greenblatt and Mirvish, 1973). Anderson et al. (1985) did not observe increased tumors in female C57BL/6 or B6C3F1 mice at 1.84 g/L in drinking water; however, from conception through gestation, lactation, and life, sodium nitrite at 0.184 g/L (but not at 1.84 g/L) enhanced the incidences of lymphomas and lung tumors in male B6C3F₁ mice. Negative findings were reported in male $(C57BL \times C3H)F_1$ mice given a single intragastric dose of 50 mg sodium nitrite/kg body weight at 15 days of age and sacrificed at 70 weeks (Rijhsinghani et al., 1982). Male and female C57BL/6 mice given 0.5% sodium nitrite in feed for 1 year did not exhibit higher tumor incidences than did the controls (Krishna Murthy et al., 1979). No 2-year dosed feed studies in mice have been reported.

Sodium nitrite can also promote carcinogenesis. In drinking water, 5, 50, 500, and 2,000 ppm sodium nitrite accelerated leukemia development induced by the Rauscher, Mazurenko, and Gross leukemia viruses in Balb/c mice (Ilnitsky and Kolpakova, 1997). At 0.3% in drinking water, sodium nitrite promoted forestomach carcinogenesis in male Fisher rats pre-treated with *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (Yoshida *et al.*, 1994). In a multi-organ model in

TABLE 2 Neoplasms in Rats and Mice Concurrently Exposed to Sodium Nitrite in Drinking Water and Secondary Amines in Feed

Strain and Species	Amine	Neoplasm Site	Reference
MRC-Wistar rats (males)	Morpholine	Liver	Montesano and Magee, 1971; Mirvish <i>et al.</i> , 1983
Wistar rats	Bis(2-hydroxy-propyl)amine	Nasal cavity, esophagus, liver, lung, and urinary bladder	Yamamoto et al., 1989
Swiss mice	Piperazine, morpholine, and <i>N</i> -methylaniline	Lung	Greenblatt et al., 1971
	Methylurea and morpholine	Lung	Mirvish et al., 1972, 1975
(C57BL×C3H)F ₁ mice	Diethylamine hydrochloride	Liver	Rijhsinghani et al., 1982

TABLE 3 Neoplasms in Rodents Concurrently Exposed to Sodium Nitrite and Secondary Amines in Feed or Drinking Water

Strain and Species	Amine	Neoplasm Site	Reference
Rats (strain not specified)	Aminopyrine, disulfiram, and thiram	Esophagus, tongue, forestomach, nasal cavity, and liver	Lijinsky, 1980, 1984a,b; Lijinsky and Reuber, 1980
	N,N-dimethyl-dodecylamine-N-oxide	Liver (males)	Lijinsky, 1984a
	Methylurea	Neurogenic and lymphoid	Koestner and Denlinger, 1975
F344 rats (males)	Diphenhydramine and chlorpheniramine	Liver	Lijinsky, 1984a
	Allantoin	Forestomach	Lijinsky, 1984a
Sprague-Dawley rats	Heptamethyleneimine	Respiratory and alimentary canal	Taylor and Lijinsky, 1975
Wistar rats	Sarcosine ethyl ester hydrochloride	Esophagus	Xiang et al., 1995
Balb/c mice	Ethambutol	Lung and hematopoietic system	Biancifiori et al., 1975
Strain A mice	Piperazine	Lung	Greenblatt and Mirvish, 1973
B6C3F ₁ mice (males)	Cimetidine	Lung and hematopoietic system	Anderson et al., 1985
Syrian golden hamsters	Morpholine	Liver and lung	Shank and Newberne, 1976

which rats were initiated with various carcinogens, 0.3% sodium nitrite in drinking water strongly enhanced the development of glandular stomach lesions but inhibited the development of glandular stomach lesions

inhibited the development of glandular stomach lesions when these animals were given catechol or 3-methoxycatechol, with or without prior carcinogen exposure (Hirose *et al.*, 1993). In addition, the carcinogenesis-promoting effects of catechol were evident only in combination with sodium nitrite.

Humans

No adequate epidemiology studies of sodium nitrite and human cancer were found in the literature. Rogers et al. (1995) reported no associations between nitrite intake and risk of laryngeal or oral cancer. In epidemiological studies, Risch et al. (1985) reported a direct association between nitrite intake and stomach cancer risk. La Vecchia et al. (1995, 1997) compared subjects with low methionine (<1.5 mg/day) and low nitrite (<2.7 mg/day) intake with subjects with high methionine (>1.9 mg/day) and high nitrite (>2.7 mg/day) intake and reported an association between nitrite intake and stomach cancer risk. Boeing et al. (1991) reported a significantly elevated risk for stomach cancer for users of well water compared with those who used central water supplies in Germany. The study did not report measurements of nitrate in the water but assumed that well water contained considerable amounts of nitrate. An increased death rate from gastric cancer among the residents of the English town of Worsop was thought to be related to the high concentration of nitrate (90 mg/L) in the public water supply (Hill et al., 1973). In Columbia, where gastric cancer is common, the high intake of nitrate is reflected in the high urinary excretion rate of nitrate (Tannenbaum et al., 1979). Patients with precancerous gastric lesions had high nitrite concentrations in their gastric juice (Ruddell et al., 1976).

Vermeer *et al.* (1998) demonstrated that nitrate intake resulted in a significant rise in mean salivary nitrate and nitrite concentrations and that *N*-nitrosodimethylamine and *N*-nitrosopiperidine were detected in the urine samples.

GENETIC TOXICITY

Sodium nitrite is a direct-acting, base-pair substitution mutagen in organisms ranging from bacteria to mammals. It also has been shown to induce chromosomal effects in mammalian cells in vitro and in vivo. In an acidic environment, sodium nitrite reacts with amines to form nitrosamines or with amides to form nitrosamides. These compounds are mutagenic in a variety of systems. Nitrosamines require metabolic activation for expression of mutagenic activity, but nitrosamides do not. Positive results have been reported for sodium nitrite, with and without S9 metabolic activation enzymes, in Salmonella gene mutation studies with strains that revert by base-pair substitution (Ehrenberg et al., 1980; Katz et al., 1980; De Flora, 1981; Ishidate et al., 1984; Brams et al., 1987; Zeiger et al., 1992; Balimandawa et al., 1994). Genotoxicity of sodium nitrite is not often detected in strains of S. typhimurium that mutate via frameshift mechanisms (Zeiger et al., 1992; Balimandawa et al., 1994). Gene reversion (Kosako and Nishioka, 1982) and DNA damage (De Flora et al., 1984) were also observed in Escherichia coli WP tester strains after exposure to sodium nitrite in the presence of S9. Furthermore, sodium nitrite-induced gene mutations were reported in Saccharomyces cerevisiae (Lemontt, 1977; Fahrig, 1979), Candida utilis (Grimmelikhuijzen and Slater, 1973), and C. albicans (Kakar and Magee, 1982).

In cultured mammalian cells, sodium nitrite was reported to induce gene mutations (Tsuda *et al.*, 1973; Kodama *et al.*, 1976), chromosomal aberrations (Kodama *et al.*, 1976; Ishidate and Odashima, 1977; Tsuda and Kato, 1977; Ishidate *et al.*, 1981; Tsuda *et al.*, 1981), and sister chromatid exchanges (SCEs) (Abe and Sasaki, 1977; Tsuda *et al.*, 1981; Inoue *et al.*, 1985); in none of these experiments was S9 required for the positive response. HeLa cells incubated for 1 to 36 hours had increased levels of unscheduled DNA synthesis (DNA repair) at concentrations above 1 mM sodium nitrite (Lynch *et al.*, 1983).

In vivo, increased frequencies of micronuclei and 8-azaguanine- and ouabain-resistant mutations, but not chromosomal aberrations, were seen in cells of Syrian golden hamster embryos 24 hours after oral administration of 125, 250, or 500 mg/kg sodium nitrite to the dams (Inui *et al.*, 1979a). No increases in chromosomal aberrations were noted in lymphocytes of Wistar rats 48 hours after a single gavage treatment of 300 mg/kg sodium nitrite (Lilly *et al.*, 1979). However, positive results were reported for induction of chromosomal aberrations in bone marrow cells of pregnant female albino rats exposed to 210 mg/kg per day in

drinking water for 13 days (El Nahas et al., 1984). In this same study, the liver cells of embryos exposed trans- placentally for the first 13 days of gestation also showed increased numbers of chromosomal aberrations. SCE induction increased with increasing dose in bone marrow cells of Swiss albino mice treated with 2.5 to 200 mg/kg sodium nitrite by intraperitoneal injection (Giri et al., 1986). In addition to the demonstrated genotoxicity of sodium nitrite, concerns about the effects of the compound arise from its ability to transform primary and secondary amines into N-nitroso compounds, which are generally mutagenic after S9 activation (Whong et al., 1983). Acid conditions facilitate the reaction of nitrite with amines (Ehrenberg et al., 1980), and this reaction is further catalyzed by alcohols and aldehydes (Ehrenberg et al., 1980; Törnqvist et al., 1983; Valin et al., 1985), ultimately producing the actual nitrosating agent, nitrous anhydride (Brambilla et al., 1983).

There are numerous reports of mutagenic activity detected after combined administration of sodium nitrite with amino compounds. For example, sodium nitrite combined with the dye metanil yellow induced dose-related increases in SCEs in the bone marrow of Swiss mice; the increase was significantly greater than the increase in SCEs induced by sodium nitrite alone (Giri *et al.*, 1986). Amino acid derivatives in food stuffs (Amadori compounds, <1 μ M), when reacted with sodium nitrite (>1 mM) under acidic conditions at normal body temperatures (37° C), produced muta-

genic nitrosated products and induced high levels of unscheduled DNA synthesis in HeLa cells when present in culture medium for 1 to 36 hours (Lynch *et al.*, 1983).

Transplacental exposure of cells of Syrian golden hamster embryos to a combination of aminopyrine plus sodium nitrite, administered to dams via gavage on days 11 or 12 of gestation, induced a significant increase in 8-azaguanine-resistant mutations compared to either compound administered individually (Inui *et al.*, 1980). In a similar study, transplacental exposure to sodium nitrite plus morpholine, administered simultaneously by gavage to pregnant Syrian golden hamsters on days 11 or 12 of gestation, induced significant increases in 8-azaguanine- and ouabain-resistant mutations, as well as micronuclei, in embryonic fibroblasts (Inui *et al.*, 1979b).

STUDY RATIONALE

Sodium nitrite was nominated by the FDA for toxicity and carcinogenesis studies based on its widespread use in foods and the fact that many nitroso compounds are carcinogenic. Studies were performed to evaluate the toxic and carcinogenic potential of sodium nitrite given to rats and mice in 14-week and 2-year drinking water studies. Tests for mutagenicity in *S. typhimurium* and induction of micronuclei in rat and mouse bone marrow and mouse peripheral blood were employed to characterize the genetic toxicity of sodium nitrite.

MATERIALS AND METHODS

PROCUREMENT AND CHARACTERIZATION OF SODIUM NITRITE

Sodium nitrite was obtained from J.T. Baker, Inc. (Phillipsburg, NJ), in two lots (A42340 and H05714). Identity, purity, and stability analyses were conducted by the analytical chemistry laboratory, Midwest Research Institute (Kansas City, MO) (Appendix J). Reports on analyses performed in support of the sodium nitrite studies are on file at the National Institute of Environmental Health Sciences.

The chemical, a white crystalline solid, was identified as sodium nitrite by infrared and ultraviolet/visible spectroscopy. Purity of both lots was determined by elemental analyses, weight loss on drying, spark source mass spectrometry, and high-performance liquid chromatography (HPLC). The purity of lot A42340 was also analyzed by differential scanning calorimetry, a United States Pharmacopeia (USP) XXI titrimetric assay, and American Chemical Society tests for chloride and sulfate. Elemental analyses for sodium and nitrogen were in agreement with the theoretical values for sodium nitrite. For lot A42340, weight loss on drying indicated $0.006\% \pm 0.002\%$ water. HPLC of lot A42340 revealed a major peak and a single impurity with an area of 0.2% of the major peak area. HPLC of lot H05714 revealed a major peak and a single impurity with an area of 0.15% of the major peak. The overall purity was determined to be 99% or greater.

Stability studies of the bulk chemical were performed by the analytical chemistry laboratory using permanganate titration. These studies indicated that sodium nitrite was stable as a bulk chemical for 2 weeks when stored protected from light at temperatures up to 60° C. To ensure stability, the bulk chemical was stored at 5° C, protected from light, in closed containers under an inert atmosphere during the 14-week study and in Nalgene[®] containers at room temperature, protected from light, during the 2-year studies. No degradation of the bulk chemical was detected.

PREPARATION AND ANALYSIS OF DOSE FORMULATIONS

The dose formulations were prepared every 2 weeks (14-week studies) or approximately every 4 weeks (2-year studies) by mixing sodium nitrite with water (Table J2). Stability studies of a 0.075 mg/mL dose formulation were performed by the analytical chemistry laboratory using ultraviolet/visible spectrophotometry by measuring absorbance at 347 nm of an aliquot of the sample treated with a salt solution (sodium sulfate and sodium acetate) and a color reagent (hydrochloric acid, resorcinol and zinconyl chloride). Stability was confirmed for at least 35 days for dose formulations stored at 5° C or at room temperature in the dark.

Periodic analyses of the dose formulations of sodium nitrite were conducted by the study laboratory using ultraviolet/visible spectroscopy as described for the stability study. During the 14-week studies, the dose formulations were analyzed at the beginning, midpoint, and end of the studies; animal room samples of these dose formulations were also analyzed (Table J3). During the 2-year studies, the dose formulations were analyzed approximately every 8 to 12 weeks; animal room samples were also analyzed periodically (Table J4). All 32 dose formulations analyzed during the 14-week studies were within 10% of the target concentrations. All 39 dose formulations analyzed during the 2-year studies were within 10% of the target concentrations. Results of periodic referee analyses performed by the analytical chemistry laboratory agreed with the results obtained by the study laboratory (Table J5).

14-WEEK STUDIES

The 14-week studies were conducted to evaluate the cumulative toxic effects of repeated exposure to sodium nitrite and to determine the appropriate doses to be used in the 2-year studies.

Male and female F344/N rats and B6C3F₁ mice were obtained from Taconic Farms, Germantown, NY. On receipt, the rats and mice were 5 weeks old. Rats were quarantined for 14 or 15 days and mice for 11 days; animals were 6 (mice) or 7 (rats) weeks old on the first day of the studies. Before initiation of the studies, five male and five female rats and mice were randomly selected for parasite evaluation and gross observation for evidence of disease. At the end of the studies, serologic analyses were performed on five male and five female rats using the protocols of the NTP Sentinel Animal Program (Appendix M).

Groups of 10 male and 10 female rats and mice were exposed to 0, 375, 750, 1,500, 3,000 and 5,000 ppm sodium nitrite in drinking water for 14 weeks. Clinical pathology study groups of 15 male and 15 female rats were given the same exposure concentrations for 70 to 71 days. Feed and water were available *ad libitum*. Rats were housed five per cage, and mice were housed individually. Feed consumption was measured weekly, and water consumption was recorded daily by cage. Animal room feed samples were monitored for total nitrosamine content (rats: 3.8 to 6.1 ppb; mice: 3.6 to 13.4 ppb). Core study animals were weighed and clinical findings were recorded initially, weekly, and at the end of the studies. Details of the study design and animal maintenance are summarized in Table 4.

Blood was collected from the retroorbital sinus of up to 10 clinical pathology study rats on days 5 and 19 and from all core study rats at the end of the study for hematology and clinical chemistry analyses. Blood samples for hematology analyses were placed in tubes containing potassium EDTA or acid-citrate-dextrose as the anticoagulant. All automated hematology measurements were performed on a Serono-Baker 9000 automated cell counter using reagents supplied by the manufacturer (Serono-Baker Diagnostics, Allentown, PA). Leukocyte differentials were counted on slides stained with a modified Wright's stain using an Ames Hema-Tek II slide stainer (Miles Laboratory, Ames Division, Elkhart, IN). Smears made from preparations of equal volumes of new methylene blue and whole blood and incubated for at least 20 minutes at room temperature were examined microscopically for the quantitative determination of reticulocytes and Heinz bodies. Methemoglobin assays were performed using an Instrumentation Laboratory CO-Oximeter 282 with reagents from the manufacturer (Instrumentation Laboratory, Inc., Lexington, MA). Blood for clinical chemistry determinations was placed into tubes and allowed to clot. All clinical chemistry analyses were performed with a Serono-Baker Centrifichem 600 Analyzer and System 400 pipette. Reagents for bile acids were obtained from Nyconed Diagnostics (Oslo, Norway), and reagents for sorbitol dehydrogenase were obtained from Sigma Diagnostics (St. Louis, MO). Determination of ervthrocvte glutathione concentration was performed using a spectrophotometric assay on whole, acid-citratedextrose-anticoagulated blood (Fairbanks and Klee, 1987). The hematology parameters measured and the clinical chemistry assays performed are listed in Table 4.

On day 70 (2000 or 2200 hours) or 71 (0900 hours), two blood samples each were collected from up to five male and five female clinical pathology study rats at three time points. Samples for methemoglobin analyses were collected from the retroorbital sinus under CO₂ anesthesia and placed in tubes containing potassium EDTA. Samples for nitrosamine analyses were collected from the abdominal aorta and placed in tubes containing acid-citrate-dextrose. Using vacutainers with no rubber parts, the samples for nitrosamine analyses were transferred to glass culture tubes with Teflon[®]-lined caps (Baxter Healthcare Corp., McGraw Park, IL) containing 0.3 g sulfamic acid (J.T. Baker Chemical Co., Phillipsburg, NJ) and frozen until analysis. After blood samples were obtained from special study animals on day 70 or 71, the stomachs were removed; stomach contents were extruded through an anterior incision into wide-mouth borosilicate glass vials with Teflon[®]-lined caps, washed with 10 mL of saline, and frozen with 0.3 g sulfamic acid until analysis for gastric nitrosamines. Serum and stomach nitrosamine concentrations were determined using the Thermal Energy Analyzer at Thermedics, Inc., (Woburn, MA), as described by Fine and Rounbehler (1975).

At the end of the 14-week studies, samples were collected for sperm motility and vaginal cytology evaluations on male rats and male and female mice exposed to 0, 375, 1,500 or 5,000 ppm and female rats

exposed to 0, 375, 750, or 3,000 ppm. The parameters evaluated are listed in Table 4. Methods used were those described in the NTP's sperm morphology and vaginal cytology evaluations protocol (NTP, 1987). For 12 consecutive days prior to scheduled terminal sacrifice, the vaginal vaults of the females were moistened with saline, if necessary, and samples of vaginal fluid and cells were stained. Relative numbers of leukocytes, nucleated epithelial cells, and large squamous epithelial cells were determined and used to ascertain estrous cycle stage (i.e., diestrus, proestrus, estrus, and metestrus). Male animals were evaluated for sperm morphology, count, and motility. The left testis and epididymis were isolated and weighed. The tail of the epididymis (cauda epididymis) was then removed from the epididymal body (corpus epididymis) and weighed. Test yolk (rats) or modified Tyrode's buffer (mice) was applied to slides and a small incision was made at the distal border of the cauda epididymis. The sperm effluxing from the incision were dispersed in the buffer on the slides, and the numbers of motile and nonmotile spermatozoa were counted for five fields per slide by two observers. Following completion of sperm motility estimates, each left cauda epididymis was placed in buffered saline solution. Caudae were finely minced, and the tissue was incubated in the saline solution and then heat fixed at 65° C. Sperm density was then determined microscopically with the aid of a hemacytometer.

Necropsies were performed on all core study animals at the end of the studies. The heart, right kidney, liver, lung, spleen, right testis and thymus were weighed. Tissues for microscopic examination were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in paraffin, sectioned to a thickness of 6 μ m, and stained with hematoxylin and eosin. A complete histopathologic examination was performed on core study animals in the control and 5,000 ppm groups. The forestomach of rats and mice, testis of male mice, and spleen of female mice were examined to a no-effect level. Table 4 lists the tissues and organs routinely examined.

2-YEAR STUDIES

Study Design

Groups of 50 male and 50 female rats and mice were given 0, 750, 1,500 or 3,000 ppm sodium nitrite in drinking water for 105 weeks (rats) or 104 to 105 weeks (mice). Groups of 10 male and 10 female special study rats and mice were exposed to the same

concentrations for 12 months for toxicokinetic studies (plasma nitrite and blood methemoglobin concentrations) and then discarded. Additional groups of 15 male and 15 female sentinel rats and mice were given a single gavage dose of sodium nitrite (40 mg/kg for rats and 62.5 mg/kg for mice) for toxicokinetic studies at 18 months.

Source and Specification of Animals

Male and female F344/N rats and $B6C3F_1$ mice were obtained from Taconic Laboratory Animals and Services, Germantown, NY, for use in the 2-year studies. Rats were quarantined for 11 or 12 days and mice for 13 or 14 days before the beginning of the studies. Five male and five female rats and mice were randomly selected for parasite evaluation and gross observation of disease. Rats and mice were approximately 6 weeks old at the beginning of the studies. The health of the animals was monitored during the studies according to the protocols of the NTP Sentinel Animal Program (Appendix M).

Animal Maintenance

Male rats were housed two or three per cage and females three or five per cage; male mice were housed individually and females three or five per cage. Water and feed were available *ad libitum*. Water consumption was measured over a 1-week period at 4-week intervals, beginning during the first week of the study. Cages and racks were rotated every 2 weeks. Further details of animal maintenance are given in Table 4. Information on feed composition and contaminants is provided in Appendix L.

Clinical Examinations and Pathology

All animals were observed twice daily. Clinical findings were recorded on days 8 and 36, at 4-week intervals thereafter, and at necropsy for core study animals. Body weights were recorded at the beginning of the study, on days 8 and 36, at 4-week intervals thereafter, and at necropsy for core study animals. Special study rats were weighed at 2 weeks and 3 months, special study mice at 12 months, and aged sentinel rats and mice prior to gavage dosing at 18 months. Blood was taken from the retroorbital sinus of special study rats at 2 weeks and 3 months, from special study mice at 12 months, and from aged sentinel rats and mice at 18 months. Blood was placed in tubes and mixed with potassium EDTA. Samples for plasma nitrite determinations were separated by centrifugation and nitrite concentrations were determined by ultraviolet spectroscopy. Whole blood samples were analyzed for methemoglobin using Instrumentation Laboratory CO-Oximeter 282 with reagents from the manufacturer. The sample times and the parameters measured are listed in Table 4.

Necropsies were performed on core study animals and five male and five female aged sentinel rats and mice. Microscopic examinations were performed on all core study animals. At necropsy, all organs and tissues were examined for grossly visible lesions, and all major tissues were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in paraffin, sectioned to a thickness of 5 μ m, and stained with hematoxylin and eosin for microscopic examination. For all paired organs (i.e., adrenal gland, kidney, ovary), samples from each organ were examined. Tissues examined microscopically are listed in Table 4.

Microscopic evaluations were completed by the study laboratory pathologist, and the pathology data were entered into the Toxicology Data Management System. The slides, paraffin blocks, and residual wet tissues were sent to the NTP Archives for inventory, slide/block match, and wet tissue audit. The slides, individual animal data records, and pathology tables were evaluated by an independent quality assessment laboratory. The individual animal records and tables were verified, and the histotechnique was evaluated.

For the 2-year studies, a quality assessment pathologist evaluated slides from all tumors and all potential target organs, which included the adrenal gland, clitoral gland, rectum, kidney (males), liver, lung, mammary gland, pancreas (males), pituitary gland, spleen, skin, stomach (forestomach and glandular), testis (and epididymis and seminal vesicle), and thyroid gland of rats and the adrenal gland, small intestine (males), kidney (males), liver, lung, mesentery (females), skin, spleen, and stomach [forestomach and glandular (males)] of mice.

The quality assessment report and the reviewed slides were submitted to the NTP Pathology Working Group (PWG) chairperson, who reviewed the selected tissues and addressed any inconsistencies in the diagnoses made by the laboratory and quality assessment pathologists. Representative histopathology slides containing examples of lesions related to chemical administration, examples of disagreements in diagnoses between the laboratory and quality assessment pathologists, or lesions of general interest were presented by the chairperson to the PWG for review. The PWG consisted of the quality assessment pathologist and other pathologists experienced in rodent toxicologic pathology. This group examined the tissues without any knowledge of dose groups or previously rendered diagnoses. When the PWG consensus differed from the opinion of the laboratory pathologist, the diagnosis was changed. Final diagnoses for reviewed lesions represent a consensus between the laboratory pathologist, reviewing pathologist(s), and the PWG. Details of these review procedures have been described, in part, by Maronpot and Boorman (1982) and Boorman et al. (1985). For subsequent analyses of the pathology data, the decision of whether to evaluate the diagnosed lesions for each tissue type separately or combined was generally based on the guidelines of McConnell et al. (1986).

TABLE 4

Experimental Design and Materials and Methods in the Drinking Water Studies of Sodium Nitrite

14-Week Studies	2-Year Studies	
Study Laboratory Microbiological Associates, Inc. (Bethesda, MD)	Battelle Columbus Laboratories (Columbus, OH)	
Strain and Species Rats: F344/N Mice: B6C3F ₁	Rats: F344/N Mice: B6C3F ₁	
Animal Source Taconic Farms (Gemantown, NY)	Taconic Laboratory Animals and Services (Germantown, NY)	
Time Held Before StudiesRats:14 days (males) or 15 days (females)Mice:11 days	Rats: 11 days (males) or 12 days (females) Mice: 13 days (males) or 14 days (females)	
Average Age When Studies Began Rats: 7 weeks Mice: 6 weeks	6 weeks	
Date of First Exposure Rats: 10 August 1989 (males) and 11 August 1989 (females) Mice: 7 August 1989	Rats: 14 August 1995 (males) and 15 August 1995 (females) Mice: 2 August 1995 (males) and 3 August 1995 (females)	
Duration of Exposure 14 weeks	Rats: 105 weeks Mice: 104 to 105 weeks	
Date of Last ExposureRats:9 November 1989 (males) and 10 November 1989 (females)Mice:6 November 1989 (males) and 7 November 1989 (females)	Rats: 11-13 August 1997 (males) and 13-15 August 1997 (females) Mice: 28-30 July 1997 (males) and 30-31 July 1997 and 1 August 1997 (females)	
Necropsy Dates Rats: 9 November 1989 (males) and 10 November 1989 (females) Mice: 6 November 1989 (males) and 7 November 1989 (females)	Rats: 11-13 August 1997 (males) and 13-15 August 1997 (females) Mice: 28-30 July 1997 (males) and 30-31 July 1997 and 1 August 1997 (females)	
Average Age at NecropsyRats:20 weeksMice:19 weeks (males) and 20 weeks (females)	110 weeks	
Size of Study Groups Rats: core study, 10 males and 10 females; clinical pathology study, 15 males and 15 females Mice: 10 males and 10 females	Core study: 50 males and 50 females; special study, 10 males and 10 females; aged sentinel animal study, 15 males and 15 females	
Method of Distribution Animals were distributed randomly into groups of approximately equal initial mean body weights	Animals were distributed randomly into groups of approximately equal initial mean body weights	
Animals per Cage Rats: 5 Mice: 1	 Rats: core study, 2 or 3 (males) or 5 (females); special study, 2 or 3 (males) or 5 (females); aged sentinel animal study, 3 Mice: core and special studies, 1 (male) or 5 (females); aged sentinel animal study, 1 (male) or 3 (females) 	

TABLE 4

Experimental Design and Materials and Methods in the Drinking Water Studies of Sodium Nitrite

14-Week Studies	2-Year Studies	
Method of Animal Identification Tail tattoo	Tail tattoo	
Diet NIH-07 open formula powdered diet (Zeigler Brothers, Inc., Gardners, PA), available <i>ad libitum</i> , changed weekly	 Rats: NTP-2000 pelleted diet, irradiated beginning 22 July 1996, changed weekly Mice: NTP-2000 pelleted diet, irradiated beginning 16 July 1996, changed weekly (males), or twice weekly (females) 	
Water Charcoal-filtered deionized water via amber glass bottles with stainless steel sipper tubes, available <i>ad libitum</i> and changed twice weekly	Tap water (Columbus, OH, municipal supply) via amber glass bottles with stainless steel sipper tubes, available <i>ad libitum</i> and changed twice weekly (rats and female mice) or weekly (male mice	
Cages Solid-bottom polycarbonate (Lab Products, Inc., Rochelle Park, NJ), changed twice weekly (rats) or weekly (mice); rotated every 2 weeks	Solid-bottom polycarbonate (Lab Products, Inc., Maywood, NJ), changed twice weekly (rats and female mice) or weekly (male mice rotated every 2 weeks	
Bedding Sani-Chips [®] (P.J. Murphy Forest Products Corp., Montville, NJ), changed twice weekly (rats) or once weekly (mice)	Sani-Chips [®] (P.J. Murphy Forest Products Corp., Montville, NJ), changed twice weekly (rats and female mice) or once weekly (male mice)	
Cage Filters DuPont 2024 spun-bonded polyester filter (Snow Filtration Co., Cincinnati, OH), changed every 2 weeks.	DuPont 2024 spun-bonded polyester filter (Snow Filtration Co., Cincinnati, OH), changed twice weekly (rats and female mice) or weekly (male mice)	
Racks Stainless steel (Lab Products, Inc., Rochelle Park, NJ), rotated and changed every 2 weeks	Stainless steel, drawer-type (Lab Products, Inc., Maywood, NJ), rotated every 2 weeks	
Animal Room Environment Temperature: $72^{\circ} \pm 3^{\circ}$ F Relative humidity: $50\% \pm 15\%$ Room fluorescent light: 12 hours/day Room air changes: ≥ 10 /hour	Temperature: $72^{\circ} \pm 3^{\circ}$ F Relative humidity: $50\% \pm 15\%$ Room fluorescent light: 12 hours/day Room air changes: ≥ 10 /hour	
Exposure Concentrations 0, 375, 750, 1,500, 3,000, or 5,000 ppm in drinking water, available <i>ad libitum</i>	0, 750, 1,500, or 3,000 ppm in drinking water, available ad libitum	
Type and Frequency of Observation Rats and mice were observed twice daily. Core study animals were weighed and clinical findings were recorded initially, weekly, and at the end of the studies. Drinking water consumption was measured daily.	All rats and mice were observed twice daily. Core study animals were weighed initially and clinical findings and body weights were recorded on day 8, day 36, at 4-week intervals thereafter, and at necropsy. Special study rats were weighed at 2 weeks and 3 month special study mice were weighed at 12 months, and aged sentinel animal rats and mice were weighed at 18 months. Drinking water consumption by the core study animals was measured over a 1-weel period at 4-week intervals, beginning during the first week of the study.	

TABLE 4

Experimental Design and Materials and Methods in the Drinking Water Studies of Sodium Nitrite

14-Week Studies	2-Year Studies
Method of Sacrifice CO ₂ asphyxiation	CO ₂ asphyxiation
Necropsy Necropsy was performed on all core study rats and mice. Organs weighed were heart, right kidney, liver, lung, spleen, right testis, and thymus.	Necropsy was performed on all core study rats and mice and five male and five female aged sentinel rats and mice.
Clinical Pathology Blood for hematology and clinical chemistry was collected from the retroorbital sinus of anesthetized clinical pathology study rats on days 5 and 19 and from core study rats at the end of the study. Two blood samples each were collected from the abdominal aorta of 15 male and 15 female clinical pathology study rats on day 70 (2000 or 2200 hours) or 71 (0900 hours) for hemoglobin, methemoglobin and nitrosamine concentrations; stomach contents were also collected for nitrosamine concentrations. Blood and stomach contents were collected from five males and five females at each time point. <i>Hematology:</i> hematocrit; hemoglobin concentration; erythrocyte, reticulocyte, and platelet counts; mean cell volume; mean cell hemoglobin; mean cell hemoglobin concentration; leukocyte count and differentials; erythrocyte and platelet morphologic assessments; methemoglobin concentration; reduced glutathione concentration in erythrocytes; and Heinz body count. <i>Clinical chemistry:</i> urea nitrogen, creatinine, total protein, albumin, alanine aminotransferase, alkaline phosphatase, creatine kinase, sorbitol dehydrogenase, and bile acids <i>Nitrosamine concentrations:</i> serum and gastric nitrosamine	None
Histopathology Complete histopathology was performed on 0 and 5,000 ppm core study animals. In addition to gross lesions and tissue masses, the following tissues were examined: adrenal gland, bone and marrow.	Complete histopathology was performed on all core study animals. In addition to gross lesions and tissue masses, the following tissues were examined: adrenal gland, bone and marrow, brain, clitoral

st following tissues were examined: adrenal gland, bone and marrow, brain, clitoral gland, esophagus, gallbladder (mice), heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, liver, lung, lymph nodes (mandibular and mesenteric), mammary gland (except male mice), muscle, nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, skin, stomach (forestomach and glandular), testis (and epididymis and seminal vesicle), thymus, thyroid gland, trachea, urinary bladder, and uterus. The forestomach of 750 (males), 1,500, and 3,000 ppm rats and the forestomach, testis, and spleen of all remaining mice were also examined.

gland, bone and marrow, brain, clitoral gland, esophagus, gallbladder (mice), heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, liver, lung, lymph nodes (mandibular and mesenteric), mammary gland (except male mice), nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, skin, stomach (forestomach and glandular), testis (and epididymis and seminal vesicle), thymus, thyroid gland, trachea, urinary bladder, and uterus.

TABLE 4 Experimental Design and Materials and Methods in the Drinking Water Studies of Sodium Nitrite

14-Week Studies	2-Year Studies
Sperm Motility and Vaginal Cytology At the end of the studies, samples were collected for sperm motility or vaginal cytology evaluations from male rats and male and female mice in the 0, 375, 1,500, and 5,000 ppm groups and female rats in the 0, 375, 750, and 3,000 ppm groups. The left cauda, epididymis, and testis were weighed. The following parameters were evaluated: spermatid heads per gram testis, spermatid heads per testis, spermatid count, motility, and concentration. Vaginal samples were collected for up to 12 consecutive days prior to the end of the studies for vaginal cytology evaluations. The length of the estrous cycle and the length of time spent in each stage of the cycle were evaluated.	None
Plasma Nitrite and Blood Methemoglobin Concentrations None	 Blood was collected from the retroorbital sinus of 10 male and 10 female special study rats at 2 weeks and 3 months and from 10 male and 10 female mice at 12 months. Blood was collected from two animals per group per time point (0600, 1200, 2100, 2400, and 0300 hours). Blood was collected from the retroorbital sinus of 15 male and 15 female aged sentinel rats and mice after a single gavage dose of 40 mg/kg (rats) or 62.5 mg/kg (mice) at 18 months. Two or three animals were sampled at each time point (2, 5, 10, 30, or 60 minutes after dosing). Plasma nitrite and blood methemoglobin concentrations were determined.

STATISTICAL METHODS

Survival Analyses

The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958) and is presented in the form of graphs. Statistical analyses for possible dose-related effects on survival used Cox's (1972) method for testing two groups for equality and Tarone's (1975) life table test to identify dose-related trends. All reported P values for the survival analyses are two sided.

Calculation of Incidence

The incidences of neoplasms or nonneoplastic lesions are presented in Tables A1, A5, B1, B5, C1, C4, D1, and D5 as the numbers of animals bearing such lesions at a specific anatomic site and the numbers of animalswith that site examined microscopically. For calculation of statistical significance, the incidences of most neoplasms (Tables A3, B3, C3, and D3) and all nonneoplastic lesions are given as the numbers of animals affected at each site examined microscopically. However, when macroscopic examination was required to detect neoplasms in certain tissues (e.g., harderian gland, intestine, mammary gland, and skin) before microscopic evaluation, or when neoplasms had multiple potential sites of occurrence (e.g., leukemia or lymphoma), the denominators consist of the number of animals on which a necropsy was performed. Tables A3, B3, C3, and D3 also give the survivaladjusted neoplasm rate for each group and each sitespecific neoplasm. This survival-adjusted rate (based on the Poly-3 method described below) accounts for differential mortality by assigning a reduced risk of neoplasm, proportional to the third power of the

fraction of time on study, to animals that do not reach terminal sacrifice.

Analysis of Neoplasm and Nonneoplastic Lesion Incidences

The Poly-k test (Bailer and Portier, 1988; Portier and Bailer, 1989; Piegorsch and Bailer, 1997) was used to assess neoplasm and nonneoplastic lesion prevalence. This test is a survival-adjusted quantal-response procedure that modifies the Cochran-Armitage linear trend test to take survival differences into account. More specifically, this method modifies the denominator in the quantal estimate of lesion incidence to approximate more closely the total number of animal years at risk. For analysis of a given site, each animal is assigned a risk weight. This value is one if the animal had a lesion at that site or if it survived until terminal sacrifice; if the animal died prior to terminal sacrifice and did not have a lesion at that site, its risk weight is the fraction of the entire study time that it survived, raised to the kth power.

This method yields a lesion prevalence rate that depends only upon the choice of a shape parameter for a Weibull hazard function describing cumulative lesion incidence over time (Bailer and Portier, 1988). Unless otherwise specified, a value of k=3 was used in the analysis of site-specific lesions. This value was recommended by Bailer and Portier (1988) following an evaluation of neoplasm onset time distributions for a variety of site-specific neoplasms in control F344 rats and B6C3F1 mice (Portier et al., 1986). Bailer and Portier (1988) showed that the Poly-3 test gave valid results if the true value of k was anywhere in the range from 1 to 5. A further advantage of the Poly-3 method is that it does not require lesion lethality assumptions. Variation introduced by the use of risk weights, which reflect differential mortality, was accommodated by adjusting the variance of the Poly-3 statistic as recommended by Bieler and Williams (1993).

Tests of significance included pairwise comparisons of each exposed group with controls and a test for an overall exposure-related trend. Continuity-corrected Poly-3 tests were used in the analysis of lesion incidence, and reported P values are one sided. Values of P greater than 0.5 are presented as 1-P with the letter N added to indicate a lower incidence or negative trend in neoplasm occurrence relative to the control group (e.g., P=0.99 is presented as P=0.01N).

Analysis of Continuous Variables

Two approaches were employed to assess the significance of pairwise comparisons between exposed and control groups in the analysis of continuous variables. Organ and body weight data, which historically have approximately normal distributions, were analyzed with the parametric multiple comparison procedures of Dunnett (1955) and Williams (1971, 1972). Clinical pathology, blood and plasma concentration, toxicokinetic, spermatid, and epididymal spermatozoal data, which have typically skewed distributions, were analyzed using the nonparametric multiple comparison methods of Shirley (1977) and Dunn (1964). Jonckheere's test (Jonckheere, 1954) was used to assess the significance of the dose-related trends and to determine whether a trend-sensitive test (Williams' or Shirley's test) was more appropriate for pairwise comparisons than a test that does not assume a monotonic dose-related trend (Dunnett's or Dunn's test). Prior to statistical analysis, extreme values identified by the outlier test of Dixon and Massey (1951) were examined by NTP personnel, and implausible values were eliminated from the analysis. Because vaginal cytology data are proportions (the proportion of the observation period that an animal was in a given estrous stage), an arcsine transformation was used to bring the data into closer conformance with a normality assumption. Treatment effects were investigated by applying a multivariate analysis of variance (Morrison, 1976) to the transformed data to test for simultaneous equality of measurements across the exposure concentrations.

Historical Control Data

The concurrent control group represents the most valid comparison to the treated groups and is the only control group analyzed statistically in NTP bioassays. However, historical control data are often helpful in interpreting potential treatment-related effects, particularly for uncommon or rare neoplasm types. For meaningful comparisons, the conditions for studies in the historical database must be generally similar. Until recently, the NTP historical control database consisted of animals fed NIH-07 diet. In 1995, the NTP changed the diet fed to animals used in toxicity and carcinogenesis studies conducted by the NTP. This new diet (NTP-2000) contains less protein and more fiber and fat than the NIH-07 diet previously used (Rao, 1996, 1997). This dietary change was instituted primarily to increase longevity and decrease the incidence and/or severity of some spontaneous neoplasms and nonneoplastic lesions in the rats and mice used in NTP studies. This study of sodium nitrite is one of the first in which the animals on study were fed the NTP-2000 diet. Because the incidence of some neoplastic and nonneoplastic lesions are affected by the dietary change, use of the existing historical control database (NIH-07) diet is not appropriate for all neoplasm types.

Currently, the number of studies in which the NTP-2000 diet was used is limited. This diet was used in four studies (indium phosphide, sodium nitrite, p,p'-dichlorodiphenyl sulfone, and naphthalene) reported at the May 18, 2000, peer review and in two others (methacrylonitrile and p-nitrotoluene) not vet reported. Therefore, a database of incidences of neoplastic lesions was created for this group of six studies. Four routes of administration were used in these six studies: p-nitrotoluene and p,p'-dichlorodiphenyl sulfone were administered by dosed feed; sodium nitrite was administered in the drinking water; methacrylonitrile was administered by gavage using deionized water; and naphthalene and indium phosphide were administered via whole body inhalation. Based on the extensive NTP historical database using the NIH-07 diet, incidences of the vast majority of spontaneous neoplasms are not significantly different between control groups irrespective of the route of administration. There is no reason to expect this to be different with the NTP-2000 diet. Clearly, control animals from dosed feed and dosed water studies are treated no differently and no differences in incidence of neoplasms are expected. There are some exceptions, and if comparisons are necessary for these neoplasm types, only studies with similar routes of administration will be used

The set of six studies using the NTP-2000 diet will be the primary historical control group used for comparison. However, where appropriate, the larger historical database (NIH-07 diet) may be used to augment the smaller NTP-2000 database.

QUALITY ASSURANCE METHODS

The 13-week and 2-year studies were conducted in compliance with Food and Drug Administration Good Laboratory Practice Regulations (21 CFR, Part 58). In addition, as records from the 2-year studies were submitted to the NTP Archives, these studies were audited retrospectively by an independent quality assurance contractor. Separate audits covering completeness and accuracy of the pathology data, pathology specimens, final pathology tables, and a draft of this NTP Technical Report were conducted. Audit procedures and findings are presented in the reports and are on file at NIEHS. The audit findings were reviewed and assessed by NTP staff, so all comments had been resolved or were otherwise addressed during the preparation of this Technical Report.

GENETIC TOXICOLOGY

The genetic toxicity of sodium nitrite was assessed by testing the ability of the chemical to induce mutations in various strains of *Salmonella typhimurium* and micronucleated erythrocytes in rat and mouse bone marrow and mouse peripheral blood. The protocols for these studies and the results are given in Appendix E.

The genetic toxicity studies of sodium nitrite are part of a larger effort by the NTP to develop a comprehensive database that would permit a critical anticipation of a chemical's carcinogenicity in experimental animals based on numerous considerations, including the molecular structure of the chemical and its observed effects in short-term *in vitro* and *in vivo* genetic toxicity tests (structure-activity relationships). These short-term genetic toxicity tests were originally developed to clarify mechanisms of chemical-induced DNA damage growing out of the earlier electrophilicity/mutagenicity relationship proposed by Miller and Miller (1977) and the somatic mutation theory of cancer (Straus, 1981; Crawford, 1985). Therefore, the information obtained from these tests applies only to mutagenic carcinogens.

For mutagenic carcinogens, the combination of DNA reactivity and *Salmonella* mutagenicity is highly correlated with the induction of carcinogenicity in multiple species and genders of rodents and at multiple tissue sites (Ashby and Tennant, 1991). Data from NTP studies show that a positive response in *Salmonella* is the most predictive *in vitro* test for rodent carcinogenicity (89% of the *Salmonella* mutagens are rodent carcinogens) and that there is no

complementarity among the *in vitro* genetic toxicity tests (Tennant *et al.*, 1987; Zeiger *et al.*, 1990). That is, no battery of tests that included the *Salmonella* test improved the predictivity of the *Salmonella* test alone. Although other *in vitro* genetic toxicity tests correlate less well with rodent carcinogenicity compared with the *Salmonella* test, these other tests can provide useful information on the types of DNA and chromosomal effects induced by the chemical under investigation.

The predictivity for carcinogenicity of a positive response in the acute *in vivo* bone marrow chromosome aberration test or micronucleus test appears to be less than that in the *Salmonella* test (Shelby *et al.*, 1993; Shelby and Witt, 1995). However, clearly positive results in long-term

peripheral blood micronucleus tests are associated with high predictivity for rodent carcinogenicity (Witt et al., 2000); negative results in this assay do not correlate well with either negative or positive results in rodent carcinogenicity studies. Because of the theoretical and observed associations between induced genetic damage and adverse effects in somatic and germ cells, the determination of in vivo genetic effects is important to the overall understanding of the risks associated with exposure to a particular chemical. Most organic chemicals that are identified by the International Agency for Research on Cancer as human carcinogens, other than hormones, are genotoxic. The vast majority of these are detected by both the Salmonella assay and rodent bone marrow cytogenetics tests (Shelby, 1988; Shelby and Zeiger, 1990).

RESULTS

RATS 14-WEEK STUDY

Except for one female exposed to 3,000 ppm sodium nitrite, all rats survived until the end of the study (Table 5). Final mean body weights and body weight gains of males exposed to 3,000 or 5,000 ppm and females exposed to 5,000 ppm were significantly less than those of the controls. Water consumption by the 5,000 ppm male group and the 3,000 and 5,000 ppm female groups was less than that by the controls at weeks 2 and 14. Drinking water concentrations of

375, 750, 1,500, 3,000, or 5,000 ppm sodium nitrite resulted in average daily doses of approximately 30, 55, 115, 200, or 310 mg sodium nitrite/kg body weight to males and 40, 80, 130, 225, or 345 mg/kg to females. Clinical findings related to sodium nitrite exposure included brown discoloration in the eyes and cyanosis of the mouth, tongue, ears, and feet of males exposed to 3,000 or 5,000 ppm and of females exposed to 1,500 ppm or greater. Males in the 5,000 ppm group were hypoactive, and a few females exposed to 375 ppm or greater developed alopecia.

 TABLE 5

 Survival, Body Weights, and Water Consumption of Rats in the 14-Week Drinking Water Study of Sodium Nitrite

			ean Body Weight ^b (Final Weight Relative	Water		
Dose (ppm)	Survival ^a	Initial	Final	Change	to Controls (%)		mption [°] Week 14
Male							
0	10/10	153 ± 5	366 ± 4	213 ± 4		23.3	16.8
375	10/10	155 ± 4	347 ± 6	192 ± 5	95	18.6	18.6
750	10/10	155 ± 4	351 ± 8	196 ± 7	96	21.7	19.2
1,500	10/10	150 ± 4	360 ± 4	211 ± 3	98	24.5	17.0
3,000	10/10	160 ± 5	$344 \pm 6*$	$184 \pm 4^{**}$	94	19.5	16.6
5,000	10/10	150 ± 3	310 ± 8**	160 ± 8**	85	13.1	14.4
Female							
0	10/10	128 ± 4	202 ± 4	75 ± 2		18.9	14.7
375	10/10	127 ± 4	207 ± 3	80 ± 3	102	22.0	14.4
750	10/10	125 ± 4	198 ± 3	73 ± 4	98	18.6	15.5
1,500	10/10 9/10 ^d	130 ± 3	206 ± 3	76 ± 4	102	17.2	14.1
3,000	9/10 ^u	133 ± 4	195 ± 3	$63 \pm 5*$	96	14.5	9.3
5,000	10/10	135 ± 4	$191 \pm 3*$	$56 \pm 3^{**}$	94	11.0	8.7

* Significantly different (P≤0.05) from the control group by Williams' or Dunnett's test

****** P≤0.01

^a Number of animals surviving at 14 weeks/number initially in group

Weights and weight changes are given as mean \pm standard error. Subsequent calculations are based on animals surviving to the end of the study.

d Water consumption is expressed as grams per animal per day.

Week of death: 4

The hematology and clinical chemistry data for rats are presented in Tables 6 and F1. In general, methemoglobin concentrations were increased in all exposed groups of male and female rats throughout the study. Increases in the numbers of erythrocytes containing Heinz bodies, another marker of oxidative red cell injury, occurred on day 5 in the 5,000 ppm male and female groups; this alteration was transient and numbers returned to control levels by day 19. Alterations in other variables evaluating the red cell mass occurred at all time points. On day 5, an increase in erythropoietic activity was evidenced by increased reticulocyte counts in the 3,000 and 5,000 ppm males and females. Reticulocyte count increases continued on day 19 and were accompanied by increases in nucleated erythrocyte counts in 3,000 and 5,000 ppm males and 5,000 ppm females. Also, on day 19, there was an apparent decrease in the erythron, evidenced by decreases in the hemoglobin concentration in the 5,000 ppm males and females; the hematocrit values for these animals were also consistent with, but not statistically significant for, a decrease in the erythron. However, the erythrocyte counts did not support a decreased erythron and were in fact increased for the 3,000 and 5,000 ppm rats on day 19. There were decreases in the mean cell volumes for 5,000 ppm males and females on day 19, suggesting the presence of smaller erythrocytes in the circulation. The mean cell hemoglobin values in these rats were decreased at this time point and would be consistent with the decreased mean cell volume. Also, on day 19, the mean cell hemoglobin concentrations were decreased in 3,000 and 5,000 ppm males and females. The apparent decrease in the erythron was transient and, by week 14, was replaced by an increased erythron, evidenced by increased hemoglobin concentrations (3,000 and 5,000 ppm males and females), hematocrit values (3,000 ppm females and 5,000 ppm males and females) and erythrocyte counts (5,000 ppm females).

Reticulocyte counts were still increased in 3,000 and 5,000 ppm males and 5,000 ppm females at week 14, but the magnitude of the increase in nucleated erythrocyte counts had lessened. The decreases in mean cell volumes, mean cell hemoglobin values, and mean cell hemoglobin concentrations on day 19 disappeared and, by study termination, mean cell volumes and mean cell hemoglobin values were increased in 3,000 ppm males and females and 5,000 ppm females.

Platelet counts were increased on day 5 in 3,000 ppm females and 5,000 ppm males and females and on day 19 in 5,000 ppm males and females but fell to control levels by week 14.

Increases in urea nitrogen concentrations occurred on day 19 in 5,000 ppm males and females and at week 14 in all exposed groups of males and 1,500 ppm or greater females. Creatinine concentrations, another marker of renal function, were increased on day 5 in 3,000 and 5,000 ppm females and on day 19 in females exposed to 1,500 ppm or greater but had returned to control levels by week 14; male rats were not affected. On day 5, there was a decrease in the serum activity of alkaline phosphatase in various male and female exposed groups; this effect disappeared with time in most groups.

N-Nitrosodimethylamine and *N*-nitrosopyrrolidine were not detected in the blood of male or female exposed groups (levels of detection were less than 2.0 ppb for the highest level of sensitivity). Total nitrosamine concentrations in the blood of exposed males and females at different time points (9 a.m., 8 p.m., and 10 p.m.) were not significantly different from control values (Table F2). *N*-Nitrosodimethylamine and *N*-nitrosopyrrolidine were not detected in the stomach contents of exposed males or females.

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
Male						
Hematology						
n						
n Day 5	9	6	10	7	8	9
Day 19	10	10	9	10	10	9
Week 14	10	10	10	9	10	10
		- •		-		
Hematocrit (%)	,				,	,
Day 5	41.6 ± 0.5^{b}	$41.1 \pm 0.6^{\circ}$	$39.2 \pm 0.6^{*}$	40.0 ± 0.4^{d}	41.0 ± 0.7^{b}	39.5 ± 0.6^{b}
Day 19	43.5 ± 0.2	43.9 ± 0.4	44.3 ± 0.4^{b}	42.8 ± 1.0	46.3 ± 1.1	37.7 ± 1.3^{b}
Week 14	43.8 ± 0.6	44.1 ± 0.5	42.0 ± 0.6	42.2 ± 0.6	45.5 ± 0.5	$46.5 \pm 0.7*$
Hemoglobin (g/dL)						
Day 5	14.5 ± 0.2^{b}	14.2 ± 0.2^{c}	$13.6 \pm 0.2*$	13.8 ± 0.1^{d}	14.2 ± 0.2^{b}	13.8 ± 0.2^{b}
Day 19	14.9 ± 0.2 14.9 ± 0.1	14.2 ± 0.2 15.0 ± 0.1	15.0 ± 0.2 15.1 ± 0.1^{b}	13.0 ± 0.1 14.7 ± 0.3	14.2 ± 0.2 15.3 ± 0.3	$12.5 \pm 0.4^{**b}$
Week 14	14.9 ± 0.1 15.0 ± 0.2	15.0 ± 0.1 15.2 ± 0.1	13.1 ± 0.1 14.7 ± 0.2	14.7 ± 0.3 14.7 ± 0.2	15.5 ± 0.5 $15.7 \pm 0.1*$	12.5 ± 0.4 $16.0 \pm 0.3^{**}$
Erythrocytes $(10^{6}/\mu L)$	10.0 ± 0.2	10.2 ± 0.1	17.7 - 0.2	17.7 - 0.2	10.7 - 0.1	10.0 ± 0.5
Day 5	7.08 ± 0.08^{b}	6.95 ± 0.13^{c}	6.90 ± 0.10	6.79 ± 0.08^{d}	6.94 ± 0.13^{b}	6.89 ± 0.12^{b}
~		0.93 ± 0.13 7.65 ± 0.10	0.90 ± 0.10 $7.90 \pm 0.08 *^{b}$	0.79 ± 0.08 7.54 ± 0.17	0.94 ± 0.13 $8.44 \pm 0.15^{**}$	$8.10 \pm 0.21^{**b}$
Day 19 Week 14	7.61 ± 0.05 8.30 ± 0.12	7.65 ± 0.10 8.39 ± 0.08		7.91 ± 0.17 7.91 ± 0.10	$8.44 \pm 0.13^{++}$ 8.29 ± 0.08	
week 14 $(106/1)$	8.30 ± 0.12	8.39 ± 0.08	7.97 ± 0.13	7.91 ± 0.10	8.29 ± 0.08	8.92 ± 0.25
Reticulocytes $(10^6/\mu L)$	0.45 . 0.00	0.45 . 0.05	0.50 . 0.05**	0.51 . 0.05	0.67 . 0.0644	b co . o ootted
Day 5	0.45 ± 0.03	0.47 ± 0.05	$0.72 \pm 0.05 **$	0.51 ± 0.05	$0.67 \pm 0.06^{**}$	$0.69 \pm 0.03^{**d}$
Day 19	0.21 ± 0.02	0.19 ± 0.01	0.21 ± 0.02	0.23 ± 0.03	0.37 ± 0.02 **	$0.58 \pm 0.05 **$
Week 14	0.22 ± 0.02	0.22 ± 0.03	0.26 ± 0.02	0.18 ± 0.02	$0.30 \pm 0.03*$	$0.37 \pm 0.04 **$
Nucleated erythrocytes (
Day 5	1.00 ± 0.33	3.00 ± 0.45	2.80 ± 0.65	1.57 ± 0.69	2.75 ± 1.03	2.78 ± 0.49
Day 19	0.60 ± 0.22	0.90 ± 0.23	0.89 ± 0.35	1.20 ± 0.44	$2.70 \pm 0.52 **$	5.33 ± 1.12 **
Week 14	0.70 ± 0.30	0.70 ± 0.21	0.60 ± 0.27	0.89 ± 0.20	1.10 ± 0.41	1.70 ± 0.50
Mean cell volume (fL)	,			,	,	,
Day 5	58.8 ± 0.3^{b}	$59.2 \pm 0.3^{\circ}$	56.9 ± 0.2 **	59.0 ± 0.4^{d}	59.1 ± 0.4^{b}	57.4 ± 0.3^{b}
Day 19	57.1 ± 0.4	57.4 ± 0.5	56.2 ± 0.5^{b}	56.9 ± 0.5	54.9 ± 0.9	$46.4 \pm 0.5^{**b}$
Week 14	52.8 ± 0.2	52.5 ± 0.2	52.8 ± 0.1	53.3 ± 0.3	$55.0 \pm 0.2 **$	$52.4 \pm 1.2 **$
Mean cell hemoglobin (pg)					
Day 5	20.4 ± 0.1^{b}	$20.5 \pm 0.1^{\circ}$	$19.8 \pm 0.1*$	20.3 ± 0.1^{d}	20.5 ± 0.2^{b}	20.0 ± 0.1^{b}
Day 19	19.6 ± 0.1	19.6 ± 0.2	$19.1 \pm 0.2 *^{b}$	19.6 ± 0.2	$18.1 \pm 0.3^{**}$	$15.4 \pm 0.2^{**}$
Week 14	19.0 ± 0.1 18.1 ± 0.1	19.0 ± 0.2 18.1 ± 0.1	19.1 ± 0.2 $18.5 \pm 0.1*$	$13.5 \pm 0.1^*$	18.9 ± 0.1 **	$18.1 \pm 0.5^{**}$
Mean cell hemoglobin c			10.0 - 0.1	10.0 ± 0.1	10.7 - 0.1	10.1 - 0.5
Day 5	34.7 ± 0.2^{b}	$34.6 \pm 0.1^{\circ}$	34.7 ± 0.1	34.5 ± 0.2^{d}	34.7 ± 0.2^{b}	34.9 ± 0.2^{b}
Day 19	34.7 ± 0.2 34.3 ± 0.2	34.0 ± 0.1 34.1 ± 0.2	34.0 ± 0.2^{b}	34.3 ± 0.2 34.4 ± 0.3	$33.0 \pm 0.2^{**}$	$33.1 \pm 0.3^{**b}$
Week 14	34.3 ± 0.2 34.4 ± 0.2	34.1 ± 0.2 34.4 ± 0.2	34.0 ± 0.2 35.1 ± 0.2	34.4 ± 0.3 34.8 ± 0.1	33.0 ± 0.2	33.1 ± 0.3
Platelets $(10^3/\mu L)$	34.4 ± 0.2	$J_{7,7} \pm 0.2$	55.1 ± 0.2	J4.0 ± 0.1	$5+.5 \pm 0.1$	J4.4 ± 0.3
	$999.9\pm23.9^{\text{b}}$	$1,028.6 \pm 43.3^{c}$	$1 140.8 \pm 21.1*$	966.3 ± 51.6^{d}	$1,008.7 \pm 23.2^{b}$	1,166.4 ± 42.0* ^b
Day 5	$777.7 \pm 23.9^{\circ}$	$1,028.6 \pm 43.3$ 753.9 ± 24.5	$1,140.8 \pm 31.1*$ 827.4 ± 23.7^{b}	$300.3 \pm 31.0^{\circ}$	$1,000.7 \pm 23.2^{\circ}$	$1,100.4 \pm 42.0^{**}$ $1,815.2 \pm 129.0^{**}$
Day 19	763.6 ± 17.9			777.3 ± 45.5	759.1 ± 30.6	
Week 14	577.7 ± 21.4	608.0 ± 13.0	597.9 ± 15.1	588.3 ± 18.3	606.1 ± 16.3	673.4 ± 56.4
Methemoglobin (g/dL)	0.02 . 0.02	0.04 + 0.02		0.00 . 0.02	1.07 . 0.412.0	2.07 / 0.751
Day 5	0.03 ± 0.02	0.04 ± 0.02	$4.36 \pm 0.78^{**c}$	$0.08 \pm 0.03 **$	$1.37 \pm 0.41 **^{e}$	
Day 19	0.09 ± 0.05	0.06 ± 0.02	$0.28 \pm 0.12*$	0.38 ± 0.12 **	$1.25 \pm 0.37 **$	$3.26 \pm 0.36 **$
Week 14	0.03 ± 0.01	0.08 ± 0.01 **	$0.12 \pm 0.02 **$	$0.25 \pm 0.07 **$	0.71 ± 0.20 **	$3.38 \pm 0.80 **$
Heinz bodies $(10^6/\mu L)^f$						
Day 5	0.002 ± 0.001	0.005 ± 0.001	$0.009 \pm 0.002*$	0.010 ± 0.004	0.007 ± 0.002	$0.013 \pm 0.004 **$
Day 19	0.004 ± 0.002	0.004 ± 0.002	0.003 ± 0.001	0.004 ± 0.002	0.006 ± 0.002	0.006 ± 0.002
Week 14	0.170 ± 0.114	0.170 ± 0.114	0.470 ± 0.128	0.267 ± 0.133	0.240 ± 0.122	0.350 ± 0.144

TABLE 6 Selected Hematology and Clinical Chemistry Data for Rats in the 14-Week Drinking Water Study of Sodium Nitrite^a

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
Male (continued)						
Clinical Chemistry						
n						
n Day 5	10	10	10	9	10	10
Day 19	10	10	10	9	10	10
Week 14	10	10	10	10	10	10
Urea nitrogen (mg/dL)						
Day 5	20.4 ± 0.5	18.3 ± 0.7	21.7 ± 0.5	19.7 ± 1.0	19.9 ± 0.6	21.3 ± 0.6
Day 19	21.0 ± 0.7	21.4 ± 0.4	20.8 ± 0.5	22.3 ± 0.5	22.0 ± 0.3	$24.9\pm0.7**$
Week 14	17.8 ± 0.5	$20.5\pm0.9*$	$21.2 \pm 0.7 **$	$20.4\pm0.8*$	$22.3 \pm 1.4 **$	$22.0\pm0.8**$
Alkaline phosphatase (I						
Day 5	570 ± 12	586 ± 14	$445 \pm 8**$	$544 \pm 11^{*}_{h}$	$504 \pm 8**$	$441 \pm 5^{**}$
Day 19	448 ± 8	455 ± 8	450 ± 8	423 ± 13^{b}	$402 \pm 6^{**}$	$333 \pm 11**$
Week 14	216 ± 6	233 ± 9	231 ± 9	209 ± 6	213 ± 6	210 ± 7
Female						
Hematology						
n						
Day 5	9	8	9	9	8	9
Day 19	10	10	10	10	10	10
Week 14	10	10	10	10	9	10
Hematocrit (%)						
Day 5	45.6 ± 1.4	44.3 ± 1.2	46.0 ± 0.9^{b}	46.0 ± 0.7	$45.1 \pm 1.0^{\circ}$	44.8 ± 0.6
Day 19	46.8 ± 0.5	46.0 ± 0.6	45.2 ± 0.5	46.6 ± 0.8	48.5 ± 1.3	42.7 ± 1.8
Week 14	43.8 ± 0.4	43.5 ± 0.4	42.1 ± 0.4	43.0 ± 0.4	$47.1 \pm 0.4 **$	51.3 ± 0.6 **
Hemoglobin (g/dL)			h			
Day 5	15.3 ± 0.4	14.8 ± 0.3	15.4 ± 0.2^{b}	15.4 ± 0.2	15.3 ± 0.2^{c}	15.2 ± 0.1
Day 19	15.7 ± 0.1	15.3 ± 0.1	15.2 ± 0.2	15.6 ± 0.2	15.9 ± 0.4	$13.9 \pm 0.6*$
Week 14	15.2 ± 0.1	15.0 ± 0.1	14.7 ± 0.1	15.0 ± 0.1	$16.2 \pm 0.1 **$	17.5 ± 0.1 **
Erythrocytes $(10^6/\mu L)$	7 (2 + 0.2)	7 77 + 0 21	7.64 ± 0.13^{b}	7.50 ± 0.12	7 44 L 0 20 ^C	7 40 + 0.00
Day 5	7.62 ± 0.26 7.87 ± 0.12	7.27 ± 0.21 7.72 ± 0.13	$7.64 \pm 0.13^{\circ}$ 7.54 ± 0.08	7.56 ± 0.13 7.82 ± 0.17	$7.44 \pm 0.20^{\circ}$	7.49 ± 0.09 8 71 ± 0 20**
Day 19 Week 14	7.87 ± 0.12 7.64 ± 0.07	7.72 ± 0.13 7.61 ± 0.05	7.54 ± 0.08 7.31 ± 0.06	7.83 ± 0.17 7.35 ± 0.07	$8.36 \pm 0.11*$ 7.74 ± 0.05	$8.71 \pm 0.20 **$ $8.49 \pm 0.15 **$
Reticulocytes $(10^{6}/\mu L)$	/.04 ± 0.0/	1.01 ± 0.05	1.51 ± 0.00	1.55 ± 0.07	1.14 ± 0.03	$0.47 \pm 0.13^{++}$
Day 5	0.29 ± 0.03	0.34 ± 0.02	0.36 ± 0.03	$0.44 \pm 0.05*$	$0.63 \pm 0.03 **$	0.73 ± 0.07 **
Day 19	0.29 ± 0.03 0.14 ± 0.01	0.34 ± 0.02 $0.17 \pm 0.01*$	0.30 ± 0.03 0.14 ± 0.01	$0.44 \pm 0.03^{*}$ $0.20 \pm 0.02^{**}$	$0.03 \pm 0.03^{++}$ $0.41 \pm 0.05^{*+}$	0.73 ± 0.07 ** 0.65 ± 0.07 **
Week 14	0.14 ± 0.01 0.21 ± 0.02	0.17 ± 0.01 0.15 ± 0.02	0.14 ± 0.01 0.18 ± 0.02	0.20 ± 0.02	0.41 ± 0.03	0.03 ± 0.07
Nucleated erythrocytes		0.12 - 0.02	0.10 - 0.02	0.20 - 0.00	0.20 - 0.05	0.10 - 0.05
Day 5	1.80 ± 0.44^{b}	1.13 ± 0.35	1.44 ± 0.48	1.56 ± 0.53	2.40 ± 0.43^{b}	2.22 ± 0.36
Day 19	0.60 ± 0.22	0.40 ± 0.16	0.90 ± 0.48	1.10 ± 0.38	0.60 ± 0.27	3.00 ± 0.78 *
Week 14	1.00 ± 0.30	0.60 ± 0.22	0.80 ± 0.25	1.60 ± 0.34	1.00 ± 0.37	1.70 ± 0.42
Mean cell volume (fL)						
Day 5	59.9 ± 0.4	60.9 ± 0.3	60.3 ± 0.4^{b}	60.8 ± 0.3	60.7 ± 0.5^{c}	59.8 ± 0.3
Day 19	59.5 ± 0.5	59.6 ± 0.6	60.0 ± 0.4	59.5 ± 0.5	58.0 ± 1.0	$48.9 \pm 1.0 \texttt{**}$
Week 14	57.2 ± 0.1	57.2 ± 0.3	57.6 ± 0.2	$58.6 \pm 0.2 **$	$60.8 \pm 0.2 **$	$60.5\pm0.7\text{**}$
Mean cell hemoglobin	(pg)		L		2	
Day 5	20.1 ± 0.2	20.3 ± 0.2	20.1 ± 0.2^{b}	20.3 ± 0.1	20.7 ± 0.3^{c}	20.3 ± 0.1
Day 19	19.9 ± 0.2	19.9 ± 0.2	20.1 ± 0.1	19.9 ± 0.3	19.0 ± 0.4	$15.8 \pm 0.3 **$
Week 14	19.9 ± 0.1	19.7 ± 0.1	20.1 ± 0.1	$20.5 \pm 0.1 **$	$20.9 \pm 0.1 **$	$20.7 \pm 0.3 **$

TABLE 6 Selected Hematology and Clinical Chemistry Data for Rats in the 14-Week Drinking Water Study of Sodium Nitrite

TABLE 6
Selected Hematology and Clinical Chemistry Data for Rats in the 14-Week Drinking Water Study
of Sodium Nitrite

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
Female (continued)						
Hematology (continued	l)					
1						
Day 5	9	8	9	9	8	9
Day 19	10	10	10	10	10	10
Week 14	10	10	10	10	9	10
Iean cell hemoglobin	concentration (g/dL))				
Day 5	33.6 ± 0.3	33.3 ± 0.2	33.4 ± 0.3^{b}	33.4 ± 0.2	34.0 ± 0.3^{c}	33.9 ± 0.3
Day 19	33.5 ± 0.2	33.4 ± 0.2	33.6 ± 0.1	33.4 ± 0.3	$32.9 \pm 0.2^*$	$32.4 \pm 0.2^{**}$
Week 14	34.7 ± 0.2	34.4 ± 0.1	34.9 ± 0.2	34.9 ± 0.2	34.3 ± 0.2	34.2 ± 0.2
latelets $(10^3/\mu L)$	5 0.2	5 0.1	5	5 = 0.2	2	5 = 0.2
Day 5	794.6 ± 41.0	891.1 ± 27.6	847.3 ± 35.4^b	866.9 ± 16.3	$995.3 \pm 34.5 * *^{c}$	931.8 ± 43.9**
Day 19	701.8 ± 24.7	703.4 ± 22.4	698.4 ± 30.7	709.4 ± 16.3	726.7 ± 61.2	$1,631.0 \pm 171.7^{**}$
Week 14	656.6 ± 17.0	611.5 ± 10.8	668.7 ± 21.3	613.6 ± 11.3	645.3 ± 21.9	617.5 ± 14.9
fethemoglobin (g/dL)	000.00 - 17.0	01110 - 1010	0000.7 - 21.0	010.0 - 11.0	0.0.0 - 21.0	017.00 - 11.09
Day 5	0.02 ± 0.01	$0.10 \pm 0.05*$	0.05 ± 0.01	$0.21 \pm 0.08 **$	$2.41 \pm 0.76 **$	$4.95 \pm 0.92 **$
Day 19	0.02 ± 0.01	$0.11 \pm 0.03^*$	$0.18 \pm 0.04 **$	$2.01 \pm 0.49 **$	$3.78 \pm 0.79^{**}$	$6.66 \pm 0.36^{**}$
Week 14	0.06 ± 0.02	$0.14 \pm 0.02^{**}$	$0.16 \pm 0.02^{**}$	$0.48 \pm 0.05^{**c}$	$0.99 \pm 0.20 **$	$2.27 \pm 0.54^{**}$
leinz bodies $(10^6/\mu L)$	0.00 - 0.02	0.11 = 0.02	0.10 - 0.02	0.10 - 0.00	0.337 - 0.20	2.27 - 0.01
Day 5	0.002 ± 0.001	0.001 ± 0.001	0.002 ± 0.001	0.002 ± 0.001	0.006 ± 0.002	$0.010 \pm 0.002^{*3}$
Day 19	0.002 ± 0.001 0.002 ± 0.001	0.001 ± 0.001 0.002 ± 0.001	0.002 ± 0.001 0.001 ± 0.001	0.002 ± 0.001 0.003 ± 0.002	0.002 ± 0.002	0.002 ± 0.001
Week 14	0.300 ± 0.123	0.230 ± 0.117	0.350 ± 0.117	0.210 ± 0.107	0.178 ± 0.118	0.240 ± 0.122
Clinical Chemistry						
1						
Day 5	10	9	9	9	10	10
Day 19	10	10	10	10	10	10
Week 14	10	10	10	10	9	10
Jrea nitrogen (mg/dL)						
Day 5	22.1 ± 1.1	21.2 ± 0.6	21.3 ± 0.6	20.3 ± 0.7^{d}	21.0 ± 0.5	22.5 ± 0.6 .
Day 19	$24.4 \pm 1.0^{\circ}$	24.2 ± 0.7	23.2 ± 0.5	23.9 ± 0.5	24.1 ± 0.6	$30.6 \pm 0.8 **$
Week 14	17.8 ± 0.6	19.0 ± 0.4	19.0 ± 0.7	$21.7 \pm 0.4 **$	$22.3 \pm 0.7 **$	$21.5 \pm 0.5 **$
reatinine (mg/dL)						
Day 5	$0.63 \pm 0.03^{\circ}$	0.62 ± 0.03	0.70 ± 0.04	0.65 ± 0.02^{d}	$0.71 \pm 0.01 *^{c}$	$0.73 \pm 0.03 *^{c}$
Day 19	0.58 ± 0.04^{d}	$0.65 \pm 0.03*$	0.60 ± 0.02	$0.69 \pm 0.03 **$	$0.73 \pm 0.04 **$	$0.81 \pm 0.03 **$
Week 14	0.66 ± 0.02	0.68 ± 0.03	0.67 ± 0.02	0.68 ± 0.03	0.68 ± 0.03	0.69 ± 0.02
lkaline phosphatase (l	IU/L)					
Day 5	424 ± 21	423 ± 15	415 ± 14^{b}	377 ± 13	$345 \pm 11**$	$315 \pm 12^{**}$
Day 19	350 ± 10	$299 \pm 22*$	340 ± 5	$315 \pm 16*$	$288 \pm 16^{**}$	$257 \pm 4**$
Week 14	178 ± 5	176 ± 8	180 ± 5	167 ± 3	164 ± 3	$142 \pm 5^{**}$

* Significantly different (P≤0.05) from the control group by Dunn's or Shirley's test

** P≤0.01

а Mean \pm standard error. Statistical tests were performed on unrounded data. b

n=10

d n=8

e n=7

f Total number of erythrocytes with Heinz bodies

c n=9

The relative kidney weights of males and females exposed to 3,000 and 5,000 ppm were significantly increased. The relative spleen weights of males exposed to 1,500 ppm or greater and females exposed to 3,000 or 5,000 ppm were significantly greater than those of the controls (Table G1).

Sperm motility in 1,500 and 5,000 ppm males was significantly decreased relative to the controls (Table H1). There were no significant differences in vaginal cytology parameters between exposed and control females (Table H2).

Microscopically, no abnormal changes were seen in the kidney or spleen. Microscopic examination of the bone marrow demonstrated increases in the incidences of erythropoietic activity in males (5/10, 5/10, 5/10, 8/10, 8/10, 9/10) and females (1/10, 0/10, 1/10, 3/10, 7/10, 10/10). The increased incidences of erythropoiesis were consistent with the hematologic findings of regenerative anemia.

All the 5,000 ppm males and females had squamous cell hyperplasia of the forestomach; none was seen in the controls or 3,000 ppm animals. The average severity of forestomach hyperplasia was minimal in males and mild in females. Hyperplastic lesions were focal and were primarily observed near the limiting ridge between the forestomach and the glandular stomach. Hyperplasia was characterized by thickening of the squamous epithelium, and hyperkeratosis was often a component of the lesion.

Exposure Concentration Selection Rationale: Based on decreased final mean body weights and body weight gains of males and females exposed to 5,000 ppm and increased incidences of squamous cell hyperplasia of the forestomach in 5,000 ppm males and females, the sodium nitrite concentrations selected for the 2-year drinking water study in rats were 750, 1,500, and 3,000 ppm.

2-YEAR STUDY

Survival

Estimates of 2-year survival probabilities for male and female rats are shown in Table 7 and in the Kaplan-Meier survival curves (Figure 1). Survival of exposed groups was similar to that of the control groups.

Body Weights, Water and Compound Consumption, and Clinical Findings

Mean body weights of males and females exposed to 3,000 ppm were less than those of the control groups

throughout the study (Figure 2 and Tables 8 and 9). Water consumption by males and females exposed to 3,000 ppm was less than that by the controls throughout the study, and that by the other exposed groups was generally less after week 14 (Tables K1 and K2). Drinking water concentrations of 750, 1,500, or 3,000 ppm sodium nitrite resulted in average daily doses of approximately 35, 70, or 130 mg/kg body weight to males and 40, 80, or 150 mg/kg to females. There were no clinical findings related to exposure to sodium nitrite; the brown discoloration and cyanosis seen in the 14-week studies were not observed.

TABLE 7 Survival of Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Male				
Animals initially in study	50	50	50	50
Moribund	16	4	12	8
Natural deaths	5	8	2	6
Animals surviving to study termination	29	38 ^c	36	36
Percent probability of survival at end of study ^a	58	76	72	72
Mean survival (days) ^b	665	697	703	702
Survival analysis ^d	P=0.215N	P=0.075N	P=0.128N	P=0.137N
Female				
Animals initially in study	50	50	50	50
Moribund	11	6	10	15
Natural deaths	6	13	4	2
Animals surviving to study termination	33	31	36	33
Percent probability of survival at end of study	66	62	72	66
Mean survival (days)	695	693	698	694
Survival analysis	P=0.853N	P=0.890	P=0.657N	P=1.000N

^a Kaplan-Meier determinations

^b Mean of all deaths (uncensored, censored, and terminal sacrifice)

^c Includes one animal that died during the last week of the study

^d The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposed group columns. A negative trend or lower mortality in an exposure group is indicated by **N**.




FIGURE 1 Kaplan-Meier Survival Curves for Male and Female Rats Exposed to Sodium Nitrite in Drinking Water for 2 Years




FIGURE 2 Growth Curves for Male and Female Rats Exposed to Sodium Nitrite in Drinking Water for 2 Years

46

 TABLE 8

 Mean Body Weights and Survival of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite

Weeks	0 1	opm		750 ppm	1		1,500 ppm			3,000 pp	n
on	Av. Wt.	No. of	Av. Wt.	Wt. (% of	No. of	Av. Wt.	Wt. (% of	No. of	Av. Wt.	Wt. (% of	No. of
Study	(g)	Survivors	(g)		Survivors	(g)		Survivors	(g)	controls)	
1	107	50	107	100	50	107	100	50	107	101	50
2	144	50	144	100	50	143	99	50	134	93	50
6	259	50	254	98	50	254	98	50	242	94	50
10	314	50	307	98	50	304	97	50	288	92	50
14	354	50	348	98	50	341	96	50	322	91	50
18	381	50	376	99	50	367	96	50	349	92	50
22	406	50	399	98	50	392	97	50	369	91	50
26	426	50	416	97	50	410	96	50	385	90	50
30	438	50	435	99	50	423	97	50	400	91	50
34	450	50	446	99	50	435	97	50	412	92	50
38	458	49	460	100	50	443	97	50	418	91	50
42	466	49	462	99	50	450	97	50	422	91	50
46	478	49	474	99	50	463	97	50	433	91	50
50	487	49	486	100	50	470	97	50	437	90	50
54	492	49	487	99	50	473	96	50	441	90	50
58	491	49	495	101	50	477	97	50	445	91	50
62	499	48	495	99	49	481	96	49	448	90	50
66	499	48	494	99	49	480	96	49	444	89	50
70	499	48	499	100	47	481	96	49	452	91	50
74	501	46	498	99	47	477	95	48	449	90	50
78	501	44	497	99	47	481	96	48	446	89	48
82	502	43	493	98	46	479	95	47	445	89	47
86	497	40	495	100	45	481	97	45	445	90	46
90	494	36	499	100	44	480	97	44	441	89	44
94	495	33	496	100	42	481	97	44	440	89	42
98	492	31	488	99	40	480	98	43	442	90	41
102	496	30	485	98	38	483	97	39	441	89	38
Mean fo	or weeks										
1-13	206		203	99		202	98		193	94	
14-52	434		430	99		419	97		395	91	
53-102	497		494	99		480	97		445	90	

Weeks	0	opm		750 ppm	l		1,500 ppm			3,000 pp	m
on	Av. Wt.	No. of	Av. Wt.	Wt. (% of		Av. Wt.	Wt. (% of	No. of	Av. Wt.	Wt. (% of	No. of
Study	(g)	Survivors	(g)		Survivors	(g)	controls)		(g)		Survivors
1	96	50	95	99	50	96	100	50	95	99	50
2	118	50	116	98	50	115	98	50	111	94	50
6	168	50	164	98	50	164	97	50	159	95	50
10	187	50	182	97	50	183	98	50	177	94	50
14	201	50	196	98	50	195	97	50	188	94	50
18	212	50	206	97	50	204	96	50	197	93	50
22	220	50	214	97	50	212	96	50	204	93	50
26	227	50	221	97	50	218	96	50	211	93	50
30	238	50	231	97	50	227	95	50	217	91	50
34	245	50	236	97	50	234	96	50	224	91	50
38	254	50	245	97	50	241	95	50	231	91	50
42	260	50	251	97	50	246	95	50	235	90	50
46	271	50	259	96	50	252	93	50	241	89	50
50	281	50	269	96	49	264	94	49	250	89	50
54	286	50	276	96	49	270	94	49	256	90	49
58	293	50	284	97	49	276	94	49	261	89	49
62	302	50	291	96	49	287	95	49	265	88	49
66	307	50	293	95	49	288	94	49	269	88	49
70	315	50	305	97	48	299	95	49	276	88	47
74	319	49	312	98	48	305	96	49	279	88	47
78	329	48	319	97	47	313	95	49	285	87	46
82	332	45	320	97	46	314	95	46	287	87	46
86	333	45	325	98	46	319	96	46	291	87	46
90	339	43	327	97	44	323	95	45	290	86	46
94	346	41	330	96	42	326	94	42	302	87	42
98	350	37	333	95	38	332	95	40	308	88	39
102	344	35	337	98	34	332	97	38	312	91	37
	or weeks										
1-13	142		139	98		140	99		136	96	
14-52	241		233	97		229	95		220	91	
53-102	323		312	97		306	95		283	88	

TABLE 9Mean Body Weights and Survival of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite

Determination of Plasma Nitrite and Blood Methemoglobin Concentrations

At 2 weeks and 3 months, no nitrite was detected in the plasma of control male or female rats. Plasma nitrite concentrations tended to increase with increasing exposure concentrations of sodium nitrite. Generally, plasma nitrite concentrations were high at night when the rats were actively feeding and drinking, and were low during the day when the rats were less active (Tables I1 through I4). Blood methemoglobin concentrations followed the same pattern (Figures I1 and I2).

In 18-month-old male and female rats administered a single dose of 40 mg/kg sodium nitrite by gavage, plasma nitrite and blood methemoglobin concentrations peaked at 30 minutes (Tables I5 and I6).

Pathology and Statistical Analyses

This section describes the statistically significant or biologically noteworthy changes in the incidences of neoplasms and/or nonneoplastic lesions of the forestomach, mammary gland, liver, kidney, and skin and in the incidences of mononuclear cell leukemia. Summaries of the incidences of neoplasms and nonneoplastic lesions, individual animal tumor diagnoses, statistical analyses of primary neoplasms that occurred with an incidence of at least 5% in at least one animal group, and historical incidences for the neoplasms mentioned in this section are presented in Appendix A for male rats and Appendix B for female rats.

Forestomach: The incidences of hyperplasia of the squamous epithelium were significantly increased in males and females exposed to 3,000 ppm (Tables 10, A5, and B5). Hyperplasia was generally a minimal change affecting the epithelium of the limiting ridge at the junction of the forestomach and glandular stomach (Plates 1 and 2). In a few cases, severe hyperplasia was seen both at and away from the limiting ridge. Hyperplasia was characterized primarily by variable degrees of folding of the squamous epithelium and was usually accompanied by a variable degree of thickening of the overlying keratin layer (hyperkeratosis). No forestomach neoplasms were observed following exposure to sodium nitrite.

TABLE 10 Incidences of Epithelial Hyperplasia of the Forestomach in Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Male				
Number Examined Microscopically Epithelium, Hyperplasia ^a	$ \begin{array}{ccc} 50 \\ 12 & (1.5)^{b} \end{array} $	50 9 (1.4)	50 10 (1.3)	50 44** (1.2)
Female				
Number Examined Microscopically Epithelium, Hyperplasia	50 8 (1.8)	50 6 (1.5)	50 8 (1.5)	50 40** (1.2)

** Significantly different (P≤0.01) from the control group by the Poly-3 test

 $\frac{a}{b}$ Number of animals with lesion

Average severity grade of lesions in affected animals: 1=minimal, 2=mild, 3=moderate, 4=marked

Mammary Gland: The incidence of fibroadenoma was significantly increased in females exposed to 1,500 ppm sodium nitrite and exceeded the historical range for NTP controls given NTP-2000 diet (all routes) (Tables 11, B3, and B4a) or NIH-07 diet (drinking water route) (24%-58%; Table B4a). The incidences in the 750 and 3,000 ppm groups also exceeded the range for the NTP controls given NTP-2000 diet; the incidence in the control group was greater than in these exposed groups and equaled the highest incidence in the NTP-2000 historical control database. Also, when combined with adenomas, there were no significant increases in the incidences of these neoplasms. The incidences of carcinoma were not increased in the exposed groups. The incidences of multiple fibroadenoma were greater in females exposed to 750 ppm and 1,500 ppm than in controls. Fibroadenomas are the most common benign neoplasms that occur in the mammary gland of female F344/N rats. However, unlike benign neoplasms in other tissues that usually progress to malignancy, fibroadenomas are generally considered to represent an end-stage lesion, and progression to carcinoma is rare. Microscopically, fibroadenomas in exposed rats were similar to those in the controls and were characterized by collections of glandular epithelium arranged in acini and ducts and surrounded by fibrous connective tissue. The relative amounts of glandular and fibrous elements varied among neoplasms. Epithelial cells were well differentiated and arranged in a single layer of cuboidal epithelium, which was often vacuolated.

 TABLE 11

 Incidences of Neoplasms of the Mammary Gland in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Number Necropsied	50	50	50	50
Fibroadenoma, Multiple ^a	7	13	13	5
Fibroadenoma (includes multiple) ^b				
Overall rate ^{c}	21/50 (42%)	27/50 (54%)	31/50 (62%)	25/50 (50%)
Adjusted rate ^d	45.7%	58.5%	66.7%	54.4%
Terminal rate ^e	15/33 (46%)	17/31 (55%)	26/36 (72%)	16/33 (49%)
First incidence (days)	547	541	541	626
Poly-3 test ^f	P=0.268	P=0.149	P=0.029	P=0.263
Adenoma (includes multiple)	2	1	0	3
Fibroadenoma or Adenoma	23	27	31	28
Carcinoma	1	1	2	2

^a Number of animals with lesion

^b Historical incidence for 2-year studies with control groups given NTP-2000 diet (mean ± standard deviation): 108/299 (36.1% ± 6.2%); range 28%-42%

Number of animals with neoplasm per number of animals necropsied

d Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

^e Observed incidence at terminal kill

¹ Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice.

Liver: There were significant increases in the incidences of chronic active inflammation in 1,500 and 3,000 ppm males (0 ppm, 13/50; 750 ppm, 19/50; 1,500 ppm, 25/50, 3,000 ppm, 24/50; Table A5). This was generally a minor lesion, characterized by a few to several scattered aggregates of mixed mononuclear inflammatory cells, mainly lymphocytes and macrophages. Chronic active inflammation of the liver is a common spontaneous lesion in F344/N rats and may be obscured in rats with mononuclear cell Because of the lower incidences of leukemia. mononuclear cell leukemia, this common background lesion was more easily observed microscopically. The marginally increased incidences of chronic active inflammation in 1,500 and 3,000 ppm males were not considered to be related to sodium nitrite exposure.

Kidney: The incidence of nephropathy was marginally increased in females exposed to 3,000 ppm (14/50, 16/50, 20/50, 23/50; Table B5). It is unclear whether the slightly increased incidences of nephropathy were directly related to sodium nitrite exposure. Nephropathy is a common spontaneous renal lesion in F344/N rats.

Skin: The incidence of fibroma of the subcutis was significantly increased in males exposed to 1,500 ppm (0/50, 1/50, 6/50, 3/50; Table A3). The incidence in this group slightly exceeded the historical range for NTP controls (all routes) given NTP-2000 diet (Table A4a). The lack of a dose response for fibroma or a significant increase in the incidences of fibro-sarcomas (1/50, 0/50, 0/50, 2/50) and the fact that the combined incidences of fibroma or fibrosarcoma (1/50, 1/50, 6/50, 5/50) are within the historical range for NTP controls given NTP-2000 diet (Table A4a) suggest that these neoplasms were not related to sodium nitrite exposure. Fibromas and fibrosarcomas are the most common neoplasms that occur in the skin of F344/N rats.

Mononuclear Cell Leukemia: The incidences of mononuclear cell leukemia were significantly decreased in males and females exposed to 1,500 or 3,000 ppm and were less than the historical ranges for NTP controls (all routes) given NTP-2000 diet (Tables 12, A3, A4b, B3, and B4b). These findings indicate that sodium nitrite reduced the incidence of mononuclear cell leukemia in F344/N rats, thereby resulting in increased survival.

TABLE 12

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Male				
Mononuclear Cell Leukemia ^a				
Overall rate ^b	17/50 (34%)	12/50 (24%)	7/50 (14%)	3/50 (6%)
Adjusted rate ^c	37.9%	25.7%	15.0%	6.6%
Terminal rate ^d	7/29 (24%)	7/38 (18%)	1/36 (3%)	1/36 (3%)
First Incidence (days)	486	552	620	698
Poly-3 test ^e	P<0.001N	P=0.151N	P=0.010N	P<0.001N
Female				
Mononuclear Cell Leukemia ^f				
Overall rate	15/50 (30%)	10/50 (20%)	1/50 (2%)	1/50 (2%)
Adjusted rate	32.1%	21.9%	2.2%	2.2%
Terminal rate	8/33 (24%)	4/31 (13%)	0/36 (0%)	1/33 (3%)
First incidence (days)	513	616	638	730 (T)
Poly-3 test	P<0.001N	P=0.191N	P<0.001N	P<0.001N

Incidences of Mononuclear Cell Leukemia in Rats in the 2-Year Drinking Water Study of Sodium Nitrite

(T)Terminal sacrifice

^a Historical incidence for 2-year studies with control groups given NTP-2000 feed (mean \pm standard deviation): 130/299 (43.5% \pm 9.6%); range ^b 32%-54%

^b Number of animals with neoplasm per number of animals necropsied

^c Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

d Observed incidence at terminal kill

^e Beneath the control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not creach terminal sacrifice. A negative trend or a lower incidence in an exposure group is indicated by N.

f Historical incidence: 87/299 (29.1% ± 8.5%); range 16%-42%

MICE 14-WEEK STUDY

All mice survived until the end of the study (Table 13). Final mean body weight and body weight gain of 5,000 ppm males and body weight gain of 3,000 ppm males were significantly less than those of the controls. Water consumption by the 1,500, 3,000, and 5,000 ppm male groups was slightly less than that by the controls at week 13. Drinking water concentrations of 375, 750, 1,500, 3,000, or 5,000 ppm sodium nitrite resulted in average daily doses of approximately 90, 190, 345, 650, or 990 mg/kg to males and 120, 240, 445, 840, or 1,230 mg/kg to females. There were no chemical-

related clinical findings; no cyanosis or brownish discoloration was observed.

Relative spleen weights of 3,000 and 5,000 ppm males and absolute and relative heart, kidney, liver, and spleen weights of females exposed to 3,000 or 5,000 ppm were greater than those of the control groups (Table G2).

Sperm motility in 5,000 ppm males was decreased relative to the controls (Table H3), and the estrous cycles of 1,500 and 5,000 ppm females were significantly longer than that of the controls (Table H4).

 TABLE 13

 Survival, Body Weights, and Water Consumption of Mice in the 14-Week Drinking Water Study of Sodium Nitrite

Dose	Survival ^a	M 	ean Body Weight ^b (g	Final Weight Relative	Water Consumption ^c		
(ppm)		mua	Final	Change	to Controls (%)	Week 2	Week 13
Male							
0	10/10	21.4 ± 0.4	33.6 ± 0.9	12.2 ± 0.7		6.8	5.4
375	10/10	21.3 ± 0.4	33.9 ± 0.8	12.6 ± 0.5	101	10.4	4.9
750	10/10	21.3 ± 0.4	33.0 ± 0.6	11.7 ± 0.4	98	9.4	5.7
1,500	10/10	21.4 ± 0.4	33.1 ± 1.0	11.7 ± 0.6	99	10.1	5.1
3,000	10/10	21.5 ± 0.3	31.6 ± 1.0	$10.1 \pm 0.7*$	94	8.4	4.9
5,000	10/10	21.5 ± 0.4	30.3 ± 0.7**	$8.8 \pm 0.3 **$	90	7.1	5.0
Female							
0	10/10	18.0 ± 0.2	29.9 ± 0.9	12.0 ± 0.7		9.5	6.7
375	10/10	18.0 ± 0.4	30.7 ± 1.1	12.7 ± 0.9	103	10.1	5.9
750	10/10	17.7 ± 0.3	30.3 ± 1.2	12.6 ± 1.0	101	10.1	6.7
1,500	10/10	18.0 ± 0.4	30.8 ± 1.1	12.8 ± 0.9	103	9.6	6.1
3,000	10/10	18.0 ± 0.4	30.4 ± 1.0	12.4 ± 0.7	102	8.4	6.7
5,000	10/10	18.1 ± 0.4	27.3 ± 0.6	9.2 ± 0.5	91	6.8	6.6

* Significantly different (P≤0.05) from the control group by Williams' or Dunnett's test

** P≤0.01

^a Number of animals surviving at 14 weeks/number initially in group

Weights and weight changes are given as mean \pm standard error.

Water consumption is expressed as grams per animal per day.

Compared to the controls, there were increased incidences of microscopic lesions of the forestomach, spleen, and testis in exposed mice (Table 14). The incidences of squamous cell hyperplasia (focal) of the forestomach at the limiting ridge in 5,000 ppm males and females were significantly greater than those in the control groups. The severity of forestomach hyperplasia ranged from minimal to mild. The lesion was characterized by a focal increase in the thickness of all cell layers of the squamous epithelium. Minimal hyperkeratosis was associated with the hyperplasia and was characterized by thickening of the cornified layer and fraying of the outermost portion.

The incidences of extramedullary hematopoiesis in the spleen of 3,000 and 5,000 ppm males and females exposed to 1,500 ppm or greater were significantly greater than those in the control groups (Table 14). The severity of extramedullary hematopoiesis was minimal to mild, and the lesion was characterized by larger and more numerous clusters of small, dark hematopoietic cells in the red pulp.

The incidences of degeneration of the testis in 3,000 and 5,000 ppm males were significantly greater

than that in the control group (Table 14). Testicular degeneration was minimal to mild and was characterized by an increase in the size of residual bodies within the lumen of seminiferous tubules. Compared to the controls, in which the residual bodies were generally small, dark-staining cytoplasmic fragments, the residual bodies in exposed mice were typically large and spherical with glassy, eosinophilic staining and a smudged, basophilic core. The significance of the testicular degeneration was uncertain; degeneration may have been the result of a Sertoli cell defect in the processing of residual bodies.

Exposure Concentration Selection Rationale: Based on decreased body weights of males exposed to 5,000 ppm, increased incidences and severities of forestomach hyperplasia and spleen extramedullary hematopoiesis in males and females exposed to 5,000 ppm, and increased incidences of testicular degeneration in males exposed to 3,000 or 5,000 ppm, the sodium nitrite exposure concentrations selected for use in the 2-year drinking water study in mice were 750, 1,500, and 3,000 ppm.

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
Male						
Forestomach ^a Focal Hyperplasia ^b	10 0	<u>10</u> c	10	10	10 0	
Spleen Extramedullary Hematopoiesis	10 0	10	10	10 0	10 5* (1.0)	10 10** (1.8)
Testis Degeneration	10 0	10	10	10 0	10 9** (1.0)	10 9** (1.4)
Female						
Forestomach Focal Hyperplasia	10 0	10	10	10	10 0	10 6** (1.5)
Spleen Extramedullary Hematopoiesis	10 0	10	10 0	10 10** (1.0)	10 9** (1.6)	10 10** (1.8)

TABLE 14 Incidences of Selected Nonneoplastic Lesions in Mice in the 14-Week Drinking Water Study of Sodium Nitrite

* Significantly different (P \le 0.05) from the control group by the Fisher exact test

 $a^{**} P \le 0.01$

Number of animals necropsied b

Number of animals with lesion c

d

Organ not examined microscopically Average severity grade of lesions in affected animals: 1=minimal, 2=mild, 3=moderate, 4=marked

2-YEAR STUDY

Survival

Estimates of 2-year survival probabilities for male and female mice are shown in Table 15 and in the Kaplan-Meier survival curves (Figure 3). Survival of exposed groups was similar to that of the controls.

Body Weights, Water and Compound Consumption, and Clinical Findings

Mean body weights of exposed groups were generally similar to those of the controls throughout the study,

except mean body weights of 3,000 ppm females were consistently less than those of the controls (Figure 4 and Tables 16 and 17). Water consumption by the exposed groups was generally less than that by the control groups (Tables K3 and K4). Drinking water concentrations of 750, 1,500, or 3,000 ppm resulted in average daily doses of approximately 60, 120, or 220 mg/kg for males and 45, 90, or 165 mg/kg for females. There were no clinical findings related to exposure to sodium nitrite.

 TABLE 15

 Survival of Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Male				
Animals initially in study	50	50	50	50
Aoribund	3	2	3	1
Vatural deaths	8	3	5	10
animals surviving to study termination	39	45	42	39
Percent probability of survival at end of study ^a		90	84	78
Mean survival (days) ^b	708	713	713	699
Survival analysis ^c	P=0.659	P=0.199N	P=0.616N	P=1.000
emale				
Animals initially in study	50	50	50	50
Aoribund	1	7	2	4
Vatural deaths	9	9	11	5
animals surviving to study termination	40	34	37	41
ercent probability of survival at end of study	80	68	74	82
Mean survival (days)	702	704	709	705
Survival analysis	P=0.537N	P=0.340	P=0.721	P=0.963N

^a Kaplan-Meier determinations

^b Mean of all deaths (uncensored, censored, and terminal sacrifice)

^c The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposed group columns. A negative trend or lower mortality in an exposure group is indicated by **N**.




FIGURE 3 Kaplan-Meier Survival Curves for Male and Female Mice Exposed to Sodium Nitrite in Feed for 2 Years




FIGURE 4 Growth Curves for Male and Female Mice Exposed to Sodium Nitrite in Feed for 2 Years

TABLE 16

Mean Body Weights and Survival of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite

Weeks on Study	0 ppm		750 ppm			1,500 ppm				3,000 ppn	3,000 ppm		
	Av. Wt. (g)	No. of Survivors	Av. Wt. (g)	Wt. (% of controls)	No. of Survivors	Av. Wt. (g)	Wt. (% of controls)	No. of Survivors	Av. Wt. (g)	Wt. (% of controls)			
1	22.6	50	22.7	100	50	22.6	100	50	22.6	100	50		
2	23.7	50	23.7	100	50	23.6	100	50	23.4	99	50		
6	29.5	50	29.6	100	50	29.1	99	50	28.3	96	50		
10	34.9	50	34.5	99	50	33.7	97	50	32.7	94	50		
14	39.1	50	38.9	100	50	37.7	96	50	36.2	93	50		
18	43.2	50	42.9	99	50	41.9	97	50	40.2	93	50		
22	45.6	50	44.9	99	50	44.0	97	50	42.1	92	50		
26	47.5	50	46.6	98	50	45.7	96	50	44.6	94	50		
30	49.6	50	48.9	99	50	48.3	97	50	46.9	95	50		
34	50.8	50	50.1	99	50	49.2	97	50	48.4	95	50		
38	50.6	50	49.7	98	50	48.7	96	50	48.1	95	50		
42	50.9	50	49.9	98	50	48.4	95	50	48.6	96	50		
46	50.8	50	49.4	97	50	48.3	95	50	48.6	96	50		
50	50.3	50	49.0	97	50	48.0	95	50	48.3	96	50		
54	51.3	50	50.5	98	50	49.2	96	50	49.5	97	50		
58	51.1	50	49.6	97	50	49.3	97	50	49.8	98	50		
62	51.4	50	50.4	98	50	49.4	96	50	49.5	96	50		
66	50.7	50	49.8	98	49	49.0	97	50	48.8	96	50		
70	50.0	50	49.7	99	49	48.8	98	50	48.7	97	49		
73	49.4	49	49.5	100	49	48.8	99	50	48.1	97	48		
78	49.4	48	49.1	99	49	48.2	98	50	47.6	96	48		
82	48.7	48	48.4	99	49	48.2	99	50	46.6	96	46		
86	47.2	48	46.9	99	49	46.8	99	48	45.4	96	44		
90	46.4	47	46.4	100	47	46.1	99	48	44.7	96	44		
94	44.7	45	44.4	99	45	44.5	100	45	44.1	99	43		
98	43.0	43	43.7	102	45	43.6	101	43	42.8	100	41		
102	40.2	40	41.3	103	45	41.4	103	42	41.0	102	39		
Mean fo	or weeks												
1-13	27.7		27.6	100		27.3	99		26.8	97			
14-52	47.8		47.0	98		46.0	96		45.2	95			
53-102	48.0		47.7	99		47.2	98		46.7	97			

TABLE 17

Mean Body Weights and Survival of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite

Weeks on Study	0 ppm		750 ppm			1,500 ppm			3,000 ppm		
	Av. Wt. (g)	No. of Survivors	Av. Wt. (g)	Wt. (% of controls)	No. of Survivors	Av. Wt. (g)	Wt. (% of controls)	No. of Survivors	Av. Wt. (g)	Wt. (% of controls)	
1	18.9	50	18.9	100	50	18.8	100	50	18.9	100	50
2	19.4	50	19.7	102	50	19.5	101	50	19.4	100	50
6	23.7	50	23.9	101	50	23.9	101	50	23.2	98	50
10	28.2	50	28.4	101	50	28.2	100	50	26.9	95	50
14	31.4	50	32.6	104	50	31.5	100	50	30.3	97	50
18	35.6	50	37.8	106	50	36.5	103	50	34.4	97	50
22	40.0	50	41.7	104	50	40.6	102	50	38.2	96	50
26	43.2	50	44.9	104	50	43.7	101	50	41.1	95	50
30	46.6	50	47.4	102	50	46.2	99	50	43.3	93	50
34	49.2	50	49.6	101	50	48.8	99	50	45.4	92	50
38	51.1	50	51.1	100	50	50.0	98	50	46.9	92	50
42	53.4	50	53.3	100	50	52.3	98	50	48.8	91	50
46	54.2	50	54.6	101	50	54.0	100	50	50.8	94	50
50	55.3	50	55.6	101	50	54.8	99	50	52.5	95	50
54	56.1	50	55.3	99	50	55.2	98	50	53.0	95	50
58	56.7	50	57.0	101	50	56.6	100	50	54.2	96	50
62	58.8	50	58.2	99	50	58.4	99	50	56.1	95	49
66	58.3	49	57.5	99	50	57.4	99	50	55.4	95	49
70	57.7	49	56.8	98	49	56.5	98	49	54.4	94	48
73	56.1	49	56.1	100	49	55.0	98	49	53.7	96	48
78	55.5	49	56.3	101	49	55.0	99	48	53.8	97	47
82	55.0	47	55.6	101	49	54.2	99	48	54.2	99	46
86	53.5	45	53.7	100	49	53.5	100	48	53.2	99	46
90	52.6	43	52.8	100	48	53.1	101	45	51.2	97	46
94	52.1	42	52.1	100	43	52.3	100	45	49.6	95	46
98	52.0	41	51.4	99	37	51.4	99	44	49.3	95	44
102	51.1	41	50.7	99	35	50.7	99	41	48.9	96	41
Mean fo	or weeks										
1-13	22.6		22.7	100		22.6	100		22.1	98	
14-52	46.0		46.9	102		45.8	100		43.2	94	
53-102	55.0		54.9	100		54.6	99		52.8	96	

Determinations of Plasma Nitrite and Blood Methemoglobin Concentrations

At 12 months, no nitrite was detected in the plasma of control or 750 ppm male mice (Table I7) or in any group of female mice (data not shown). In general, there was an exposure concentration-related increase in plasma nitrite in the 1,500 and 3,000 ppm male mice; peak plasma nitrite concentrations occurred around midnight. Blood methemoglobin concentrations were similar among exposed groups of males and females (Tables I7 and I8).

Pathology and Statistical Analyses

This section describes the statistically significant or biologically noteworthy changes in the incidences of neoplasms and/or nonneoplastic lesions of the forestomach, glandular stomach, lung, and skin. Summaries of the incidences of neoplasms and nonneoplastic lesions, individual animal tumor diagnoses, statistical analyses of primary neoplasms that occurred with an incidence of at least 5% in at least one animal group, and historical incidences for the neoplasms mentioned in this section are presented in Appendix C for male mice and Appendix D for female mice.

Forestomach: The incidences of squamous cell papilloma or carcinoma (combined) in female mice occurred with a positive trend, and the incidence in 3,000 ppm females exceeded the historical range for NTP controls given NTP-2000 diet (all routes)

(Tables 18, D3, and D4) or NIH-07 diet (drinking water route) (range 0%-4%; Table D4). Because both of these historical databases are rather small, the historical incidences of forestomach squamous cell papilloma or carcinoma (combined) in NTP controls given NIH-07 diet in studies with other routes of chemical administration were evaluated, such as feed controls and inhalation controls (Table D4). The incidence of squamous cell papilloma or carcinoma (combined) in the 3,000 ppm females exceeded these historical incidences with the exception of corn oil gavage studies, where as many as five papillomas, but no carcinomas, were observed in one control group. Hyperplasia of the squamous epithelium was observed more frequently in 3,000 ppm females than in the controls (Table 18). Forestomach neoplasms were not observed in male mice exposed to sodium nitrite. Proliferative lesions involving the squamous epithelium represent a continuum, progressing from focal hyperplasia to papilloma to squamous cell carcinoma. Hyperplasia was generally a mild change affecting the squamous epithelium of the limiting ridge at the junction of the forestomach and glandular stomach. Papillomas (Plate 3) consisted of a solitary stalk of lamina propria protruding into the lumen with multiple finger-like projections arising from the stalk. The epithelium covering the projections was hyperplastic. In carcinomas, there was a focal invasion of the squamous epithelium into the lamina propria; however, there was no infiltration of neoplastic cells through the serosa of the forestomach, and there was no metastasis.

TABLE 18

Incidences of Neoplasms and Nonneoplastic Lesions of the Forestomach and Glandular Stomach
in Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Female				
Forestomach ^a	50	50	50	50
Epithelium, Hyperplasia ^b	2 $(2.5)^{c}$	3 (2.0)	3 (2.0)	6 (2.5)
Squamous Cell Papilloma	1	0	1	3
Squamous Cell Carcinoma	0	0	0	2
Squamous Cell Papilloma or Carcinoma ^d				
Overall rate ^e	1/50 (2%)	0/50 (0%)	1/50 (2%)	5/50 (10%)
Adjusted rate ¹	2.2%	0.0%	2.1%	10.7%
Terminal rate ^g	1/40 (3%)	0/34 (0%)	1/37 (3%)	4/41 (10%)
First incidence (days)	728 (T)	1	728 (T)	708
Poly-3 test ⁿ	P=0.011	P=0.500N	P=0.756N	P=0.106
Aale				
Glandular Stomach	50	50	50	50
Epithelium, Hyperplasia	0	0	2 (1.5)	10** (2.0)

** Significantly different (P≤0.01) from the control group by the Poly-3 test

(T)Terminal sacrifice

h Number of animals necropsied

Number of animals with lesion

Average severity grade of lesions in affected animals: 1=minimal, 2=mild, 3=moderate, 4=marked.

Historical incidence for 2-year studies with control groups given NTP-2000 feed (mean \pm standard deviation): 2/250 (0.8% \pm 1.1%); range, e 0%-2%

f Number of animals with neoplasm per number of animals necropsied

Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

^g Observed incidence at terminal kill

h Beneath the control incidence is the P value associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A lower incidence in an exposure group is indicated by N.

¹ Not applicable; no neoplasms in animal group

Glandular Stomach: The incidence of epithelial hyperplasia was significantly greater in 3,000 ppm males than in the controls (Table 18). Hyperplasia of the glandular stomach epithelium was focally extensive and was characterized by a distorted and irregular arrangement of the glandular elements of the gastric mucosa. In the hyperplastic areas, the proportion of the gastric glands with mucus-secreting cells was reduced to 25% compared to 50% in the normal area (Plates 4 and 5). In addition, the parietal cells in the mid portion of the gastric glands were less distinct in the hyperplastic areas. Instead of large, cuboidal cells with eosinophilic cytoplasm (characteristic of normal parietal cells), the parietal cell area tended to be composed of smaller, elongated, basophilic cells with

vesiculated, fusiform nuclei and relatively scant cytoplasm consistent with chief cells (Plate 6). There were no neoplasms of the glandular stomach.

Lung: The incidences of alveolar/bronchiolar adenoma or carcinoma (combined) in exposed groups of females were slightly greater than that in the control group. (1/50, 6/50, 5/50, 6/50; Table D3). However, the incidences of these lesions were within the historical range for controls (all routes) given NTP-2000 diet [17/250 ($6.8\% \pm 5.6\%$), range 0%-12%]. The increased incidences were not statistically significant or exposure concentration related and were not accompanied by increased incidences of preneoplastic lesions; therefore, the lung neoplasms in exposed females were not

considered to be related to sodium nitrite exposure.

Skin: The incidence of fibrosarcoma in 750 ppm females was significantly greater than that in the controls (0 ppm, 0/50; 750 ppm, 5/50; 1,500 ppm, 1/50; 3,000 ppm, 2/50; Table D3). The incidence exceeded the historical range for NTP controls (all routes) given NTP-2000 diet [3/250 ($1.2\% \pm 1.8\%$), range 0%-4%]. The lack of a dose response for fibrosarcomas and the fact that the combined incidence of fibroma or fibrosarcoma (0/50, 5/50, 1/50, 3/50) fell within the historical range for NTP controls given NTP-2000 diet suggest that these neoplasms were not related to sodium nitrite exposure. The most frequent spontaneous mesenchymal neoplasms of the subcutaneous skin in female mice in the order of occurrence were fibrosarcomas, sarcomas, and lipomas.

GENETIC TOXICOLOGY

Sodium nitrite (100-10,000 μ g/plate) was mutagenic in *Salmonella typhimurium* strain TA100, with and without Aroclor 1254-induced hamster and rat liver S9 enzymes; no mutagenicity was observed in strain TA98 (Table E1; Zeiger *et al.*, 1992). When sodium nitrite

was administered by intraperitoneal injection at 6.25 to 200 mg/kg to male rats three times at 24-hour intervals, no significant increase in the frequency of micronucleated polychromatic erythrocytes was observed in any of the dose groups (Table E2). The initial trial was judged to be positive, based on the trend test (P=0.001); however, results of a repeat trial, in which 50 mg/kg was the highest nonlethal dose tested, were negative, and the rat bone marrow micronucleus test with sodium nitrite was judged to be negative overall. A similar study in which male mice were administered 7.81 to 250 mg/kg also gave negative results (Table E3). A third in vivo study, a peripheral blood micronucleus test in male and female mice administered sodium nitrite (375 to 5,000 ppm) for 14 weeks, showed no significant increase in the frequency of micronucleated normochromatic erythrocytes in either males or females (Table E4). Thus, sodium nitrite demonstrated mutagenic activity in a strain of S. typhimurium that mutates via base-pair substitution, but no indication of chromosomal damage was observed in three micronucleus studies conducted in rats and mice in vivo.

DISCUSSION AND CONCLUSIONS

Sodium nitrite is used as a color fixative and preservative in meats and fish. It is also used in manufacturing diazo dyes, nitroso compounds, and other organic compounds; in dyeing and printing textile fabrics; and in bleaching fibers; in photography; as a laboratory reagent and a corrosion inhibitor; in metal coatings for phosphatizing and detinning; and in the manufacture of rubber chemicals. Sodium nitrite also has been used in human and veterinary medicine as a vasodilator, a bronchial dilator, an intestinal relaxant, and an antidote for cyanide poisoning. Sodium nitrite was nominated for toxicity and carcinogenesis studies by the FDA based on its widespread use and because many nitroso compounds are carcinogenic.

In the 14-week studies, survival of rats exposed to sodium nitrite was not affected. Rats exposed to 3,000 or 5,000 ppm showed reduced body weight gains and water consumption. It is likely that animals that do not drink do not eat; therefore, reduced water consumption may have contributed to the reduction in body weight gains through decreased feed consumption. The possibility of decreased feed consumption is supported by the transient decreases in the serum activities of alkaline phosphatase. It has been demonstrated that the intestinal alkaline phosphatase isoenzyme is a major component of rat serum alkaline phosphatase activity (Righetti and Kaplan, 1971) and that fasting or feed restriction causes decreases in serum alkaline phosphatase activity (Jenkins and Robinson, 1975; Imai et al., 1991). Thus, the decreases in alkaline phosphatase activity could be related to a loss of the normal circulating intestinal fraction as a result of decreased feed consumption early in the study. In another study, Til et al. (1997) administered sodium nitrite in drinking water to male and female Wistar rats at 81 or 2,432 mg/L (81 or 2,432 ppm) for 13 weeks. The authors reported reduced water consumption in the 2,432 mg/L group but reported no changes in body weights or feed consumption. Apparently, the drinking water became unpalatable with high sodium nitrite content.

A treatment-related increase in methemoglobin concentrations was a prominent finding in the sodium nitrite-exposed rats. This effect occurred by day 5 and continued throughout the study; a no-observed-adverseeffect level was not determined for methemoglobin formation in male or female animals. Development of methemoglobinemia has been reported for rats (Chow et al., 1980; Til et al., 1997) and other species (Bruning-Fann and Kaneene, 1993) administered sodium nitrite. The production of methemoglobin would be consistent with oxidative injury to erythrocytes (Smith and Beutler, 1966) and could account for the increased numbers of Heinz bodies observed on day 5 in 5,000 ppm male and female rats. It has been demonstrated that as the glutathione concentration is depleted in the cell, globin sulfhydryl groups become susceptible to oxidation (Berzofsky et al., 1971; Rachmilewitz, 1974). Thus, the maintenance of adequate red cell glutathione concentrations in the exposed animals' erythrocytes in this study may account for the lack of a stronger Heinz body effect.

Cvanosis or brownish discoloration of mucous membranes and skin occurred in the 1,500 ppm female and 3,000 and 5,000 ppm male and female rats in the 14-week study; this finding was considered to be consistent with sodium nitrite exposure and methemoglobin formation. In studies with pigs, it has been reported that clinical findings become apparent when the methemoglobin concentration reaches 20% of the total hemoglobin content, but fatalities do not occur until a concentration of greater than 75% methemoglobin is achieved (London et al., 1967). In the present study, depending on the gender and sampling time, the percentage of methemoglobin varied from approximately 0.5% to 13% for the 1,500 ppm groups, 5% to 24% for the 3,000 ppm groups and 13% to 50% for the 5,000 ppm groups. This suggests that biologically significant exposure concentration-related increases in methemoglobin concentration were induced, but the percentages of methemoglobin did not achieve lethal levels. In general, female rats had higher methemoglobin concentrations than male rats, which may be related to a higher sodium nitrite consumption by the females. There were increased erythrocyte counts on day 19 and an increased erythron at week 14 in the 3,000 and 5,000 ppm male and female rats. Because methemoglobin cannot bind oxygen, a

consequence of increased methemoglobin formation would include hypoxia (Jain, 1986a; Harvey, 1989). A secondary polycythemia may result from increased erythropoiesis as a compensatory physiological response to tissue hypoxia and the resultant increased production of erythropoietin (Jain, 1986b). The elevated reticulocyte and nucleated erythrocyte counts and bone marrow erythroid hyperplasia observed would be consistent with increased erythropoietic activity related to hypoxia and would account for the increased erythron.

Because reticulocytes are larger than mature red cells, the increased mean cell volume and mean cell hemoglobin values that occurred at week 14 would be consistent with reticulocytosis. This explanation, however, would suggest that the mean cell volumes and mean cell hemoglobin values also should have increased for affected animals on days 5 and 19. This did not happen, and the mean cell volume and mean cell hemoglobin values for the 5,000 ppm animals decreased on day 19. This suggests that more than one mechanism affected red cell size, that the factor(s) resulting in small cells had more influence at the early time points, and that this effect abated with time. Additionally, while the magnitude of methemoglobinemia remained fairly constant for the 5,000 ppm groups, the magnitude of the erythropoietic response appeared to diminish with time. The mechanism for this amelioration is unknown but may reflect an acclimation of the animals to lower tissue oxygen concentrations. Additionally, it has been reported that nitrate administration has goitrogenic activity in rats (Bruning-Fann and Kaneene, 1993). If nitrite administration had a similar action in the present study, it may have altered the basal metabolic rate of rats through altered thyroid gland function.

A transient increase in platelet counts occurred in 5,000 ppm male and female rats in the 14-week study. The mechanism for the platelet count alterations is unknown. However, it has been reported that nitric oxide, nitrate, and peroxynitrites inhibit platelet aggregation (Torfgoard and Ahlner, 1994; Brown *et al.*, 1998) and that nitric oxide administration may cause increased platelet counts in humans (Mellgren *et al.*, 1998).

Nitrite and nitrate are end-products of nitric oxide metabolism. Thus, administration of nitrite may have altered nitric oxide metabolism, which may have contributed to the increase in platelet counts.

In the 14-week study, survival of exposed mice was not affected. Male mice exposed to 5,000 ppm had reduced body weight gains. The brownish discoloration and cyanosis seen in rats were not observed in mice. Mice may have a higher erythrocyte methemoglobin reductase activity than do rats (Smith and Beutler, 1966), and this may, in part, help explain the observed difference between rats and mice. Increased relative spleen weights occurred in the 3,000 and 5,000 ppm male and female mice, and increased splenic extramedullary hematopoiesis was observed. Since the spleen is an erythropoietically active tissue in adult mice (Brodsky et al., 1966), the splenic extramedullary hematopoiesis observed in mice would be consistent with methemoglobin formation and tissue hypoxia. In another study, Inai et al. (1979) reported hemosiderin deposition in the liver, spleen, and lymph nodes of ICR mice exposed to sodium nitrite in drinking water and suggested that a hemolytic event had occurred. No hemosiderin deposition was observed in the present studies.

In the 14-week studies, increased incidences of focal forestomach hyperplasia occurred in the 5,000 ppm male and female rats and mice. *N*-Nitroso compounds were not detected in the stomach contents of exposed rats. Evidence of cytotoxicity (necrosis or inflammation) of the forestomach was not observed. Yoshida *et al.* (1994) also observed that male Fischer rats administered sodium nitrite at 0.3% (3,000 ppm) in drinking water for 4 weeks had significantly increased incidences of hyperplasia of the mucosa in the forestomach and increased BrdU-labeling indices of the forestomach and glandular stomach. The mechanism of action of sodium nitrite in inducing forestomach hyperplasia is unknown.

In the 14-week studies, exposure to 3,000 or 5,000 ppm induced testicular degeneration in male mice; exposure to 5,000 ppm reduced sperm motility in male rats and mice and increased estrous cycle lengths in female mice. Further investigation by continuous breeding studies in Swiss mice showed no reproductive toxicity of sodium nitrite (NTP, unpublished data).

In the 2-year studies, survival of exposed rats was similar to that of the controls. Body weights were less than those of the controls in male and female rats exposed to 3,000 ppm. This finding agrees with that of Maekawa *et al.* (1982), who reported lower body weight gains in F344 rats exposed to 0.25% (2,500 ppm) sodium nitrite in drinking water for

2 years. The reduced body weights were probably related to lower water consumption as in the 14-week studies.

Exposure to 3,000 ppm sodium nitrite for 2 years induced hyperplasia of the forestomach epithelium in male and female rats. The results agree with Maekawa et al. (1982) who reported no increased neoplasm incidences in F344 rats given 0.25% (2,500 ppm) sodium nitrite for 2 years, and Garcia and Lijinsky (1973) reported no tumor induction in MRC Wistar rats exposed to 2 g/L (2,000 ppm) sodium nitrite in drinking water for 2 years. In contrast, Mirvish et al. (1980) reported that MRC Wistar rats exposed to 3.0 g/L (3,000 ppm) sodium nitrite in drinking water for life developed squamous papillomas of the forestomach, and Lijinsky et al. (1983) reported induction of hepatocellular neoplasms in female F344 rats exposed to 2,000 ppm in drinking water for 104 weeks and sacrificed at 127 to 130 weeks. It should be noted that the animals in the latter studies were kept longer than 2 years. In a multi-organ carcinogenesis model, male F344 rats pretreated with carcinogens and then given 0.3% (3,000 ppm) sodium nitrite in drinking water until week 28 exhibited an increased incidence of neoplasms in the forestomach (Hirose et al., 1993). The authors concluded that sodium nitrite promoted the development of forestomach neoplasms. Together, the data appear to indicate that sodium nitrite is a weak carcinogen, requiring more than a 2-year exposure period to express fully its carcinogenic activity in rats.

There was a significant increase in the incidence of fibroadenomas in the mammary gland of female rats exposed to 1,500 ppm sodium nitrite for 2 years. However, no increase occurred in the 3,000 ppm group and no concomitant increase in the incidences of adenomas or carcinomas was observed. Given the high background incidence (concurrent and historical control incidences) of fibroadenomas, the incidence in the 1,500 ppm group was not considered treatment related.

Maekawa *et al.* (1982) reported that F344 rats administered 0.125% (1,250 ppm) or 0.25% (2,500 ppm) sodium nitrite in drinking water for 2 years had lower incidences of mononuclear cell leukemia than the controls. The authors attributed the reduced incidences of mononuclear cell leukemia to a slight atrophy of the hematopoietic organs. Lijinsky *et al.* (1983) also reported a reduction in the incidences of mononuclear cell leukemia in F344 rats exposed to 2,000 ppm sodium nitrite in drinking water. Dietary administration of sodium nitrite at 0.2% (2,000 ppm) or 0.5% (5,000 ppm) to male F344 rats also induced exposure-related decreases in the incidences and lengthened the time of onset of lymphomas, leukemias, and testicular interstitial cell tumors (Grant and Butler, 1989). Body weights of rats exposed to sodium nitrite were also lower than those of the controls. Elwell et al. (1996) cited splenic toxicity, methemoglobinemia, and Heinz body formation as factors that may be related to the reduced incidences of mononuclear cell leukemia in F344 rats. The present studies showed significant increases in methemoglobin concentrations (14-week studies) and decreased incidences of mononuclear cell leukemia (2-year studies) in male and female rats exposed to 1,500 or 3,000 ppm sodium nitrite; toxic injury or atrophy of the spleen was not detected. Microscopic examination at 14 weeks showed treatment-related hematopoietic activity in the bone marrow of male and female rats. The increased methemoglobin concentrations and lower body weights of the exposed rats may be factors in the reduced incidences of mononuclear cell leukemia.

Exposure to 3,000 ppm sodium nitrite for 2 years was associated with a positive trend in the incidences of squamous cell papilloma or carcinoma (combined) in the forestomach of female mice which may have been related to exposure to sodium nitrite. The 10% incidence of squamous cell papilloma or carcinoma (combined) in the 3,000 ppm group fell outside the upper end of the historical range of 4% for forestomach neoplasms. In addition, the finding of two squamous cell carcinomas in the 3,000 ppm group was supportive of a chemical-related effect because forestomach carcinomas are rarely observed in controls in drinking water studies. In NTP drinking water studies, no forestomach carcinomas were seen in 340 female mice given NIH-07 diet; forestomach carcinoma was observed in 1 of 250 control females given NTP-2000 diet. Although increased incidences of forestomach neoplasms were not observed in exposed rats or male mice, the forestomach was clearly a target organ because hyperplasia was observed in both rats and mice in the 14-week studies and in rats in the 2-year study. Interestingly, although forestomach hyperplasia was not observed in male mice in the 2-year study, hyper-plasia of the glandular epithelium of the stomach was seen in 3,000 ppm males. In contrast, Inai et al. (1979) reported no increase in the incidence of forestomach

tumors in ICR mice exposed to sodium nitrite at up to 0.5% (5,000 ppm) in drinking water for 109 weeks.

Genotoxic carcinogens such as methylnitrosourea and 7,12-dimethylbenz[a]anthracene reportedly interact directly with DNA in forestomach carcinogenesis (Kroes and Wester, 1986; Doi et al., 1994; Masui et al., 1997). Cytotoxicity and sustained cell proliferation have been suggested to play a role in the induction of forestomach neoplasms by nongenotoxic carcinogens such as butylated hydroxyanisole and ethyl acrylate (Ghanayem et al., 1986; Clayson et al., 1991; Ito et al., 1993; Benford et al., 1994). Sodium nitrite is mutagenic in Salmonella assays, but evidence of cytotoxicity (necrosis or inflammation) of the forestomach at earlier time points in this study was not observed. The mechanism of action of sodium nitrite in the development of forestomach neoplasms in 3,000 ppm mice is unclear and needs to be investigated further.

Mirvish (1995) reported that ingested sodium nitrite is converted to nitrous acid (HNO₂) by gastric acid, which dimerizes (with loss of water) to give dinitrogentrioxide (N_2O_3) . This intermediate reacts with secondary amines and amides, producing carcinogenic N-nitroso compounds. The rate-limiting factor for nitrosation is the concentration of secondary amines or amides (Greenblatt and Mirvish, 1973). The NTP-2000 diet contains about 13.8% protein by weight, of which 4% is fish meal. Previously, NTP studies used NIH-07 diet containing 22.8% protein by weight, of which 10% was fish meal. It should be noted that fish meal is reported to contain high amounts of amines (Singer and Lijinsky, 1976; Groenen et al., 1982). No Nnitrosocompounds were detected in the stomach contents in the present studies. The lower protein and fish meal content in the NTP-2000 diet may have limited the production of the carcinogenic N-nitroso compounds in the stomach. The assumption was supported by Furukawa et al. (2000), who reported increased renal carcinogenicity in F344 rats given a diet containing 32% and 64% fish meal together with 0.12% sodium nitrite in drinking water. No increased carcinogenicity was found in rats fed 8% fish meal and 0.12% sodium nitrite in drinking water. Mirvish (1975) estimated that the intragastric nitrosation rate is proportional to the square of the nitrite concentration. Accordingly, doubling the nitrite concentration in drinking water, as in the present studies (750, 1,500 and 3,000 ppm), should not lead to a dramatic increase in nitrosation. In addition, because in vivo nitrosation can be inhibited by vitamins C and E (Tannenbaum, 1988; Hecht, 1997), the roles of these vitamins in the rodent bioassay system are not known.

Sodium nitrite was mutagenic in *Salmonella typhimurium* strain TA100, with and without Aroclor 1254-induced hamster and rat liver S9 enzymes; no mutagenicity was observed in strain TA98. The results of acute bone marrow micronucleus tests in male rats and mice with sodium nitrite administered by intraperitoneal injection were negative. In addition, a peripheral blood micronucleus assay conducted using mice from the 14-week study gave negative results.

CONCLUSIONS

Under the conditions of this 2-year drinking water study, there was *no evidence of carcinogenic activity** of sodium nitrite in male or female F344/N rats exposed to 750, 1,500, or 3,000 ppm. There was *no*

evidence of carcinogenic activity of sodium nitrite in male $B6C3F_1$ mice exposed to 750, 1,500, or 3,000 ppm. There was equivocal evidence of carcinogenic activity of sodium nitrite in female $B6C3F_1$ mice based on the positive trend in the incidences of squamous cell papilloma or carcinoma (combined) of the forestomach.

Exposure to sodium nitrite in drinking water resulted in increased incidences of epithelial hyperplasia in the forestomach of male and female rats and in the glandular stomach of male mice.

Decreased incidences of mononuclear cell leukemia occurred in male and female rats.

^{*} Explanation of Levels of Evidence of Carcinogenic Activity is on page 11. A summary of the Technical Reports Review Subcommittee comments and the public discussion on this Technical Report is on page 13.

REFERENCES

Abe, S., and Sasaki, M. (1977). Studies on chromosomal aberrations and sister chromatid exchanges induced by chemicals. *Proc. Jpn. Acad.* **53**, 46-49.

The Aldrich Library of FT-IR Spectra (1985). 1st ed. (C.J. Pouchert, Ed.), Vol. 1. Aldrich Chemical Company, Inc., Milwaukee, WI.

American Conference of Governmental Industrial Hygienists (ACGIH) (1999). 1999 TLVs[®] and BEIs[®]. Based on the Documentations for Threshold Limit Values for Chemical Substances and Physical Agents. Biological Exposure Indices. Cincinnati, OH.

Anderson, L.M., Giner-Sorolla, A., Haller, I.M., and Budinger, J.M. (1985). Effects of cimetidine, nitrite, cimetidine plus nitrite, and nitrosocimetidine on tumors in mice following transplacental plus chronic lifetime exposure. *Cancer Res.* **45**, 3561-3566.

Aoyagi, M., Matsukura, N., Uchida, E., Kawachi, T., Sugimura, T., Takayama, S., and Matsui, M. (1980). Induction of liver tumors in Wistar rats by sodium nitrite given in pellet diets. *JNCI* **65**, 411-414.

Archer, M.C. (1982). Hazards of nitrate, nitrite, and nitro compounds in human nutrition. In *Nutritional Toxicology* (J.N. Hathcock, Ed.), Vol. 1, pp. 327-381. Academic Press, San Diego, CA.

Ashby, J., and Tennant, R.W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. *Mutat. Res.* **257**, 229-306.

Bailer, A.J., and Portier, C.J. (1988). Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. *Biometrics* **44**, 417-431.

Balimandawa, M., de Meester, C., and Leonard, A. (1994). The mutagenicity of nitrite in the Salmonella/ microsome test system. *Mutat. Res.* **321**, 7-11.

Behroozi, K., Robinson, S., Gruener, N., and Shuval, H.I. (1972). The effect of chronic exposure to sodium nitrite on the electroencephalogram of rats. *Environ. Res.* **5**, 409-417.

Benford, D.J., Price, S.C., Lawrence, J.N., Grasso, P., and Bremmer, J.N. (1994). Investigations of the genotoxicity and cell proliferative activity of dichlorvos in mouse forestomach. *Toxicology* **92**, 203-215.

Berzofsky, J.A., Peisach, J., and Blumberg, W.E. (1971). Sulfheme proteins: Optical and magnetic properties of sulfmyoglobin and its derivatives. *J. Biol. Chem.* **246**, 3367-3377.

Biancifiori, C., Montesano, R., and Bolis, G.B. (1975). Indagini sulla cancerogenesi da sodio nitrito e/o etambutolo in topi Balb/c/Cb/Sc. *Lav. Ist. Anat. Istol. Patol. Perugia* **35**, 45-56.

Bieler, G.S., and Williams, R.L. (1993). Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity. *Biometrics* **49**, 793-801.

Boeing, H., Frentzel-Beyme, R., Berger, M., Berndt, V., Göres, W., Körner, M., Lohmeier, R., Menarcher, A., Männl, H.F.K., Meinhardt, M., Müller, R., Ostermeier, H., Paul, F., Schwemmle, K., Wagner, K.H., and Wahrendort, J. (1991). Casecontrol study of stomach cancer in Germany. *Int. J. Cancer* 47, 858-864.

Boorman, G.A., Montgomery, C.A., Jr., Eustis, S.L., Wolfe, M.J., McConnell, E.E., and Hardisty, J.F. (1985). Quality assurance in pathology for rodent carcinogenicity studies. In *Handbook of Carcinogen Testing* (H.A. Milman and E.K. Weisburger, Eds.), pp. 345-357. Noyes Publications, Park Ridge, NJ. Brambilla, G., Cavanna, M., Faggin, P., Maura, A., Pino, A., Ricci, R., and Robbiano, L. (1983). Genotoxic effects in rodents given high oral doses of ranitidine and sodium nitrite. *Carcinogenesis* **4**, 1281-1285.

Brams, A., Buchet, J.P., Crutzen-Fayt, M.C., De Meester, C., Lauwerys, R., and Leonard, A. (1987). A comparative study, with 40 chemicals, of the efficiency of the Salmonella assay and the SOS chromotest (kit procedure). *Toxicol. Lett.* **38**, 123-133.

Brodsky, I., Dennis, L.H., Kahn, S.B., and Brady, L.W. (1966). Normal mouse erythropoiesis I. The role of the spleen in mouse erythropoiesis. *Cancer Res.* **26**, 198-201.

Brown, A.S., Moro, M.A., Masse, J.M., Cramer, E.M., Radomski, M., and Darley-Usmar, V. (1998). Nitric oxide-dependent and independent effects on human platelets treated with peroxynitrite. *Cardiovasc. Res.* **40**, 380-388.

Bruning-Fann, C.S., and Kaneene, J.B. (1993). The effects of nitrate, nitrite, and N-nitroso compounds on animal health. *Vet. Hum. Toxicol.* **35**, 237-253.

Calabrese, E.J., Moore, G.S., and McCarthy, M.S. (1983). The effect of ascorbic acid on nitrite-induced methemoglobin formation in rats, sheep, and normal human erythrocytes. *Regul. Toxicol. Pharmacol.* **3**, 184-188.

Carmella, S.G., Borukhova, A., Desai, D., and Hecht, S.S. (1997). Evidence for endogenous formation of tobacco-specific nitrosamines in rats treated with tobacco alkaloids and sodium nitrite. *Carcinogenesis* **18**, 587-592.

Chapin, R.E., and Sloane, R.A. (1997). Reproductive assessment by continuous breeding: Evolving study design and summaries of ninety studies. Sodium Nitrite. *Environ. Health Perspect.* **105**, 345-347.

Chen, W., Weisburger, J.H., Fiala, E.S., Spratt, T.E., Carmella, S.G., Chen, D., and Hecht, S.S. (1996). Gastric carcinogenesis: 2-Chloro-4-methylthiobutanoic acid, a novel mutagen in salted, pickled Sanma hiraki fish, or similarly treated methionine. *Chem. Res. Toxicol.* **9**, 58-66. Chow, C.K., Chen, C.J., and Gairola, C. (1980). Effect of nitrate and nitrite in drinking water on rats. *Toxicol. Lett.* **6**, 199-206.

Clayson, D.B., Iverson, F., Nera, E.A., and Lok, E. (1991). Early indicators of potential neoplasia produced in the rat forestomach by non-genotoxic agents: The importance of induced cellular proliferation. *Mutat. Res.* **248**, 321-331.

Code of Federal Regulations (CFR) 21, Part 58.

Code of Federal Regulations (CFR) **21**, §§ 172.175, 172.177, 181.34, and 573.700.

Code of Federal Regulations (CFR) 40, Part 302.

Code of Federal Regulations (CFR) 49, §172.101

Cox, D.R. (1972). Regression models and life-tables. *J. R. Stat. Soc.* **B34**, 187-220.

Crawford, B.D. (1985). Perspectives on the somatic mutation model of carcinogenesis. In *Advances in Modern Environmental Toxicology. Mechanisms and Toxicity of Chemical Carcinogens and Mutagens* (M.A. Mehlman, W.G. Flamm, and R.J. Lorentzen, Eds.), pp. 13-59. Princeton Scientific Publishing Co., Inc., Princeton, NJ.

Darad, R., De, A.K., and Aiyar, A.S. (1983). Toxicity of nitrite and dimethylamine in rats. *Toxicol. Lett.* **17**, 125-130.

De Flora, S. (1981). Study of 106 organic and inorganic compounds in the *Salmonella*/microsome test. *Carcinogenesis* **2**, 283-298.

De Flora, S., Zanacchi, P., Camoirano, A., Bennicelli, C., and Badolati, G.S. (1984). Genotoxic activity and potency of 135 compounds in the Ames reversion test and in a bacterial DNA-repair test. *Mutat. Res.* **133**, 161-198.

Dixon, W.J., and Massey, F.J., Jr. (1951). *Introduction* to *Statistical Analysis*, 1st ed., pp. 145-147. McGraw-Hill Book Company, Inc., New York. Doi, S.-T., Kimura, M., and Katsuki, M. (1994). Sitespecific mutation of the human c-Ha-*ras* transgene induced by dimethylbenzanthracene causes tissuespecific tumors in mice. *Jpn. J. Cancer Res.* **85**, 801-807.

Dollahite, J.W., and Rowe, L.D. (1974). Nitrate and nitrite intoxication in rabbits and cattle. *Southwest. Vet.* **27**, 246-248.

Druckery, V.H., Steinhoff, D., Beuthner, H., Schneider, H., and Klärner, P. (1963). Screening of nitrite for chronic toxicity in rats. *Arzneimittelforschung* **13**, 320-323.

Dunn, O.J. (1964). Multiple comparisons using rank sums. *Technometrics* **6**, 241-252.

Dunnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. *J. Am. Stat. Assoc.* **50**, 1096-1121.

Ehrenberg, L., Hussain, S., Noor Saleh, M., and Lundquist, U. (1980). Nitrous esters—A genetical hazard from nitrogen oxides (NO_x)? *Hereditas* **92**, 127-130.

Ellis, M., Hiss, Y., and Shenkman, L. (1992). Fatal methemoglobinemia caused by inadvertent contamination of a laxative solution with sodium nitrite. *Isr. J. Med. Sci.* **28**, 289-291.

El Nahas, S.M., Globus, M., Vethamany-Globus, S. (1984). Chromosomal aberrations induced by sodium nitrite in bone marrow of adult rats and liver cells of transplacentally exposed embryos. *J. Toxicol. Environ. Health* **13**, 643-647.

Elwell, M.R., Dunnick, J.K., Hailey, J.R., and Haseman, J.K. (1996). Chemicals associated with decreases in the incidence of mononuclear cell leukemia in the Fischer rat. *Toxicol. Pathol.* **24**, 238-245.

Fahrig, R. (1979). Evidence that induction and suppression of mutations and recombination by chemical mutagens in *S. cerevisiae* during mitosis are jointly correlated. *Mol. Gen. Genet.* **168**, 125-139.

Fairbanks, V.F., and Klee, G.G. (1987). Biochemical aspects of hematology. In *Fundamentals of ClinicalChemistry*, 3rd ed. (N.W. Tietz, Ed.), pp. 789-824. W.B. Saunders Co., Philadelphia, PA.

Fine, D.H., and Rounbehler, D.P. (1975). Trace analysis of volatile N-nitroso compounds by combined gas chromotography and thermal energy analysis. *J. Chromatogr.* **109**, 271-279.

Fine, D.H., Ross, P., Rounbehler, D.P., Silvergleid, A., and Song, L. (1977). Formation in vivo of volatile N-nitrosamines in man after ingestion of cooked bacon and spinach. *Nature* **265**, 753-755.

Food and Drug Administration (FDA) (1980). Re-Evaluation of the Pathology Findings of Studies on Nitrite and Cancer: Histologic Lesions in Sprague-Dawley Rats. Final Report submitted by the Universities Associated for Research and Education in Pathology to the Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, Washington, DC.

Friedman, M.A., Greene, E.J., and Epstein, S.S. (1972). Rapid gastric absorption of sodium nitrite in mice. *J. Pharm. Sci.* **61**, 1492-1494.

Furukawa, F., Nishikawa, A., Ishiwata, H., Takahashi, M., Hayashi, Y., and Hirose, M. (2000). Renal carcinogenicity of concurrently administered fish meal and sodium nitrite in F344 rats. *Jpn. J. Cancer* **91**, 139-147.

Gangolli, S.D., van den Brandt, P.A., Feron, V.J., Janzowsky, C., Koeman, J.H., Speijers, G.J.A., Spiegelhalder, B., Walker, R., and Wishnok, J.S. (1994). Nitrate, nitrite, and *N*-nitroso compounds. *Europ. J. Pharmacol. Environ. Toxicol. Pharmacol. Section* **292**, 1-38.

Garcia, H., and Lijinsky, W. (1973). Studies of the tumorigenic effect in feeding of nitrosamino acids and of low doses of amines and nitrite to rats. *Z. Krebsforsch. Klin. Onkol. Cancer Res. Clin. Oncol.* **79**, 141-144.

Ghanayem, B.I., Maronpot, R.R., and Matthews, H.B. (1986). Association of chemically induced forestomach cell proliferation and carcinogenesis. *Cancer Lett.* **32**, 271-278.

Giri, A.K., Talukder, G., and Sharma, A. (1986). Sister chromatid exchange induced by metanil yellow and nitrite singly and in combination in vivo on mice. *Cancer Lett.* **31**, 299-303.

Globus, M., and Samuel, D. (1978). Effect of maternally administered sodium nitrite on hepatic erythropoiesis in fetal CD-1 mice. *Teratology* **18**, 367-378.

Gowans, W.J. (1990). Fatal methaemoglobinaemia in a dental nurse: A case of sodium nitrite poisoning. *Br. J. Gen. Pract.* **40**, 470-471.

Grant, D., and Butler, W.H. (1989). Chronic toxicity of sodium nitrite in the male F344 rat. *Food Chem. Toxicol.* **27**, 565-571.

Greenblatt, M., and Lijinsky, W. (1972). Failure to induce tumors in Swiss mice after concurrent administration of amino acids and sodium nitrite. *J. Natl. Cancer Inst.* **48**, 1389-1392.

Greenblatt, M., and Mirvish, S.S. (1973). Doseresponse studies with concurrent administration of piperazine and sodium nitrite to strain A mice. *J. Natl. Cancer Inst.* **50**, 119-124.

Greenblatt, M., Mirvish, S., and So, B.T. (1971). Nitrosamine studies: Induction of lung adenomas by concurrent administration of sodium nitrite and secondary amines in Swiss mice. *J. Natl. Cancer Inst.* **46**, 1029-1034.

Grimmelikhuijzen, C.J.P., and Slater, E.C. (1973). Antimycin-insensitive mutants of *Candida utilis*. I. Isolation and characterization of mutant 28. *Biochim. Biophys. Acta* **305**, 67-79.

Groenen, P.J., Luten, J.B., Dhont, J.H., de Cock-Bethbeder, M.W., Prins, L.A., and Vreeken, J.W. (1982). Formation of volatile *N*-nitrosamines from food products, especially fish, under simulated gastric conditions. *IARC Sci. Pub.* **41**, 99-112.

Grudzinski, I.P., and Law, F.C.P. (1998a). Induction of cell death in the intestinal crypt of mice following oral administration of nitrate and nitrite. *Bull. Environ. Contam. Toxicol.* **60**, 185-193.

Grudzinski, I.P., and Law, F.C.P. (1998b). Nitriteinduced cell proliferation and polyamine synthesis in the small intestine of mice. *Bull Environ. Contam. Toxicol.* **61**, 800-806.

Grudzinski, I., and Szymanski, A. (1991a). The effect of acute poisoning with potassium nitrate and sodium nitrite on the processes of intestinal absorption of D-xylose in rats. *Arch. Environ. Contam. Toxicol.* **21**, 453-461.

Grudzinski, I., and Szymanski, A. (1991b). The effect of subchronic poisoning with potassium nitrate and sodium nitrite on the processes of intestinal absorption of D-xylose in rats. *Arch. Environ. Contam. Toxicol.* **21**, 447-452.

Grudzinski, I., Szymanski, A., and Chomiczewski, K. (1991). The effect of exercise associated with subchronic poisoning with potassium nitrate and sodium nitrite on the processes of intestinal absorption of D-xylose in rats. *Arch. Environ. Contam. Toxicol.* **21**, 462-467.

Harvey, J.W. (1989). Erythrocyte metabolism. In *Clinical Biochemistry of Domestic Animals*, 4th ed. (J.J. Kaneko, Ed.), pp. 185-234. Academic Press, Inc., San Diego, CA.

Hecht, S. (1997). Approaches to cancer prevention based on an understanding of *N*-nitrosamine carcinogenesis. *Proc. Soc. Exp. Biol. Med.* **216**, 181-191.

Heisler, E.G., Siciliano, J., Krulick, S., Feinberg, J., and Schwartz, J.H. (1974). Changes in nitrate and nitrite content, and search for nitrosamines in storageabused spinach and beets. *J. Agric. Food Chem.* **22**, 1029-1032.

Hill, M.J., Hawksworth, G., and Tattersall, G. (1973). Bacteria, nitrosamines and cancer of the stomach. *Br. J. Cancer* **28**, 562-567.

Hirneth, H., and Classen, H.G. (1984). Inhibition of nitrate-induced increase of plasma nitrite and methemoglobin in rats by simultaneous feeding of ascorbic acid or tocopherol. *Arzneimittelforschung* **34**, 988-991.

Hirose, M., Tanaka, H., Takahashi, S., Futakuchi, M., Fukushima, S., and Ito, N. (1993). Effects of sodium nitrite and catechol, 3-methoxycatechol, or butylated hydroxyanisole in combination in a rat multiorgan carcinogenesis model. *Cancer Res.* **53**, 32-37.

Hlinak, Z., Krejci, I., Hondlik, J., and Yamamoto, A. (1990). Behavioral consequences of sodium nitrite hypoxia in male rats: Amelioration with alaptide treatment. *Methods Find. Exp. Clin. Pharmacol.* **12**, 385-393.

Hsu, J.-D., Hsu, C.-L., Chou, F.-P., Wen, P.H., and Wang, C.J. (1997). Potential effect of sodium nitrite on the expression of nuclear proto-oncogenes during 2-acetyl aminofluorene-induced hepatocarcinogenesis in rats. *Chem-Biol. Interact.* **108**, 1-18.

Ilnitsky, A.P., and Kolpakova, A.S. (1997). The enhancing effect of sodium nitrite on virus-induced leukemia in mice. *Cancer Detect. Prev.* **21**, 312-318.

Imai, K., Yoshimura, S., Hashimoto, K., and Boorman, G.A. (1991). Effects of dietary restriction on age-associated pathological changes in Fischer 344 rats. In *Biological Effects of Dietary Restriction* (L. Fishbein, Ed.), ILSI monograph, pp. 87-98. Springer-Verlag, New York.

Imaizumi, K., Tyuma, I., Imai, K., Kosaka, H., and Ueda, Y. (1980). In vivo studies on methemoglobin formation by sodium nitrite. *Int. Arch. Occup. Environ. Health* **45**, 97-104.

Inai, K., Aoki, Y., and Tokuoka, S. (1979). Chronic toxicity of sodium nitrite in mice, with reference to its tumorigenicity. *Gann* **70**, 203-208.

Inoue, K., Shibata, T., Kosaka, H., Uozumi, M., Tsuda, S., and Abe, T. (1985). Induction of sisterchromatid exchanges by *N*-nitrosocimetidine in cultured human lymphocytes and its inhibition by chemical compounds. *Mutat. Res.* **156**, 117-121. Integrated Laboratory Systems (ILS) (1990). Micronucleus Data Management and Statistical Analysis Software, Version 1.4. ILS, P.O. Box 13501, Research Triangle Park, NC 27707.

Inui, N., Nishi, Y., Taketomi, M., and Mori, M. (1979a). Transplacental action of sodium nitrite on embryonic cells of Syrian golden hamster. *Mutat. Res.* **66**, 149-158.

Inui, N., Nishi, Y., Mori, M., Taketomi, M., Yamamoto, M., and Tanimura, A. (1979b). Detection of 8 azaguanine resistant mutants of embryonic cells induced by products formed in the stomach on oral administration of sodium nitrite plus aminopyrine to pregnant golden hamsters. *Proc. Jpn. Acad.* **55**, 286-289.

Inui, N., Nishi, Y., Hasegawa, M.M., Taketomi, M., Yamamoto, M., and Tanimura, A. (1980). Induction of 8-azaguanine-resistant mutation and neoplastic transformation of hamster embryonic cells by coadministration of sodium nitrite and aminopyrine. *J. Cancer Res. Clin. Oncol.* **97**, 119-128.

Ishidate, M., Jr., and Odashima, S. (1977). Chromosome tests with 134 compounds on Chinese hamster cells in vitro—A screening for chemical carcinogens. *Mutat. Res.* **48**, 337-353.

Ishidate, M., Jr., Sofuni, T., and Yoshikawa, K. (1981). Chromosomal aberration tests *in vitro* as a primary screening tool for environmental mutagens and/or carcinogens. *Gann Monogr. Cancer Res.* **27**, 95-108.

Ishidate, M., Jr., Sofuni, T., Yoshikawa, K., Hayashi, M., Nohmi, T., Sawada, M., and Matsuoka, A. (1984). Primary mutagenicity screening of food additives currently used in Japan. *Food Chem. Toxicol.* **22**, 623-636.

Ishiwata, H., Tanimura, A., and Ishidate, M. (1975). Studies on in vivo formation of nitroso compounds (V). Formation of dimethylnitrosamine from nitrate and dimethylamine by bacteria in human saliva. *J. Food Hygiene Soc. Jpn.* **16**, 234-239.

Ito, N., Hirose, M., and Takahashi, S. (1993). Cell proliferation and forestomach carcinogenesis. *Environ. Health Perspect.* **101** (Suppl. 5), 107-110.

Jain, N.C. (1986a). Hemolytic anemias of noninfectious origin. In *Schalm's Veterinary Hematology*, 4th ed. (N.C. Jain, Ed.), pp. 627-654. Lea and Febiger, Philadelphia, PA.

Jain, N.C. (1986b). Clinical and laboratory evaluation of anemias and polycythemias. In *Schalm's Veterinary Hematology*, 4th ed. (N.C. Jain, Ed.), pp. 563-576. Lea and Febiger, Philadelphia, PA.

Jenkins, F.P., and Robinson, J.A. (1975). Serum biochemical changes in rats deprived of food or water for 24 h. *Proc. Nutr. Soc.* **34**, 37A.

Jonckheere, A.R. (1954). A distribution-free *k*-sample test against ordered alternatives. *Biometrika* **41**, 133-145.

Kakar, S.N., and Magee, P.T. (1982). Genetic analysis of *Candida albicans:* Identification of different isoleucine-valine, methionine, and arginine alleles by complementation. *J. Bacteriol.* **151**, 1247-1252.

Kaplan, E.L., and Meier, P. (1958). Nonparametric estimation from incomplete observations. *J. Am. Stat. Assoc.* **53**, 457-481.

Katz, M., Kazmer, S., and Weinstein, D. (1980). An analysis of weak mutagens in the Ames assay. *J. Environ. Pathol. Toxicol.* **3**, 171-187.

Kawabe, M., Takaba, K., Yoshida, Y., and Hirose, M. (1994). Effects of combined treatment with phenolic compounds and sodium nitrite on two-stage carcinogenesis and cell proliferation in the rat stomach. *Jpn. J. Cancer Res.* **85**, 17-25.

Khera, K.S. (1982). Reduction of teratogenic effects of ethylenethiourea in rats by interaction with sodium nitrite in vivo. *Food Chem. Toxicol.* **20**, 273-278.

Kirk-Othmer Concise Encyclopedia of Chemical Technology (1985). Sodium Compounds: Sodium Nitrite (M. Grayson, Ed.), pp. 1083-1084. John Wiley and Sons, New York.

Klein, M.L., and McDonald, I.R. (1982). Properties of the paraelectric-solid and molten phases of sodium nitrite. *Proc. R. Soc. Lond.* A382, 471-482.

Knight, T.M., Forman, D., Al-Dabbagh, S.A., and Doll, R. (1987). Estimation of dietary intake of nitrate and nitrite in Great Britain. *Food Chem. Toxicol.* **25**, 277-285.

Knobeloch, L., Salna, B., Hogan, A., Postle, J., and Anderson, H. (2000). Blue babies and nitratecontaminated well water. *Environ. Health Perspect*. **108**, 675-678.

Kodama, F., Umeda, M., and Tsutsui, T. (1976). Mutagenic effect of sodium nitrite on cultured mouse cells. *Mutat. Res.* **40**, 119-124.

Koestner, A., and Denlinger, R.H. (1975). Induction of neurogenic and lymphoid neoplasms by the feeding of threshold levels of methyl- and ethylnitrosourea precursors to adult rats. *Food Cosmet. Toxicol.* **13**, 605-609.

Kosako, M., and Nishioka, H. (1982). New forward mutation assay using low-concentration streptomycin resistance mutation in *E. coli* strains with plasmid pKM 101 [in Japanese, English abstract]. *Sci. Eng. Rev. Doshisha Univ.* **22**, 239-249.

Krishna Murthy, A.S., Baker, J.R., Smith, E.R., and Zepp, E. (1979). Neoplasms in rats and mice fed butylurea and sodium nitrite separately and in combination. *Int. J. Cancer* **23**, 253-259.

Kroes, R., and Wester, P.W. (1986). Forestomach carcinogenesis: Possible mechanisms of action. *Food Chem. Toxicol.* **24**, 1083-1089.

La Vecchia, C., D'Avanzo, B., Airoldi, L., Braga, C., and Decarli, A. (1995). Nitrosamine intake and gastric cancer risk. *Eur. J. Cancer Prev.* **4**, 469-474.

La Vecchia, C., Negri, E., Franceschi, S., and Decarli, A. (1997). Case-control study on influence of methionine, nitrite, and salt on gastric carcinogenesis in northern Italy. *Nutr. Cancer* **27**, 65-68.

Lemontt, J.F. (1977). Mutagenesis of yeast by hydrazine: Dependence upon post-treatment cell division. *Mutat. Res.* **43**, 165-178.

Lijinsky, W. (1980). Significance of *in vivo* formation of N-nitroso compounds. *Oncology* **37**, 223-226.

Lijinsky, W. (1984a). Induction of tumours in rats by feeding nitrosatable amines together with sodium nitrite. *Food Chem. Toxicol.* **22**, 715-720.

Lijinsky, W. (1984b). Induction of tumors of the nasal cavity in rats by concurrent feeding of thiram and sodium nitrite. *J. Toxicol. Environ. Health* **13**, 609-614.

Lijinsky, W., and Reuber, M.D. (1980). Tumours induced in Fischer 344 rats by the feeding of disulfiram together with sodium nitrite. *Food Cosmet. Toxicol.* **18**, 85-87.

Lijinsky, W., Kovatch, R., and Riggs, C.W. (1983). Altered incidences of hepatic and hemopoietic neoplasms in F344 rats fed sodium nitrite. *Carcinogenesis* **9**, 1189-1191.

Lilly, L.J., Cobon, A.M., and Newton, M.F. (1979). Chromosomal aberrations induced in rat lymphocytes by in vivo exposure to chemicals. A short-term method of carcinogenicity screening. *Meth. Find. Exp. Clin. Pharmacol.* **1**, 225-231.

London, W.T., Henderson, W., and Cross, R.F. (1967). An attempt to produce chronic nitrite toxicosis in swine. *J. Am. Vet. Med. Assoc.* **150**, 398-402.

Lynch, S.C., Gruenwedel, D.W., and Russell, G.F. (1983). Mutagenic activity of a nitrosated early Maillard product: DNA synthesis (DNA repair) induced in HeLa S3 carcinoma cells by nitrosated 1-(*N*-L-tryptophan)-1-deoxy-D-fructose. *Food Chem. Toxicol.* **21**, 551-556.

McConnell, E.E., Solleveld, H.A., Swenberg, J.A., and Boorman, G.A. (1986). Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. *JNCI* **76**, 283-289.

MacGregor, J.T., Wehr, C.M., Henika, P.R., and Shelby, M.D. (1990). The *in vivo* erythrocyte micronucleus test: Measurement at steady state increases assay efficiency and permits integration with toxicity studies. *Fundam. Appl. Toxicol.* **14**, 513-522. Maekawa, A., Ogiu, T., Onodera, H., Furuta, K., Matsuoka, C., Ohno, Y., and Odashima, S. (1982). Carcinogenicity studies of sodium nitrite and sodium nitrate in F-344 rats. *Food Chem. Toxicol.* **20**, 25-33.

Maronpot, R.R., and Boorman, G.A. (1982). Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. *Toxicol. Pathol.* **10**, 71-80.

Masui, T., Tezuka, N., Nakanishi, H., Inada, K., Miyashita, N., and Tatematsu, M. (1997). Induction of invasive squamous cell carcinomas in the forestomach of (C3H \times MSM)F1, MSM, and C3H mice by N-methyl-N-nitrosourea and mutational analysis of the H-ras and p53 genes. *Cancer Lett.* **111**, 97-104.

Mellgren, K., Mellgren, G., Lundin, S., Wennmalm, A., and Wadenvik, H. (1998). Effect of nitric oxide gas on platelets during open heart operations. *Ann. Thorac. Surg.* **65**, 1335-1341.

The Merck Index (1996). 12th ed. (S. Budavari, Ed.), pp. 8793-8794. Merck & Company, Inc., Whitehouse Station, NJ.

Miller, J.A., and Miller, E.C. (1977). Ultimate chemical carcinogens as reactive mutagenic electrophiles. In *Origins of Human Cancer* (H.H. Hiatt, J.D. Watson, and J.A. Winsten, Eds.), pp. 605-627. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

Mirvish, S.S. (1975). Formation of N-nitroso compounds: Chemistry, kinetics, and in vivo occurrence. *Toxicol. Appl. Pharmacol.* **31**, 325-351.

Mirvish, S.S. (1995). Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. *Cancer Lett.* **93**, 17-48.

Mirvish, S.S., Greenblatt, M., and Kommineni, V.R. (1972). Nitrosamide formation in vivo: Induction of lung adenomas in Swiss mice by concurrent feeding of nitrite and methylurea or ethylurea. *J. Natl. Cancer Inst.* **48**, 1311-1315.

Mirvish, S.S., Patil, K., Ghadirian, P., and Kommineni, V.R. (1975). Disappearance of nitrite from the rat stomach: Contribution of emptying and other factors. *J. Natl. Cancer Inst.* **54**, 869-875.

Mirvish, S.S., Bulay, O., Runge, R.G., and Patil, K. (1980). Study of the carcinogenicity of large doses of dimethylnitramine, N-nitroso-L-proline, and sodium nitrite administered in drinking water to rats. *JNCI* 64, 1435-1442.

Mirvish, S.S., Salmasi, S., Cohen, S.M., Patil, K., and Mahboubi, E. (1983). Liver and forestomach tumors and other forestomach lesions in rats treated with morpholine and sodium nitrite, with and without sodium ascorbate. *JNCI* **71**, 81-85.

Montesano, R., and Magee, P.N. (1971). Evidence of formation of N-methyl-N-nitrosourea in rats given N-methylurea and sodium nitrite. *Int. J. Cancer* 7, 249-255.

Morales-Suarez-Varela, M.M., Llopis-Gonzales, A., and Tejerizo-Perez, M.L. (1995). Impact of nitrates in drinking water on cancer mortality in Valencia, Spain. *Eur. J. Epidemiol.* **11**, 15-21.

Morrison, D.F. (1976). *Multivariate Statistical Methods*, 2nd ed., pp. 170-179. McGraw-Hill Book Company, New York.

National Academy of Sciences (NAS) (1981). The Health Effects of Nitrate, Nitrite, and N-Nitroso Compounds. National Academy Press, Washington, DC.

National Institute for Occupational Safety and Health (NIOSH) (1976). National Occupational Health Survey (1972-1974) (database). U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, Cincinnati, OH.

National Institute for Occupational Safety and Health (NIOSH) (1990). National Occupational Exposure Survey (1981-1983), unpublished provisional data as of July 1, 1990. NIOSH, Cincinnati, OH.

National Institute for Occupational Safety and Health (NIOSH) (1997). NIOSH Pocket Guide to Chemical Hazards. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Washington, DC.

National Toxicology Program (NTP) (1987). Technical Protocol for Sperm Morphology and Vaginal Cytology Evaluations in Toxicity Testing for Rats and Mice, 10/31/82 version (updated April 1987). Research Triangle Park, NC.

Newberne, P.M. (1979). Nitrite promotes lymphoma incidence in rats. *Science* **204**, 1079-1081.

Noel, M.E., Vaubel, J.E., and Goldman, M. (1974). The influence of sodium nitrite on spleen, liver, kidney, adrenal, ovary, and uterus of the rat. *Proc. S.D. Acad. Sci.* **53**, 232-235.

Pankow, D., Ponsold, W., Liedke, M.D., Gessner, G., Pfordte, A. (1975). Adaptation of rats following sodium-nitrite-induced methemoglobinemia [in German]. *Acta Biol. Med. Ger.* **34**, 1205-1209.

Phillips, W.E.J. (1968). Nitrate content of foods, public health implications. *Can. Inst. Food Technol. J.* **1**, 98-103.

Piegorsch, W.W., and Bailer, A.J. (1997). *Statistics for Environmental Biology and Toxicology*, Section 6.3.2. Chapman and Hall, London.

Portier, C.J., and Bailer, A.J. (1989). Testing for increased carcinogenicity using a survival-adjusted quantal response test. *Fundam. Appl. Toxicol.* **12**, 731-737.

Portier, C.J., Hedges, J.C., and Hoel, D.G. (1986). Age-specific models of mortality and tumor onset for historical control animals in the National Toxicology Program's carcinogenicity experiments. *Cancer Res.* **46**, 4372-4378.

Rachmilewitz, E.A. (1974). Denaturation of the normal and abnormal hemoglobin molecule. *Semin. Hematol.* **11**, 441-462.

Rao, G.N. (1996). New diet (NTP-2000) for rats in the National Toxicology Program toxicity and carcinogenicity studies. *Fundam. Appl. Toxicol.* **32**, 102-108.

Rao, G.N. (1997). New nonpurified diet (NTP-2000) for rodents in the National Toxicology Program's toxicology and carcinogenesis studies. *J. Nutr.* **127**, 842s-846s.

Riemann, H. (1950). On the toxicity of hydroxylamine. *Acta. Pharmacol.* **6**, 285-292.

Righetti, A.B., and Kaplan, M.M. (1971). The origin of the serum alkaline phosphatase in normal rats. Biochem. Biophys. Acta. **230**, 504-509.

Rijhsinghani, K.S., Abrahams, C., Krakower, C., Swerdlow, M., and Ghose, T. (1982). Tumor induction in C57BL \times C3HF1 mice following single oral administration of diethylamine hydrochloride sodium nitrite (NaNO2). *Cancer Detect. Prev.* **5**, 283-290.

Risch, H.A., Jain, M., Choi, N.W., Fodor, J.G., Pfeiffer, C.J., Howe, G.R., Harrison, L.W., Craib, K.J.P., and Miller, A.B. (1985). Dietary factors and the incidence of cancer of the stomach. *Am. J. Epidemiol.* **122**, 947-959.

Rogers, M.A.M., Vaughan, T.L., Davis, S., and Thomas, D.B. (1995). Consumption of nitrate, nitrite, and nitrosodimethylamine and the risk of upper aerodigestive tract cancer. *Cancer Epidemiol. Biomarkers Prevent.* **4**, 29-36.

Rubenchik, B.L., Osinkovskaya, N.D., Mikhailenko, V.M., Furman, M.A., and Boim, T.M. (1990). The carcinogenic danger of nitrite pollution of the environment. *J. Environ. Pathol. Toxicol. Oncol.* **10**, 290-296.

Ruddell, W.S.J., Bone, E.S., Hill, M.J., Blendis, L.M., and Walters, C.L. (1976). Gastric-juice nitrite. A risk factor for cancer in the hypochlorhydric stomach? *Lancet* **2**, 1037-1039.

Sadtler Standard Spectra. Sadtler Research Laboratories, Philadelphia.

Shank, R.C., and Newberne, P.M. (1976). Doseresponse study of the carcinogenicity of dietary sodium nitrite and morpholine in rats and hamsters. *Food Cosmet. Toxicol.* **14**, 1-8.

Shelby, M.D. (1988). The genetic toxicity of human carcinogens and its implications. *Mutat. Res.* **204**, 3-15.

Shelby, M.D., and Witt, K.L. (1995). Comparison of results from mouse bone marrow chromosome aberration and micronucleus tests. *Environ. Mol. Mutagen.* **25**, 302-313.

Shelby, M.D. and Zeiger, E. (1990). Activity of human carcinogens in the Salmonella and rodent bone marrow cytogenetics tests. *Mutat. Res.* **234**, 257-261.

Shelby, M.D., Erexson, G.L., Hook, G.J., and Tice, R.R. (1993). Evaluation of a three-exposure mouse bone marrow micronucleus protocol: Results with 49 chemicals. *Environ. Mol. Mutagen.* **21**, 160-179.

Shirley, E. (1977). A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. *Biometrics* **33**, 386-389.

Shuval, H.I., and Gruener, N. (1972). Epidemiological and toxicological aspects of nitrates and nitrites in the environment. *Am. J. Public Health* **62**, 1045-1052.

Shuval, G.M., and Gruener, N. (1977). Infant methemoglobinemia and other health effects of nitrates in drinking water. *Prog. Water Technol.* **8**, 183-193.

Singer, G.M., and Lijinsky, W. (1976). Naturally occurring nitrosatable compounds. I. Secondary amines in food stuffs. *J. Agric. Food Chem.* 24, 550-553.

Sinha, D.P., and Sleight, S.D. (1971). Pathogenesis of abortion in acute nitrite toxicosis in guinea pigs. *Toxicol. Appl. Pharmacol.* **18**, 340-347.

Smith, J.E., and Beutler, E. (1966). Methemoglobin formation and reduction in man and various animal species. *Am. J. Physiol.* **210**, 347-350.

Smith, R.P., and Layne, W.R. (1969). A comparison of the lethal effects of nitrite and hydroxylamine in the mouse. *J. Pharmacol. Exp. Ther.* **165**, 30-35.

Speijers, G.J.A. (1996). Nitrite. In *Toxicological* Evaluation of Certain Food Additives and Contaminants in Food, pp. 269-324. No. 35, WHO, Geneva.

Stephany, R.W., and Schuller, P.L. (1980). Daily dietary intakes of nitrate, nitrite, and volatile N-nitrosamines in the Netherlands using the duplicate portion sampling technique. *Oncology* **37**, 203-210.

Straus, D.S. (1981). Somatic mutation, cellular differentiation, and cancer causation. *JNCI* 67, 233-241.

Tannenbaum, S.R. (1988). Mechanisms of endogenous nitrosation. In *Chemical Carcinogenesis*. *Models and Mechanisms* (F. Feo, P. Pani, A. Columbano, and R. Garcea, Eds.), pp. 629-637. Plenum Press, New York.

Tannenbaum, S.R., Sinskey, A.J., Weisman, M., and Bishop, W.R. (1974). Nitrite in human saliva. Its possible relationship to nitrosamine formation. *J. Natl. Cancer Inst.* **53**, 79-84.

Tannenbaum, S.R., Weissman, M., and Fett, D. (1976). The effect of nitrate intake on nitrite formation in human saliva. *Food Cosmet. Toxicol.* **14**, 549-552.

Tannenbaum, S.R., Fett, D., Young, V.R., Land, P.D., and Bruce, W.R. (1978a). Nitrite and nitrate are formed by endogenous synthesis in the human intestine. *Science* **200**, 1487-1489.

Tannenbaum, S.R., Archer, M.C., Wishnok, J.S., and Bishop, W.W. (1978b). Nitrosamine formation in human saliva. *JNCI* **2**, 251-253.

Tannenbaum, S.R., Moran, D., Rand, W., Cuello, C., and Correa, P. (1979). Gastric cancer in Columbia. IV. Nitrite and other ions in gastric contents of residents from a high-risk region. *JNCI* **62**, 9-12.

Tarone, R.E. (1975). Tests for trend in life table analysis. *Biometrika* **62**, 679-682.

Taylor, H.W., and Lijinsky, W. (1975). Tumor induction in rats by feeding heptamethyleneimine and nitrite in water. *Cancer Res.* **35**, 812-815.

Tennant, R.W., Margolin, B.H., Shelby, M.D., Zeiger, E., Haseman, J.E., Spalding, J., Caspary, W., Resnick, M., Stasiewicz, S., Anderson, B., and Minor, R. (1987). Prediction of chemical carcinogenicity in rodents from *in vitro* genetic toxicity assays. *Science* **236**, 933-941.

Til, H.P., Kuper, C.F., and Falke, H.E. (1997). Nitriteinduced adrenal effects in rats and the consequences for the no-observed-effect level. *Food Chem. Toxicol.* **35**, 349-355.

Torfgård, K.E., and Ahlner, J. (1994). Mechanism of action of nitrates. *Cardiovasc. Drugs Ther.* **8**, 701-717.

Törnqvist, M., Rannug, U., Jonsson, A., and Ehrenberg, L. (1983). Mutagenicity of methyl nitrite in *Salmonella typhimurium. Mutat. Res.* **117**, 47-54.

Tsuda, H., and Kato, K. (1977). High rate of endoreduplications and chromosomal aberrations in hamster cells treated with sodium nitrite in vitro. *Mutat. Res.* **56**, 69-74.

Tsuda, H., Inui, N., and Takayama, S. (1973). In vivo transformation of newborn hamster cells by sodium nitrite. *Biochem. Biophys. Res. Comm.* **55**, 1117-1124.

Tsuda, H., Kushi, A., Yoshida, D., and Goto, F. (1981). Chromosomal aberrations and sister-chromatid exchanges induced by gaseous nitrogen dioxide in cultured Chinese hamster cells. *Mutat. Res.* **89**, 303-309.

United States Environmental Protection Agency (USEPA) (1986).

43 USC 300f.

Valin, N., Haybron, D., Groves, L., and Mower, H.F. (1985). The nitrosation of alcohol-induced metabolites produces mutagenic substances. *Mutat. Res.* **158**, 159-168.

Van Loon, A.J.M., Botterweck, A.A.M., Goldbohm, R.A., Brants, H.A.M., van Klaveren, J.D., and van den Brandt, P.A. (1998). Intake of nitrate and nitrite and the risk of gastric cancer: a prospective cohort study. *Brit. J. Cancer* **78**, 129-135.

Vermeer, I.T.M., Pachen, D.M.F.A., Dallinga, J.W., Kleinjans, J.C.S., and van Maanen, J.M.S. (1998). Volatile *N*-nitrosamine formation after intake of nitrate at the ADI level in combination with an amine-rich diet. *Environ. Health Perspect.* **106**, 459-463.

Veszelovsky, E., Holford, N.H., Thomsen, L.L., Knowles, R.G., and Baguley B.C. (1995). Plasma nitrate clearance in mice: Modeling of the systemic production of nitrate following the induction of nitric oxide synthesis. *Cancer Chemother. Pharmacol.* **36**, 155-159.

Vleeming, W., van de Kuil, A., te Biesebeek, J.D., Meulenbelt, J., and Boink, A.B. (1997). Effect of nitrite on blood pressure in anaesthetized and freemoving rats. *Food Chem. Toxicol.* **35**, 615-619.

Vorhees, C.V., Butcher, R.E., Brunner, R.L., and Wootten, V. (1984). Developmental toxicity and psychotoxicity of sodium nitrite in rats. *Food Chem. Toxicol.* **22**, 1-6.

White, J.W., Jr. (1975). Relative significance of dietary sources of nitrate and nitrite. J. Agric. Food Chem. 23, 886-891.

White, J.W., Jr. (1976). Relative significance of dietary sources of nitrate and nitrite. J. Agric. Food Chem. 24, 202.

Whong, W.-Z., Long, R., Ames, R.G., and Ong, T.-M. (1983). Rule of nitrosation in the mutagenic activity of coal dust: A postulation for gastric carcinogenesis in coal miners. *Environ. Res.* **32**, 298-304.

Williams, D.A. (1971). A test for differences between treatment means when several dose levels are compared with a zero dose control. *Biometrics* **27**, 103-117.

Williams, D.A. (1972). The comparison of several dose levels with a zero dose control. *Biometrics* **28**, 519-531.

Witt, K.L., Knapton, A., Wehr, C.M. Hook, G.J., Mirsalis, J., Shelby, M.D., and MacGregor, J.T. (2000). Micronucleated erythrocyte frequency in peripheral blood of B6C3F₁ mice from short-term, prechronic, and chronic studies of the NTP Carcinogenesis Bioassay Program. *Environ. Mol.* Mutagen. **36**, 163-194.

Wolff, I.A., and Wasserman, A.E. (1972). Nitrates, nitrites, and nitrosamines. *Science* **177**, 15-19.

World Health Organization (WHO) (1974). Toxicological Evaluation of Certain Food Additives with a Review of General Principles and of Specifications. Technical Report Series 539. World Health Organization, Geneva.

Xiang, Y.Y., Wang, D.Y., Tanaka, M., Igarashi, H., Kamo, T., Shen, Q., Sugimura, H., and Kino, I. (1995). Efficient and specific induction of esophageal tumors in rats by precursors of N-nitrososarcosine ethyl ester. *Pathol. Int.* **45**, 415-421.

Xu, G., Song, P., Reed, P.I. (1992). The relationship between gastric mucosal changes and nitrate intake via drinking water in a high-risk population for gastric cancer in Moping County, China. *Eur J. Cancer Prevent.* **1**, 437-443.

Yamamoto, K., Nakajima, A., Eimoto, H., Tsutsumi, M., Maruyama, H., Denda, A., Nii, H., Mori, Y., and Konishi, Y. (1989). Carcinogenic activity of endogenously synthesized N-nitrosobis(2-hydroxypropyl)amine in rats administered bis(2-hydroxypropyl)amine and sodium nitrite. *Carcinogenesis* **10**, 1607-1611.

Yang, C.-Y., Cheng, M.-F., Tsai, S.-S., Hsieh, Y.-L. (1998). Calcium, magnesium, and nitrate in drinking water and gastric cancer mortality. *Jap. J. Cancer Res.* **89**, 124-130.

Yoshida, A., Harada, T., and Maita, K. (1993). Tumor induction by concurrent oral administration of ethylenethiourea and sodium nitrite in mice. *Toxicol. Pathol.* **21**, 303-310.

Yoshida, Y., Hirose, M., Takaba, K., Kimura, J., and Ito, N. (1994). Induction and promotion of forestomach tumors by sodium nitrite in combination with ascorbic acid or sodium ascorbate in rats with or without N-methyl-N'-nitro-*N*-nitrosoguanidine pretreatment. *Int. J. Cancer* **56**, 124-128. Zeiger, E., Haseman, J.E., Shelby, M.D., Margolin, B.H., and Tennant, R.W. (1990). Evaluation of four in vitro genetic toxicity tests for predicting rodent carcinogenicity: Confirmation of earlier results with 41 additional chemicals. *Environ. Mol. Mutagen.* **16** (Suppl. 18), 1-14.

Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., and Mortelmans, K. (1992). Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. *Environ. Mol. Mutagen.* **19** (Suppl. 21), 2-141.

APPENDIX A SUMMARY OF LESIONS IN MALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF SODIUM NITRITE

TABLE A1	Summary of the Incidence of Neoplasms in Male Rats	
	in the 2-Year Drinking Water Study of Sodium Nitrite	82
TABLE A2	Individual Animal Tumor Pathology of Male Rats	
	in the 2-Year Drinking Water Study of Sodium Nitrite	86
TABLE A3	Statistical Analysis of Primary Neoplasms in Male Rats	
	in the 2-Year Drinking Water Study of Sodium Nitrite	104
TABLE A4a	Historical Incidence of Skin Fibroma or Fibrosarcoma	
	in Control Male F344/N Rats	108
TABLE A4b	Historical Incidence of Mononuclear Cell Leukemia	
	in Control Male F344/N Rats	109
TABLE A5	Summary of the Incidence of Nonneoplastic Lesions in Male Rats	
	in the 2-Year Drinking Water Study of Sodium Nitrite	110

Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite^a

Disposition Summary Animals initially in study 50 50 50 50 Early deaths 16 4 12 8 Nutual deaths 5 8 2 6 Survivors 1 1 1 1 Terminal scriftee 29 37 36 36 Alimentary System 2 50 50 50 50 Ecophagus (50) (50) (50) (50) (50) Intestine large, colon (50) (50) (50) (50) (50) Carinoma 1 (2%) 1 (2%) 1 (2%) Intestine large, colon (50) (50) (50) (49) (50) (49) Intestine small, duodenum (49) (50) (49) (50) (49) Intestine small, giptum (50) (49) (50) (49) Intestine small, duodenum (50) (50) (50) (49) Intestine small, ciptumatin primary site <th></th> <th>0 ppm</th> <th>750 ppm</th> <th>1,500 ppm</th> <th>3,000 ppm</th>		0 ppm	750 ppm	1,500 ppm	3,000 ppm
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Disposition Summary				
Early daths 1 2 8 Natural daths 5 8 2 6 Survivors 1 7 7 36 36 Diel last week of study 1 1 7 7 36 36 Animal sexamined microscopically 50 50 50 50 50 50 Alimentary System 1 2% 1 2% 50 <td></td> <td>50</td> <td>50</td> <td>50</td> <td>50</td>		50	50	50	50
Natural deaths 5 8 2 6 Died last week of study 1 1 1 Terminal sacrifice 29 37 36 36 Animels examined microscopically 50 50 50 50 Animetary System 50 50 50 50 50 Kinentary System 1 2% 1 2					
barviors Died last week of study Terminal sacrifice 29 37 36 36 Animals examined microscopically 50 50 50 50 50 Alinentary System Sophagus (50) (50) (50) (50) (50) Carcinoma 1 (2%) Liciomyosarcoma 1 (2%) Testine large, colon (50) (50) (50) (49) testine small, jejunum (50) (48) (50) (49) testine small, jejunum (50) (48) (50) (49) testine small, jejunum (50) (48) (50) (49) testine small, jejunum (50) (49) (50) (49) testine small, jejunum (50) (49) (50) (49) tiestine small, jejunum (50) (40) (50) (50) (40) tiestine small, jejunum (50) (50) (50) (50) (50) (50) Termister large, colon 1 (2%) Tel, jeinoyosarcoma, metastatic, intestine large, colon 1 (10%) Tati mucosa (2) (1) Pharyngeal, squamous cell carcinoma 2 (4%) Liciomyosarcoma, metastatic, 1 (2%) tentestine large, colon 1 (10%) Acrinus, adenoma 1 (2%) Sarcoma, metastatic, 1 (2%) telesentery (12) (7) (5) (50) (49) Liciomyosarcoma, metastatic, 1 (2%) Tel, sarcoma (2) (1) Pharyngeal, squamous cell carcinoma 2 (4%) Acrinus, adenoma (2) (1) Pharyngeal, squamous cell carcinoma 1 (2%) Sarcoma, metastatic, uncertain primary site (2%) Sarcoma, metastatic, uncertain primary si	Moribund	16	4	12	8
Died last week of study 1 Terminal sacrifice 29 37 36 36 Nnimals examined microscopically 50 50 50 50 Alimentary System 50 50 50 50 Sophagus (50) (50) (50) (50) (50) Carcinoma 1 (2%) 1 (2%) Schwannoma nalignant, metastatic, heart 1 (2%) 1 (2%) Schwannoma nalignant, metastatic, heart 1 (2%) (49) (50) (50) (49) Itestine large, colun (50) (49) (50) (50) (49) (50) (49) (50) (49) (50) (50) (49) (50) (50) (49) (50) (50) (49) (50) (50) (50) (49) (50) (50) (50) (50) (50) (50) (50) (50) (50) (50) (50) (50) (50) (50) (50) (2%) (2%) (2%) (2%) (2%) (2%) (2%) (2%) (2%)	Natural deaths	5	8	2	6
Terminal sacrifice 29 37 36 36 Animals examined microscopically 50 50 50 50 Sophagus (50) (50) (50) (50) Intestine large, colon (50) (50) (50) (50) Leiomyosarcoma 1 (2%) 1 (2%) Schwannoma malignant, metastatic, heart 1 (2%) (50) (50) (50) Schwannoma malignant, metastatic, heart 1 (2%) (2%) (49) (50) (50) (49) intestine small, jejunum (50) (48) (50) (49) (50)<	Survivors				
Animals examined microscopically 50 50 50 50 Minentary System Sophagus (50) (50) (50) (50) Carcinoma 1 (2%) 1 (2%) 1 (2%) Leiomyosarcoma 1 (2%) 1 (2%) Schwannom analignant, metastatic, heart 1 (2%) 1 (2%) Intestine large, cecum (50) (50) (50) (49) Intestine small, duodenum (49) (50) (50) (49) intestine small, iduudenum (50) (49) (50) (49) iver (50) (50) (50) (49) iver (50) (50) (50) (50) Restrictor 1 (2%) 1 (2%) 1 (2%) Sarcoma, metastatic, ucertain primary site 1 (2%) 1 (1%) Sarcoma, metastatic, ucertain primary site 1 (1%) 1 (1%) Fat, sarcoma 1 (1%) 1 (2%) 1 (2%) Intestine large, colon 1 (2%) 1 (2%) 1 (2%) Carinux adenocarcinoma					
Limentary System (50) (49) (50) (50) (5	Terminal sacrifice	29	37	36	36
	nimals examined microscopically	50	50	50	50
	Alimentary System				
intestine large, colon (50) (50) (50) (50) Carcinoma 1 (2%) 1 (2%) 1 (2%) schwannoma malignant, metastatic, heart 1 (2%) 1 (2%) intestine large, cecum (50) (50) (50) (49) intestine small, duodenum (49) (50) (50) (49) intestine small, jejunum (50) (49) (50) (49) Liver (50) (50) (50) (49) Liver (50) (50) (50) (50) (49) Liver (50) (50) (50) (50) (50) (50) Histocytic sarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%) Sarcoma, metastatic, uncertain primary site 1 (2%) 1 (2%) 1 (13%) Fat, leiomyosarcoma, metastatic, heart 1 (2%) 1 (13%) 7 Schwannoma malignant, metastatic, heart 1 (2%) 1 (13%) 7 Fat, seroma 1 (14%) 1 (13%) 1 (13%) Tat geneyosarcoma, metastatic, intestine large, colon 1 (14%) 1 (2%) 1 (2%) <		(50)	(50)	(50)	(50)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			(50)		
Schwanoma malignant, metastatic, heart 1 (2%) ntestine large, cecum (50) (50) (50) (50) ntestine small, duodenum (49) (50) (50) (49) itestine small, jejunum (50) (49) (50) (49) itestine small, jejunum (50) (50) (50) (49) Histiocytic sarcoma $1 (2\%)$ $1 (2\%)$ $1 (2\%)$ $1 (2\%)$ Histiocytic sarcoma $1 (2\%)$ $1 (2\%)$ $1 (2\%)$ $1 (2\%)$ Sarcoma, metastatic, uncertain primary site $1 (14\%)$ $1 (10\%)$ $1 (13\%)$ Fat, sarcoma $1 (14\%)$ $1 (10\%)$ $1 (13\%)$ refatic large, colon $1 (14\%)$ $1 (2\%)$ $1 (2\%)$ refatic large, colon $1 (14\%)$ $1 (2\%)$ $1 (2\%)$ refat, sarcoma $2 (4\%)$	Carcinoma		1 (2%)		
ntestine large, cecum (50) (50) (50) (49) ntestine small, duodenum (49) (50) (50) (50) ntestine small, jejunum (50) (48) (50) (49) ntestine small, ileum (50) (49) (50) (49) iver (50) (50) (50) (50) (49) Leiomyosarcoma, metastatic, intestine large, colon 1 (2%) 1 (2%) Schwanoma malignant, metastatic, heart 1 (2%) 1 (13%) Fat, leiomyosarcoma, metastatic, intestine large, colon 1 (14%) 1 (13%) Taral mucosa (2) (10) 1 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)					1 (2%)
ntestine small, duodenum (49) (50) (50) (50) ntestine small, jejunum (50) (48) (50) (49) itestine small, lieum (50) (49) (50) (49) iver (50) (50) (50) (50) (50) Heptocellular adenoma 1 (2%) 1 (2%) Leiomyosarcoma, metastatic, 1 (2%) 1 (2%) Sarcoma, metastatic, uncertain primary site 1 (2%) 1 (2%) Schwannoma malignant, metastatic, heart 1 (2%) 1 (13%) Fat, sarcoma 1 (14%) 1 (13%) Fat, sarcoma 1 (14%) 1 1 (2%) Dral mucosa (2) (1) 1					
testine small, jejunum (50) (48) (50) (49) testine small, jejunum (50) (49) (50) (49) testine small, jejunum (50) (50) (50) (50) Hepatocellular adenoma (1 (2%)) Histiocytic sarcoma metastatic, intestine large, colon (1 (2%)) Sarcoma, metastatic, nucertain primary site (11) (7) (5) (8) Fat, leiomyosarcoma, metastatic, intestine large, colon (1 (14%)) ral mucosa (2) (1) Pharyngeal, squamous cell carcinoma (50) (50) (50) (50) (49) Leiomyosarcoma, metastatic, intestine large, colon (2) (1) Pharyngeal, squamous cell carcinoma (50) (50) (50) (49) Leiomyosarcoma, metastatic, intestine large, colon (2) (1) Pharyngeal, squamous cell carcinoma (2) (2) (2) Acinus, adenocarcinoma (2) (4%) Acinus, adenocarcinoma (2) (4%) Acinus, adenocarcinoma (2) (4%) Acinus, adenoma (2) (2%) (50) (50) (50) Sarcoma, metastatic, intestine large, colon (2) (2%) Acinus, adenoma (2) (4%) Sarcoma (2) (50) (50) (50) (50) Sarcoma (50) (50) (50) (50) Sarcoma (50) (50) (50) (50) Sarcoma (50) (50) (50) (50) Sarcoma, metastatic, uncertain primary site (2%) Sarcoma, metastatic, uncertain primary site (50) (50) (50) (50) Sarcoma, metastatic, uncertain primary site (50) (50) (50) (50) (50) Sarcoma, metastatic, uncertain primary site (2%) Sarcoma, metastatic, uncertain primary site (50) (50) (50) (50) (50) Carcinoid tumor benign (50) (50) (50) (50) (50) Carcinoid tumor benign (1 (2%))					
testine small, lieum (50) (49) (50) (49) ver (50) (50) (50) (50) Hepatocellular adenoma 1 (2%) 1 (2%) Histiocytic sarcoma 1 (2%) 1 (2%) Leiomyosarcoma, metastatic, uncertain primary site 1 (2%) 1 (2%) Sarcoma, metastatic, uncertain primary site 1 (2%) 1 (2%) Schwannoma malignant, metastatic, heart 1 (2%) 1 (2%) Sarcoma, metastatic, uncertain primary site 1 (14%) 1 (13%) Fat, leiomyosarcoma, metastatic, intestine large, colon 1 (14%) 1 (13%) Fat, sarcoma 1 (14%) 1 1 (13%) ral mucosa (2) (1) 1 (2%) 1 (2%) 1 (2%) (10%) 1 (2%) 1 (2%) (2%) (2%) (2%) (2%) (2%) (2%) (2%) (2%) (2%) (2%) (2%) (2%) <					
ver(50)(50)(50)(50)(50)Hepatocellular adenoma1(2%)Histiocytic sarcoma1(2%)Leiomyosarcoma, metastatic, intestine large, colon1(2%)Sarcoma, metastatic, uncertain primary site1(2%)Schwannoma malignant, metastatic, heart1(2%)Senterry(11)(7)(5)(8)Fat, leiomyosarcoma, metastatic, intestine large, colon1(13%)Fat, sarcoma1(14%)1(100%)ral mucosa(2)(1)(100%)Increas(50)(50)(50)(49)Leiomyosarcoma, metastatic, intestine large, colon1(2%)(2%)Acinus, adenoma2(4%)1(2%)Acinus, adenoma1(2%)1(2%)Sarcoma, metastatic, uncertain primary site1(2%)1(2%)Guamous cell papilloma1(2%)1(2%)Guamous cell papilloma1(2%)1(2%)Carcinoid tumor benign1(2%)1(2%)Leiomyosarcoma1(2%)1(2%)Carcinoid tumor benign1(2%)1(2%)Leiomyosarcoma1(2%)1(2%)Leiomyosarcoma1(2%)1(2%)Carcinoid tumor benign1(2%)1(2%)Leiomyosarcoma1(2%)1(2%)Carcinoid tumor benign1(2%) </td <td></td> <td></td> <td></td> <td></td> <td></td>					
Hepatocellular adenoma1 (2%)Histicoytic sarcoma1 (2%)Histicoytic sarcoma, metastatic,1 (2%)Leiomyosarcoma, metastatic,1 (2%)Sarcoma, metastatic, uncertain primary site1 (2%)Sentery(11)(7)(5)(8)Fat, leiomyosarcoma, metastatic,intestine large, colon1 (14%)ral mucosa(2)(1)(7)(5)(8)Fat, sarcoma1 (14%)ral mucosa(2)(1)(7)Pharyngeal, squamous cell carcinoma1 (100%)intestine large, colon1 (2%)Acinus, adenocarcinoma2 (4%)Acinus, adenoma1 (2%)Acinus, adenoma1 (2%)Marking, GSD(50)(70)(50)(71)(72)(72)1 (2%)(72)1 (2%)(73)1 (2%)(74)1 (2%)(75)(50)(75)(50)(75)(50)(75)(50)(75)(50)(75)(50)(75)(50)(76)(76)			. ,		· · ·
Histocytic sarcoma1 (2%)1 (2%)Leiomyosarcoma, metastatic, intestine large, colon1 (2%)Sarcoma, metastatic, uncertain primary site1 (2%)Sarcoma, metastatic, uncertain primary site1 (2%)sentery(11)(7)(5)(8)Fat, leiomyosarcoma, metastatic, intestine large, colon1 (14%)Fat, sarcoma1 (14%)ral mucosa(2)(1)Pharyngeal, squamous cell carcinoma1 (10%)mcreas(50)(50)(50)Acinus, adenocarcinoma1 (2%)Acinus, adenocarcinoma1 (2%)Acinus, carcinoma1 (2%)Sarcoma, metastatic, uncertain primary site1 (2%)Suroma, metastatic, uncertain primary site1 (2%)Acinus, calcinoma1 (2%)Macmade1 (2%)Suroma1 (2%)Carcinojd tumor benign1 (2%)Leiomyosarcoma1 (2%)Suroma1 (2%)		(50)	(50)		(50)
Leiomyosarcoma, metastatic, intestine large, colon1 (2%) 1 (2%)Sarcoma, metastatic, uncertain primary site1 (2%)Schwannoma malignant, metastatic, heart1 (2%)sentery(11)(7)(5)(8)Fat, leiomyosarcoma, metastatic, intestine large, colon1 (14%)1 (13%)Fat, sarcoma1 (14%)1(100%)ral mucosa(2)(1)(1)Pharyngeal, squamous cell carcinoma1 (100%)(10%)ncreas(50)(50)(50)(49)Leiomyosarcoma, metastatic, intestine large, colon1 (2%)1 (2%)Acinus, adenocarcinoma2 (4%)1 (2%)Acinus, adenocarcinoma1 (2%)1 (2%)omach, forestomach(50)(50)(50)Sarcoma, metastatic, uncertain primary site1 (2%)1 (2%)omach, glandular(50)(50)(50)(50)Carcinoid tumor benign1 (2%)1 (2%)1 (2%)Leiomyosarcoma1 (2%)1 (2%)1 (2%)			1 (20/)	1 (2%)	1 (20/)
intestine large, colon1 (2%)Sarcoma, metastatic, uncertain primary site1 (2%)Schwannom malignant, metastatic, heart1 (2%)lesentery(11)(7)(5)(8)Fat, leiomyosarcoma, metastatic, intestine large, colon1 (11%)Fat, sarcoma1 (14%)1 (10%)ral mucosa(2)(1)Pharyngeal, squamous cell carcinoma1 (100%)narceas(50)(50)(50)Leiomyosarcoma, metastatic, intestine large, colon1 (2%)Acinus, adenocarcinoma2 (4%)1 (2%)Acinus, adenoma1 (2%)1 (2%)omach, forestomach(50)(50)(50)Sarcoma, metastatic, uncertain primary site1 (2%)1 (2%)omach, forestomach(50)(50)(50)(50)Sarcoma, metastatic, uncertain primary site1 (2%)1 (2%)Carcinoid tumor benign1 (2%)1 (2%)1 (2%)Leiomyosarcoma1 (2%)1 (2%)1 (2%)			1 (2%)		1 (2%)
Sarcoma, metastatic, uncertain primary site1 (2%)Schwannoma malignant, metastatic, heart1 (2%)lesentery(11)(7)(5)(8)Fat, leiomyosarcoma, metastatic, intestine large, colon1 (14%)1 (13%)Fat, sarcoma1 (14%)1 (100%)1ral mucosa(2)(1)1Pharyngeal, squamous cell carcinoma1 (100%)49)ancreas(50)(50)(50)Leiomyosarcoma, metastatic, intestine large, colon1 (2%)Acinus, adenocarcinoma2 (4%)1 (2%)Acinus, adenoma1 (2%)1 (2%)Acinus, adenoma1 (2%)1 (2%)Comach, forestomach(50)(50)(50)Squamous cell papilloma1 (2%)1 (2%)comach, gladular(50)(50)(50)(50)Carcinoid tumor benign1 (2%)1 (2%)Leiomyosarcoma1 (2%)1 (2%)					1 (20/)
Schwannoma malignant, metastatic, heart1(2%)fesentery(11)(7)(5)(8)Fat, leiomyosarcoma, metastatic, intestine large, colon1(13%)Fat, sarcoma1(14%)1ral mucosa(2)(1)Pharyngeal, squamous cell carcinoma1(100%)ancreas(50)(50)(50)(49)Leiomyosarcoma, metastatic, intestine large, colon1(2%)Acinus, adenocarcinoma2(4%)1Acinus, adenoma1(2%)1Acinus, carcinoma1(2%)1Squamous cell papilloma1(2%)1Squamous cell papilloma1(2%)1(50)(50)(50)(50)(50)Carcinoid tumor benign1(2%)1Leiomyosarcoma1(2%)1					
fesentery(11)(7)(5)(8)Fat, leiomyosarcoma, metastatic, intestine large, colon1(14%)1(13%)Fat, sarcoma(2)(1)1(100%)Pharyngeal, squamous cell carcinoma1(100%)(49)1Leiomyosarcoma, metastatic, intestine large, colon(50)(50)(50)(49)Leiomyosarcoma, metastatic, intestine large, colon1(2%)1(2%)Acinus, adenocarcinoma2(4%)1(2%)Acinus, adenoma1(2%)1(2%)Acinus, carcinoma1(2%)1(2%)Sarcoma, metastatic, uncertain primary site1(2%)1(2%)Squamous cell papilloma1(2%)1(2%)Carcinoid tumor benign1(2%)1(2%)Leiomyosarcoma1(2%)1(2%)		1 (2%)			1 (270)
Fat, leiomyosarcoma, metastatic, intestine large, colon1 (13%)Fat, sarcoma1 (14%)Fat, sarcoma(1)ral mucosa(2)(1)Pharyngeal, squamous cell carcinoma1 (100%)ancreas(50)(50)(50)ancreas(50)(50)(50)Leiomyosarcoma, metastatic, intestine large, colon1 (2%)Acinus, adenocarcinoma2 (4%)1 (2%)Acinus, adenoma1 (2%)1 (2%)Comach, forestomach(50)(50)(50)Sarcoma, metastatic, uncertain primary site1 (2%)Squamous cell papilloma1 (2%)1 (2%)tomach, glandular(50)(50)(50)Carcinoid tumor benign1 (2%)1 (2%)Leiomyosarcoma1 (2%)1 (2%)			(7)	(5)	(8)
intestine large, colon1 (13%)Fat, sarcoma1 (14%)ral mucosa(2)ral mucosa(2)Pharyngeal, squamous cell carcinoma1 (100%)ancreas(50)(50)(50)Leiomyosarcoma, metastatic, intestine large, colon1 (2%)Acinus, adenocarcinoma2 (4%)Acinus, adenoma1 (2%)Acinus, adenoma1 (2%)Squamous cell papilloma1 (2%)Squamous cell papilloma1 (2%)tomach, glandular(50)(50)(50)Carcinoid tumor benign1 (2%)Leiomyosarcoma1 (2%)		(11)	()	(3)	(0)
Fat, sarcoma1 (14%)ral mucosa(2)(1)Pharyngeal, squamous cell carcinoma1 (100%)ancreas(50)(50)(50)Leiomyosarcoma, metastatic, intestine large, colon1 (2%)Acinus, adenocarcinoma2 (4%)Acinus, adenoma1 (2%)Acinus, adenoma1 (2%)tomach, forestomach(50)(50)Squamous cell papilloma1 (2%)tomach, glandular(50)(50)Carcinoid tumor benign1 (2%)Leiomyosarcoma1 (2%)Leiomyosarcoma1 (2%)					1 (13%)
ral mucosa (2) (1) Pharyngeal, squamous cell carcinoma 1 (100%) ancreas (50) (50) (50) (49) Leiomyosarcoma, metastatic, intestine large, colon 1 (2%) Acinus, adenocarcinoma 2 (4%) Acinus, adenoma 1 (2%) Acinus, adenoma 1 (2%) tomach, forestomach (50) (50) (50) (50) (50) Sarcoma, metastatic, uncertain primary site 1 (2%) Squamous cell papilloma 1 (2%) 1 (2%) Squamous cell papilloma 1 (2%) (50) (50) (50) (50) Carcinoid tumor benign 1 (2%)			1 (14%)		1 (1570)
Pharyngeal, squamous cell carcinoma1 (100%)ancreas(50)(50)(50)(49)Leiomyosarcoma, metastatic, intestine large, colon1 (2%)Acinus, adenocarcinoma2 (4%)1 (2%)Acinus, adenoma1 (2%)1 (2%)Acinus, adenoma1 (2%)1 (2%)Komach, forestomach(50)(50)(50)Sarcoma, metastatic, uncertain primary site1 (2%)1 (2%)Squamous cell papilloma1 (2%)1 (2%)tomach, glandular(50)(50)(50)Carcinoid tumor benign1 (2%)1 (2%)Leiomyosarcoma1 (2%)1 (2%)		(2)	()	(1)	
ancreas (50) (50) (50) (49) Leiomyosarcoma, metastatic, intestine large, colon1 (2%) Acinus, adenocarcinoma2 (4%) 1Acinus, adenoma2 (4%) 1Acinus, adenoma1 (2%) 1Acinus, adenoma1 (2%) 1Acinus, adenoma1 (2%) 1tomach, forestomach(50) (50) (50) (50) Sarcoma, metastatic, uncertain primary site1 (2%) 1Squamous cell papilloma1 (2%) 1 (2%) tomach, glandular (50) (50) (50) (50) Carcinoid tumor benign1 (2%) 1 (2%) Leiomyosarcoma1 (2%) 1 (2%)					
$\begin{array}{c c} \mbox{Leiomyosarcoma, metastatic,} & & & & & 1 (2\%) \\ \mbox{intestine large, colon} & & & 2 (4\%) & & & & \\ \mbox{Acinus, adenoma} & & & 2 (4\%) & & & & \\ \mbox{Acinus, adenoma} & & & & 1 (2\%) & & & \\ \mbox{Acinus, carcinoma} & & & & 1 (2\%) & & & \\ \mbox{tomach, forestomach} & & (50) & (50) & (50) & (50) & (50) & \\ \mbox{Sarcoma, metastatic, uncertain primary site} & & & & 1 (2\%) & \\ \mbox{Squamous cell papilloma} & & 1 (2\%) & & & 1 (2\%) & \\ \mbox{tomach, glandular} & & (50) & & (50) & & (50) & & (50) & & \\ \mbox{Carcinoid tumor benign} & & & & 1 (2\%) & & \\ \mbox{Leiomyosarcoma} & & 1 (2\%) & & & \\ \end{tabular}$		(50)	(50)		(49)
Acinus, adenocarcinoma 2 (4%) Acinus, adenoma 1 (2%) Acinus, carcinoma 1 (2%) tomach, forestomach (50) (50) (50) Sarcoma, metastatic, uncertain primary site 1 (2%) 1 (2%) Squamous cell papilloma 1 (2%) 1 (2%) tomach, glandular (50) (50) (50) Carcinoid tumor benign 1 (2%) 1 (2%) Leiomyosarcoma 1 (2%) 1 (2%)	Leiomyosarcoma, metastatic,				
Acinus, adenoma 1 (2%) Acinus, carcinoma 1 (2%) tomach, forestomach (50) (50) (50) Sarcoma, metastatic, uncertain primary site 1 (2%) 1 (2%) Squamous cell papilloma 1 (2%) 1 (2%) tomach, glandular (50) (50) (50) Carcinoid tumor benign 1 (2%) 1 (2%) Leiomyosarcoma 1 (2%) 1 (2%)					1 (2%)
Acinus, carcinoma 1 (2%) tomach, forestomach (50) (50) (50) Sarcoma, metastatic, uncertain primary site 1 (2%) 1 (2%) Squamous cell papilloma 1 (2%) 1 (2%) tomach, glandular (50) (50) (50) Carcinoid tumor benign 1 (2%) 1 (2%) Leiomyosarcoma 1 (2%) 1 (2%)			2 (4%)		
tomach, forestomach (50) (50) (50) (50) Sarcoma, metastatic, uncertain primary site 1 (2%) 1 (2%) Squamous cell papilloma 1 (2%) 1 (2%) tomach, glandular (50) (50) (50) Carcinoid tumor benign 1 (2%) 1 (2%) Leiomyosarcoma 1 (2%) 1 (2%)				1 (2%)	
Sarcoma, metastatic, uncertain primary site1 (2%)Squamous cell papilloma1 (2%)tomach, glandular(50)(50)(50)Carcinoid tumor benign1 (2%)Leiomyosarcoma1 (2%)			1 (2%)		
Squamous cell papilloma 1 (2%) 1 (2%) tomach, glandular (50) (50) (50) Carcinoid tumor benign 1 (2%) 1 (2%) Leiomyosarcoma 1 (2%) 1 (2%)		(50)	(50)	(50)	(50)
tomach, glandular (50) (50) (50) (50) Carcinoid tumor benign Leiomyosarcoma 1 (2%)		1 (22.1)		1 (201)	1 (2%)
Carcinoid tumor benign1 (2%)Leiomyosarcoma1 (2%)	1 1 1		(50)		(50)
Leiomyosarcoma 1 (2%)		(50)	(50)		(50)
		1 (20/)		1 (2%)	
National metastatic uncertain numary sue		1 (2%)			1 (20/)
Schwannoma malignant, metastatic, heart 1 (2%)		1 (20/)			1 (2%)

Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Cardiovascular System				
Blood vessel	(50)	(50)	(50)	(50)
Heart	(50)	(50)	(50)	(50)
Schwannoma malignant	1 (2%)			
Endocrine System				
Adrenal cortex	(50)	(50)	(50)	(50)
Adenoma			1 (2%)	
drenal medulla	(50)	(50)	(50)	(50)
Pheochromocytoma malignant	1 (2%)	1 (2%)		1 (2%)
Pheochromocytoma benign	5 (10%)	10 (20%)	6 (12%)	9 (18%)
Bilateral, pheochromocytoma benign	1 (2%)	· /	× /	1 (2%)
slets, pancreatic	(50)	(50)	(50)	(49)
Adenoma	4 (8%)		× /	1 (2%)
Carcinoma	1 (2%)			2 (4%)
Parathyroid gland	(45)	(48)	(49)	(48)
Adenoma	X = 7		1 (2%)	x -7
Pituitary gland	(50)	(49)	(50)	(50)
Sarcoma NOS	()		()	1 (2%)
Pars distalis, adenoma	13 (26%)	13 (27%)	15 (30%)	10 (20%)
Pars intermedia, adenoma	10 (20/0)	12 (2770)	(50/0)	1 (2%)
'hyroid gland	(50)	(50)	(50)	(50)
C-cell, adenoma	12 (24%)	8 (16%)	7 (14%)	4 (8%)
C-cell, adenoma, multiple	12 (24/0)	8 (10/0)	/ (14/0)	1 (2%)
C-cell, carcinoma	2 (4%)		2 (4%)	1 (2%) 1 (2%)
Follicular cell, adenoma	1 (2%)		$\frac{2}{1}$ (470) 1 (2%)	1 (2%) 1 (2%)
Follicular cell, carcinoma	1 (2%)		1 (270)	1 (270)
General Body System None				
Genital System	(50)		(50)	(50)
Epididymis	(50)	(50)	(50)	(50)
Preputial gland	(50)	(50)	(50)	(50)
Adenoma	E (100/)	3 (6%)	$\frac{1}{7}$ (2%)	2(4%)
Carcinoma	5 (10%)	1 (2%)	7 (14%)	5 (10%)
rostate	(50)	(50)	(50)	(50)
eminal vesicle	(50)	(50)	(50)	(49)
estes	(50)	(50)	(50)	(50)
Bilateral, interstitial cell, adenoma	37 (74%)	44 (88%)	38 (76%)	40 (80%)
Interstitial cell, adenoma	10 (20%)	2 (4%)	9 (18%)	6 (12%)
Hematopoietic System				
Hematopoietic System Bone marrow	(50)	(50)	(50)	(50)

Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Hematopoietic System (continued)				
Lymph node	(5)	(4)	(4)	(2)
Carcinoma, metastatic, thyroid gland	1 (20%)	(1)		(-)
Deep cervical, histiocytic sarcoma	- (-*,*)	1 (25%)		
Pancreatic, sarcoma, metastatic,		- ()		
uncertain primary site				1 (50%)
Lymph node, mandibular	(48)	(50)	(50)	(50)
Histiocytic sarcoma		1 (2%)		
Lymph node, mesenteric	(50)	(50)	(50)	(50)
Sarcoma, metastatic, uncertain primary site	(2.0)	((1))		1 (2%)
Spleen	(50)	(50)	(50)	(50)
Fibroma	()		<u> </u>	1 (2%)
Fibrosarcoma		1 (2%)		(-, •)
Histiocytic sarcoma		- (-, -,		1 (2%)
Sarcoma, metastatic, uncertain primary site				1 (2%)
Thymus	(50)	(49)	(49)	(48)
Histiocytic sarcoma	<u> </u>	1 (2%)	X · /	X -7
Integumentary System				
Mammary gland	(45)	(47)	(47)	(47)
Carcinoma			1 (2%)	
Fibroadenoma	3 (7%)	5 (11%)	2 (4%)	
Fibroadenoma, multiple			1 (2%)	
Skin	(49)	(50)	(50)	(50)
Basal cell adenoma		1 (2%)		
Basal cell carcinoma	1 (2%)			
Fibroma		1 (2%)	5 (10%)	3 (6%)
Fibroma, multiple			1 (2%)	
Fibrosarcoma	1 (2%)			2 (4%)
Keratoacanthoma	2 (4%)	3 (6%)	4 (8%)	3 (6%)
Keratoacanthoma, multiple				1 (2%)
Lipoma	1 (2%)			× /
Sarcoma			1 (2%)	
Squamous cell carcinoma		1 (2%)	× /	
Frichoepithelioma		1 (2%)		
Musculoskeletal System	(50)	(50)	(50)	(50)
Bone	(50)	(50)	(50)	(50)
Osteosarcoma	1 (20/)			1 (2%)
Maxilla, osteosarcoma	1 (2%)			(1)
Skeletal muscle	(1)			(1)
Sarcoma, metastatic, uncertain primary site				1 (100%)
Nervous System				
Brain	(50)	(50)	(50)	(50)
	(30)	1 (2%)	(30)	(30)
Histiocytic sarcoma		[[7.70]		

Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Respiratory System				
Lung	(50)	(50)	(50)	(50)
Alveolar/bronchiolar adenoma	2 (4%)	3 (6%)	2 (4%)	2 (4%)
Alveolar/bronchiolar carcinoma			1 (2%)	
Carcinoma, metastatic, thyroid gland	1 (2%)			
Histiocytic sarcoma		1 (2%)		
Leiomyosarcoma, metastatic,				
intestine large, colon				1 (2%)
Schwannoma malignant, metastatic, heart	1 (2%)			
Trachea	(50)	(50)	(50)	(50)
Special Senses System				
Harderian gland		(2)		
Histiocytic sarcoma		1 (50%)		
Zymbal's gland	(1)	. ,		(2)
Carcinoma	1 (100%)			2 (100%)
Urinary System				
Kidney	(50)	(50)	(50)	(50)
Renal tubule, adenoma			1 (2%)	
Urinary bladder	(49)	(50)	(50)	(50)
Transitional epithelium, papilloma	1 (2%)			
Systemic Lesions				
Multiple organs ^b	(50)	(50)	(50)	(50)
Histiocytic sarcoma	· · ·	1 (2%)		1 (2%)
Leukemia mononuclear	17 (34%)	12 (24%)	7 (14%)	3 (6%)
Lymphoma malignant		1 (2%)		
Mesothelioma malignant	3 (6%)	3 (6%)	4 (8%)	1 (2%)
Neoplasm Summary				
Total animals with primary neoplasms ^c	49	49	50	50
Total primary neoplasms	129	120	123	107
Total animals with benign neoplasms	47	48	49	49
Total benign neoplasms	93	94	99	86
Total animals with malignant neoplasms	30	22	21	20
Total malignant neoplasms	36	26	24	20
Total animals with metastatic neoplasms	2	20	<i>Δ</i> - Τ	21
				11
Total metastatic neonlasms	n			
Total metastatic neoplasms Total animals with malignant neoplasms	6			11

а Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms

b

c

	2	4	4	4	5	5	5	5 4	55	6	6	6	6	6	6	6	6	6	6	7	7	7	7	7
Number of Dove on Study				•														•		2	2	2	2	2
Number of Days on Study	5 2	0 0	8		2	2			38 99									8		2				2
	Z	0	0	9	3	9	0	3	99	3	0	0	4	I	0	0	0	0	3	4	9	9	9	9
	0	0	0	0	0	0	0	0 (0 0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Carcass ID Number	3	1	0	3	1	1	4	4 () 2	0	2	4	2	3	1	0	2	1	4	1	0	1	1	1
	4	5	8	2	8	0	1	0 4	4 0								6						7	9
Alimentary System																								
Esophagus	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
intestine argeç olon	+	+	+		+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Schwannoma malignant, metastatic, heart				Х																				
Intestine arger, ectum	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, cecum	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, duodenum	+	+	+	Μ	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, jejunum	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestines malli, leum	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Liver	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Schwannoma malignant, metastic, heart				Х																				
Mesentery			+				+								+	+	+							
Oral mucosa														+										
Pancreas	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Salivaryg lands	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomachf orestomach	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Squamous cell papilloma																								
Stomach, glandular	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Leiomyosarcoma					,					X														
Schwannoma malignant, metastatic, heart				Х						Λ														
sensumonia manghant, meastaire, neart				1																				
Cardiovascular System																								
Blood vessel	+	$^+$	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Heart	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Schwannoma malignant				Х																				
Endoarina System																								
Endocrine System												,					,	,						
Adrenal cortex	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+		+
Adrenal medulla	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pheochromocytoma malignant																								
Pheochromocytoma benign												Х												
Bilateral, pheochromocytoma benign				+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Islets, pancreatic	+	+	+																					Х
Bilateral, pheochromocytoma benign (slets, pancreatic Adenoma	+	+	+		'																			
Islets, pancreatic	+	+	+																					
Islets, pancreatic Adenoma Carcinoma	+	+ M	+	M	+	+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+
Islets, pancreatic Adenoma Carcinoma Parathyroid gland							+ -				+ +	+++			+ +			+ +					+ +	
Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland	+	+	+	+	+	+	+ -	+ -	+ +	+				+	+									+
Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma	+	+	+	+	+	+		+ -	+ + X	+	+		+	+	+ X		+	$^+_{\rm X}$					+	
Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Thyroid gland	+	+	+	+	+	+	+ -	+ -	+ + X	+	+	+	+	+	+ X +	+	+	$^+_{\rm X}$	+	+			++	+ X
Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Thyroid gland C-cell, adenoma	+	+	+	+	+	+	+ -	+ -	+ + X	+	+	+	+	+	+ X +	+	+	$^+_{\rm X}$	+	+	+	+	+	+ X
Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Thyroid gland C-cell, adenoma C-cell, carcinoma	+	+	+	+	+	+	+ -	+ -	+ + X	+	+	+	+	+	+ X +	+	+	+ X +	+	+		+	++	+ X
slets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Chyroid gland C-cell, adenoma C-cell, carcinoma Follicular cell, adenoma	+	+	+	+	+	+	+ -	+ -	+ + X	+	+	+	+	+	+ X +	+	+	+ X + X	+	+	+	+	++	+ X
slets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Chyroid gland C-cell, adenoma C-cell, carcinoma	+	+	+	+	+	+	+ -	+ -	+ + X	+	+	+	+	+	+ X +	+	+	+ X + X	+	+	+	+	++	+ X
slets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Fhyroid gland C-cell, adenoma C-cell, carcinoma Follicular cell, adenoma Follicular cell, carcinoma	+	+	+	+	+	+	+ -	+ -	+ + X	+	+	+	+	+	+ X +	+	+	+ X + X	+	+	+	+	++	+ X
slets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Chyroid gland C-cell, adenoma C-cell, carcinoma Follicular cell, adenoma Follicular cell, carcinoma General Body System None	+	+	+	+	+	+	+ -	+ -	+ + X	+	+	+	+	+	+ X +	+	+	+ X + X	+	+	+	+	++	+ X
slets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Chyroid gland C-cell, adenoma C-cell, carcinoma Follicular cell, adenoma Follicular cell, carcinoma General Body System None Genital System	+	+	+	+	+	+	+ -	+ -	+ + X	+	+	+	+	+	+ X +	+	+	+ X + X	+	+	+	+	++	+ X
Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Thyroid gland C-cell, adenoma C-cell, carcinoma Follicular cell, adenoma Follicular cell, acarcinoma General Body System None Genital System Epididymis	+	+	+	+	+	+	+ -	+ -	+ + X	+	+	+	+	+	+ X +	+	+	+ X + X	+	+	+	+	++	+ X
Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Thyroid gland C-cell, adenoma C-cell, carcinoma Follicular cell, adenoma Follicular cell, acrcinoma General Body System None Genital System	+	+	+	+	+	+	+ -	+ -	+ + X	+	+	+	+	+	+ X +	+	+	+ X + X	+	+	+	+	++	+ X

+: Tissue examined microscopically A: Autolysis precludes examination M: Missing tissue I: Insufficient tissue X: Lesion present Blank: Not examined

	7	7	7	7	7	7	7	7	7	7	7	7 /		7 7	7	7	7	7	7	7	7	7	7	7	
Number of Dave on Study	2	2	2	2	2	2	2	2	2	2	2	/ 2 /	, , , ,	/ / > ~	2	2	2	2	2	2	2	2	3	2	
Number of Days on Study	2 9	2 9	2 9	2 9	3 0	3 0	3 0	3 0	3 0				33) (33)0	3 0	3 0	3 0	3 1	3 1	3 1	3 1	3 1			
	0	0	0	0	0	0	0	0	0	0	0	0			0	0	0	0	0	0	0	0	0	0	T ()
Carcass ID Number	03	0 3	0	0	0	0 0	0 0		0 2			-	2 3	$0 0 \\ 3 4$	4	0 4	0 5	0 0	2	0 3	3	0 3	0 3		Total /Tissues
	0	8	2	7	1	7								96			0			1	3		7		Tumors
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Intestine argeç olon	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Schwannoma malignant, metastatic, heart																									1
ntestind arger ectum	+	+	+	+	+	+	+	+	+	+	+	+ •	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+ •	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
ntestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+ •	+ -	+ +	+	+	+	+	+	+	+	+	+	+	49
ntestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
ntestines malli leum	+	+	+	+	+	+	+	+	+	+	+	+ •	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Liver	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Schwannoma malignant, metastic, heart																									1
Mesentery	+	+				+										+					+	+			11
Dral mucosa						+																			2
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ + 	+	+	+	+	+	+	+	+	+	+	50
Salivaryg lands Stomachf orestomach	+	+	+	+	+	+	++	++	++	++			+ - + -	+ + + +	+	++	++	++	++	+	+	+	+	+	50 50
Squamous cell papilloma	+	+	+	Ŧ	Ŧ	Ŧ		+ X	7	Τ'	Τ'	Γ.		· +	+	+	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	+	+	- T	50 1
Stomach, glandular	+	+	+	+	+	+			+	+	+	+ -	L -	+ +	+	+	+	+	+	+	+	+	+	+	50
Leiomyosarcoma	1	'			'	'	'			'	'	'			'	'								'	50
Schwannoma malignant, metastatic, heart																									
2 · · · · · · · · · · · · · · · · · · ·																									
Cardiovascular System																									
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Heart	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Schwannoma malignant																									1
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+ •	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma malignant																					Х				1
Pheochromocytoma benign		Х								Х				Х					Х						5
Bilateral, pheochromocytoma benign												X													1
slets, pancreatic	+	+	+	+	+	+	+	+	+		+ X	+ •	+ -	+ +	+	+ X	+	+	+	+ X	+	+	+	+	50
Adenoma											л					Х				Х	v				4
Carcinoma Parathyroid gland	L	<u>т</u>	<u>т</u>	<u>_</u>	ـ ــ	<u>ـــ</u>	+	+	+	+	+	+ -	_ x	А+	т.	+	+	-L	_ _	+	X +	<u>т</u>	М	+	1 45
Parathyroid gland Pituitary gland	+	+ +	+ +	τ +	+	+	+	+	т +		+			/1 + + +		+								+	45 50
Pars distalis, adenoma	-1	Т	т	T	т Х	F	X	x	1	1	'			хх			Х	1-	T	Т	Х	Т	т	1.	13
Thyroid gland	+	+	+	+	+	+			+	+	+			ал + +			+	+	+	+	+	+	+	+	50
C-cell, adenoma	x	X				'			x :						'	'	x	x			X	'		X	12
C-cell, carcinoma												2	X											••	2
Follicular cell, adenoma												1	-												1
Follicular cell, carcinoma																									1
General Body System																									
Genital System		,	,													,						,	,		
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+ •	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
Preputial gland Carcinoma	+	+	+	+	+	+	+	+	+	+	+	+ · X	+ -	+ +	+	+	+	+	+	+	+	+	+	+	50
L ALCIDOMA						Х											Х								5

Number of Days on Study	2 5 2	4 0 0					5 5 8	5 7 3	8	8	6 0 5	1	2	2	3	3	6 4 8	6	8	8	7 2 4	7 2 9	7 2 9		7 2 9	
Carcass ID Number	034		0	03	0	0 1 0	0 4	0 4	0 0	0 2	0 0	0 2	0 4	0 2	0 3	0 1	0 0	0 2	0 1	0 4	0 1	0 0	0 1	0	0 1	
Genital System (continued) Prostate Seminaly esicle Testes Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	+ + +	+++++	+ + + X	· + · +	+ + + X	+ + + X	+ + + X	+ + X	++++++	+ + + X	++++++	+ + +	+++	+ + + X	+ + +	+ + +	+ +	+++++++	+ + +	+ + + X	+++++	+++++	+++++	+++	+ + + X	
Hematopoietic System Bone marrow Lymph node Carcinoma, metastatic, thyroid gland Lymph node, mandibular Lymph node, mesenteric Spleen Thymus	+ + + +	++++++	+++++++++++++++++++++++++++++++++++++++	+ + + +	+ + + + + +	+ + + + + + +	+ + + + +	+ + + + +	+ + + + + +	+ + + + +	+ + + + + + +	+ + + + + +	+ + + + + +	+ + M + +	+ + + + + +	+ + + + + +	+ + + + + +	+ + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + X + + +	+ + + + +	+ + + + +	+ + + + +	+ + + + + +	+ + + + +	
Integumentary System Mammaryg land Fibroadenoma Skin Basal cell carcinoma Fibrosarcoma Keratoacanthoma Lipoma	M +	M +	(+ + X	+	[+	+ +	++	+ M	+ X +	+	++	+	+ X +	+	+	+	+ +	+	+ +	M +	+ + X X	+ +	+		+ +	
Musculoskeletal System Bone Maxilla, osteosarcoma Skeletal muscle	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Respiratory System Lung Alveolar/bronchiolar adenoma Carcinoma, metastatic, thyroid gland Schwannoma malignant, metastatic, heart Nose Trachea	+ + + + +	+++++	+++++++++++++++++++++++++++++++++++++++	+ X + +	+++++++++++++++++++++++++++++++++++++++	+++++	+++++	+++++	+++++	+ + + +	++++++	+++++	++++++	+++++	++++++	+ + + +	++++++	+ + + +	+++++	+ X + +	+++++	+++++	+++++	+ X + +	+ + + +	
Special Senses System Zymbal's gland Carcinoma												+ X								*						
Urinary System Kidney Urinary bladder Transitional epithelium, papilloma	+++	+ +	+	+++	+++	+ +	+++	+++	+++	+ +	+ +	+ +	+ M		+ + X	+ +	+ +	+ +	+++	++++	+++	+++	+++	+++	+ +	
Systemic Lesions Multiple organs	+	+	+	+	+	+ X	+	+ X	+	+	+	+ X	+	+	+ X	+	+	+	+	+	+	+	+	+	+	

Individual Animal Tumor Pathology of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm

individual Annual Funiti Funiti Facilitação							_	cai	_			-9			I D		J	•-	~ •						- 1	phu
Number of Days on Study	7 2 9	2	2 2	7 2 9	7 3 0	7 3 0	7 3 0	7 3 0	3	7 3 0	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1		7 3 1									
Carcass ID Number	0 3 0	3	5 4	4		0	0 0 9		0 2 2	2	2	2	2	3	4	0 4 8	0 4 9	0 5 0	0 0 2	0 2 8	0 3 1	0 3 3	0 3 6	3	0 4 5	Total Tissues/ Tumors
G enital System (continued) Prostate Seminaly esicle	+	- +	- +	· +	+	+	+	++++	+	+	+	+	++++	+	+	++++	+	++++	+	++++	+	+	+	+	+++	50 50
Festes Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	+ X	- + : X	- + X X	+ ; X		+ X	+	50 50 37 10																		
Jematopoietic System Bone marrow Jymph node	+	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 5
Carcinoma, metastatic, thyroid gland symph node, mandibular symph node, mesenteric pleen	+ + +	- + - +	- + - +	· + · +	++++++	+ + +	1 48 50 50																			
Thymus	+	· +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 50
Integumentary System Mammaryg land Fibroadenoma Skin	+	- +	- +	· +	++++	++	+	+	+	+	+	+	M +		+ X +	+	+	+	+	+	+	+	+	++	+	45 3 49
Basal cell carcinoma Fibrosarcoma Keratoacanthoma Lipoma					х						х															1 1 2 1
Musculoskeletal System Bone Maxilla, osteosarcoma Skeletal muscle	+	- +	- +	+	+	+ X	+	+	+	+	+	+	+	+	+	+	++	+	+	+	+	+	+	+	+	50 1 1
Nervous System Brain	+	- +	- +	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System .ung Alveolar/bronchiolar adenoma Carcinoma, metastatic, thyroid gland	+	- +	- +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	50 2 1
Schwannoma malignant, metastatic, heart Nose Irachea	+ +	- +	- + - +	· + · +	+++	+ +	1 50 50																			
Special Senses System /ymbal's gland Carcinoma																										1 1
J rinary System Lidney Jrinaryb ladder Transitional epithelium, papilloma	+ +	- +	- +	• +	+++	+++	+++	+ +	+ +	+ +	+++	++++	+ +	+++	+ +	+++	+ +	+ +	+++	+ +	+ +	+++	+ +	+ +	+++	50 49 1
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant	+	- +	- + X X		+	+	+ X	+	+	+ X	+	+	+ X	+ X	+ X	+	+ X	+	+ X	+	+	+	+	+	+	50 17 3

Individual Animal Tumor Patholog	gy of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm	
	4 4 4 5 5 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7	
Number of Days on Study	1 8 8 5 8 0 4 4 6 8 9 9 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
	5 0 1 2 2 1 1 6 9 0 1 3 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	
	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
Carcass ID Number	5 6 5 7 6 8 6 6 9 8 5 6 5 5 5 6 6 7 7 7 7 7 8	
	9 2 5 1 6 5 0 9 9 7 1 5 3 4 6 8 7 8 0 2 3 4 7 8 0	
Alimentary System		
Esophagus	+ + + + + + + + + + + + + + + + + + + +	
Intestine argeç olon	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Carcinoma	Х	
Intestind arger ectum	+ + + + + + + + + + + + + + + + + + + +	
Intestine large, cecum	+ + + + + + + + + + + + + + + + + + + +	
Intestine small, duodenum	+ + + + + + + + + + + + + + + + + + + +	
Intestine small, jejunum	A + + + + A + + + + + + + + + + + + + + + + + + +	
Intestines malli leum	A + + + + + + + + + + + + + + + + + + +	
Liver	+ + + + + + + + + + + + + + + + + + + +	
Histiocytic sarcoma	X	
Mesentery	+ + + +	
Fat, sarcoma	X	
Pancreas	+ + + + + + + + + + + + + + + + + + +	
Acinus, adenocarcinoma	X	
Acinus, carcinoma	7A	
Salivaryg lands	+ + + + + + + + + + + + + + + + + + + +	
Stomachf orestomach		
Stomach, glandular	+ + + + + + + + + + + + + + + + + + + +	
Stormach, grandular		
Cardiovascular System		
Blood vessel	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Heart	+ + + + + + + + + + + + + + + + + + + +	
Endocrine System		
Adrenal cortex	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Adrenal medulla	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Pheochromocytoma malignant	Х	
Pheochromocytoma benign	X X X X X X X X	
Islets, pancreatic	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Parathyroid gland	+ + + + + M + + + + + + + + + + + + + + + + + + +	
Pituitary gland	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Pars distalis, adenoma	X X X X X X X X	
Thyroid gland	+ + + + + + + + + + + + + + + + + + + +	
C-cell, adenoma	X X	
General Body System None		
Genital System		
Epididymis	+ + + + + + + + + + + + + + + + + + + +	
Preputial gland	+ + + + + + + + + + + + + + + + + + + +	
Adenoma		
Carcinoma	Х	
Prostate	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
a · · · · ·		
Seminal vesicle	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Seminal vesicle Testes	+ + + + + + + + + + + + + + + + + + +	
	+ + + + + + + + + + + + + + + + + + +	

Individual Animal Tumor Pathology of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm	

Individual Animal Tumor Pathology of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm

												_				-									
	7	' 7	7	7	7	7	7	7	7	7	7 ′	77	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	2	2	2	2	2	2	3	3	3	3	3	3 3	3	3	3	3	3	3	3	3	3	3	3	3	
	9	9	9	9	9	9	0	0	0	0	0 (0 0	0 0	0	0	0	0	1	1	1	1	1	1	1	
	C) ()	0 (0	0	1	0	0	0	0	0 (0 () ()	0	0	0	0	0	0	0	0	0	0	0	Total
Carcass ID Number	8				9	0	5					88		9	9	9	9	5	6	7	8	9	9		Tissues/
	3				7		7				9			2					1			Ó			Tumors
Alimentary System																									-
Esophagus	+	- +	- +	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Intestine argeç olon	+	- +	- +	+	+	+	+	+	+	+	+ •	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Carcinoma																									1
Intestind arger ectum	+	- +	- +	+	+	+	+	+	+	+	+ •	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	- +	- +	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	- +	- +	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	++	50 48
Intestine small, jejunum Intestines malli leum	+	- +	- +	+	+	+	+	+	+	+	+ •	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	48 49
	т L	 -	· ·	- T	- -	- -	+ +	+ +	т _	- -	+ -	+ +	- T	+ +	+	+	- -	- -	+	+ +	+ +	+ +	+ +	+	
Liver Histiogytic sarcoma	+	+	+	Ŧ	Ŧ	-	7	Τ'	т	т	Τ.	r 1	+	Ŧ	Ŧ	-	-	-	-	Ŧ	-	-	-	7"	50 1
Histiocytic sarcoma																						,			
Mesentery														+								+			7
Fat, sarcoma													,												1
Pancreas	+	- +	- +	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Acinus, adenocarcinoma																								X	2
Acinus, carcinoma						J	ч	Т	<u>т</u>	+	<u>т</u>	L .	_ ,			J	J	5						X +	1
Salivaryg lands Stomachf arastamach	+	- +	- +	+	+	+	+	+	+	+	+ •		- +	+	+	+	+	+	+	+	+	+	+	++	50
Stomachf orestomach	+	- +	- +	+	+	+	+	+	+	+	+ •		- +	+	+	+	+	+	+	+	+	+	+	+	50 50
Stomach, glandular	+	+	+	Ŧ	Ŧ	-	7"	Τ'	т	т	- ·	r T	+	Ŧ	т	T	Т	Т	-	Ŧ	-	-	-	Τ.	30
Cardiovascular System																									
Blood vessel	+	- +	• +	+	+	+	+	+	+	+	+ •	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Heart	+	- +	- +	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																									
Adrenal cortex	+	- +	- +	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal medulla	+	- +	- +	· +	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma malignant					,																				1
Pheochromocytoma benign		Х							X	x															10
Islets, pancreatic	+			+	+	+	+				+ •	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Parathyroid gland	+	- +		+	+	M	+			+	+ •	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	48
Pituitary gland	+	- +		+	+	+	+				+ •	+ +	- +	+	+	+	+	+	+	+	+	+	+		49
Pars distalis, adenoma			x			X				x	ĺ							x				x		•	13
Thyroid gland	+				+	+	+	+			+ •	+ +	- +	+	+	+	+		+	+	+	+	+	+	50
C-cell, adenoma						X			X						X				X						8
Conoral Rody System																									
General Body System None																									
Conital System																									
Genital System Epididymis	-			+	+	+	+	+	+	+	+ -	+ -		+	+	+	+	+	+	+	+	+	+	+	50
Preputial gland	т 4			+	+	+	+	+	+	+	+ -	· · ·	- +	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma	X	т 7	r	1.	1	X				'				1		'	'	Х	'					'	3
Carcinoma	7	•				л												Λ							1
Prostate	1			+	+	+	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	+	+	+	+	+	50
Seminal vesicle	т 	т 			+	т +	+	+	+	+	+ -	 + -		+	+	+	+	+	+	+	+	+	+	+	50 50
Festes	T L	т 		- T	+	+	+	+	+	+	· ·	· -		+	+	+	+	+	+	+	+	+	+	+	50
Bilateral, interstitial cell, adenoma	+ v	- + X X	, +	\mathbf{v}	\mathbf{v}	+ X	\mathbf{v}	\mathbf{v}	\mathbf{v}^{\top}	Τ.	r · v ·	r T V V	- + X X	\mathbf{v}		50 44									
Interstitial cell, adenoma	Δ	<u>ь</u> Л	x		л	Λ	л	л	л		Λ	<u>~</u> 2	<u>а</u> А	л	л	л	л	л	л	л	Λ	Λ	Λ	л	44
merstitiai cen, auchoma			Λ																						2

Mesothelioma malignant

4 4 4 5 5 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 1 8 8 5 8 0 4 4 6 8 9 9 2 2 2 2 2 2 2 2 2 2 2 2 2 $2 \ \ 2 \ \ 1 \ \ 1 \ \ 6 \ \ 9 \ \ 0 \ \ 1 \ \ 3 \ \ 9$ 99 9 9 9 9 9 9 5 0 1 9 9 9 9 0 **Carcass ID Number** 7 6 6 7 5 6 5 8 6 6 9 8 5 6 5 5 5 5 6 7 7 7 7 7 8 9 2 5 1 6 5 0 9 97 5 3 4 6 8 7 8 0 2 3 1 4 7 8 0 Hematopoietic System Bone marrow Lymph node Deep cervical, histiocytic sarcoma Х Lymph node, mandibular + + + Histiocytic sarcoma Х Lymph node, mesenteric Spleen Fibrosarcoma Thymus +Μ + ++ Histiocytic sarcoma Х **Integumentary System** Mammary gland Fibroadenoma Skin Basal cell adenoma Fibroma Х Keratoacanthoma Х Х Squamous cell carcinoma Х Trichoepithelioma Musculoskeletal System Bone +**Nervous System** Brain + + + Histiocytic sarcoma Х **Respiratory System** Lung Alveolar/bronchiolar adenoma Histiocytic sarcoma Х Nose + + + Trachea + + **Special Senses System** Eye +Harderian gland + Х Histiocytic sarcoma **Urinary System** Kidney + + + + + +Urinary bladder + + Systemic Lesions Multiple organs + + + + + + ++ + ++ Histiocytic sarcoma Х ХХ Х Х Leukemia mononuclear Х Х Х Х Lymphoma malignant

Х

Х

Individual Animal Tumor Pathology of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm

Individual Animal Tumor Pathology of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm

	5, 01 11		. 1.		,			-	cui				• • •	an		/tu	ay			110		1 11			10	o ppm
Number of Days on Study		7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	3	3	7 7 3 3 0 (3 3	3	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	3	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	3	
Carcass ID Number		0 8 3	0 8 4	0 8 8	9	0 9 7	0	5	6	6	7 7) 0 7 8 9 1	8	0 8 6	9	0 9 4	9	9	5	0 6 1	0 7 5	0 8 9	0 9 0	0 9 3	9	Total Tissues/ Tumors
Hematopoietic System																										
Bone marrow		+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node Deep cervical, histiocytic sarcoma																										4
Lymph node, mandibular		+	+	+	+	+	+	+	+	+ •	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																										1
Lymph node, mesenteric		+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Spleen		+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Fibrosarcoma			Х																							1
Thymus Histioautia saraoma		+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	49 1
Histiocytic sarcoma																										1
Integumentary System																										
Mammaryg land		+	+	+	+	Μ	+	+	+	+ ·	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Fibroadenoma			Х					Х		Х	У								Х							5
Skin		+	+	+	+	+	+	+	+	+ ·	+ -	+ +		+	+	+	+	+	+	+	+	+	+	+	+	50
Basal cell adenoma													Х													1
Fibroma Keratoacanthoma										,	X															1 3
Squamous cell carcinoma										4	1															1
Trichoepithelioma																Х										1
Musculoskeletal System Bone		+	+	+	+	+	+	+	+	+ ·	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Nervous System																										
Brain		+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																										1
Respiratory System																										
Lung		+	+	+	+	+	+	+	+	+ •	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma								Х										Х		Х						3
Histiocytic sarcoma																										1
Nose		+	+	+	+	+	+	+	+	+ ·	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Trachea		+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Special Senses System Eye																										1
Harderian gland										+																2
Histiocytic sarcoma																										1
Luin our System																										
Urinary System Kidney			,									, ,			,							,	,			50
Urinary bladder		+	+	+	+	+	+	+	+	+ ·	+ -	, + + +	+	+ +	+	+	+	 +	+	+	+	+	+	+	+	50 50
		'	1	'	1	1	ſ	'	'				1.	1	1	'	1		1	'		1	1		1	50
Systemic Lesions																										
Multiple organs		+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																										1
Leukemia mononuclear							Х			Х	2	ζ	Х					Х								12
Lymphoma malignant Mesothelioma malignant											-	,														1
											2	(3

Individual Animal Tumor Pathology of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm

	, 01 10 101					_					8				uuj) FI /-	
	4	5	5	5	5	6	66	6	6	7	7	7	7 7	77	7	7	7	7	7	7	7	7	7	
Number of Days on Study	0	0	5	8	9	2	89	9	9	0	1	2	2 2	2 2	2	2	2	2	2	2	2	2	2	
UU	0	5		2		0			7		6		8 9		9			9	9	9		9		
	1	1	1	1	1	1	1 1	1	1	1	1	1	1 1	1	1	1	1	1	1	1	1	1	1	
Carcass ID Number	1	1	1	1	-											1				1				
Carcass ID Number	3 7	2 6	2 4	8			54 03		02		4 0		3 (6)		1	2		1 5	1 8	9		2 9		
		-		-	-		-			-	-						-	-	-	-		-		
Alimentary System Esophagus	+	+	+	+	+	+	+ +	. +	. +	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	
Intestine large, colon	+	+	+	+	+	+	 + +	. +	. +	+	+	+	+ -	 + +	. +	+	+	+	+	+	+	+	+	
Intestine large, rectum	+	+	+	+	+	+	 + +	. +	. +	+	+	+	+ -	· ·	. +	+	+	+	+	+	+	+	+	
Intestine large, cecum	+	+	+	+	+	+	· ·	. +	. +	+	+	+	+ -	 + +	. +	+	+	+	+	+	+	+	+	
Intestine small, duodenum	+	+	+	+	+	+	· ·	. +	. +	+	+	+	+ -	 + +	. +	+	+	+	+	+	+	+	+	
Intestine small, jejunum	+	+	+	+	+	+	+ +	· +	· +	+	+	+	+ -	 + +	· +	+	+	+	+	+	+	+	+	
Intestine small, ileum	+	+	+	+	+	+	+ +	• +	· +	+	+	+	+ -	 + +	· +	+	+	+	+	+	+	+	+	
Liver	+	+	+	+	+	+	+ +	· +	· +	+	+	+	+ -	 + +	· +	+	+	+	+	+	+	+		
Hepatocellular adenoma					-								Ż											
Mesentery											+		1	-				+						
Oral mucosa					+																			
Pharyngeal, squamous cell carcinoma					x																			
Pancreas	+	+	+	+	+	+	+ +	. +	+ +	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	
Acinus, adenoma	1																							
Salivary glands	+	+	+	+	+	+	+ +	. +	+ +	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	+	+	+	+	+	+	+ +	· +	• +	+	+	+	+ -	 + +	• +	+	+	+	+	+	+	+	+	
Squamous cell papilloma	1													x										
Stomach, glandular	+	+	+	+	+	+	+ +	• +	• +	+	+	+	+ -	+ +		+	+	+	+	+	+	+	+	
Carcinoid tumor benign																						x		
Tongue																								
-																								—
Cardiovascular System																								
Blood vessel	+	+	+	+	+	+	+ +	• +	• +	+	+	+	+ -	+ + 	• +	+	+	+	+	+	+	+	+	
Heart	+	+	+	+	+	+	+ +	• +	• +	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	
Endocrine System																								
Adrenal cortex	+	+	+	+	+	+	+ +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	
Adenoma																								
Adrenal medulla	+	+	+	+	+	+	+ +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	
Pheochromocytoma benign												X							Х		Х			
Islets, pancreatic	+	+	+	+	+	+	+ +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	
Parathyroid gland	+	+	+	+	+	+	+ +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+		+	+	
Adenoma																					Х			
Pituitary gland	+	+	+	+	+	+	+ +	+	+	+	+	+	+ -	+ +		+	+	+	+	+	+	+	+	
Pars distalis, adenoma		Х	Х	Х												Х		Х			Х			
Thyroid gland	+	+	+	+	+	+	+ +	+	+		+	+	+ -	+ +	+	+	+		+	+	+	+	+	
C-cell, adenoma										Х		Х						Х						
C-cell, carcinoma				Х																				
Follicular cell, adenoma														Х										
General Body System																								
Peritoneum																						+		
Genital System																								
Epididymis	+	+	+	+	+	+	+ +		. +	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	
Preputial gland	+	+	+	+	+	+	 + +	· +	· +	+	+	+	+ -	, , + +	· +	+	+	+	+	+	+	+	+	
Adenoma	r						, г	ſ	X	'		•		. г	1.	1		'	·	'	1			
Carcinoma									Λ			X	x					Х						
Prostate	+	+	+	+	+	+	+ +	. +	. +	+	+	л. +	+ -	+ +	+	+	+	л +	+	+	+	+	+	
Seminal vesicle	+	+	+	+	+	+	, т + +		. +	+	+	+	+ -	, r + +	. +	+	+	+	+	+	+	+	+	
Testes	+	+	+	+	+	+	 + +	· +	. +	+	+	+	+ -	 + +	· +	+	+	+	+	+	+	+	+	
Bilateral, interstitial cell, adenoma	r				x ·	x ·	XX	v	v	ÿ		X			X	1		ÿ	Х	\mathbf{x}	1	ÿ	X	
Interstitial cell, adenoma		Х		Х	Λ.	<u> </u>	<u>л</u> л		Л		Х		ху		. Л		Х	Λ	л	л		л	21	
musulai cen, auchoma		л		л							л		л 2	<i>r</i>		Л	л							

Individual Animal Tumor Pathology of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm

Individual Allinai Tullor Fatilolog	, 01 1/ 1	-									0					/								- FF
	7	7	7	7	7	7	77	7	7	7	7	7	7	7 7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	2			3	3	3	3 3			3	3	3		3 3			3	3	3	3	3		3	
	9	9	0	0	0	0	0 0	0	0	0	0	0	0	0 () 0	1	1	1	1	1	1	1	1	
	1	1	1	1	1	1	1 1	1	1	1	1	1	1	1 1	1	1	1	1	1	1	1	1	1	Total
Carcass ID Number	1			1	1																		4	
Carcass ID Number	3	4		4	0	2 0	2 2 5 8		3 2	3 4	3	4	4 .	44		03	0	1	2 1	2	3			Tissues/
	3	/	1	4	0	0	3 0	0	Z	4	3	1	3	0 0	· 9	3	0	0	1	/	0	9	2	Tumors
Alimentary System																								
Esophagus	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+ +	+ +	+ +	+	+	+	+	+	+	+	50
Intestine large, colon	+	+ +	+	+	+	+	+ +	+ +	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	50
Intestine large, rectum	+	+	+	+	+	+	+ +	+	+	+	+	+	+ ·	+ +	+ +	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+ +	+	+	+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	50
Intestine small, jejunum	+	+	+	$^+$	$^+$	+	+ +	+	+	$^+$	+	+	+ ·	+ +	+ +	+	+	$^+$	+	+	$^+$	$^+$	+	50
Intestine small, ileum	+	+	+	+	+	+	+ +	+	+	+	+	+	+ ·	+ -	- +	- +	+	+	+	+	+	+	+	50
Liver	+	+	+	+	+	+	+ +	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	50
Hepatocellular adenoma																								1
Mesentery							+		+										+					5
Oral mucosa																								1
Pharyngeal, squamous cell carcinoma																								1
Pancreas	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	50
Acinus, adenoma						Х																		1
Salivary glands	+	+	+	+	+	+	+ +	• +	+	+	+	+	+	+ -	+ +	• +	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+ -	- +	+	+	+	+	+	+	+	+	50
Squamous cell papilloma																								1
Stomach, glandular	+	• +	+	+	+	+	+ +	- +	+	+	+	+	+	+ +	- +	• +	+	+	+	+	+	+	+	50
Carcinoid tumor benign																								1
Tongue											+													1
Cardiovacaular System																								
Cardiovascular System Blood vessel	L		+	1	+	1	ц. ц.			1	-	-	<u>т</u> .			L	+	-	+	-	-	-	+	50
Heart	г 4		+	+	+	+	+ +		· +	+	+	+	+ .	+ -		· +	+	+	+	+	+	+	+	50
licalt	1	1		1	1	1			1	1	I	1	1			1		1	1	1	1			50
Endocrine System																								
Adrenal cortex	+	+	+	+	+	+	+ +	+	+	+	+	+	+ -	+ -	+ +	+ +	+	+	+	+	+	+	+	50
Adenoma													2	X										1
Adrenal medulla	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+ +	+ +	+	+	+	+	+	+	+	+	50
Pheochromocytoma benign		Х																			Х			6
Islets, pancreatic	+	+ +	+	+	+	+	+ +	• +	+	+	+	+	+ ·	+ -	+ +	• +	+	+	+	+	+	+	+	50
Parathyroid gland	+	+	+	+	+	+	+ +	+	M	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+	49
Adenoma																								1
Pituitary gland	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+ -	- +	+	+	+	+	+	+	+	+	50
Pars distalis, adenoma		Х		Х		Х	Х								Х		Х		Х					15
Thyroid gland	+	+	+	+	+	+	+ +	+		+	+	+	+ ·	+ -	+ +			+	+	+	+	+	+	50
C-cell, adenoma					Х				Х							Х							Х	7
C-cell, carcinoma																		Х						2
Follicular cell, adenoma																								1
Conoral Body System																								
General Body System Peritoneum																								1
																								1
Genital System																								
Epididymis	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	50
Preputial gland	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+ -	- +	+	+	+	+	+	+	+	+	50
Adenoma																								1
Carcinoma			Х						Х		Х							Х						7
Prostate	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
Seminal vesicle	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+ +	+ +	- +	+	+	+	+	+	+	+	50
Testes	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
Bilateral, interstitial cell, adenoma	Х	Ľ.	Х	Х	Х	Х	ХХ	X	X	Х	Х	Х	X	ХУ	Χ	X	Х	Х	Х	Х	Х	Х		38
Interstitial cell, adenoma																								9

TABLE A2

	4	5	5	5	5	6			6			7	7	7	77	7	7	7	7	7	7	7	7	7
Number of Days on Study	0					2		9			0	1			2 2		2	2 9	2 9	2 9	2 9	2 9	2	
	0	5	1	2	3	0	0	4	5	/	8	6	4	8	99	9	9	9	9	9	9	9	9	9
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1 1	1	1	1	1	1	1	1	1	1
Carcass ID Number	3	2	2	0	2	4	5	4	1	0	0	4	1	3	0 () 1	1	1	1	1	1	2	2	3
	7	6	4	8	3	4	0	3	7	2	5	0	4	6	7 9) 1	2	3	5	8	9	2	9	1
Hematopoietic System																								
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	+	+
Lymph node						+	+		+															
Lymph node, mandibular	+	+	. +	+	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+
Lymph node, mesenteric	+	+	. +	. +	+	+	+	+	+	+	+	+	+ .	+ .	+ -	- +	+	+	+	+	+	+	+	+
Spleen	, +	, -						- -		, _	- -	- -	· -	· 上 .					, 	, ,	, ,	, ,		+
Fhymus	+	+	. +	. +	+	+	+	+	+	+	+	+	+	+ •	+ -	- +	+	+	+	+	+	+	+	
i nymus	Т		Г	r	1.	1	'	'	'		1		1				15		1	1	1	'		,
Integumentary System																								
Mammaryg land	+	+	• +	+	+	+	+	+	+	+	+	+	M	+ ·	+ +	- +	+	+	+	+	+	+	+	+
Carcinoma																								
Fibroadenoma											Х			2	X									
Fibroadenoma, multiple															У									
Skin	+	+	• +	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	+ +	+	+	+	+	+	+	+	+
Fibroma								Х				Х												
Fibroma, multiple										Х														
Keratoacanthoma																		Х					Х	
Sarcoma	Х																							
Musculoskeletal System																								
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	+ +	+	+	+	+	+	+	+	+
~ ~																								
Nervous System																								
Brain	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+
Respiratory System																								
Lung	+	+	. +	+	+	+	+	+	+	+	+	+	+	+ .	+ +	- +	+	+	+	+	+	+	+	+
Alveolar/bronchiolar adenoma							·					X												
Alveolar/bronchiolar carcinoma												Λ					Х							
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+ .	+ -	- +	л +	+	+	+	+	+	+	+
Trachea	+	+	· +	· +	+	+	+	+	+	+	+	+	+	+ •	+ -	+ +	+	+	+	+	+	+	+	+
																						—	—	
Special Senses System																								
Еуе					+																			
Urinary System																								
Kidney	+	+	• +	+	+	+	+	+	+	+	+	+	+	+ •	+ -	+ +	+	+	+	+	+	+	+	+
Renal tubule, adenoma				X																				
Urinary bladder	+	+	+			+	+	+	+	+	+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	+	+
Systemic Lesions																								
Multiple organs	+	+	• +	• +	+	+	+	+		+	+	+	+ ·	+ ·	+ -	- +	+	+	+	+	+	+	+	+
Leukemia mononuclear Mesothelioma malignant					Х		Х	Х		Х	Х		Х											Х

Individual Animal Tumor Pathology of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm

	555 01 1010				- •	-			211		5		ates	~~		~J		~ •			1 11			-,-	oo ppm
Number of Days on Study		77 22 999	3	3	7 3 0	3	3	3 3	7 7 3 3 0 0	3	7 3 0	3	7 3 0	3	3	3	3	3	3	7 3 1	7 3 1	7 3 1	7 3 1	3	
Carcass ID Number	3	1 1 3 4 3 7	0		1 1 0	2		2 3	1 1 3 3) 2	3	3	4	4	4		4	0	0	1	1 2 1	2	1 3 8	1 3 9	4	Total Tissues/ Tumors
Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Thymus	- - -	+ + + + + +	- + - + - +	· + · + · +	+++++++	+++++++	+ + + + + + + + + + + + + + + + + + + +	+ - + - + - + -	+ + + + + + + + + + + + + + + + + + + +	+ + + + +	+++++++	+ + + +	+++++++	+++++++++++++++++++++++++++++++++++++++	+ + + +	+ + + +	+++++++++++++++++++++++++++++++++++++++	+ + + +	+ + + + + +	+ + + +	+ + + + +	+++++++	+ + + M	+ + + + + +	50 4 50 50 50 49
Integumentary System Mammaryg land Carcinoma Fibroadenoma Fibroadenoma, multiple	-	+ + X		+	+	+	+ ·	+ -	+ M	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	47 1 2 1
Skin Fibroma Fibroma, multiple Keratoacanthoma Sarcoma	-	+ +	- +	+	+	+	+ -	+ -	+ +	+	+	+		+ X	Х	+ X	+	+	+	+	+	+	+ X	+ X	50 5 1 4 1
Musculoskeletal System Bone	-	- +	• +	· +	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Nervous System Brain	-	+ +	• +	+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma	-	+ +	- +	+	+	+	+ ·	+ -	+ +	+	+	+		Х		+	+	+	+	+	+	+	+	+	50 2 1
Nose Trachea	-	- +	- +	+ +	+	+	+ ·	+ -	+ +	+	+	+				+ +	+	+	+	+	+	+	+	+ +	50 50
Special Senses System Eye																									1
Urinary System Kidney Renal tubule, adenoma Urinary bladder	-	- + - +	- + - +	· +	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1 50
Systemic Lesions Multiple organs Leukemia mononuclear	-	- +	- +	+	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 7
Mesothelioma malignant								X				Х													4

Individual Animal Tumor Pathology of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm 5 7 7 5 5 5 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 2 2 5 8 0 2 3 3 59 9 0 1 1 2 2 2 2 2 2 2 2 2 2 2 5 7 8 5 0 9 9 9 9 9 9 9 0 3 1 9 5 2 6 8 5 9 9 9 9 1 **Carcass ID Number** 9 5 7 5 8 8 7 6 66 7 96 7 5 5 5 6 6 77 8 8 8 9 3 1 8 9 1 0 7 7 6 1 5 74 94 5 7 2 5 4 6 2 3 5 5 **Alimentary System** Esophagus + + + Intestine large, colon Leiomyosarcoma Х Intestine large, rectum Intestine large, cecum Intestine small, duodenum Intestine small, jejunum Α Intestine small, ileum + + + + Liver + + Histiocytic sarcoma Х Leiomyosarcoma, metastatic, intestine large, colon Х Sarcoma, metastatic, uncertain primary site Х Mesentery + Fat, leiomyosarcoma, metastatic, intestine large, colon X Pancreas M + Leiomyosarcoma, metastatic, intestine large, colon Х Salivary glands + Stomach, forestomach Sarcoma, metastatic, uncertain primary site X Stomach, glandular ++ Sarcoma, metastatic, uncertain primary site Х **Cardiovascular System** Blood vessel + + + + + + +Heart + + + **Endocrine System** Adrenal cortex + + + Adrenal medulla + + Pheochromocytoma malignant Pheochromocytoma benign Х Х Х Х Х Х Bilateral, pheochromocytoma benign Islets, pancreatic ++Μ Adenoma Х Carcinoma X Parathyroid gland +Pituitary gland Sarcoma NOS Х Pars distalis, adenoma Х Х Х Pars intermedia, adenoma Х Thyroid gland +Х C-cell, adenoma Х C-cell, adenoma, multiple C-cell, carcinoma Х Follicular cell, adenoma Х **General Body System** None

Individual Animal Tumor Pathology of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm

Carcass ID Number119968Alimentary SystemEsophagus+Esophagus+Intestine large, colon+LeiomyosarcomaIntestine large, rectum+Intestine large, cecum+Intestine small, duodenum+Intestine small, jejunum+Intestine small, jejunum+Intestine small, ileum+Liver+Histiocytic sarcoma-Leiomyosarcoma, metastatic, intestine large, colon-Sarcoma, metastatic, uncertain primary site-MesenteryFat, leiomyosarcoma, metastatic, intestine large, colonSalivary glands+Stomach, forestomach+Sarcoma, metastatic, uncertain primary siteStomach, glandular+Sarcoma, metastatic, uncertain primary siteStomach, glandular+Heart ++Heart ++Phochromocytoma malignantPheochromocytoma benignXBilateral, pheochromocytoma benignXIslets, pancreatic+Adenoma+	9		5	$ \begin{array}{c} 1 \\ 5 \\ 6 \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ +$	$ \begin{array}{c} 1 \\ 5 \\ 8 \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ +$	$1 \\ 6 \\ 0 \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ +$	6	6 6	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	7 0 1 - + - +	7	$ \begin{array}{c} 1 \\ 7 \\ 3 \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ +$	8	8	$ \begin{array}{c} 1 \\ 9 \\ 1 \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ + \\ +$				$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	8 9 + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	9	Total Tissues/ Tumors 50 50 1 50 49 50 49 50 1 1 1 8 8 1 1 8 1 50 50 1 1 50
Esophagus + + + Intestine large, colon + + Leiomyosarcoma + + Intestine large, rectum + + Intestine large, cecum + + Intestine small, duodenum + + Intestine small, jejunum + + Intestine small, jejunum + + Liver + + Histiocytic sarcoma Leiomyosarcoma, metastatic, intestine large, colon Sarcoma, metastatic, uncertain primary site Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Toradiovascular System Blood vessel + + Heart + + + Endocrine System Adrenal cortex + + + Adrenal medulla + + Pheochromocytoma malignant Pheochromocytoma benign Islets, pancreatic + + +	+ + + + + + + + + + + + + + + + + + + +	- + + + + + + + + + + + + + + + + + + +		+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +		+ + + + + + + + + + + + + + + + + + +	· + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	++++++++	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	$50 \\ 1 \\ 50 \\ 49 \\ 50 \\ 49 \\ 50 \\ 1 \\ 1 \\ 1 \\ 8 \\ 1 \\ 49 \\ 1 \\ 50 \\ 50 \\ 1 \\ 50 \\ 50 \\ 1 \\ 50 \\ 50$
Intestine large, colon + + + Leiomyosarcoma Intestine large, rectum + + Intestine large, cecum + + Intestine small, duodenum + + Intestine small, jejunum + + Intestine small, jejunum + + Intestine small, ileum + + Liver + + Histiocytic sarcoma Leiomyosarcoma, metastatic, intestine large, colon Sarcoma, metastatic, uncertain primary site Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Stomach, forestomach + + Stomach, glandular + + Stomach, glandular + + Stomach, glandular + + Meart + + + Endocrine System Adrenal cortex + + + Adrenal medulla + + Pheochromocytoma malignant Pheochromocytoma benign Islets, pancreatic + + +	+ + + + + + + + + + + + + + + + + + + +	- + + - + + - + + - + + - + + - + + - + + - + + - + + - + + - + + - +	· + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ - + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +		+ + + + + + + + + + + + + + + + + + +	· + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	$50 \\ 1 \\ 50 \\ 49 \\ 50 \\ 49 \\ 50 \\ 1 \\ 1 \\ 1 \\ 8 \\ 1 \\ 49 \\ 1 \\ 50 \\ 50 \\ 1 \\ 50 \\ 50 \\ 1 \\ 50 \\ 50$
Leiomyosarcoma Intestine large, rectum + + Intestine large, cecum + + Intestine small, duodenum + + Intestine small, jejunum + + Intestine small, jejunum + + Intestine small, jejunum + + Liver + + Histiocytic sarcoma Leiomyosarcoma, metastatic, intestine large, colon Sarcoma, metastatic, uncertain primary site Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Stomach, forestomach + + Stomach, glandular + + Stomach, glandular + + Meart + + + Endocrine System Blood vessel + + + Heart + + + Heart + + + Heart + + + Pheochromocytoma malignant Pheochromocytoma benign Islets, pancreatic + + +	+ + + + + + + + + + + + + + + + + + + +	- + + - + + - + + - + + - + + - + + - + + - + - + - + - + - + - + + + + + + + + + + + + + + + +	· + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	+ - + - + - + - + - + - + - + - + - + -	+ + + + + + + + + + + + + + + + + + +	- + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	· + + + + + + + + + + + + + + + + + + +	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	$ \begin{array}{c} 1\\ 50\\ 49\\ 50\\ 49\\ 49\\ 50\\ 1\\ 1\\ 8\\ 1\\ 49\\ 1\\ 50\\ 50\\ 1\\ 50 \end{array} $
Intestine large, rectum + + Intestine large, cecum + + Intestine small, duodenum + + Intestine small, jejunum + + Intestine small, jejunum + + Intestine small, jejunum + + Histiocytic sarcoma Leiomyosarcoma, metastatic, intestine large, colon Sarcoma, metastatic, uncertain primary site Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Stomach, forestomach + + Stomach, glandular + + Stomach, glandular + + Stomach, glandular System Blood vessel + + + Heart + + + Endocrine System Adrenal cortex + + + Adrenal medulla + + + Pheochromocytoma malignant Pheochromocytoma benign Islets, pancreatic + + +	+ + + + + + + + + + + + + + + + + + + +	- + + - + + - + + - + + - + + - + + - + + - + - + - + - + - + - + - + - + + + + + + + + + + + + + +	· + + · + · + · + · + · + · + · · +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ - + - + - + - + - + - + - + - + - + -	+ + + + + + + + + + + + + + + + + + +	- + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	· + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + +	$50 \\ 49 \\ 50 \\ 49 \\ 49 \\ 50 \\ 1 \\ 1 \\ 1 \\ 8 \\ 49 \\ 1 \\ 50 \\ 50 \\ 1 \\ 50 \\ 50 \\ 1 \\ 50 \\ 50$
Intestine large, cecum + + + Intestine small, duodenum + + Intestine small, jejunum + + Intestine small, ileum + + Liver + + Histiocytic sarcoma Leiomyosarcoma, metastatic, intestine large, colon Sarcoma, metastatic, uncertain primary site Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Blood vessel + + + Heart - + + + Endocrine System Adrenal cortex + + + Adrenal medulla + + + Pheochromocytoma malignant Pheochromocytoma benign Islets, pancreatic + + +	+ + + + + + + + + + + + + + + + + + + +	- + + - + - + - + - + - + - + - + - + -	· + + · + · + · + · + · + · + · + · · +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ - + - + - + - + - + - + - + - + - + -	+ + + + + + + + + + + + + + + + + + +	- + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	· + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + +	49 50 49 50 1 1 1 8 49 49 1 50 50 1 50
Intestine small, duodenum + + Intestine small, jejunum + + Intestine small, jejunum + + Liver + + Histiocytic sarcoma Leiomyosarcoma, metastatic, intestine large, colon Sarcoma, metastatic, uncertain primary site Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Meart + + + Heart + + + + + + Heart + + + + + + + Heart + + + + + + + + Heart + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	- + + - + - + - + - + - + - + - + - + -	· + + · + · + · + · + · + · + · · +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ - + - + - + - + - + - + - + - + - + -	+ + + + + + + + + + + + + + + + + + +	- + + - + - + - + - + - + - + - + - + - + - + - + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	· + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + +	50 49 49 50 1 1 1 8 49 49 1 50 50 1 50
Intestine small, jejunum + + Intestine small, ileum + + Liver + + Histiocytic sarcoma Leiomyosarcoma, metastatic, intestine large, colon Sarcoma, metastatic, uncertain primary site Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Meart + + + Heart - + + + Adrenal cortex + + + Adrenal medulla + + + Pheochromocytoma malignant Pheochromocytoma benign Islets, pancreatic + + +	+++++++++++++++++++++++++++++++++++++++	- + + - + + - + + - + + - + + - + + - + + - + + - + + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + + + + + + + + + + + +	· + · + · + · · + · · +	+ + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + +	+ + + + + +	+ - + - + - + - + - + - + - + - + - + -	+ + + + + + + + + + + + + + + + + + + +	- + + - + - + - + - + - + - + - + - + - + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + +	49 49 50 1 1 1 8 49 1 50 50 1 50
ntestine small, ileum + + hitsion + + Liver + + Histiocytic sarcoma Leiomyosarcoma, metastatic, intestine large, colon Sarcoma, metastatic, uncertain primary site Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Cardiovascular System Blood vessel + + Heart + + Heart + + Heart + + Heochromocytoma malignant Pheochromocytoma benign Silets, pancreatic + + +	+ + + +	- + + - + + - + + - + + - + + - + + - + + + + + + + + + + + + + +	· + · + · + · +	+ + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + +	+ + + + + + +	+ - + - + - + - + - + - + - + - + - + -	+ + + + + + + + + + + + + + + + + + + +	- + - + - +	+ + + + + + + + +	+ + + + +	+ + + + + +	+ + + + + +	+ + + + + +	+ + + + + +	+ + + + + + +	+ + + + + + + +	+ + + + + +	+ + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	49 50 1 1 8 49 1 50 50 1 50
Liver + + Histiocytic sarcoma Leiomyosarcoma, metastatic, intestine large, colon Sarcoma, metastatic, uncertain primary site Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Meart + + Heart + + + Heart + + + Heart + + + Heart + + + Heart - + + + Adrenal cortex + + + Adrenal medulla + + Pheochromocytoma malignant Pheochromocytoma benign Siletes, pancreatic + + +	+++++++++++++++++++++++++++++++++++++++	- + - + - + - +	· + · + · +	+ + + +	+ + + + + +	- + + + + +	- + + + + +	+ - + - + - + - + -	+ + + + + + + + + + + + + + + + + +	- + - + - + - +	- + + + + +	· + + + + +	- + + + + + +	- + + + + +	- + + + + +	++++++	- + + + + +	- + + + + +	+ + + +	- + + + + +	+ + + + +	+ + +	50 1 1 8 1 49 1 50 50 1 50
Histiocytic sarcoma Leiomyosarcoma, metastatic, intestine large, colon Sarcoma, metastatic, uncertain primary site Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Cardiovascular System Blood vessel + + Heart + + + Heart + + + Endocrine System Adrenal cortex + + + Adrenal medulla + + Pheochromocytoma malignant Pheochromocytoma benign Silets, pancreatic + + +	+++++	- + - + - + - +	· + · + · +	+ + + +	+ + + + +	++++++	+++++	- + - + - + -	+ + + + + +	- + - + - +	+ + + +	- + + + +	- + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + +	· + + + + +	++++++	+ + + + +	+ + +	1 1 8 1 49 1 50 50 1 50
Leiomyosarcoma, metastatic, intestine large, colon Sarcoma, metastatic, uncertain primary site Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Cardiovascular System Blood vessel + + Heart + + + Heart + + + Endocrine System Adrenal cortex + + + Adrenal medulla + + Pheochromocytoma malignant Pheochromocytoma benign Islets, pancreatic + + +	++++++	- + - + - +	· + · + · +	+ + + +	+ + + + +	+ + + +	+ + + +	+ - + - + -	+ + + + + +	- + - + - +	+ + + + + +	+ + + +	+ + + +	+ + + +	+ + + +	++++++	+ + + +	+ + + +	+++++++++++++++++++++++++++++++++++++++	+ + + +	+ + +	+ + + +	1 1 8 1 49 1 50 50 1 50
Sarcoma, metastatic, uncertain primary site Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Stomach, glandular + + Heart + + + Endocrine System Adrenal cortex + + + Adrenal medulla + + Pheochromocytoma malignant Pheochromocytoma benign Islets, pancreatic + + +	++++++	- + - + - +	· + · + · +	+ + + +	+ + + + +	+ + + +	+++++++++++++++++++++++++++++++++++++++	+ - + - + -	+ + + + + +	- + - + - +	+ + + + +	+ + + +	+ + + +	+ + + +	+ + + +	+++++++++++++++++++++++++++++++++++++++	+ + + +	+ + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + +	++++++	1 8 1 49 1 50 50 1 50
Mesentery Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Cardiovascular System Blood vessel + + Heart + + + Endocrine System Adrenal cortex + + + Adrenal medulla + + Pheochromocytoma malignant Pheochromocytoma benign Silets, pancreatic + + +	+++++	- + - + - +	· + · + · +	+ + + +	++++++	+++++++	+++++++++++++++++++++++++++++++++++++++	+ - + - + -	+ + + + + +	- + - + - +	+ + + + +	+ + + +	+ + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	++++++	+ + + +	+ + +	+++++++++++++++++++++++++++++++++++++++	1 49 1 50 50 1 50
Fat, leiomyosarcoma, metastatic, intestine large, colon Pancreas + Pancreas + Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + Stomach, forestomach + Stomach, forestomach + Stomach, forestomach + Stomach, glandular + Stomach, glandular + Sarcoma, metastatic, uncertain primary site Cardiovascular System Blood vessel + Heart + + Heart + + Adrenal cortex + Adrenal medulla + Pheochromocytoma benign X Bilateral, pheochromocytoma benign K	++++++	- + - + - +	· + · + · +	+ + + +	+ + +	+ + +	++++++	+ - + - + -	+ + + + + + + + + + + + + + + + + + + +	- + - + - +	++++++	+ + + +	++++++	++++++	++++++	++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	++++++	+++++++	+ + +	++++++	1 49 1 50 50 1 50
colon++Pancreas++Leiomyosarcoma, metastatic, intestine large, colon-Salivary glands++Stomach, forestomach++Sarcoma, metastatic, uncertain primary site-Stomach, glandular++Sarcoma, metastatic, uncertain primary site-Stomach, glandular++Sarcoma, metastatic, uncertain primary site-Cardiovascular System-Blood vessel++Heart +++Heart ++++Endocrine System-Adrenal cortex++Adrenal medulla++Pheochromocytoma malignant-Pheochromocytoma benignXBilateral, pheochromocytoma benign-Islets, pancreatic++	+ + +	- + - + - +	· + · + · +	+ + + +	+ + + +	+ + + +	++++++	+ - + - + -	+ + + + + +	- + - + - +	++++++	+++++++	++++++	+++++++++++++++++++++++++++++++++++++++	++++++	++++++	++++++	+++++++	++++++	++++++	+ + +	++++++	49 1 50 50 1 50
Leiomyosarcoma, metastatic, intestine large, colon Salivary glands + + Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Cardiovascular System Blood vessel + + + Heart + + + Heart + + + Endocrine System Adrenal cortex + + + Adrenal medulla + + + Pheochromocytoma malignant Pheochromocytoma benign Silateral, pheochromocytoma benign	+ + +	- + - + - +	· + · + · +	+ + + +	+++++	+++++	+++++	+ -+ -+ -+ -+ -+ -+ -+ -+ -+ -+ -+ -+ -+	+ + + + + + + +	- + - + - +	++++++	+ + +	+ + +	+ + +	++++++	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	1 50 50 1 50
Salivary glands + + + Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Cardiovascular System Blood vessel + + Heart + + + Endocrine System Adrenal cortex + + + Adrenal medulla + + + Pheochromocytoma malignant Pheochromocytoma benign Silets, pancreatic + + +	+++++	- + - +	· + · +	+ + +	+++++	+++++	+ +	+ - + -	+ + + + + +	- + - + - +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + +	+ +	+ + +	+ + +	+ + +	+ + +	+++++++++++++++++++++++++++++++++++++++	+ + +	+ + +	+ + +	50 50 1 50
Stomach, forestomach + + Sarcoma, metastatic, uncertain primary site + + Stomach, glandular + + Sarcoma, metastatic, uncertain primary site + + Cardiovascular System - - Blood vessel + + + Heart + + + + Endocrine System - - - Adrenal cortex + + + Adrenal medulla + + + Pheochromocytoma malignant - - - Pheochromocytoma benign X - - silateral, pheochromocytoma benign - + +	++++	- + - + - +	· + · + · +	+ + +	++++	++++	+ + +	+ -+ -+ -+ -+ -+ -+ -+ -+ -+ -+ -+ -+ -+	+ + + + + +	- + - + - +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	50 1 50
Sarcoma, metastatic, uncertain primary site Stomach, glandular + + Sarcoma, metastatic, uncertain primary site Cardiovascular System Blood vessel + + Heart + + + Endocrine System Adrenal cortex + + + Adrenal medulla + + + Pheochromocytoma malignant Pheochromocytoma benign Silateral, pheochromocytoma benign slets, pancreatic + + +	+	- +	· + · +	+ +	+	+	+	+ -	+ +	- + - +	++	++	++	+	+	+	+	+	+	+	+	+	1 50
Stomach, glandular + + + Sarcoma, metastatic, uncertain primary site - - Cardiovascular System - + + Blood vessel + + + Heart + + + + Endocrine System - - - Adrenal cortex + + + Adrenal medulla + + + Pheochromocytoma malignant - + + Bilateral, pheochromocytoma benign X Bilateral, pheochromocytoma benign -	+	- +	· +	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	50
Sarcoma, metastatic, uncertain primary site Cardiovascular System Blood vessel + + Heart + + + Endocrine System Adrenal cortex + + + Adrenal medulla + + + Pheochromocytoma malignant Pheochromocytoma benign Silateral, pheochromocytoma benign Silates, pancreatic + + +	+	- +	· +	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	
Blood vessel + + + Heart + + + Endocrine System Adrenal cortex + + Adrenal medulla + + + Pheochromocytoma malignant Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic + +		- +	. +	+																			1
Blood vessel + + + Heart + + + Endocrine System Adrenal cortex + + Adrenal medulla + + + Pheochromocytoma malignant Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic + +	1	- +	+	+																			
Endocrine System Adrenal cortex + Adrenal medulla + Pheochromocytoma malignant Pheochromocytoma benign X Bilateral, pheochromocytoma benign Islets, pancreatic +	-				+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal cortex++Adrenal medulla++Pheochromocytoma malignant-Pheochromocytoma benignXBilateral, pheochromocytoma benign-Islets, pancreatic++	+	- +	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50	
Adrenal medulla + + Pheochromocytoma malignant + Pheochromocytoma benign X Bilateral, pheochromocytoma benign + (slets, pancreatic +																							
Pheochromocytoma malignant Pheochromocytoma benign X Bilateral, pheochromocytoma benign Islets, pancreatic + + +	+	- +	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma benign X Bilateral, pheochromocytoma benign (slets, pancreatic + +	+	- +	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	50
Bilateral, pheochromocytoma benign slets, pancreatic + + +					Х																		1
Islets, pancreatic + +											Х											Х	9
																					Х		1
Adenoma	+	- +	• +	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	49
			37																				1
Carcinoma			X																				2
Parathyroid gland + +	+	- M	1 +	+	+	+	+	+ -	+ +	- +	+	+	+	+	M	+	+	+	+	+	+		48
Pituitary gland + + + Sarcoma NOS	+	- +	. +	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	50 1
			Х						v	v	v					v					v		
Pars distalis, adenoma X Pars intermedia, adenoma			л						Å	ХХ	л					Х					Х		10 1
Fhyroid gland + +	لل ا			+	+	+	+	+ -	+ +		+	+	+	+	+	+	+	+	+	+	+	+	50
C-cell, adenoma		r	1-		1	'			X	1		'				Х							30 4
C-cell, adenoma, multiple								1	* *			Х				1							4
C-cell, carcinoma												21											1
Follicular cell, adenoma																							1

Individual Animal Tumor Pathology of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm

Number of Days on Study	5 2 0	5 2 3	5 5 1	5 8 9	6 0 5	6 2 2	6 3 6	3		9		0	7 1 0	1 2		2 2	2 2	2	2	2 2	2	7 2 9	7 2 9	7 2 9	2	
Carcass ID Number	1 9 3	1 5 1	1 7 8	1 5 9	1 8 1	1 8 0	1 7 7	1 6 7		6		9	1 6 4		1 5 : 4 :		1 1 5 6 7 2					1 8 2	1 8 3	1 8 5	1 9 5	
Genital System																										
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ •	+ •	+ -	+ -			+ ·	+	+	+	+	+	
Preputiag land Adenoma	+	+	+	+	+	+	+	+	+	+	+ X	+	+ -	+ •	+ -	+ -	+ -			-	+	+	+	+	+	
Carcinoma		Х		x	Х						л				X			χ								
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+ -			+ -	+ -			+ -	+	+	+	+	+	
Seminaly esicle	М	+	+	+	+	+	+	+	+	+	+	+	+ -	+ •	+ -	+ -	+ -			+ •	+	+	+	+	+	
Testes	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ •	+ •	+ -	+ -			+ -	+	+	+	+	+	
Bilateral, interstitial cell, adenoma				Х	Х				Х	Х	Х	X	XX	XZ	X Z	K D	ΧУ	Х	C	2	X	Х	Х	Х	Х	
Interstitial cell, adenoma	Х	Х																	У	ζ						
Hematopoietic System																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ •	+ -	+ -	+ -			+ -	+	+	+	+	+	
Histiocytic sarcoma			Х																							
Lymph node										+			-	+												
Pancreatic, sarcoma, metastatic,																										
uncertain primary site										Х																
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ •	+ •	+ -	+ -	+		+ -	+	+	+	+	+	
Lymph node, mesenteric	+	+	+	+	+	+	+	+		+	+	+	+ -	+ •	+ •	+ -	+ -			+ -	+	+	+	+	+	
Sarcoma, metastatic, uncertain primary site										Х																
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ •	+ •	+ -	+ -			+ -	+	+	+	+	+	
Fibroma	Х																									
Histiocytic sarcoma			Х							Х																
Sarcoma, metastatic, uncertain primary site Thymus	+	+	+	+	+	+	+	+			+	+	± -	± .	± .	∟ -	÷ -			∟.	+	+	М	+	+	
Thymus																							141			
Integumentary System																										
Mammaryg land	М	+	+	+	+	М	+	+	+	+	+	+	+ -	+ ·	+ -	+ -	+ -	- +		+ •	+	+	+	+	+	
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ •	+ •	+ -	+ -				+	+	+	+	+	
Fibroma	37									Х						7				2	X					
Fibrosarcoma Keratoacanthoma	Х														x	Κ										
Keratoacanthoma, multiple														4	1									Х		
Keratoacantilonia, muniple																								Λ		
Musculoskeletal System																										
	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ ·	+ •	+ -	+ -	+		+ -	+	+	+	+	+	
Bone Osteosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ •	+ •	+ -	+ -			+ -	+	+	+	+	+	
Osteosarcoma Skeletal muscle	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ -	+ •	+ -	+ -			+ -	+	+	+	+	+	
Bone Osteosarcoma	+	+	+	+	+	+	+	+	+	+ + X	+	+	+ -	+ ·	+ -	+ -	+ -			F -	+	+	+	+	+	
Bone Osteosarcoma Skeletal muscle Sarcoma, metastatic, uncertain primary site	+	+	+	+	+	+	+	+	+		+	+	+ -	+ ·	+ •	+ -	+ -			+ ·	+	+	+	+	+	
Bone Osteosarcoma Skeletal muscle	+ +	+ +	+	+ +	+ +	+ +	+ +	+ +	+ +		+ +	+ +	+ -	+ ·	+ -	+ -	+ -			+ ·	+	+	+ +	+ +	+ +	
Bone Osteosarcoma Skeletal muscle Sarcoma, metastatic, uncertain primary site Nervous System Brain	+	+	+	+	+	+	+	+	+		+	+	+ -	+ ·	+ -	+ -	+ -			+ -	+	+	+	++	+	
Bone Osteosarcoma Skeletal muscle Sarcoma, metastatic, uncertain primary site Nervous System Brain Respiratory System	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +		+ +	+ +	+ -	+ ·	+ -	+ -	+ -	+		+ ·	+ +	+ +	+ +	++		
Bone Osteosarcoma Skeletal muscle Sarcoma, metastatic, uncertain primary site Nervous System Brain Respiratory System Lung	+ + +	+ + +	+ + +	+ + +	+ + +	+ + X	+ + +	+ + +	+ + +		+ +	+ +	+ -	+ -	+ ·	+ -	+ -			+ ·	+ +	+ + +	+ + +	+ + +		
Bone Osteosarcoma Skeletal muscle Sarcoma, metastatic, uncertain primary site Nervous System Brain Respiratory System Lung Alveolar/bronchiolar adenoma	+ +	+ +	+ +	+ + +	+ +	+ + X	+ + +	+ + +	+ + +		+ + +	+ + +	+ -+	+ · ·	+ ·	+ -	+ -			+ -	+ +	+ + +	+ + +	+ +		
Bone Osteosarcoma Skeletal muscle Sarcoma, metastatic, uncertain primary site Nervous System Brain Respiratory System Lung	+ + + +	+ + + +	+ + + +	+ + + +	+ + + +		+ + + +	+ + + +	+ + + +		+ + + +	+ + + + +		+ · + ·	+ ·	+ -	+ -			+ ·	+ + + +	+ + + +	+ + + +	+ + + +		

Individual Animal Tumor Pathology of Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm

		-		-	-	-						8						-					-		- ,.	oo ppiii
Number of Days on Study	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	3															
Carcass ID Number	1 9 6	1 9 8	9	2 0 0	5	5	1 5 8	1 6 0	6	1 6 8	1 6 9	7	1 7 1	7	1 7 3	8	1 8 7	1 9 1	9	1 5 3	1 8 6	1 8 8	1 8 9	1 9 0	9	Total Tissues/ Tumors
Genital System																										
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Preputiag land Adenoma	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	50 2
Carcinoma												Λ														5
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Seminal esicle	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	49
Testes	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		50
Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х		Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	40 6
Hematopoietic System																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																										1
Lymph node Pancreatic, sarcoma, metastatic,																										2
uncertain primary site																										1
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Sarcoma, metastatic, uncertain primary site																										1
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Fibroma Histiocytic sarcoma																										1
Sarcoma, metastatic, uncertain primary site																										1
Thymus	+	+	+	+	+	+	+	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Integumentary System																										
Mammaryg land	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	47
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Fibroma Fibrosarcoma		Х																								3 2
Keratoacanthoma																Х					Х					3
Keratoacanthoma, multiple																										1
Musculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Osteosarcoma Skeletal muscle																Х										1 1
Sarcoma, metastatic, uncertain primary site																										1
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System																										
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma																Х										2
Leiomyosarcoma, metastatic, intestine large, colon																										1
Nose Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
11aunta	+	+	+	+	+	+	Ŧ	Ŧ	+	+	+	+	Ŧ	т	т	т	Ŧ	Ŧ	т	Ŧ	+	+	+	+	Ŧ	50

102

Number of Days on Study	5 5 5 5 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7
tumber of Days on Study	0 3 1 9 5 2 6 8 5 7 8 5 0 5 9 9 9 9 9 9 9 9 9 9 9 9
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Carcass ID Number	9 5 7 5 8 8 7 6 6 6 7 9 6 7 5 5 5 6 6 7 7 8 8 8 9 3 1 8 9 1 0 7 7 6 1 5 7 4 9 4 5 7 2 5 4 6 2 3 5 5
Special Senses System	
Eye Zymbal's gland	+
Carcinoma	X
Urinary System	
Kidney	+ + + + + + + + + + + + + + + + + + +
Urinary bladder	+ + + + + + + + + + + + + + + + + + + +
Systemic Lesions	
Multiple organs	+ + + + + + + + + + + + + + + + + + +
Histiocytic sarcoma Leukemia mononuclear	X X X
Mesothelioma malignant	X

Individual Animal Tumor Path	ology of Ma	le l	Rat	s ir	n th	le 2	2-Y	ear	r D	rin	iki	ng	Wa	ate	er S	stu	dy	of	So	diı	um	Ni	itri	te:	3,	,000 ppm
Number of Days on Study	7 2 9	7 2 9	7 2 9	7 2 9	7 3 0	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1															
Carcass ID Number	1 9 6	1 9 8	1 9 9	2 0 0	1 5 2	1 5 6	1 5 8	1 6 0	1 6 3	1 6 8	1 6 9	1 7 0	1 7 1	1 7 2	1 7 3	1 8 4	1 8 7	1 9 1	1 9 4	1 5 3	1 8 6	1 8 8	1 8 9	1 9 0	1 9 2	Total Tissues/ Tumors
Special Senses System Eye Zymbal's gland Carcinoma										+ X					+											2 2 2
Urinary System Kidney Urinary bladder	+ +	+ +	++	+++	+ +	+++	+ +	+ +	+ +	+++	+++	+ +	+ +	+ +	+ +	+ +	+++	+ +	+++	+ +	+++	+ +	+ +	++	+++	50 50
Systemic Lesions Multiple organs Histiocytic sarcoma Leukemia mononuclear Mesothelioma malignant	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	50 1 3 1

Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Adrenal Medulla: Benign Pheochromocytoma Overall rate ^a 6/50 (12%)	10/50 (200/)	(/50 (120/)	10/50 (200/)	
Overall rate ^a 6/50 (12%)	10/50 (20%)	6/50 (12%)	10/50 (20%)	21.70/
Adjusted rate ^b	14.7%	21.7%	13.1%	21.7%
Cerminal rate ^c	5/29 (21%)	7/38 (18%)	4/36 (11%)	8/36 (22%)
irst incidence (days)	620 D 0 226	481 D. 0.287	724 D. 0. 52501	605 D. 0. 207
oly-3 test ^d	P=0.336	P=0.287	P=0.535N	P=0.287
drenal Medulla: Benign or Malignant Pheochromo	ocytoma			
Overall rate	7/50 (14%)	10/50 (20%)	6/50 (12%)	11/50 (22%)
djusted rate	17.2%	21.7%	13.1%	23.9%
erminal rate	6/29 (21%)	7/38 (18%)	4/36 (11%)	9/36 (25%)
irst incidence (days)	620	481	724	605
oly-3 test	P=0.314	P=0.397	P=0.408N	P=0.307
ung: Alveolar/bronchiolar Adenoma				
Overall rate	2/50 (4%)	3/50 (6%)	2/50 (4%)	2/50 (4%)
djusted rate	5.0%	6.7%	4.4%	4.4%
erminal rate	2/29 (7%)	3/38 (8%)	1/36 (3%)	1/36 (3%)
irst incidence (days)	729 (T)	729 (T)	716	622
bly-3 test	P=0.474N	P=0.549	P=0.647N	P=0.647N
ung: Alveolar/bronchiolar Adenoma or Carcinoma verall rate		2/50 (69/)	3/50 (6%)	2/50 (4%)
	2/50 (4%)	3/50 (6%)	()	
djusted rate	5.0%	6.7%	6.5%	4.4%
erminal rate	2/29 (7%)	3/38 (8%)	2/36 (6%)	1/36 (3%)
irst incidence (days)	729 (T)	729 (T)	716	622 D 0 (47) I
oly-3 test	P=0.487N	P=0.549	P=0.559	P=0.647N
lammary Gland: Fibroadenoma				
Overall rate	3/50 (6%)	5/50 (10%)	3/50 (6%)	0/50 (0%)
djusted rate	7.3%	11.1%	6.5%	0.0%
erminal rate	1/29 (3%)	5/38 (13%)	2/36 (6%)	0/36 (0%)
rst incidence (days)	589	729 (T)	708	e
oly-3 test	P=0.047N	P=0.405	P=0.611N	P=0.102N
lammary Gland: Fibroadenoma or Carcinoma				
verall rate	3/50 (6%)	5/50 (10%)	4/50 (8%)	0/50 (0%)
djusted rate	7.3%	11.1%	8.7%	0.0%
erminal rate	1/29 (3%)	5/38 (13%)	3/36 (8%)	0/36 (0%)
irst incidence (days)	589	729 (T)	708	
bly-3 test	P=0.058N	P=0.405	P=0.559	P=0.102N
ancreatic Islets: Adenoma				
	4/50 (00/)	0/50 (00/)	0/50 (00/)	1/40 (20/)
verall rate	4/50 (8%)	0/50 (0%)	0/50 (0%)	1/49 (2%)
djusted rate	9.9%	0.0%	0.0%	2.2%
erminal rate	4/29 (14%)	0/38 (0%)	0/36 (0%)	0/36 (0%)
irst incidence (days)	729 (T)	_	—	638
oly-3 test	P=0.135N	P=0.047N	P=0.045N	P=0.147N

Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Pancreatic Islets: Adenoma or Carcinoma	5/50 (100/)	0/50 (00/)	0/50 (00/)	2/40 ((0/)
Overall rate Adjusted rate	5/50 (10%) 12.4%	0/50 (0%)	0/50 (0%)	3/49 (6%)
5	5/29 (17%)	0.0%	0.0%	6.6%
Ferminal rate		0/38 (0%)	0/36 (0%)	1/36 (3%)
First incidence (days)	729 (T) P=0.426N	 P=0.022N		636 P=0.205N
Poly-3 test	P=0.426N	P=0.022N	P=0.021N	P=0.295N
Pituitary Gland (Pars Distalis): Adenoma				
Overall rate	13/50 (26%)	13/49 (27%)	15/50 (30%)	10/50 (20%)
Adjusted rate	31.5%	28.8%	31.5%	21.8%
Terminal rate	10/29 (35%)	10/37 (27%)	12/36 (33%)	9/36 (25%)
First incidence (days)	589	481	505	622
Poly-3 test	P=0.191N	P=0.488N	P=0.587	P=0.218N
Dronutial Claude Adapama				
Preputial Gland: Adenoma Dverall rate	0/50 (0%)	3/50 (6%)	1/50 (2%)	2/50 (4%)
Adjusted rate	0.0%	6.7%	2.2%	4.4%
Ferminal rate	0/29 (0%)	3/38 (8%)	0/36 (0%)	1/36 (3%)
First incidence (days)	0/29 (070)	729 (T)	697	698
Poly-3 test	P=0.397	P=0.139	P=0.526	P=0.265
ory-s test	r=0.397	F=0.139	r=0.520	r=0.203
Preputial Gland: Carcinoma				
Overall rate	5/50 (10%)	1/50 (2%)	7/50 (14%)	5/50 (10%)
Adjusted rate	12.0%	2.2%	15.3%	10.6%
erminal rate	3/29 (10%)	1/38 (3%)	5/36 (14%)	2/36 (6%)
First incidence (days)	400	729 (T)	724	523
oly-3 test	P=0.397	P=0.085N	P=0.446	P=0.555N
Preputial Gland: Adenoma or Carcinoma				
Dverall rate	5/50 (10%)	4/50 (8%)	8/50 (16%)	7/50 (14%)
Adjusted rate	12.0%	8.9%	17.4%	14.9%
erminal rate	3/29 (10%)	4/38 (11%)	5/36 (14%)	3/36 (8%)
First incidence (days)	400	729 (T)	697	523
oly-3 test	P=0.301	P=0.455N	P=0.340	P=0.465
	1 0.501	1 0.1001	1 0.510	1 0.100
kin: Keratoacanthoma				
Overall rate	2/50 (4%)	3/50 (6%)	4/50 (8%)	4/50 (8%)
Adjusted rate	4.9%	6.6%	8.7%	8.8%
erminal rate	1/29 (3%)	2/38 (5%)	4/36 (11%)	4/36 (11%)
first incidence (days)	486	680	729 (T)	729 (T)
oly-3 test	P=0.310	P=0.543	P=0.389	P=0.385
kin: Keratoacanthoma or Squamous Cell Carcinoma				
Overall rate	2/50 (4%)	4/50 (8%)	4/50 (8%)	4/50 (8%)
Adjusted rate	2/50 (4%) 4.9%	4/30 (8%) 8.7%	4/30 (8%) 8.7%	4/50 (8%) 8.8%
erminal rate	4.9% 1/29 (3%)	8.7% 2/38 (5%)	8.7% 4/36 (11%)	8.8% 4/36 (11%)
First incidence (days)	486	2/38 (5%) 480	4/36 (11%) 729 (T)	4/36 (11%) 729 (T)
	486 P=0.372	480 P=0.389	/29(1) P=0.389	/29(1) P=0.385
Poly-3 test	r=0.372	r=0.389	r-0.389	r-0.383

TABLE A	43
---------	----

Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Skin: Keratoacanthoma, Trichoepithelioma, Basal	Cell Adenoma, Basal Co	ell Carcinoma, or S	Squamous Cell Car	cinoma
Overall rate	3/50 (6%)	6/50 (12%)	4/50 (8%)	4/50 (8%)
Adjusted rate	7.3%	13.1%	8.7%	8.8%
erminal	1/29 (3%)	4/38 (11%)	4/36 (11%)	4/36 (11%)
Tirst incidence (days)	486	480	729 (T)	729 (T)
oly-3 test	P=0.525N	P=0.299	P=0.560	P=0.555
kin: Fibroma				
verall rate	0/50 (0%)	1/50 (2%)	6/50 (12%)	3/50 (6%)
djusted rate	0.0%	2.2%	13.0%	6.6%
erminal	0/29 (0%)	1/38 (3%)	3/36 (8%)	2/36 (6%)
rst incidence (days)	—	729 (T)	694	697
oly-3 test	P=0.103	P=0.521	P=0.024	P=0.142
kin: Fibroma, Fibrosarcoma, or Sarcoma				
verall rate	1/50 (2%)	1/50 (2%)	7/50 (14%)	5/50 (10%)
djusted rate	2.5%	2.2%	14.9%	10.8%
erminal	1/29 (3%)	1/38 (3%)	3/36 (8%)	3/36 (8%)
rst incidence (days)	729 (T)	729 (T)	400	520
ly-3 test	P=0.054	P=0.736N	P=0.050	P=0.136
estes: Adenoma				
verall rate	47/50 (94%)	46/50 (92%)	47/50 (94%)	46/50 (92%)
djusted rate	98.9%	96.3%	96.7%	95.1%
erminal rate	29/29 (100%)	37/38 (97%)	35/36 (97%)	36/36 (100%)
rst incidence (days)	486	552	505	520
ly-3 test	P=0.200N	P=0.416N	P=0.478N	P=0.248N
hyroid Gland (C-cell): Adenoma				
verall rate	12/50 (24%)	8/50 (16%)	7/50 (14%)	5/50 (10%)
djusted rate	29.3%	17.8%	15.2%	10.9%
erminal rate	10/29 (35%)	8/38 (21%)	5/36 (14%)	4/36 (11%)
rst incidence (days)	620	729 (T)	708	636
ly-3 test	P=0.028N	P=0.157N	P=0.092N	P=0.028N
hyroid Gland (C-cell): Adenoma or Carcinoma		o / • • • · · · · ·		
verall rate	14/50 (28%)	8/50 (16%)	9/50 (18%)	6/50 (12%)
djusted rate	34.1%	17.8%	19.4%	13.1%
erminal rate	12/29 (41%)	8/38 (21%)	6/36 (17%)	4/36 (11%)
rst incidence (days)	620	729 (T)	582	636
ly-3 test	P=0.027N	P=0.066N	P=0.091N	P=0.017N
ll Organs: Mononuclear Cell Leukemia				
verall rate	17/50 (34%)	12/50 (24%)	7/50 (14%)	3/50 (6%)
djusted rate	37.9%	25.7%	15.0%	6.6%
erminal	7/29 (24%)	7/38 (18%)	1/36 (3%)	1/36 (3%)
rst incidence (days)	486	552	620	698
ply-3 test	P<0.001N	P=0.151N	P=0.010N	P<0.001N

Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
All Organs: Malignant Mesothelioma				
Overall rate	3/50 (6%)	3/50 (6%)	4/50 (8%)	1/50 (2%)
Adjusted rate	7.3%	6.6%	8.6%	2.2%
Terminal rate	2/29 (7%)	2/38 (5%)	2/36 (6%)	0/36 (0%)
First incidence (days)	558	641	593	705
Poly-3 test	P=0.211N	P=0.615N	P=0.569	P=0.267N
All Organs: Benign Neoplasms				
Overall rate	47/50 (94%)	48/50 (96%)	49/50 (98%)	49/50 (98%)
Adjusted rate	98.9%	99.0%	99.7%	99.1%
Ferminal rate	29/29 (100%)	38/38 (100%)	36/36 (100%)	36/36 (100%)
First incidence (days)	486	481	505	520
Poly-3 test	P=0.775	P=0.973	P=0.951	P=0.946
All Organs: Malignant Neoplasms				
Overall rate	30/50 (60%)	22/50 (44%)	21/50 (42%)	20/50 (40%)
Adjusted rate	63.1%	45.3%	43.1%	40.6%
Terminal rate	14/29 (48%)	13/38 (34%)	10/36 (28%)	8/36 (22%)
First incidence (days)	400	480	400	520
Poly-3 test	P=0.029N	P=0.058N	P=0.036N	P=0.020N
All Organs: Benign or Malignant Neoplasms				
Overall rate	49/50 (98%)	49/50 (98%)	50/50 (100%)	50/50 (100%)
Adjusted rate	99.9%	99.6%	100.0%	100.0%
Terminal rate	29/29 (100%)	38/38 (100%)	36/36 (100%)	36/36 (100%)
First incidence (days)	400	480	400	520
Poly-3 test	P=0.998	P=1.000N	P=1.000	P=1.000

(T)Terminal sacrifice

^a Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, lung, pancreatic islets, pituitary gland, preputial gland, testis, and thyroid gland; for other tissues, denominator is number of animals necropsied.

^b Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

^c Observed incidence at terminal kill

^d Beneath the control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposure group is indicated by N.

^e Not applicable; no neoplasms in animal group

	Incidence in Controls				
Study	Fibroma	Fibrosarcoma	Fibroma or Fibrosarcoma		
Historical Incidence in Controls Given NTP	-2000 Diet ^a				
<i>p,p</i> '-Dichlorodiphenyl sulfone (feed)	2/50	0/50	2/50		
Indium phosphide (inhalation)	1/50	1/50	2/50		
Methacrylonitrile (gavage)	3/50	0/50	3/50		
Naphthalene (inhalation)	5/49	2/49	7/49		
p-Nitrotoluene (feed)	1/50	0/50	1/50		
Sodium nitrite (drinking water)	0/50	1/50	1/50		
Total (%) Mean ± standard deviation Range	12/299 (4.0%) 4.0% ± 3.7% 0%-10%	4/299 (1.3%) 1.4% ± 1.7% 0%-4%	16/299 (5.4%) 5.3% ± 4.5% 2%-14%		
		talla Calumbus I aba	ratories ^b		
Historical Incidence in Drinking Water Cor	itrols Given NIH-07 Diet at Bat	telle Columbus Labo			
Historical Incidence in Drinking Water Cor Sodium fluoride	0/80	1/80	1/80		
	0/80	1/80			
Sodium fluoride	0/80	1/80			
Sodium fluoride Overall Historical Incidence in Drinking W	0/80 ater Controls Given NIH-07 Die	1/80 et	1/80		

TABLE A4a Historical Incidence of Skin Fibroma or Fibrosarcoma in Control Male F344/N Rats

a Data as of 15 March 2000 Data as of 21 December 1999

TABLE A4b Historical Incidence of Mononuclear Cell Leukemia in Control Male F344/N Rats

Study	Incidence in Controls
Historical Incidence in Controls Given NTP-2000 Diet ^a	
p,p'-Dichlorodiphenyl sulfone (feed)	27/50
Indium phosphide (inhalation)	16/50
Methacrylonitrile (gavage)	20/50
Naphthalene (inhalation)	26/49
<i>p</i> -Nitrotoluene (feed)	24/50
Sodium nitrite (drinking water)	17/50
Overall Historical Incidence in Controls Given NTP-2000 Diet Total (%) Mean ± standard deviation Range	130/299 (43.5%) 43.5% ± 9.6% 32%-54%
Historical Incidence in Drinking Water Controls Given NIH-07 Diet at Ba	attelle Columbus Laboratories ^b
Sodium fluoride	54/80
Overall Historical Incidence in Drinking Water Controls Given NIH-07 D	liet
Total (%) Mean ± standard deviation Range	205/331 (61.9%) 61.4% ± 7.6% 49%-70%

^a Data as of 15 March 2000; includes data for lymphocytic, monocytic, mononuclear cell, and undifferentiated leukemia
 Data as of 21 December 1999; includes data for lymphocytic, monocytic, mononuclear cell, and undifferentiated leukemia

Summary of the Incidence of Nor	neoplastic Lesions in Male F	Rats in the 2-Year Drinking	Water Study of Sodium Nitrite ^a

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Disposition Summary				
	50	50	50	50
Animals initially in study	50	50	50	50
Early deaths Moribund	16	4	12	0
Natural deaths	16 5	4 8	12 2	8 6
Survivors	5	8	2	0
		1		
Died last week of study Terminal sacrifice	29	1 37	36	36
Terminal sacrifice	29	57	30	50
Animals examined microscopically	50	50	50	50
Alimentary System				
Intestine large, rectum	(50)	(50)	(50)	(50)
Parasite metazoan	5 (10%)	4 (8%)	3 (6%)	2 (4%)
Intestine large, cecum	(50)	(50)	(50)	(49)
Congestion	1 (2%)	(00)	(00)	
Liver	(50)	(50)	(50)	(50)
Angiectasis		2 (4%)	3 (6%)	1 (2%)
Basophilic focus	31 (62%)	34 (68%)	37 (74%)	42 (84%)
Clear cell focus	19 (38%)	25 (50%)	26 (52%)	23 (46%)
Cyst	19 (5670)	25 (5070)	20 (3270)	1 (2%)
Degeneration	1 (2%)			1 (270)
Degeneration, cystic	5 (10%)	15 (30%)	12 (24%)	4 (8%)
Eosinophilic focus	4 (8%)	10 (20%)	11 (22%)	6 (12%)
Fibrosis	2 (4%)	10 (2070)	11 (2270)	0 (12/0)
Hemorrhage	1 (2%)	1 (2%)		
Hepatodiaphragmatic nodule	11(22%)	6 (12%)	4 (8%)	8 (16%)
Inflammation, chronic active	13 (26%)	19 (38%)	25 (50%)	24 (48%)
Mixed cell focus	7 (14%)	7 (14%)	4 (8%)	2 (4%)
Necrosis	5 (10%)	2 (4%)	1 (2%)	4 (8%)
Regeneration	1 (2%)	1 (2%)	1 (270)	1 (2%)
Vacuolization cytoplasmic	8 (16%)	5 (10%)	4 (8%)	1 (2%)
Bile duct, hyperplasia	41 (82%)	38 (76%)	43 (86%)	38 (76%)
Mesentery	(11)	(7)	(5)	(8)
Fat, inflammation, chronic active	8 (73%)	5 (71%)	5 (100%)	6 (75%)
Fat, mineralization	1 (9%)	. (/1/0)	. (10070)	0 (10/0)
Fat, necrosis	- (///)		1 (20%)	
Oral mucosa	(2)		(1)	
Pharyngeal, cyst	1 (50%)		(-)	
Pancreas	(50)	(50)	(50)	(49)
Atrophy		1 (2%)		× /
Inflammation, chronic active		1 (2%)		
Acinus, atrophy	16 (32%)	27 (54%)	22 (44%)	28 (57%)
Acinus, hyperplasia	4 (8%)	3 (6%)	6 (12%)	8 (16%)
Salivary glands	(50)	(50)	(50)	(50)
Atrophy	()	1 (2%)		X 7
Cyst		1 (2%)		
Inflammation, chronic active	1 (2%)			
Stomach, forestomach	(50)	(50)	(50)	(50)
Edema	1 (2%)		1 (2%)	1 (2%)
Erosion	2 (4%)		- (-/*)	- (-/)
Hyperkeratosis	= ()	1 (2%)	4 (8%)	4 (8%)
Inflammation, chronic active	1 (2%)	1 (2%)	. (0,0)	1 (2%)
Mineralization	- (-/)	- (-, •)	1 (2%)	1 (2%)

^a Number of animals examined microscopically at the site and the number of animals with lesion

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Alimentary System (continued)				
Ulcer	4 (8%)	1 (2%)	2 (4%)	1 (2%)
Epithelium, hyperplasia	12 (24%)	9 (18%)	10 (20%)	44 (88%)
Stomach, glandular	(50)	(50)	(50)	(50)
Erosion	1 (2%)		3 (6%)	1 (2%)
Thrombosis	1 (2%)			
Ulcer	2 (4%)	1 (2%)	1 (2%)	
Epithelium, hyperplasia				1 (2%)
Fongue			(1)	
Epithelium, hyperplasia			1 (100%)	
Cardiovascular System				
Heart	(50)	(50)	(50)	(50)
Inflammation, chronic active	9 (18%)	15 (30%)	16 (32%)	12 (24%)
Thrombosis	1 (2%)	1 (2%)	× /	× /
Endocrine System Adrenal cortex	(50)	(50)	(50)	(50)
Accessory adrenal cortical nodule	(50)	(50)	(50)	(50)
Accessory adrenal cortical nodule Angiectasis	16 (32%)	21 (42%)	15 (30%)	22 (44%)
Hematopoietic cell proliferation	10(32%) 1(2%)	21 (4270)	15 (5070)	22 (4470)
Hyperplasia	1 (2%) 11 (22%)	15 (30%)	15 (30%)	10 (20%)
Hypertrophy	7 (14%)	7 (14%)	2 (4%)	9 (18%)
Necrosis	, (17/0)	1 (2%)	2 (⁷ / ⁰)	7 (1070)
Vacuolization cytoplasmic	3 (6%)	3 (6%)	8 (16%)	3 (6%)
Bilateral, hyperplasia	1 (2%)	5 (0/0)	0 (10/0)	5 (0/0)
Adrenal medulla	(50)	(50)	(50)	(50)
Hyperplasia	11 (22%)	18 (36%)	16 (32%)	13 (26%)
slets, pancreatic	(50)	(50)	(50)	(49)
Hyperplasia	~ /	1 (2%)		1 (2%)
Pituitary gland	(50)	(49)	(50)	(50)
Angiectasis		1 (2%)		
Cyst		2 (4%)	1 (2%)	
Hemorrhage		1 (2%)		
Pigmentation, hemosiderin			1 (2%)	
Pars distalis, angiectasis		1 (2%)	1 (2%)	1 (2%)
Pars distalis, cyst	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Pars distalis, hyperplasia	9 (18%)	9 (18%)	18 (36%)	10 (20%)
Гhyroid gland	(50)	(50)	(50)	(50)
C-cell, hyperplasia	11 (22%)	17 (34%)	16 (32%)	13 (26%)
Follicle, cyst		3 (6%)	1 (2%)	
Conorol Body System				
General Body System Peritoneum			(1)	
Inflammation, chronic active			1 (100%)	
			1 (10070)	
Genital System				
Epididymis	(50)	(50)	(50)	(50)
Degeneration	1 (2%)			

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Genital System (continued)				
Preputial gland	(50)	(50)	(50)	(50)
Cyst	3 (6%)	1 (2%)	1 (2%)	3 (6%)
Hyperplasia	1 (2%)	1 (2%)	1 (270)	1 (2%)
Inflammation, chronic active	8 (16%)	10 (20%)	6 (12%)	1 (2%)
Inflammation, suppurative	8 (1070)	10 (2070)	0 (12/0)	1 (2%) 1 (2%)
Prostate	(50)	(50)	(50)	(50)
Inflammation, chronic active	(30)	(30)		(30)
Seminal vesicle	(50)	(50)	1 (2%)	(40)
	(50)	(50)	(50)	(49)
Atrophy	34 (68%)	34 (68%)	36 (72%)	33 (67%)
Cyst	(= 0)	(1 (2%)	(- 0)
Testes	(50)	(50)	(50)	(50)
Degeneration	8 (16%)	12 (24%)	11 (22%)	11 (22%)
Mineralization	7 (14%)	1 (2%)	2 (4%)	2 (4%)
Interstitial cell, hyperplasia	9 (18%)	6 (12%)	9 (18%)	7 (14%)
Hematopoietic System Bone marrow	(50)	(50)	(50)	(50)
Atrophy	()	()	x /	1 (2%)
Myelofibrosis	1 (2%)		3 (6%)	1 (270)
Lymph node	(5)	(4)	(4)	(2)
	(3)	(4)		(2)
Ectasia Panarostia estasia	1 (2007)		1 (25%)	
Pancreatic, ectasia	1 (20%)	(50)	(50)	(50)
Lymph node, mandibular	(48)	(50)	(50)	(50)
Congestion	1 (2%)			1 (2%)
Hyperplasia	1 (2%)		1 (2%)	2 (4%)
Lymph node, mesenteric	(50)	(50)	(50)	(50)
Amyloid deposition				1 (2%)
Congestion		1 (2%)	1 (2%)	
Ectasia			1 (2%)	
Hyperplasia	1 (2%)			
Pigmentation, lipofuscin	1 (2%)	1 (2%)		
Spleen	(50)	(50)	(50)	(50)
Accessory spleen	1 (2%)	(50)	1 (2%)	(50)
Congestion	2 (4%)	3 (6%)	1 (2/0)	
Fibrosis	2 (4%)		3 (6%)	4 (8%)
		2 (4%)		
Hematopoietic cell proliferation	5 (10%)		2 (4%)	1 (2%)
Hyperplasia	1 (2%)	1 (201)		
Hyperplasia, histiocytic		1 (2%)		
Inflammation, granulomatous		1 (2%)		
Necrosis	1 (2%)	1 (2%)		
Pigmentation, hemosiderin	1 (2%)		1 (2%)	1 (2%)
Capsule, fibrosis		1 (2%)		
Lymphoid follicle, depletion cellular		1 (2%)		
Thymus	(50)	(49)	(49)	(48)
Atrophy		1 (2%)	2 (4%)	
Integumentary System				
Mammary gland	(45)	(47)	(47)	(47)
Cyst	x - 7	1 (2%)	× · /	
Galactocele		2(4%)		1 (2%)
Canadiovere		- (7/0)		1 (4/0)

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Integumentary System (continued)				
Skin	(49)	(50)	(50) (20()	(50)
Acanthosis Hyperkeratosis		1 (2%)	1 (2%) 1 (2%)	
Hyperplasia, basal cell	1 (2%)	1(2/0)	1 (270)	
Inflammation, chronic active	1 (270)			1 (2%)
Mineralization				1 (2%)
Epidermis, cyst	1 (2%)			
Musculoskeletal System None				
Nervous System				
Brain	(50)	(50)	(50)	(50)
Hemorrhage		1 (2%)	1 (2%)	
Hydrocephalus		1 (2%)		
Respiratory System				
Lung	(50)	(50)	(50)	(50)
Congestion			1 (2%)	2 (4%)
Hemorrhage Inflammation, chronic active	18 (36%)	7 (14%)	11 (229/)	1 (2%) 11 (22%)
Metaplasia, osseous	18 (30%)	1 (2%)	11 (22%)	11 (2270)
Necrosis		1 (270)	1 (2%)	
Parasite metazoan		1 (2%)	1 (270)	
Alveolar epithelium, hyperplasia	11 (22%)	11 (22%)	20 (40%)	14 (28%)
Bronchiole, epithelium, hyperplasia				1 (2%)
Bronchus, inflammation, suppurative	1 (2%)			
Interstitium, fibrosis			1 (2%)	1 (2%)
Nose	(50)	(50)	(50)	(50)
Inflammation, chronic active	1 (2%)	1 (2%)		
Inflammation, granulomatous Inflammation, suppurative		1 (2%) 1 (2%)		1 (2%)
innanination, suppurative		1 (270)		1 (270)
Special Senses System				
Eye		(1)	(1)	(2)
Hemorrhage			1 (100%)	1 (500/)
Lens capsule, mineralization				1 (50%)
Retina, degeneration			1 (1009/)	2 (100%)
Retrobulbar, inflammation, chronic active			1 (100%)	

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Urinary System				
Kidney	(50)	(50)	(50)	(50)
Congestion				1 (2%)
Crystals				1 (2%)
Cyst			2 (4%)	4 (8%)
Infarct	1 (2%)			
Mineralization	1 (2%)		1 (2%)	
Nephropathy	42 (84%)	45 (90%)	47 (94%)	47 (94%)
Pigmentation	1 (2%)	1 (2%)		
Renal tubule, degeneration				1 (2%)
Renal tubule, necrosis	1 (2%)			()
Urinary bladder	(49)	(50)	(50)	(50)
Inflammation, chronic active	(-)	1 (2%)	6 (12%)	1 (2%)

APPENDIX B SUMMARY OF LESIONS IN FEMALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF SODIUM NITRITE

Summary of the Incidence of Neoplasms in Female Rats	
in the 2-Year Drinking Water Study of Sodium Nitrite	
Individual Animal Tumor Pathology of Female Rats	
in the 2-Year Drinking Water Study of Sodium Nitrite	
Statistical Analysis of Primary Neoplasms in Female Rats	
in the 2-Year Drinking Water Study of Sodium Nitrite	
Historical Incidence of Mammary Gland Fibroadenoma	
in Control Female F344/N Rats	
Historical Incidence of Mononuclear Cell Leukemia	
in Control Female F344/N Rats	
Summary of the Incidence of Nonneoplastic Lesions in Female Rats	
in the 2-Year Drinking Water Study of Sodium Nitrite	
	in the 2-Year Drinking Water Study of Sodium Nitrite Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite Historical Incidence of Mammary Gland Fibroadenoma in Control Female F344/N Rats

Summary of the Incidence of Neoplasms in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite^a

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths				
Moribund	11	6	10	15
Natural deaths	6	13	4	2
burvivors				
Terminal sacrifice	33	31	36	33
nimals examined microscopically	50	50	50	50
Alimentary System				
intestine large, rectum	(50)	(50)	(50)	(50)
Fibroma			1 (2%)	
ntestine small, jejunum	(50)	(44)	(49)	(50)
Leiomyoma			1 (2%)	
Liver	(50)	(50)	(50)	(50)
Oral mucosa	(1)	(1)		
Squamous cell carcinoma	1 (100%)	1 (100%)		
tomach, forestomach	(50)	(50)	(50)	(50)
Squamous cell papilloma				1 (2%)
ongue		(2)	(1)	
Squamous cell carcinoma		1 (50%)	1 (100%)	
Cardiovascular System				
Blood vessel	(50)	(50)	(50)	(50)
Heart	(50)	(49)	(50)	(50)
	(50)	(1)	(30)	(30)
Endocrine System				
Adrenal cortex	(50)	(50)	(50)	(50)
Adenoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Carcinoma		1 (2%)		1 (2%)
Adrenal medulla	(50)	(50)	(45)	(49)
Pheochromocytoma benign	4 (8%)	2 (4%)		2 (4%)
ituitary gland	(50)	(50)	(50)	(50)
Pars distalis, adenoma	24 (48%)	25 (50%)	17 (34%)	21 (42%)
hyroid gland	(50)	(49)	(48)	(50)
Bilateral, C-cell, adenoma	_			1 (2%)
C-cell, adenoma	7 (14%)	4 (8%)	10 (21%)	6 (12%)
C-cell, carcinoma	2 (4%)			1 (2%)
Follicular cell, adenoma	1 (2%)			
Follicular cell, carcinoma	1 (2%)		1 (2%)	1 (2%)

General Body System

None

Summary of the Incidence of Neoplasms in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Genital System				
Clitoral gland	(46)	(48)	(49)	(49)
Adenoma	8 (17%)	8 (17%)	5 (10%)	3 (6%)
Carcinoma	2 (4%)	1 (2%)	5 (1070)	1 (2%)
Bilateral, adenoma	2 (470)	2 (4%)	1 (2%)	1 (270)
Diateral, adenoma	(50)	(49)	(50)	(50)
Granulosa cell tumor benign	(30)	1 (2%)	(50)	(50)
Schwannoma malignant		1 (270)	1 (2%)	
Sertoli cell tumor malignant			1 (2%) 1 (2%)	
Iterus	(50)	(50)	(50)	(50)
Adenocarcinoma	2 (4%)	(30)	(50)	(50)
Adenoma	2 (4/0)	1 (2%)		
	7 (14%)	3 (6%)	8 (16%)	7 (14%)
Polyp stromal Sarcoma stromal	/ (14/0)	5 (0/0)	1 (2%)	/ (14/0)
Cervix, carcinoma		1 (2%)	1 (2/0)	
		1 (270)		
Iematopoietic System				
Bone marrow	(50)	(50)	(50)	(50)
Lymph node	(2)	(1)	(2)	(1)
Carcinoma, metastatic, lung			1 (50%)	
Mediastinal, carcinoma, metastatic,				
adrenal cortex		1 (100%)		
ymph node, mandibular	(49)	(49)	(50)	(50)
Carcinoma, metastatic, Zymbal's gland				1 (2%)
ymph node, mesenteric	(50)	(50)	(50)	(50)
Spleen	(50)	(50)	(50)	(50)
hymus	(49)	(47)	(49)	(48)
ntegumentary System				
Mammary gland	(50)	(50)	(50)	(50)
Adenoma	1 (2%)	1 (2%)	(50)	3 (6%)
Adenoma, multiple	1 (2%) 1 (2%)	1 (270)		5 (670)
Carcinoma	1 (2%)	1 (2%)	2 (4%)	2 (4%)
Fibroadenoma	14 (28%)	14 (28%)	18 (36%)	20 (40%)
Fibroadenoma, multiple	7 (14%)	13 (26%)	13 (26%)	5 (10%)
kin	(50)	(50)	(50)	(50)
Basal cell adenoma	(00)	(30)	(50)	1 (2%)
Basal cell carcinoma	1 (2%)			1 (2%) 1 (2%)
Fibroma	1 (2%)		1 (2%)	1 (2%)
Fibrosarcoma	1 (2/0)		1 (270)	1 (2%)
Hemangiopericytoma	1 (2%)			1 (270)
Lipoma	1 (2/0)		2 (4%)	
Squamous cell carcinoma	1 (2%)		- (1/0)	1 (2%)
Trichoepithelioma	1 (2%) 1 (2%)			1 (270)
Pinna, melanoma malignant	1 (2/0)	1 (2%)		1 (2%)
Subcutaneous tissue, fibroma		1 (2/0)	1 (2%)	1 (270)

Musculoskeletal System

None

Summary of the Incidence of Neoplasms in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Nervous System				
Brain	(50)	(50)	(50)	(50)
Astrocytoma malignant			1 (2%)	
Spinal cord			(1)	
Respiratory System				
Lung	(50)	(50)	(50)	(50)
Alveolar/bronchiolar adenoma	3 (6%)	2 (4%)	3 (6%)	2 (4%)
Alveolar/bronchiolar carcinoma			1 (2%)	
Carcinoma, metastatic, adrenal cortex		1 (2%)	1 (20/)	
Sarcoma Nose	(50)	(40)	1 (2%)	(50)
Squamous cell carcinoma, metastatic, skin	(50)	(49)	(50)	(50) 1 (2%)
Squanous cen caremonia, inclastatic, skin				1 (270)
Special Senses System				
Zymbal's gland			(2)	(2)
Carcinoma			1 (50%)	1 (50%)
Urinary System				
Kidney	(50)	(50)	(50)	(50)
Nephroblastoma			1 (2%)	
Renal tubule, adenoma				1 (2%)
Urinary bladder	(50)	(50)	(50)	(50)
Systemic Lesions				
Multiple organs	(50)	(50)	(50)	(50)
Leukemia mononuclear	15 (30%)	10 (20%)	1 (2%)	1 (2%)
Neoplasm Summary				
Fotal animals with primary neoplasms ^c	45	45	49	45
Total primary neoplasms	107	94	95	87
otal animals with benign neoplasms	42	42	46	42
Total benign neoplasms	81	77	82	75
Total animals with malignant neoplasms	23	16	12	12
Total malignant neoplasms	26	17	13	12
Fotal animals with metastatic neoplasms		1	1	2
Total metastatic neoplasms		2	1	2

Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms а b

c

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm

	5 5 5 5 5 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7
Number of Days on Study	1 1 4 4 6 9 0 4 4 6 6 6 6 9 9 1 2 3 3 3 3 3 3 3 3
umber of Days of Study	1 3 7 8 7 6 1 4 8 1 2 9 9 3 4 4 9 0 0 0 0 0 1 1
	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Carcass ID Number	1 2 1 1 1 2 1 3 0 3 2 0 3 3 0 1 4 0 0 0 2 3 3 0 1
	1 7 7 5 0 6 3 1 5 2 0 8 9 5 6 2 4 1 4 9 8 0 8 2 4
Alimontow System	
Alimentary System Esophagus	+ + + + + + + + + + + + + + + + + + + +
Intestine argeç olon	+ + + + + + + + + + + + + + + + + + + +
Intestine arger ectum	+ + + + + + + + + + + + + + + + + + + +
Intestine large, cecum	+ + + + + + + + + + + + + + + + + + + +
Intestine small, duodenum	+ + + + + + + + + + + + + + + + + + + +
Intestine small, jejunum	+ + + + + + + + + + + + + + + + + + + +
Intestinos mallį leum	
Liver	
Mesentery	+ + + +
Oral mucosa	+ +
	$\overset{+}{\mathrm{X}}$
Squamous cell carcinoma	
Pancreas	
Salivaryg lands	+ + + + + + + + + + + + + + + + + + +
Stomachf orestomach	
Stomach, glandular	+ + + + + + + + + + + + + + + + + + + +
Cardiovascular System	
Blood vessel	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$
Heart	+ + + + + + + + + + + + + + + + + + +
Endocrine System	
Adrenal cortex	+ + + + + + + + + + + + + + + + + + + +
Adenoma	· · · · · · · · · · · · · · · · · · ·
Adrenal medulla	+ + + + + + + + + + + + + + + + + + + +
Pheochromocytoma benign Islets, pancreatic	λ + + + + + + + + + + + + + + + + + + +
Parathyroid gland	
Pituitary gland	+ + + + + + + + + + + + + + + + + + +
Pars distalis, adenoma	X X X X X X X X X X X X X X X
Thyroid gland	+ + + + + + + + + + + + + + + + + + +
C-cell, adenoma	X
C-cell, carcinoma	Х
Follicular cell, adenoma	
Follicular cell, carcinoma	X
General Body System	
None	
Genital System	
Clitoral gland	M + M + + + + + + + + M + + + + + + + +
Adenoma	1VI · 1VI · T T T T T T T 1VI T T T T T T T T T T T T T T T T T
	V
Carcinoma	Χ
Ovary	+ + + + + + + + + + + + + + + + + + + +
Uterus	+ + + + + + + + + + + + + + + + + + +
Adenocarcinoma	X
Polyp stromal	Х

+: Tissue examined microscopically A: Autolysis precludes examination M: Missing tissue I: Insufficient tissue X: Lesion present Blank: Not examined

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm

Individual Annual Funior F	athology of Fem				•						8			~~~	-J	•1					•		o bhu
	7	7	7	7	77	7	7	7	77	7	7	7	7	7 7	7	7	7	7	7	7	7	7	
Number of Days on Study	3	3	3	3	3 3	3	3	3	3 3	3	3	3	3	3 3	3	3	3	3	3	3	3	3	
and of Days on Staay	1	1	1	1	1 1	1	1	1	1 1	2	2	-	2 2		2	2	2	2	2	2	2		
	1	1		1				1				-			-	-	2	2	-	-		-	
	2	2	2	2	2 2	2	2	2	2 2	2	2	2	2 2	2 2	2	2	2	2	2	2	2	2	Total
Carcass ID Number	2	2	3	3	34	4	4	4	45	0	0	1	1	12	2	2	2	3	4	4	4	4	Tissues/
			3		7 0				90		7		8 9			5	9		2				Tumors
	2	5	5	7	/ 0	1	0	0) 0	5	'	0	. 0	/ 1	т	5	,	0	2	5	5	/	1 uniors
Alimentary System																							
Esophagus	+	+	+	+ ·	+ +	+	+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
Intestine argeç olon	+	+	+	+ -	+ +	+	+	+	+ +	- +	$^+$	+	+ -	+ +	+	$^+$	$^+$	+	$^+$	+	$^+$	+	50
Intestine arger ectum	+	+	+	+ -	+ +	+	+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+ -	+ +	+	+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+ -	+ +	+	+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
Intestine small, jejunum	+	+	+	+ .	+ +	+	+	+	+ +	- +	+	+	+ -	 + +	+	+	+	+	+	+	+	+	50
Intestines mallį leum	+	+	+	· + ·	 + +	+	+	+	 + +	· +	+	÷.	+ .	 	+	+	+	+	+	+	+	+	50
Liver	1						÷	-			÷					÷					÷		50
	Ŧ	т	Ŧ	τ.	τ	Τ'	Ŧ	т I	т т	7	Τ'	т 1		і Т	Τ.	Τ'	Ŧ	T'	Ŧ	Ŧ	Τ'	Ŧ	
Mesentery								+				+						+					7
Oral mucosa																							1
Squamous cell carcinoma																							1
Pancreas	+	+	+	+ ·	+ +	+	+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
Salivaryg lands	+	+	+	+ ·	+ +	+	+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+	+	49
Stomachf orestomach	+	$^+$	+	+ ·	+ +	+	+	+	+ +	- +	$^+$	+	+ -	+ +	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	+	50
Stomach, glandular	+	+	+	+ -	+ +	+	+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
Cardiovascular system																							
Blood vessel	+	+	+	+ ·	+ +	+	+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
Heart	+	+	+	+	+ +	+	+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
Endoaring System																							
Endocrine System Adrenal cortex	1																+						50
	Ŧ	Ŧ	Ŧ	Τ.		Ŧ	Ŧ	Ŧ	- τ		Ŧ	Ŧ	Τ -		Ŧ	Ŧ	т	T V	Ŧ	Ŧ	т	Ŧ	
Adenoma																		Х					1
Adrenal medulla	+	+	+	+	+ +		+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+		+	50
Pheochromocytoma benign					Х			Х													Х		4
Islets, pancreatic	+	+	+	+ ·	+ +	+	+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+		50
Parathyroid gland	+	+	+	+ ·	+ +	+	+	+	+ +	- +	+	Μ	+ -	+ +	Μ	+	+	+	+	+	+	+	46
Pituitary gland	+	+	+	+ ·	+ +	+	+	+	+ +	- +	$^+$	+	+ -	+ +	$^+$	$^+$	+	+	$^+$	+	$^+$	+	50
Pars distalis, adenoma	Х	Х					Х	X	Х	Х	Х	X	Χ			Х		Х					24
Thyroid gland	+	+	+	+ -	+ +	+	+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
C-cell, adenoma			Х						хх				x y	ζ								Х	7
C-cell, carcinoma												-		-			Х						2
Follicular cell, adenoma																	Λ				Х		1
Follicular cell, carcinoma																					л		1
Forneulai cen, caremonia																							1
General Body System																							
None																							
Genital System																							
	1	-	+	т.	ц	-	-	-	<u>т</u> ,	. M	т.	т.	L.	L .	+	1	-	-	<u>т</u>	-	-	-	16
Clitoral gland	+	+	+ V	Τ .	+ + v	+	\mathbf{v}	Ŧ	- +	- M	+	Ŧ		- +	+	+	\mathbf{v}	+	+	+	+	Ŧ	46
Adenoma	Х		Х		X		Х	-								Х	Х		Х		Х		8
Carcinoma									Х														2
Ovary	+	+	+	+ ·	+ +	+	+		+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
Uterus	+	+	+	+ ·	+ +	+	+	+	+ +	- +	+	+	+ -	+ +	+	+	+	+	+	+	+	+	50
Adenocarcinoma					Х																		2
Polyp stromal									Х	Х		Х			Х						Х	Х	7
i olyp su olliai																							

	5	5	5	5	5	5	6	66	6	6	6	6	6	67	7	7	7	7	7	7	7	7	7
Number of Days on Study	1	1	4	4	6			44						91		3	3	3	3	3	3	3	3
	-			8		-		4 8											0				
	2	2	2	2	2	2	2	2 2	2	2	2	2	2			2	2	2	2	2	2	2	2
Carcass ID Number	1 1	2 7	1 7	1 5	1 0			30 15		2 0	0 8			01 62	4	0 1	0 4	0 9	2 8	3 0		0 2	
Hematopoietic System																							
Bone marrow	+	+	+	+	+	+	+ •	+ +	+	+	+	+	+ •	+ +	- +	+	+	+	+	+	+	+	+
Lymph node		+						+															
Lymph node, mandibular	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+ •	+ +	- +	+	+	М	+	+	+	+	+
Lymph node, mesenteric	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+ •	+ +	- +	+	+	+	+	+	+	+	+
Spleen	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+ •	+ +	- +	+	+	+	+	+	+	+	+
Thymus	+	+	+	М	+	+	+ -	+ +	+	+	+	+	+ ·	+ +	+	+	+	+	+	+	+	+	+
Integumentary System																							
Mammaryg land	+	+	+	+	+	+	+ ·	+ +	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	$^+$	+
Adenoma																							
Adenoma, multiple																					Х		
Carcinoma																							
Fibroadenoma			Х				2	X		Х			2	X								Х	Х
Fibroadenoma, multiple												Х				Х	Х						
Skin	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+ ·	+ +	- +	+	+	$^+$	+	+	+	$^+$	+
Basal cell carcinoma		Х																					
Fibroma															Х								
Hemangiopericytoma	Х																						
Squamous cell carcinoma												Х											
Trichoepithelioma																							
Musculoskeletal System																							
Bone	+	+	+	+	+	+	+ •	+ +	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+
Nervous System																							
Brain	+	+	+	+	+	+	+ •	+ +	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+
Respiratory System																							
Lung	+	+	+	+	+	+	+ -	+ +	+	+	+			+ +	- +	+	+	+	+	+	$^+$ X	+	+
Alveolar/bronchiolar adenoma													X								<u>л</u>		
Nose	+	+	+	+	+	+	+ -	+ +	+	+	+	+		+ +		+	+	+	+	+	+	+	
ſrachea	+	+	+	+	+	+	+ •	+ +	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+
Special Senses System None																							
Urinary System																							
Kidney	+	+	+	+	+	+	+ •	+ +	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	$^+$	+
Urinary bladder	+	+	+	+	+	+	+ ·	+ +	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+
Systemic Lesions Multiple organs Leukemia mononuclear	+	+	+	+	+ X	+	+ -	+ +	+ X	+	+	+ X	+ ·	+ +	- +	+	+	+	+	+	+	+	+

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm 77 7 77 Number of Days on Study 3 2 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 Total 4 4 4 4 5 0 **Carcass ID Number** 2 2 3 3 3 4 0 1 1 1 2 2 2 2 3 4 4 4 4 Tissues/ 2 3 3 4 7 0 1 6 8 9 0 3 7 6 8 9 1 4 5 9 6 2 3 5 7 Tumors Hematopoietic System 50 Bone marrow + + + + + Lymph node 2 Lymph node, mandibular 49 Lymph node, mesenteric + + 50 Spleen + + + + + + + + 50 49 Thymus +++++++ ++ ++++ + +++ +++ ++**Integumentary System** Mammaryg land 50 + + + + +Х Adenoma 1 Adenoma, multiple 1 Carcinoma Х 1 Х Fibroadenoma Х ХХХ Х Х 14 Fibroadenoma, multiple Х Х Х 7 Х + Skin + + + + 50 Basal cell carcinoma 1 Fibroma 1 Hemangiopericytoma 1 Squamous cell carcinoma 1 Trichoepithelioma Х 1 Musculoskeletal System Bone 50 ++++++++ ++++ $^{+}$ ++++++++ $^{+}$ + + **Nervous System** Brain + + + $^+$ $^+$ $^{+}$ $^+$ + 50 ++ ++++ $^{+}$ $^{+}$ $^{+}$ + $^{+}$ ++ $^+$ $^{+}$ +**Respiratory System** Lung + 50 + Alveolar/bronchiolar adenoma 3 Х Nose + 50 + + ++Trachea + 50 + + + ++ + + ++ + + + +++ ++++ +++++**Special Senses System** None **Urinary System** 50 Kidney + + + + + +++++++++ +++ ++++++ ++Urinary bladder + + + ++ + + + + + + + +++ + ++ + + + + 50 +++Systemic Lesions Multiple organs + + + + 50 + + + + + + Leukemia mononuclear Х Х X X Х 15 Х

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm 3 4 5 5 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 3 8 3 4 0 1 4 5 6 6 7 8 8 9 9 0 1 2 2 3 3 3 3 3 3 Number of Days on Study 2 0 6 1 9 6 8 1 2 5 6 0 5 0 6 6 8 3 8 0 0 0 0 1 **Carcass ID Number** 6 7 8 9 6 7 9 5 9 6 5 9 8 5 9 8 5 7 5 6 7 89 6 5 4 2 3 5 9 8 3 5 2 6 9 0 5 7 6 9 4 9 5 2 1 5 7 7 3 **Alimentary System** Esophagus + Μ Intestine argeç olon + + + + + Μ + + Α + Intestine arger ectum + + Intestine large, cecum + + + Δ + Μ + + А + Intestine small, duodenum Α Intestine small, jejunum + Μ А ++А + ++ + + А + + А Α Intestines malli leum + + +М + + Α +++А +++ ++Liver + + + + Mesentery Oral mucosa + Squamous cell carcinoma Х + Pancreas + + ++++++ Salivaryg lands + + + + + + + Μ + + Stomachf orestomach + + ++ ++ ++ ++ +Stomach, glandular + Tongue + Squamous cell carcinoma Х **Cardiovascular System** Blood vessel + + + + ++ Heart + + ++++++ ++++++++++М + ++++ $^{+}$ **Endocrine System** Adrenal cortex + Adenoma Х Carcinoma X Adrenal medulla + + Pheochromocytoma benign Х Islets, pancreatic + Parathyroid gland Μ + Μ + М ++ + Pituitary gland $^+$ + $^{+}$ + + + + + + ++ + + + +++++++++Pars distalis, adenoma Х Х Х Х Х Х Х Х Х Х Х Х Х Thyroid gland + + + + + + + + Μ + + C-cell, adenoma Х Х **General Body System** None **Genital System** Clitoral gland +М +Adenoma Х Х Carcinoma Bilateral, adenoma Ovary + + Μ Granulosa cell tumor benign Х Uterus + + + + + X Adenoma Polyp stromal ХХ Х Cervix, carcinoma Vagina

77 7 77 Number of Days on Study 3 1 1 1 1 1 1 1 1 1 1 2 Total **Carcass ID Number** 5 6 7 7 8 8 8 8 9 0 5 5 6 6 6 6 7 7 7 7 8 8 9 9 9 Tissues/ 6 7 0 7 0 1 6 8 8 0 1 8 0 2 3 8 1 3 4 6 2 4 1 4 9 Tumors **Alimentary System** 49 Esophagus + + + + Intestine argeç olon + 48 Intestine arger ectum 50 + + + Intestine large, cecum 47 Intestine small, duodenum 49 Intestine small, jejunum 44 + Intestines malli leum 47 Liver + 50 + + + + Mesentery 5 Oral mucosa 1 Squamous cell carcinoma 1 Pancreas + 50 Salivaryg lands + + 49 Stomachf orestomach 50 Stomach, glandular 50 2 Tongue Squamous cell carcinoma 1 **Cardiovascular System** 50 Blood vessel + + +++ +++++ ++49 Heart + + + + + + + + + + + + + + + + + + $^{+}$ $^{+}$ + ++++**Endocrine System** Adrenal cortex 50 Adenoma 1 Carcinoma 1 Adrenal medulla + + 50 Pheochromocytoma benign 2 Х Islets, pancreatic + + 50 43 Parathyroid gland М Μ + +M + ++ Pituitary gland 50 + + + + + + + + + + + + + + + 25 Pars distalis, adenoma Х Х Х Х Х Х Х Х Х Х Х Х Thyroid gland + + 49 + + + + + C-cell, adenoma Х Х 4 **General Body System** None **Genital System** Clitoral gland 48 + + + + Μ Х Х Х Х 8 Adenoma Х Х Carcinoma Х 1 Bilateral, adenoma 2 Ovary 49 Granulosa cell tumor benign 1 Uterus 50 Adenoma 1 Polyp stromal 3 Х Cervix, carcinoma 1 Vagina 1

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm

													0					•								I. I.	
Number of Days on Study	3 3 2	4 8 0	5 3 6	5 4 1	6 0 9	6 1 6	6 4 8	6 5 1	6	6 6 5	6 7 6		8	6 9 0	9	0	7 1 8	7 2 3	7 2 8	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	3		
Carcass ID Number	2 6 4	7	2 8 3	2 9 5	6	2 7 8	2 9 3	2 5 5	9	2 6 6	5	9	2 8 5	5	2 9 6	8	5	2 7 9	6	2 5 2	2 6 1	2 7 5	2 8 7	2 9 7	5		
Hematopoietic System Bone marrow Lymph node	+	+++	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Mediastinal, carcinoma, metastatic, adrenal cortex Lymph node, mandibular	+	X +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M +	+	+	+	+	+	+	+	+		
.ymph node, mesenteric Spleen Thymus	+++	+ + +	+ + M	++++	+ + +	+ + M	+	+	+ + +																		
ntegumentary System Mammaryg land Adenoma Carcinoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+		
Fibroadenoma Fibroadenoma, multiple Skin Pinna, melanoma malignant	+	+	+	X +	+	+	X +	X +	+	X +	+	+	+	X +		X +		X +	X +	+	X +	+ X	+	X +			
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Respiratory System .ung Alveolar/bronchiolar adenoma	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+		
Carcinoma, metastatic, adrenal cortex Nose Frachea	+ +	X + +	+ +	M +	+ +	+ +	+ +	+ +	+ +	+ +	+ M	+ +															
Special Senses System										+																	
J rinary System Kidney Jrinary bladder	++	+++	+++	+++	+++	+ +	+++	+++	+++	+++	++++	+++	+++	+++	+++	++++	+++	+ +	+ +	+++	+++	+++	+++	+++	++		
Systemic Lesions Multiple organs Leukemia mononuclear	+	+	+	+	+	+ X	+ X	+	+	+	+ X	+	+ X	+ X	+ X	+	+	+	+	+	+	+	+	+	+		

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm 77 7777 7 7 77 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 3 2 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 Total **Carcass ID Number** 5 6 7 7 8 8 8 8 9 0 5 5 6 6 6 6 7 7 7 7 8 8 9 9 9 Tissues/ 6 7 0 7 0 1 6 8 8 0 1 8 0 2 3 8 1 3 4 6 2 4 1 4 9 Tumors Hematopoietic System Bone marrow + + + 50 + Lymph node 1 Mediastinal, carcinoma, metastatic, adrenal cortex 1 Lymph node, mandibular 49 Lymph node, mesenteric + + + + + + + 50 Spleen 50 ++++++++ + ++ + ++++Thymus 47 + **Integumentary System** Mammaryg land + + + + + + + + + ++ + 50 + +++ ++ + Adenoma 1 Carcinoma Х 1 Fibroadenoma Х ХХ 14 Х X X Х 13 Fibroadenoma, multiple Х Х ХХ Х Skin + 50 Pinna, melanoma malignant 1 Musculoskeletal System Bone + + + + ++ + $^+$ + + + + ++ + + + + + + + + 50 **Nervous System** 50 Brain + + + + + ++++++++++**Respiratory System** 50 Lung + + + $^+$ + + + Alveolar/bronchiolar adenoma Х 2 1 Carcinoma, metastatic, adrenal cortex Nose 49 + + + + Trachea ++ + + + + +++++ +++ + ++ + ++ + +++ + 49 **Special Senses System** 1 Eye **Urinary System** Kidney + 50 + + ++ +++ + Urinary bladder + + + + + + + 50 + + + + ++ + + ++ + + + ++ + + +Systemic Lesions Multiple organs + ++ 50 + Leukemia mononuclear Х Х Х Х 10

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm

	by of remark that in the 2-real Drinking water Study of Soulum Attrict. 1,500	hhm
Number of Days on Study	3 5 5 5 6 6 6 6 6 7 3 3 3	
Carcass ID Number	3 3	
Alimentary System		
Esophagus	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Intestine large, colon	+ + + + + + + + + + + + + + + + + + +	
Intestine large, rectum Fibroma	+ + + + + + + + + + + + + + + + + + + +	
Intestine large, cecum	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Intestine small, duodenum Intestine small, jejunum Leiomyoma	+ + + + + + + + + + + + + + + + + + +	
Intestine small, ileum	+ + + + + + + + + + + + + + + + + + +	
Liver	+ + + + + + + + + + + + + + + + + + +	
Mesentery	+ + +	
Pancreas	+ + + + + + + + + + + + + + + + + + +	
Salivary glands	+ + + + + + + + + + + + + + + + + + + +	
Stomach, forestomach	+ + + + + + + + + + + + + + + + + + + +	
Stomach, glandular Tangua	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Tongue Squamous cell carcinoma	, X	
Cardiovascular System		
Blood vessel	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Heart	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Endocrine System		
Adrenal cortex	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Adenoma	Х	
Adrenal medulla	+ + + + + + + + + + + + + + + + M + + + + + + + + +	
Islets, pancreatic	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Parathyroid gland	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Pituitary gland Pars distalis, adenoma	+ + + + + + + + + + + + + + + + + + +	
Thyroid gland	A A A A A A A A A A A A A A A A A A A	
C-cell, adenoma	XXXXXX	
Follicular cell, carcinoma	X	
General Body System None		
Genital System		
Clitoral gland	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Adenoma	Х	
Bilateral, adenoma		
Ovary	+ + + + + + + + + + + + + + + + + + +	
Schwannoma malignant	X	
Sertoli cell tumor malignant		
Uterus Polyp stromal	+ + + + + + + + + + + + + + + + + + +	

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm 7 7 7 7 7 7 7 7 7 7 7 7 7 7 77 7 77 777 7 7 7 7 Number of Days on Study 3 3 3 Total

 2
 2
 2
 3
 3
 3
 4
 4
 0
 0
 1
 1
 1
 2
 2
 2
 3
 3
 4
 4
 4
 5

 4
 5
 9
 0
 5
 7
 8
 3
 4
 6
 3
 5
 3
 4
 6
 3
 5
 7
 1
 1
 2
 2
 2
 3
 3
 4
 4
 4
 5

 4
 5
 9
 0
 5
 7
 8
 3
 4
 6
 3
 6
 7
 8
 3
 4
 4
 5
 7
 0
 1
 1
 1
 2
 2
 2
 3
 3
 4
 4
 5
 1
 1
 1
 2
 2
 2
 3
 3
 4
 4
 4
 5
 1
 1
 1
 2
 2
 2
 3
 3
 4
 4
 4
 5
 1
 1
 1
 2
 2
 2
 3
 3
 4
 1
 5</td **Carcass ID Number** Tissues/ **Cardiovascular System** 50 + + + + 50 + + +ł + 1 + + + 50 1 45 Μ + M 49 + + $^+$ 47 + + + ++ 50 + + + I

Alimentary System																									
Esophagus	+	+	$^+$	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	$^+$	$^+$	+	+	+	$^+$	+	5
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	5
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	$^+$	+	+	+	+	+	+	5
Fibroma											Х														
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	$^+$	+	+	+	+	+	+	5
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	$^+$	+	+	+	+	+	+	5
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	$^+$	$^+$	+	+	+	+	+	4
Leiomyoma														Х											
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	$^+$	$^+$	+	+	+	+	+	4
Liver	+	+	+	+	+	+	+	+	+	+	+ ·	+ •	+ +	+	+	+	+	$^+$	$^+$	+	+	+	+	+	5
Mesentery										+	+					+								+	
Pancreas	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	$^+$	+	+	+	+	+	+	4
Salivary glands	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	$^+$	$^+$	+	+	+	+	+	5
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+ ·	+ •	+ +	+	+	+	+	$^+$	$^+$	+	+	+	+	+	5
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	$^+$	+	+	+	+	+	+	5
Tongue																									
Squamous cell carcinoma																									

Blood vessel	+	+	+	+	$^+$	+	+	$^+$	+	$^+$	+	+	+	$^+$	+	+	+	+	$^+$	+	+	+
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Endocrine System																						
Adrenal cortex	+	+	+	+	+	+	+	+	+	$^+$	+	+	+	$^+$	+	+	+	+	+	+	+	+
Adenoma																						
Adrenal medulla	+	+	+	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	М	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	М	+
Islets, pancreatic	+	+	+	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	+
Parathyroid gland	+	+	+	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	М	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	H
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	+	+	+	+	+	+	+	4
Pars distalis, adenoma	Х	Х	Х	Х	Х					Х									Х	Х		

+ + + + + + + + +

Follicular cell, carcinoma **General Body System** None

Thyroid gland

C-cell, adenoma

Genital System		
Clitoral gland	+ + + + + + + + + + + + + + + + + + +	49
Adenoma	X X X X	5
Bilateral, adenoma	Х	1
Ovary	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	50
Schwannoma malignant		1
Sertoli cell tumor malignant	Х	1
Uterus	+ + + + + + + + + + + + + + + + + + + +	50
Polyp stromal	X X X X	8
Sarcoma stromal	Х	1

+ +

 $^+$ $^{+}$ + +

хххх

+

+

17

48

10

1

+ +

Х

+ + + + + + + +

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm

Number of Days on Study	3 5 5 5 6 6 6 6 7
Carcass ID Number	3 3
Hematopoietic System Bone marrow Lymph node	+ + + + + + + + + + + + + + + + + + +
Carcinoma, metastatic, lung Lymph node, mandibular Lymph node, mesenteric Spleen Thymus	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Integumentary System Mammary gland Carcinoma	+ + + + + + + + + + + + + + + + + + + +
Fibroadenoma Fibroadenoma, multiple Skin Fibroma Lipoma Subcutaneous tissue, fibroma	X X X X X X X X + + + + + + + + + + + +
Musculoskeletal System Bone	+ + + + + + + + + + + + + + + + + + + +
Nervous System Brain Astrocytoma malignant Peripheral nerve Spinal cord	+ + + + + + + + + + + + + + + + + + +
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Sarcoma	+ + + + + + + + + + + + + + + + + + +
Nose Trachea	+ + + + + + + + + + + + + + + + + + +
Special Senses System Eye Zymbal's gland Carcinoma	+ + X + X
Urinary System Kidney Nephroblastoma Urinary bladder	+ + + + + + + + + + + + + + + + + + +
Systemic Lesions Multiple organs Leukemia mononuclear	+ + + + + + + + + + + + + + + + + + +

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm 77 7 77 Number of Days on Study 3 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 Total 3 3 2 3 3 3 3 4 4 4 0 0 **Carcass ID Number** 2 2 1 1 1 2 2 2 2 2 3 3 4 4 4 5 Tissues/ 4 5 9 0 5 7 8 3 4 6 3 5 3 4 6 3 6 7 8 3 4 1 5 7 0 Tumors Hematopoietic System 50 Bone marrow Lymph node 2 Carcinoma, metastatic, lung 1 Х Lymph node, mandibular 50 Lymph node, mesenteric + + 50 50 Spleen + +49 Thymus **Integumentary System** 50 Mammaryg land Carcinoma 2 Х Х Fibroadenoma Х Х ХХ X X ХХ х ХХ 18 Fibroadenoma, multiple Х Х Х ХХХ Х X 13 + + 50 Skin + + + + + + + Х Fibroma 1 2 Lipoma Х Subcutaneous tissue, fibroma Х 1 Musculoskeletal System 50 Bone ++ + + + + + + ++ + ++ + +++++++ + + ++ **Nervous System** Brain 50 Astrocytoma malignant 1 Peripheral nerve 1 Spinal cord 1 **Respiratory System** Lung + 50 3 Alveolar/bronchiolar adenoma X X Alveolar/bronchiolar carcinoma Х 1 Х Sarcoma 1 Nose + 50 Trachea + ++ 50 **Special Senses System** 1 Eye Zymbal's gland 2 1 Carcinoma **Urinary System** 50 Kidney Nephroblastoma 1 50 Urinary bladder +++++++++++++++++++++++ ++ Systemic Lesions Multiple organs + 50 Leukemia mononuclear 1

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm

Individual Allinai Tulloi Tati	lology of Fen	ian	- 14	11.5 1	in th	U 	10				·6 '	, au		Ju	uj		500	114		1 11		c. 5,000 ppn
Number of Days on Study	3 6 1	4 6 5	4 7 4	1	6 6 2 2 4 6	6 2 7	2	6 6 5 8 8 0	8 8	6 9 4	0	7 7 1 1 5 8	2	7 2 3	7 3 0	3						
	3	3	3	3	3 3	3	3	3 3	3 3	3	3	3 3	3	3	3	3	3	3	3	3	3	3
Carcass ID Number	6 4	9 4	9 8		56 19	5 7		7 7 2 7	7 8 7 0	9 5		5 8 8 7		9 6	5 3	5 4	6 2	6 8	7 4	7 8	8 4	
Alimentary System																						
Esophagus	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	$^+$	$^+$	+	$^+$	$^+$	$^+$	$^+$	+
Intestine large, colon	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	$^+$	+	$^+$	+	$^+$	+	+
Intestine large, rectum	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	+	+	+	+	+	+	+
Intestine large, cecum	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	+	+	+	+	+	+	+
Intestine small, duodenum	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	$^+$	$^+$	+	$^+$	$^+$	$^+$	$^+$	+
Intestine small, jejunum	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	+	+	+	+	+	+	+
Intestine small, ileum	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	$^+$	+	+	+	$^+$	+	+
Liver	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	+	+	+	+	+	+	+
Mesentery																+				+		
Pancreas	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	$^+$	+	+	+	$^+$	+	+
Salivary glands	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	$^+$	+	+	+	$^+$	+	+
Stomach, forestomach	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	$^+$	$^+$	+	$^+$	$^+$	$^+$	$^+$	+
Squamous cell papilloma					Х																	
Stomach, glandular	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	+	+	+	+	+	+	+
Cardiovascular System																						
Blood vessel	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	$^+$	$^+$	+	$^+$	$^+$	$^+$	$^+$	+
Heart	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	+	+	+	+	+	+	+
Endocrine System																						
Adrenal cortex	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	+	+	+	+	+	+	+
Adenoma													Х									
Carcinoma								Σ	ζ													
Adrenal medulla	+	+	+	+ ·	+ +	+	+	+ +		+	+	+ +	+	+	М	+	+	+	+	+	+	+
Pheochromocytoma benign												Х										
Islets, pancreatic	+	+	+	+ •	+ +	+	+	+ +	+ +	+		+ +	+	+	+	+	+	+	+	+	+	+
Parathyroid gland	+	+	+	+ ·	+ +	+	+	+ +	- M	+	+	+ +	+	+	М	+	+	+	+	+	+	+
Pituitary gland	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	+	+	+	+	+	+	+
Pars distalis, adenoma				2	хх	Х			X	Х	Х	Х					Х					Х
Thyroid gland	+	+	+		+ +	+	+	+ +			+		+	+	+	+	+	+	+	+	+	+
Bilateral, C-cell, adenoma																						
C-cell, adenoma								Σ	ζ							Х			Х			Х
C-cell, carcinoma																						
Follicular cell, carcinoma																						
General Body System None																						
Genital System																						
Clitoral gland	М	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	; +	+	+	+	+	+	+	+	+	+
Adenoma									Х			Х				Х						
Carcinoma					Х																	
Ovary	+	+	+	+ ·	+ +	+	+	+ +	+ +	+	+	+ +	+	+	+	+	+	+	+	+	+	+
Uterus	+	+	+	+ ·	+ +	+	+	+ + 2	+ + -	+	+	+ +	+	+	+	+	+	+	+	+	+	+
Polyp stromal																						

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm

		_	_	_	_	_	_	_	_	_	_	_				_	_	_	-	-	_	-	_	_	-	
				7	7	7	7	7	7				77			7	7	7	7	7	7	7	7		7	
Number of Days on Study			3	3	3	3	3	3	3	3	3		3 3	33		3	3	3	3	3	3	3	3	3	3	
		J	0	0	1	1	1	1	1	1	1	1	1 1	. 1	2	2	2	2	2	2	2	2	2	2	2	
		3	3	4	3	3	3	3	3	3	3	3	3 3	3 3	3 3	3	3	3	3	3	3	3	3	3	3	Total
Carcass ID Number	9	9	9	0	5	6	6	6	6	7	7	8	8 9	9 9	95	5	5	6	6	7	7	7	8	8	9	Tissues/
		1	2	0	6	1	3	5	7	3	9	2	5 () 9	2	5	9	0	6	0	1	5	3	8	7	Tumors
Alimentary System																										
Esophagus	-	+	+	+	+	+	+	+	+	+ -	+ -	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Intestine argeç olon	-	+	+	+	+	+	+	+	+	+ -	+ ·	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Intestine arger ectum	-	+	+	+	+	+	+	+	+	+ ·	+ •	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	-	+	+	+	+	+	+	+	+	+ ·	+ •	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	-	+	+	+	+	+	+	+	+	+ ·	+ •	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Intestine small, jejunum	-	+	+	+	+	+	+	+	+	+ ·	+ •	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Intestines malli leum	-	+	+	+	+	+	+	+	+	+ -	+ -	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Liver	-	+	+	+	+	+	+	+	+	+ -	+ -	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Mesentery				+															-						+	4
Pancreas	-	+		+	+	+	+	+	+	+ •	+ •	+ -	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Salivaryg lands	-	+	+	+	+	+	+	+	+	+ •	+ •	+ -	+ -	+ +	, + +	+	+	+	+	+	+	+	+	+	+	50
Stomachf orestomach	-	+	+	+	+	+	+	+	+	+ •	+ •	+ -	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Squamous cell papilloma																										1
Stomach, glandular	-	+	+	+	+	+	+	+	+	+ -	+ -	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
C ardiovascular System Blood vessel																										50
Heart		T I	т	т	т	т	т	- -	т	т :	т :	т			г т 1 1	- T	- -	- -	т	т	т	т	- -	т	+	50
Hean	-	F	+	+	+	+	+	+	+	+ ·	+ ·	+	+ -		- +	+	+	+	Ŧ	+	÷	+	+	+	+	50
Endocrine System																										
Adrenal cortex	-	+	+	+	+	+	+	+	+	+	+ ·	+	+ -	+ +	+ +	+	+	+	+	$^+$	+	+	+	+	+	50
Adenoma																										1
Carcinoma																										1
Adrenal medulla	-	+	+	+	+	+	+	+	+	+ ·	+ ·	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	49
Pheochromocytoma benign																				Х						2
Islets, pancreatic	-	+	+	+	+	+	+	+	+	+ ·	+ ·	+	+ -	+ +	+ +	+	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	+	+	$^+$	50
Parathyroid gland	Ν	Λ	+	+	+	+	+	М	+	+ ·	+ ·	+	+ -	+ +	+ +	+	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	46
Pituitary gland	-	+	+	+	+	+	+	+	+	+ ·	+ ·	+	+ -	+ +	+ +	+	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	+	+	$^+$	50
Pars distalis, adenoma			Х		Х				X	X	Х			Х	ζ	Х		Х		Х		Х	Х	Х		21
Thyroid gland	-	+	+	+	+	+	+	+	+	+ -	+ ·	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Bilateral, C-cell, adenoma												2	Χ													1
C-cell, adenoma																Х								Х		6
C-cell, carcinoma																								Х		1
Follicular cell, carcinoma															Х											1
General Body System																										
None																										
Genital System																										
Clitoral gland		±.	+	+	+	+	+	+	+	+	+	+	+	L	L J	1	<u>т</u>	_L	<u>ـــ</u>	1	_L	-L	<i>т</i>	-L	+	49
	-	τ	-	Ŧ	т	т	т	т	-	- T	T .	-		r' 1	- +	+	+	+	+	+	+	+	+	+	Ŧ	
Adenoma																										3
Carcinoma																										1
Ovary	-	+	+	+	+	+	+	+	+	+ ·	+ ·	+ •	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Uterus	-	+	+	+	+	+	+	+	+	+	+ ·	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	50
Polyp stromal							Х							X	(X	Х				Х			Х	7

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm 3 4 4 5 6 6 6 6 6 6 6 7 7 7 7 7 6 7 7 7 7 7 7 7 7 Number of Days on Study 6 6 7 1 2 2 2 2 5 8 8 9 0 1 1 2 2 3 3 3 3 3 3 3 3 7 9 8 0 0 4 4 1 5 4 3 4 6 5 8 3 3 0 0 0 0 0 0 0 0 3 **Carcass ID Number** 6 9 985 6 5 9 7 7 8 9 8 5 8 7 9 5 5 6 6 7 7 8 8 4 4 8 1 1 9 7 3 2 7 0 5 6 8 7 6 6 3 4 2 8 4 8 4 -9 Hematopoietic System Bone marrow + Lymph node Lymph node, mandibular + Carcinoma, metastatic, Zymbal's gland Х Lymph node, mesenteric + + + Spleen + +++ ++Thymus + М + **Integumentary System** Mammary gland + +Adenoma Х Carcinoma Х Fibroadenoma Х ХХХ Х ХХХ ХХ Х Х Fibroadenoma, multiple Х Х Skin + + Basal cell adenoma Х Basal cell carcinoma Х Х Fibroma Fibrosarcoma Х Squamous cell carcinoma Pinna, melanoma malignant Х Musculoskeletal System Bone **Nervous System** Brain + + +++++++++++ + ++++**Respiratory System** Lung + Alveolar/bronchiolar adenoma Х Nose + Squamous cell carcinoma, metastatic, skin Х Trachea ++ + + Special Senses System + Eye + Harderian gland + Zymbal's gland + + Carcinoma Х **Urinary System** Kidney + Х Renal tubule, adenoma Urinary bladder + + Systemic Lesions Multiple organs +++++ + + + + + +

Individual Animal Tumor Pathology of Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm 7 7 7 777 Number of Days on Study 3 0 0 0 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 3 3 4 3 Total 3 3 677 **Carcass ID Number** 9 9 0 5 6 6 6 8 8 9 9 5 5 5 6 6 7 7 7 8 8 9 Tissues/ 1 2 0 6 1 3 5 7 3 9 2 5 0 9 2 5 9 0 6 0 1 5 3 8 7 Tumors Hematopoietic System 50 Bone marrow + Lymph node 1 Lymph node, mandibular 50 Carcinoma, metastatic, Zymbal's gland 1 Lymph node, mesenteric 50 50 Spleen + + +Thymus 48 +Μ **Integumentary System** Mammaryg land 50 $^+_{\rm X}$ Adenoma Х 3 Carcinoma 2 20 Fibroadenoma Х Х ХХХ Х ХХ ХХ 5 Fibroadenoma, multiple X Skin + 50 Basal cell adenoma 1 Basal cell carcinoma 1 Fibroma 1 Fibrosarcoma Х 1 Squamous cell carcinoma 1 Pinna, melanoma malignant 1 Musculoskeletal System Bone 50 **Nervous System** 50 Brain ++ + +++ +++ +++ ++ ++++**Respiratory System** Lung 50 + Alveolar/bronchiolar adenoma 2 Х 50 Nose Squamous cell carcinoma, metastic, skin 1 Trachea ++++ 50 **Special Senses System** 3 Eye + Harderian gland 1 2 Zymbal's gland Carcinoma 1 **Urinary System** 50 Kidney + + Renal tubule, adenoma 1 Urinary bladder 50 Systemic Lesions Multiple organs ++ $^{+}$ +++ + 50 +Leukemia mononuclear Х 1

Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Adrenal Medulla: Benign Pheochromocytoma				
Overall rate ^a 4/50 (8%)	2/50 (4%)	0/45 (0%)	2/49 (4%)	
Adjusted rate ^b	9.0%	4.5%	0.0%	4.6%
Cerminal rate ^C	3/33 (9%)	2/31 (7%)	0/31 (0%)	1/32 (3%)
irst incidence (days)	669	730 (T)	e	715
oly-3 test ^d	P=0.243N	P=0.339N	P=0.074N	P=0.346N
litoral Gland: Adenoma				
verall rate	8/46 (17%)	10/48 (21%)	6/49 (12%)	3/49 (6%)
djusted rate	19.2%	23.5%	13.6%	6.7%
erminal rate	8/32 (25%)	9/30 (30%)	6/35 (17%)	1/33 (3%)
		680		()
irst incidence (days)	730 (T)		730 (T)	680 D-0.077N
bly-3 test	P=0.029N	P=0.417	P=0.343N	P=0.077N
litoral Gland: Adenoma or Carcinoma				
verall rate	10/46 (22%)	11/48 (23%)	6/49 (12%)	4/49 (8%)
djusted rate	23.7%	25.8%	13.6%	8.9%
erminal rate	9/32 (28%)	10/30 (33%)	6/35 (17%)	1/33 (3%)
irst incidence (days)	567	680	730 (T)	626
oly-3 test	P=0.019N	P=0.511	P=0.177N	P=0.054N
ung: Alveolar/bronchiolar Adenoma				
verall rate	3/50 (6%)	2/50 (4%)	3/50 (6%)	2/50 (4%)
djusted rate	6.8%	4.5%	6.7%	4.5%
erminal rate	2/33 (6%)	1/31 (3%)	3/36 (8%)	2/33 (6%)
rst incidence (days)	693	680	730 (T)	730 (T)
oly-3 test	P=0.455N	P=0.499N	P=0.656N	P=0.498N
ung: Alveolar/bronchiolar Adenoma or Carcinoma				
verall rate	3/50 (6%)	2/50 (4%)	4/50 (8%)	2/50 (4%)
djusted rate	6.8%	4.5%	8.9%	4.5%
erminal rate	2/33 (6%)	1/31 (3%)	4/36 (11%)	2/33 (6%)
rst incidence (days)	693	680	730 (T)	730 (T)
lly-3 test	P=0.477N	P=0.499N	P=0.508	0.498N
lammary Gland: Fibroadenoma				
verall rate	21/50 (42%)	27/50 (54%)	31/50 (62%)	25/50 (50%)
djusted rate	45.7%	58.5%	66.7%	54.4%
erminal rate	15/33 (46%)	17/31 (55%)	26/36 (72%)	16/33 (49%)
rst incidence (days)	547	541	541	626
st incluence (days)	P=0.268	P=0.149	P=0.029	P=0.263
Iammary Gland: Adenoma				
verall rate	2/50 (4%)	1/50 (2%)	0/50 (0%)	3/50 (6%)
djusted rate	4.5%	2.3%	0.0%	6.7%
erminal rate	2/33 (6%)	1/31 (3%)	0/36 (0%)	3/33 (9%)
rst incidence (days)	730 (T)	730 (T)	—	730 (T)
oly-3 test	P=0.339	P=0.499N	P=0.233N	P=0.503

Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Mammary Gland: Fibroadenoma or Adenoma				
Overall rate	23/50 (46%)	27/50 (54%)	31/50 (62%)	28/50 (56%)
Adjusted rate	50.1%	58.5%	66.7%	61.0%
Ferminal rate	17/33 (52%)	17/31 (55%)	26/36 (72%)	19/33 (58%)
First incidence (days)	547	541	541	626
Poly-3 test	P=0.169	P=0.270	P=0.073	P=0.196
Aammary Gland: Adenoma or Carcinoma				
Overall rate	2/50 (4%)	2/50 (4%)	2/50 (4%)	5/50 (10%)
Adjusted rate	4.5%	4.5%	4.4%	11.0%
erminal rate	2/33 (6%)	2/31 (7%)	2/36 (6%)	3/33 (9%)
irst incidence (days)	730 (T)	730 (T)	730 (T)	361
oly-3 test	P=0.121	P=0.694N	P=0.687N	P=0.228
Iammary Gland: Fibroadenoma, Adenoma, or Carc	inoma			
Overall rate	23/50 (46%)	27/50 (54%)	33/50 (66%)	30/50 (60%)
Adjusted rate	50.1%	58.5%	71.0%	63.8%
erminal rate	17/33 (52%)	17/31 (55%)	28/36 (78%)	19/33 (58%)
irst incidence (days)	547	541	541	361
oly-3 test	P=0.092	P=0.270	P=0.027	P=0.124
'ituitary Gland (Pars Distalis): Adenoma				
Overall rate	24/50 (48%)	25/50 (50%)	17/50 (34%)	21/50 (42%)
djusted rate	51.9%	53.9%	36.7%	45.6%
erminal rate	16/33 (49%)	16/31 (52%)	12/36 (33%)	14/33 (42%)
irst incidence (days)	513	536	541	624
oly-3 test	P=0.207N	P=0.507	P=0.099N	P=0.342N
kin: Trichoepithelioma, Basal Cell Adenoma, Basal	Cell Carcinoma, or S	quamous Cell Car	cinoma	
Overall rate	3/50 (6%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
djusted rate	6.7%	0.0%	0.0%	6.6%
erminal rate	1/33 (3%)	0/31 (0%)	0/36 (0%)	0/33 (0%)
irst incidence (days)	513	_	_	624
oly-3 test	P=0.449	P=0.122N	P=0.119N	P=0.661N
hyroid Gland (C-cell): Adenoma				
Overall rate	7/50 (14%)	4/49 (8%)	10/48 (21%)	7/50 (14%)
djusted rate	15.8%	9.1%	22.7%	15.7%
erminal rate	7/33 (21%)	2/31 (7%)	7/36 (19%)	6/33 (18%)
irst incidence (days)	730 (T)	616	658	680
oly-3 test	P=0.399	P=0.263N	P=0.293	P=0.605N
hyroid Gland (C-cell): Adenoma or Carcinoma				
Overall rate	9/50 (18%)	4/49 (8%)	10/48 (21%)	7/50 (14%)
djusted rate	20.4%	9.1%	22.7%	15.7%
erminal rate	9/33 (27%)	2/31 (7%)	7/36 (19%)	6/33 (18%)
irst incidence (days)	730 (T)	616	658	680
Poly-3 test	P=0.518N	P=0.115N	P=0.498	P=0.382N

Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Utamera Steamed Dalam				
Uterus: Stromal Polyp Overall rate	7/50 (14%)	3/50 (6%)	8/50 (16%)	7/50 (149/)
Adjusted rate	15.8%	· /		7/50 (14%)
Ferminal rate		6.5%	17.6% 6/36 (17%)	15.7%
First incidence (days)	7/33 (21%) 730 (T)	0/31 (0%) 332		6/33 (18%) 680
oly-3 test	P=0.364	P=0.138N	626 P=0.525	P=0.605N
oly-5 lest	P=0.304	P=0.138IN	P=0.525	P=0.005IN
Jterus: Stromal Polyp or Stromal Sarcoma				
Overall rate	7/50 (14%)	3/50 (6%)	9/50 (18%)	7/50 (14%)
Adjusted rate	15.8%	6.5%	19.8%	15.7%
Cerminal rate	7/33 (21%)	0/31 (0%)	7/36 (19%)	6/33 (18%)
First incidence (days)	730 (T)	332	626	680
oly-3 test	P=0.352	P=0.138N	P=0.417	P=0.605N
All Organs: Mononuclear Cell Leukemia				
Overall rate	15/50 (30%)	10/50 (20%)	1/50 (2%)	1/50 (2%)
Adjusted rate	32.1%	21.9%	2.2%	2.2%
erminal rate	8/33 (24%)	4/31 (13%)	0/36 (0%)	1/33 (3%)
First incidence (days)	513	616	638	730 (T)
Poly-3 test	P<0.001N	P=0.191N	P<0.001N	P<0.001N
All Organs: Benign Neoplasms				
Dverall rate	42/50 (84%)	42/50 (84%)	46/50 (92%)	42/50 (84%)
Adjusted rate	87.5%	84.6%	95.2%	89.4%
Terminal rate	29/33 (88%)	25/31 (81%)	35/36 (97%)	29/33 (88%)
First incidence (days)	511	332	541	624
Poly-3 test	P=0.303	P=0.452N	P=0.140	P=0.517
All Organs: Malignant Neoplasms				
Overall rate	23/50 (46%)	16/50 (32%)	12/50 (24%)	12/50 (24%)
Adjusted rate	47.8%	34.0%	25.1%	25.5%
Cerminal rate	13/33 (39%)	7/31 (23%)	5/36 (14%)	5/33 (15%)
First incidence (days)	513	480	337	361
Poly-3 test	P=0.013N	P=0.121N	P=0.016N	P=0.018N
	1 0.0151	1 0.1211	1 0.0101	1 0.0101
All Organs: Benign or Malignant Neoplasms				
Overall rate	45/50 (90%)	45/50 (90%)	49/50 (98%)	45/50 (90%)
Adjusted rate	90.8%	90.0%	98.0%	92.6%
Ferminal rate	29/33 (88%)	26/31 (84%)	35/36 (97%)	30/33 (91%)
First incidence (days)	511	332	337	361
Poly-3 test	P=0.333	P=0.581N	P=0.124	P=0.519

(T)Terminal sacrifice

Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, clitoral gland, lung, pituitary gland, and thyroid gland; for other tissues, denominator is number of animals necropsied. Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality b

с Observed incidence at terminal kill

d Beneath the control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposure group is indicated by N.

e Not applicable; no neoplasms in animal group

TABLE B4a

Historical Incidence of Mammary Gland Fibroadenoma in Control Female F344/N Rats

Study	Incidence in Controls
Historical Incidence in Controls Given NTP-2000 Die	et ^a
p,p'-Dichlorodiphenyl sulfone (feed)	15/50
Indium phosphide (inhalation)	20/50
Methacrylonitrile (gavage)	21/50
Naphthalene (inhalation)	17/49
<i>p</i> -Nitrotoluene (feed)	14/50
Sodium nitrite (drinking water)	21/50
Overall Historical Incidence in Controls Given NTP-	2000 Diet
Total (%)	108/299 (36.1%)
Mean \pm standard deviation	$36.1\% \pm 6.2\%$
Range	28%-42%
Historical Incidence in Deinking Water Controls Cir	on NIII 07 Dist at Pattalla Columbus Laboustories ^b
Historical Incidence in Drinking Water Controls Giv	en NIH-07 Diet at Battelle Columbus Laboratories
Sodium fluoride	22/80
Overall Historical Incidence in Drinking Water Com	trols Given NIH-07 Diet
Total (%)	121/330 (36.7%)
Mean \pm standard deviation	37.6% ± 14.6%
D	0.40/ 500/

24%-58%

Range

a Data as of 15 March 2000 Data as of 21 December 1999

Study	Incidence in Controls
Historical Incidence in Controls Given NTP-2000 Die	et ^a
<i>p</i> , <i>p</i> '-Dichlorodiphenyl sulfone (feed)	8/50
Indium phosphide (inhalation)	14/50
Methacrylonitrile (gavage)	21/50
Naphthalene (inhalation)	16/49
v-Nitrotoluene (feed)	13/50
Sodium nitrite (drinking water)	15/50
Overall Historical Incidence in Controls Given NTP-	2000 Diet
Total (%)	87/299 (29.1%)
Mean \pm standard deviation	$29.1\% \pm 8.5\%$
Range	16%-42%
Historical Incidence in Drinking Water Controls Giv	ren NIH-07 Diet at Battelle Columbus Laboratories ^b
Sodium fluoride	26/80
Overall Historical Incidence in Drinking Water Cont	trols Given NIH-07 Diet
Total (%)	102/330 (30.9%)
Mean \pm standard deviation	$30.8\% \pm 10.0\%$
Range	16%-44%

TABLE B4b Historical Incidence of Mononuclear Cell Leukemia in Control Female F344/N Rats

а b

Data as of 15 March 2000; includes data for lymphocytic, monocytic, mononuclear cell, and undifferentiated leukemia Data as of 21 December 1999; includes data for lymphocytic, monocytic, mononuclear cell, and undifferentiated leukemia

TABLE B5 Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite^a

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Disposition from more				
Disposition Summary Animals initially in study Early deaths	50	50	50	50
Moribund	11	6	10	15
Natural deaths	6	13	4	2
Survivors	-			_
Terminal sacrifice	33	31	36	33
Animals examined microscopically	50	50	50	50
Alimentary System				
Esophagus	(50)	(49)	(50)	(50)
Inflammation			1 (2%)	
intestine large, colon	(50)	(48)	(50)	(50)
Parasite metazoan	(50)	1 (2%)	1 (2%)	1 (2%)
Intestine large, rectum	(50)	(50)	(50)	(50)
Inflammation, granulomatous Parasite metazoan	4 (8%)	1 (20/)	2 (10/)	1 (2%) 7 (14%)
Liver	4 (8%) (50)	1 (2%) (50)	2 (4%) (50)	7 (14%) (50)
Angiectasis	(50)	(30)	3 (6%)	5 (10%)
Basophilic focus	45 (90%)	42 (84%)	48 (96%)	45 (90%)
Clear cell focus	9 (18%)	6 (12%)	8 (16%)	7 (14%)
Cyst	. (10/0)	- (1-/0)	- (1070)	1 (2%)
Eosinophilic focus	9 (18%)	10 (20%)	8 (16%)	10 (20%)
Hemorrhage	1 (2%)	× · · · /		1 (2%)
Hepatodiaphragmatic nodule	4 (8%)	11 (22%)	7 (14%)	8 (16%)
Inflammation, chronic active	23 (46%)	23 (46%)	28 (56%)	28 (56%)
Inflammation, granulomatous			1 (2%)	1 (2%)
Mixed cell focus	11 (22%)	3 (6%)	7 (14%)	9 (18%)
Necrosis	5 (10%)	2 (4%)		4 (8%)
Pigmentation, lipofuscin			1 (2%)	
Regeneration	1 (2%)			
Vacuolization cytoplasmic	1 (2%)	5 (10%)	4 (8%)	4 (8%)
Bile duct, hyperplasia	8 (16%)	4 (8%)	4 (8%)	4 (8%)
Mesentery	(7)	(5)	(7)	(4)
Fat, inflammation, chronic active	6 (86%) 1 (140()	5 (100%)	7 (100%)	4 (100%)
Fat, necrosis	1 (14%)	(50)	(40)	(50)
Pancreas	(50)	(50)	(49)	(50) (50)
Atrophy Inflammation, chronic active			1 (2%)	1 (2%)
Acinus, atrophy	6 (12%)	6 (12%)	1 (2%) 8 (16%)	8 (16%)
Acinus, hyperplasia	1 (2%)	0 (1270)	1 (2%)	0 (1070)
Stomach, forestomach	(50)	(50)	(50)	(50)
Edema	(50)	1 (2%)	2 (4%)	2 (4%)
Erosion	1 (2%)	1 (2%)	1 (2%)	- (170)
Hyperkeratosis	1 (2%)	2 (4%)	2 (4%)	2 (4%)
Inflammation, chronic active	1 (2%)			× · · ·
Ulcer	4 (8%)	2 (4%)	2 (4%)	1 (2%)
Epithelium, hyperplasia	8 (16%)	6 (12%)	8 (16%)	40 (80%)
Stomach, glandular	(50)	(50)	(50)	(50)
Erosion		2 (4%)	1 (2%)	
Inflammation, chronic active	1 (2%)			
Mineralization	1 (2%)	3 (6%)	1 (2%)	

^a Number of animals examined microscopically at the site and the number of animals with lesion

TABLE B5 Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite

Cardiovascular System Bood vessel (50) (50) (50) Mineralization 2 (4%) (50) (50) Inflammation, chronic active 3 (6%) 4 (8%) 3 (6%) Mineralization 2 (4%) 3 (6%) 4 (8%) 3 (6%) Mineralization 2 (4%) 2 (4%) 3 (6%) 4 (8%) 3 (6%) Adronal cortex (50) (50) (50) (50) Angiectasis 40 (80%) 39 (78%) 45 (90%) Degeneration 1 (2%) 11 (22%) 11 (22%) 11 (22%) 11 (22%) Hypertplasia 15 (30%) 11 (22%) 1 (2%) 7 (14%) 7 (14%) Necrosis 2 (4%) 1 (2%) 7 (14%) 4 (9%) 1 (2%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) 7 (14%) 4 (9%) Piperplasia 6 (12%) 7 (14%) 4 (9%) 1 (2%) Pare distalis, angiectasis 1 (2%) Pare distalis, inperplasia 1 (2%) 1 (2%) 7 (14%) 4 (9%) 1 (2%) <th>3,000 ppm</th> <th>1,500 ppm</th> <th>750 ppm</th> <th>0 ppm</th> <th></th>	3,000 ppm	1,500 ppm	750 ppm	0 ppm	
Bood vesel (50) (50) (50) (50) Mineralization 2 (4%) (50) Inflammation, chronic active 3 (6%) 4 (8%) 3 (6%) Mineralization 2 (4%) Necrosis 1 (2%) Endocrine System Adrenal cortex (50) (50) (50) (50) Angiectasis 40 (80%) 39 (78%) 45 (90%) Degeneration 1 (2%) Hyperplasia 15 (30%) 11 (22%) 11 (22%) Hyperplasia 15 (30%) 11 (22%) 11 (22%) Hyperplasia 15 (30%) 1 (22%) (14%) 7 (14%) Necrosis 2 (4%) 5 (10%) 1 (2%) Addenal voltex 4 (8%) 5 (10%) 1 (2%) Addenal voltex 4 (8%) 5 (10%) 1 (2%) Hyperplasia 6 (12%) 7 (14%) 4 (9%) Hyperplasia 1 (2%) 7 (14%) 4 (9%) Hyperplasia 1 (2%) 7 (14%) 4 (9%) Hyperplasia 6 (12%) 7 (14%) 1 (2%) Hyperplasia 1 (2%) 7 (14%) 4 (9%) Hyperplasia 6 (12%) 7 (14%) 4 (9%) Hyperplasia 1 (2%) 7 (14%) 1 (2%) Hyperplasia 1 (2%) 7 (14%) 1 (2%) Hutiary gland (50) (50) (50) Angiectasis 1 (2%) 7 (14%) 1 (2%) Para distalis, angiectasis 2 (4%) 1 (2%) Para distalis, encortage 1 (2%) Para distalis, encortage 1 (2%) Para distalis, heroortage 1 (2%) Para distalis, heroortage 1 (2%) Hars intermediac, cyst 1 (2%) Inflammation, chronic active 1 (2%) Inflammation, chronic active 1 (2%) Inflammation, chronic active 1 (2%) Homortachal cyst 1 (2%) Hars intermediac, cyst 1 (2%) Hars in					Cardiovascular System
Mineralization 1 2 (4%) (50) Heart (50) (49) (50) Inflammation, chronic active 3 (6%) 4 (8%) 3 (6%) Mineralization 2 (4%) 2 (4%) 3 (6%) Necrosis 1 (2%) 1 (2%) 3 (6%) 3 (6%) Adreal cortex (50) (4%) (50) (50) (50) (50) (50) (50) (50) (50) (50) (50) (4%) (50) (50) (4%) (4%) (2%) (4%) (2%) (4%) (2%) (4%) (2%) (4%) (2%) (4%) (50) (50) (50) (50) (50) (50) (50) <t< td=""><td>(50)</td><td>(50)</td><td>(50)</td><td>(50)</td><td></td></t<>	(50)	(50)	(50)	(50)	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$					Mineralization
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	(50)	(50)		(50)	Heart
Mineralization 2 (4%) Necrosis 1 (2%) Endocrine System	3 (6%)				Inflammation, chronic active
Endocrine System (50) (50) (50) (50) Angiectasis 40 (80%) 39 (78%) 45 (90%) Degeneration Degeneration 1 (2%) 11 (22%) 11 (22%) 11 (22%) Hypertpoly 8 (16%) 7 (14%) 7 (14%) 7 (14%) Necrosis 2 (4%) 1 (2%) 1 (2%) 1 (2%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) Hypertpoly 8 (16%) 7 (14%) 4 (9%) Bilateral, hyperplasia 6 (12%) 7 (14%) 4 (9%) Mittaray gland (50) (50) (50) (50) Angiectasis 1 (2%) 7 (14%) 4 (9%) Pitutary gland (50) (50) (50) (50) Angiectasis 1 (2%) 7 (14%) 9 9 Pars distalis, angiectasis 1 (2%) 1 (2%) 1 2%) Pars distalis, enormage 1 (2%) 1 (2%) 1	· · · ·		2 (4%)		Mineralization
drenal cortex (50) (50) (50) Angictasis 40 (80%) 39 (78%) 45 (90%) Degeneration 1 (2%) 1 Hemorrhage 1 (2%) 11 (22%) Hypertpophy 8 (16%) 7 (14%) 7 (14%) Necrosis 2 (4%) 1 (2%) 1 (2%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) Vacuolization cytoplasmic 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 1 (2%) 2 (4%) 1 (2%) Cyst 1 (2%) 2 (4%) 1 (2%) Hemorrhage 3 (6%) 1 (2%) 1 (2%) Pars distalis, cyst 4 (8%) 10 (20%) 5 (10%) Pars distalis, cyst 4 (8%) 10 (20%) 5 (10%) Pars distalis, hyperplasia 10 (20%) 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) <td></td> <td></td> <td></td> <td>1 (2%)</td> <td>Necrosis</td>				1 (2%)	Necrosis
drenal cortex (50) (50) (50) Angiectasis 40 (80%) 39 (78%) 45 (90%) Degeneration 1 (2%) 1 Hemorrhage 1 (2%) 11 (22%) 11 (22%) Hyperplasia 15 (30%) 11 (22%) 7 (14%) 7 (14%) Necrosis 2 (4%) 1 (2%) 1 (2%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) drenal medulla (50) (50) (45) Hyperplasia 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 1 (2%) 1 (2%) 1 (2%) Kritikitary gland (50) (50) (50) (50) Angiectasis 1 (2%) 2 (4%) 1 (2%) 1 (2%) Pars distalis, angiectasis 2 (4%) 10 (20%) 5 (10%) Pars distalis, cyst 4 (8%) 10 (20%) 5 (10%) Pars distalis, hyperplasia 10 (20%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 10 (20%) 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) 1 (2%) </td <td></td> <td></td> <td></td> <td></td> <td>ndocrine System</td>					ndocrine System
Angicctasis 40 (80%) 39 (78%) 45 (90%) Degeneration 1 (2%) 1 Hemorrhage 1 (2%) 11 (22%) Hyperplasia 15 (30%) 11 (22%) 11 (22%) Hyperplasia 15 (30%) 7 (14%) 7 (14%) Necrosis 2 (4%) 1 (2%) 1 (2%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) Vacuolization cytoplasmic 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 6 (12%) 7 (14%) 4 (9%) Magicctasis 1 (2%) 7 (14%) 4 (9%) Angicctasis 1 (2%) 7 (14%) 4 (9%) Pituitary gland (50) (50) (50) (50) Angicctasis 1 (2%) 2 (4%) 1 (2%) 1 (2%) Pars distalis, angicctasis 2 (4%) 1 (2%) 1 (2%) Pars distalis, hemorrhage 1 (2%) 1 (2%) 1 (2%) Pars distalis, homorrhage 1 (2%) 1 (2%) 1 (2%) Ul	(50)	(50)	(50)	(50)	
Degeneration 1 (2%) Hemorrhage 1 (2%) Hyperplasia 15 (30%) 11 (22%) Hypertrophy 8 (16%) 7 (14%) 7 (14%) Necrosis 2 (4%) 1 (2%) 12%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) Adrenal medulla (50) (50) (45) Hyperplasia 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 1 (2%) 1 (2%) 1 (2%) Oxtation exploration 1 (2%) 1 (2%) 1 (2%) Vacuolization exploration, hyperplasia 1 (2%) 1 (2%) 1 (2%) Orgeneration, hemosiderin 1 (2%) 1 (2%) 1 (2%) Pars distalis, agnicetasis 2 (4%) 1 (2%) 1 (2%) Pars distalis, cyst 4 (8%) 10 (20%) 5 (10%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 1 (2%) Pars distalis, hyperplasia 10 (20%) 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) 1 (2%) Vacuolization cytoplasmic 1 (2%) 1 (2%) <td>45 (90%)</td> <td></td> <td></td> <td></td> <td></td>	45 (90%)				
Henorrhage 1 (2%) Hypertpaisa 15 (30%) 11 (22%) 11 (22%) Hypertpophy 8 (16%) 7 (14%) 7 (14%) Necrosis 2 (4%) 1 (2%) 1 (2%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) Adrenal medulla (50) (50) (45) Hyperplasia 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 0 (2%) 5 (0) Ad (9%) Angiectasis 1 (2%) 1 (2%) 2 (4%) 1 (2%) Angiectasis 1 (2%) 2 (4%) 1 (2%) 1 (2%) Pars distalis, angiectasis 2 (4%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 5 (10%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 1 (3%) Pars distalis, hyperplasia 10 (20%) 10 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) Inflammation, chronic active 1 (2%) 1 (2%) 1	- (*)	× · · · · /	()		
Hyperplasia 15 (30%) 11 (22%) 11 (22%) Hypertrophy 8 (16%) 7 (14%) 7 (14%) Necrosis 2 (4%) 1 (2%) 1 (2%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) Vacuolization cytoplasmic 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 1 (2%) 2 (4%) 1 (2%) Angiectasis 1 (2%) 2 (4%) 1 (2%) Pigmentation, hemosiderin 1 (2%) 2 (4%) 1 (2%) Pars distalis, angiectasis 2 (4%) 1 (2%) 1 (2%) Pars distalis, hemorrhage 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 10 (2%) 1 (2%) 1 (2%) Vacuolization cytoplasmic 1 (2%) 1 (2%) 2% Ultimobranchial cyst 1 (2					
Hypertrophy 8 (16%) 7 (14%) 7 (14%) Necrosis 2 (4%) 1 (2%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) Adrenal medulla (50) (50) (45) Hyperplasia 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 6 (12%) 7 (14%) 4 (9%) Dituitary gland (50) (50) (50) Argicetasis 1 (2%) 2 (4%) 1 (2%) Pigmentation, hemosiderin 1 (2%) 1 (2%) 1 (2%) Pars distalis, agicetasis 2 (4%) 1 (2%) 1 (2%) Pars distalis, cyst 4 (8%) 10 (20%) 5 (10%) Pars distalis, hemorrhage 1 (2%) 1 (2%) 1 (2%) Pars distalis, hemorrhage 1 (2%) 1 (2%) 1 (2%) Pars distalis, homorrhage 1 (2%) 1 (2%) 1 (2%) Pars distalis, homorrhage 1 (2%) 1 (2%) 1 (2%) Pars distalis, homorrhage 1 (2%) 1 (2%) 1 (2%) Chyroid gland (50) (49) (48) 1 (2%) <td>10 (20%)</td> <td>11 (22%)</td> <td>11 (22%)</td> <td></td> <td></td>	10 (20%)	11 (22%)	11 (22%)		
Necrosis 2 (4%) 1 (2%) Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) Adrenal medulla (50) (50) (45) Hyperplasia 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 1 (2%) 1 (2%) Pituitary gland (50) (50) (50) Angiectasis 1 (2%) 2 (4%) 1 (2%) Cyst 1 (2%) 2 (4%) 1 (2%) Pigmentation, hemosiderin 1 (2%) 2 (4%) 1 (2%) Pars distalis, angiectasis 2 (4%) 1 (2%) Pars distalis, angiectasis 2 (4%) Pars distalis, opserplasia 10 (20%) 10 (20%) 5 (10%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (2%) 12%) Ultimobranchial cyst 1 (2%) 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) 26 (53%) 34 (71%) Solucization cytoplasmic 1 (2%) 1 (2%) 1 (2%) 1 (2%) 2	4 (8%)				
Vacuolization cytoplasmic 4 (8%) 5 (10%) 1 (2%) Idrenal medulla (50) (50) (45) Hyperplasia 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 1 (2%) 1 (2%) tituitary gland (50) (50) (50) Angiectasis 1 (2%) 2 (4%) 1 (2%) Hemorrhage 3 (6%) 1 (2%) Pars distalis, angiectasis 2 (4%) Pars distalis, angiectasis 2 (4%) 1 (2%) Pars distalis, angiectasis 2 (4%) Pars distalis, angiectasis 2 (4%) 1 (2%) Pars distalis, angiectasis 2 (4%) Pars distalis, nemorrhage 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) Echeral Body System 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) Echeral System 1 (2%) 1 (2%) 1 (2%		× /			
Adrenal medulla (50) (50) (45) Hyperplasia 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 1 (2%) 1 (2%) Vituitary gland (50) (50) (50) Angiectasis 1 (2%) 1 (2%) Cyst 1 (2%) 2 (4%) 1 (2%) Hemorrhage 3 (6%) 1 (2%) Pars distalis, angiectasis 2 (4%) 5 (10%) Pars distalis, epsicetasis 2 (4%) 1 (2%) Pars distalis, hemorrhage 1 (2%) 1 (2%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 5 (10%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 19 (38%) 10 (2%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) 1 (2%) General Body System 24 (48%) 26 (53%) 34 (71%) Kone 1 (2%) 1 (2%) 1 (2%) <td< td=""><td>3 (6%)</td><td>1 (2%)</td><td></td><td></td><td>Vacuolization cytoplasmic</td></td<>	3 (6%)	1 (2%)			Vacuolization cytoplasmic
Hyperplasia 6 (12%) 7 (14%) 4 (9%) Bilateral, hyperplasia 1 (2%) 1 (2%) Pituitary gland (50) (50) (50) Angiectasis 1 (2%) 2 (4%) 1 (2%) Cyst 1 (2%) 2 (4%) 1 (2%) Pars distalis, angiectasis 2 (4%) 1 (2%) Pars distalis, angiectasis 2 (4%) 1 (2%) Pars distalis, angiectasis 2 (4%) 1 (2%) Pars distalis, nemorrhage 1 (2%) 10 (20%) 5 (10%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Inflammation, chronic active 1 (2%) 1 (2%) 1 (2%) Bilateral, C-cell, hyperplasia 1 (2%) 1 (2%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) 1 (2%) 1 (2%) 1 (2%) Cential System C	(49)		(50)		5 1
Bilateral, hyperplasia 1 (2%) Vituitary gland (50) (50) (50) Angiectasis 1 (2%) C (50) (50) Cyst 1 (2%) 2 (4%) 1 (2%) Pars distalis, angiectasis 2 (4%) Pars distalis, angiectasis 2 (4%) 1 (2%) Pars distalis, eyst 4 (8%) 10 (20%) 5 (10%) Pars distalis, perplasia 10 (20%) 10 (20%) 5 (10%) Pars distalis, hyperplasia 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, eyst 1 (2%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, eyst 1 (2%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 10 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) 1 (2%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) 1 (2%) 1 (2%) 1 (2%)	5 (10%)	4 (9%)		6 (12%)	Hyperplasia
bituitary gland (50) (50) (50) Angiectasis 1 (2%) 2 (4%) 1 (2%) Cyst 1 (2%) 2 (4%) 1 (2%) Hemorrhage 3 (6%) 1 (2%) 2 (4%) Pars distalis, angiectasis 2 (4%) 1 (2%) Pars distalis, angiectasis 2 (4%) 10 (20%) 5 (10%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 10 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) 1 (2%) Vacuolization cytoplasmic 1 (2%) 1 (2%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) 26 (53%) 34 (71%) 1 (2%) Central Body System Citoral gland (46) (48)	. ,				Bilateral, hyperplasia
Cyst 1 (2%) 2 (4%) 1 (2%) Hemorrhage 3 (6%) 1 (2%) Pars distalis, angicetasis 2 (4%) 1 (2%) Pars distalis, cyst 4 (8%) 10 (20%) 5 (10%) Pars distalis, cyst 4 (8%) 10 (20%) 5 (10%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 10 (20%) Ultimobranchial cyst 1 (2%) 1 (2%) 1 (2%) Vacuolization cytoplasmic 1 (2%) 1 (2%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) 1 (2%) 1 (2%) 1 (2%) General Body System 1 (2%) 1 (2%) 4(48) 4(49) Clitoral gland (46) (48) (49) 4(49) 4(49)	(50)	(50)	(50)	(50)	Pituitary gland
Hemorrhage 3 (6%) 1 (2%) Pigmentation, hemosiderin 1 (2%) Pars distalis, angiectasis 2 (4%) Pars distalis, cyst 4 (8%) 10 (20%) 5 (10%) Pars distalis, hemorrhage 1 (2%) Pars distalis, hemorrhage 1 (2%) Pars distalis, hemorrhage 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 12%) Ultimobranchial cyst 1 (2%) 1 (2%) 1 (2%) Vacuolization cytoplasmic 1 (2%) 1 (2%) 1 (2%) C-cell, hyperplasia 24 (48%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) 1 (2%) 1 (2%)					
Pigmentation, hemosiderin 1 (2%) Pars distalis, angiectasis 2 (4%) Pars distalis, oyst 4 (8%) 10 (20%) 5 (10%) Pars distalis, hemorrhage 1 (2%) Pars distalis, hyperplasia 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 19 (38%) Pars distalis, cyst 1 (2%) 1 (2%) Pars distalis, hyperplasia 10 (20%) 19 (38%) Pars distalis, cyst 1 (2%) 1 (2%) Inflammation, chronic active 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) Vacuolization cytoplasmic 1 (2%) 1 (2%) Bilateral, C-cell, hyperplasia 1 (2%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) 1 (2%) 1 (2%) General Body System Ione 1 (2%) 4(48) (48) Particular gland (46) (48) (49)	2 (4%)	1 (2%)	2 (4%)		
Pars distalis, angiectasis 2 (4%) Pars distalis, cyst 4 (8%) 10 (20%) 5 (10%) Pars distalis, hemorrhage 1 (2%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars distalis, cyst 10 (20%) 10 (20%) 19 (38%) Pars distalis, cyst 10 (20%) 10 (20%) 19 (38%) Pars distalis, cyst 10 (20%) 14 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) 1 (2%) Bilateral, C-cell, hyperplasia 24 (48%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) 1 (2%) 1 (2%) Seneral Body System None 1 (2%) 4(48) (49)				3 (6%)	Hemorrhage
Pars distalis, cyst 4 (8%) 10 (20%) 5 (10%) Pars distalis, hemorrhage 1 (2%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 19 (38%) Pars distalis, hyperplasia 10 (20%) 19 (38%) Pars intermedia, cyst 10 (20%) 19 (38%) Pars intermedia, cyst 1 (2%) 1 (2%) Inflammation, chronic active 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) Vacuolization cytoplasmic 1 (2%) 26 (53%) 34 (71%) Bilateral, C-cell, hyperplasia 24 (48%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) 1 (2%) 1 (2%) Ceneral Body System None 1 (2%) 1 (2%)			1 (2%)		
Pars distalis, hemorrhage 1 (2%) Pars distalis, hyperplasia 10 (20%) 10 (20%) Pars distalis, hyperplasia 10 (20%) 19 (38%) Pars distalis, hyperplasia (50) (49) (48) Inflammation, chronic active 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) Vacuolization cytoplasmic 1 (2%) 1 (2%) Bilateral, C-cell, hyperplasia 1 (2%)					
Pars distalis, hyperplasia 10 (20%) 10 (20%) 19 (38%) Pars intermedia, cyst 1 (49) (48) Inflammation, chronic active 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) Bilateral, C-cell, hyperplasia 1 (2%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) 1 (2%) 1 (2%) General Body System Kone (46) (48) (49)	9 (18%)	5 (10%)		4 (8%)	
Pars intermedia, cyst "hyroid gland (50) (49) (48) Inflammation, chronic active 1 (2%) Ultimobranchial cyst 1 (2%) Vacuolization cytoplasmic 1 (2%) Bilateral, C-cell, hyperplasia 24 (48%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) General Body System None Cititoral gland (46) (48) (49) Atrophy 1 (2%)					
hyroid gland (50) (49) (48) Inflammation, chronic active 1 (2%) 1 (2%) Ultimobranchial cyst 1 (2%) 1 (2%) Vacuolization cytoplasmic 1 (2%) 1 (2%) Bilateral, C-cell, hyperplasia 1 (2%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) 1 (2%) 1 (2%) General Body System None Genital System Clitoral gland (46) (48) (49) Atrophy 1 (2%) 1 (2%) 1 (2%)	12 (24%)	19 (38%)	10 (20%)	10 (20%)	
Inflammation, chronic active 1 (2%) Ultimobranchial cyst 1 (2%) Vacuolization cytoplasmic 1 (2%) Bilateral, C-cell, hyperplasia 1 (2%) C-cell, hyperplasia 24 (48%) 26 (53%) Follicle, cyst 1 (2%) General Body System Kone (46) Genital System Clitoral gland (46) (48) (49) Atrophy 1 (2%) 1 (2%) 1 (2%)	1 (2%)				
Ultimobranchial cyst 1 (2%) 1 (2%) Vacuolization cytoplasmic 1 (2%) Bilateral, C-cell, hyperplasia 1 (2%) C-cell, hyperplasia 24 (48%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) General Body System None Genital System Clitoral gland (46) (48) (49) Atrophy 1 (2%) 1 (2%) 1 (2%)	(50)		(49)	(50)	
Vacuolization cytoplasmic 1 (2%) Bilateral, C-cell, hyperplasia 1 (2%) C-cell, hyperplasia 24 (48%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) General Body System Seneral Body System Sone (46) (48) (49) Atrophy 1 (2%) 1 (2%) (49)					
Bilateral, C-cell, hyperplasia 1 (2%) C-cell, hyperplasia 24 (48%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) General Body System 1 (2%) Seneral Body System 1 (2%) Genital System (46) (48) (49) Atrophy 1 (2%)	4 (8%)	1 (2%)			
C-cell, hyperplasia 24 (48%) 26 (53%) 34 (71%) Follicle, cyst 1 (2%) General Body System 1 (2%) Seneral Body System 46) (48) (49) Atrophy 1 (2%) 1 (2%) 1 (2%)				1 (2%)	
Follicle, cyst 1 (2%) General Body System None Genital System Clitoral gland (46) (48) (49) Atrophy 1 (2%)					
General Body System None Genital System Clitoral gland (46) (48) (49) Atrophy 1 (2%)	26 (52%)		26 (53%)	24 (48%)	
Genital System litoral gland (46) (48) (49) Atrophy 1 (2%)		1 (2%)			Follicle, cyst
None Genital System Clitoral gland (46) (48) (49) Atrophy 1 (2%) (49)					General Body System
Clitoral gland (46) (48) (49) Atrophy 1 (2%) (49)					
Atrophy 1 (2%)	(49)	(49)	(48)	(46)	
	(-7)	(17)	(07)		
$V_{N} = \frac{1}{1} \frac{1}{2} \frac{1}$	3 (6%)	12 (24%)	1 (2%)	9 (20%)	Cyst
Lyperplasia 8 (17%) 4 (8%) 7 (14%)	7 (14%)				
Inflammation, chronic active $1 (2\%)$ $2 (4\%)$	1 (2%)			0 (1770)	

TABLE B5 Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Genital System (continued)				
Ovary	(50)	(49)	(50)	(50)
Cyst	4 (8%)	4 (8%)	3 (6%)	5 (10%)
Inflammation, chronic active				1 (2%)
Follicle, cyst	1 (2%)		2 (4%)	2 (4%)
Periovarian tissue, cyst	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Uterus	(50)	(50)	(50)	(50)
Cyst	(20)	2 (4%)	(00)	(00)
Dysplasia		2 (170)		1 (2%)
Fibrosis	1 (2%)			1 (270)
Hemorrhage	1 (270)	1 (2%)	2 (4%)	1 (2%)
Hydrometra	3 (6%)	4 (8%)	4 (8%)	5 (10%)
5	5 (078)	4 (870)	. ,	5 (1070)
Inflammation, chronic active Thrombosis			1 (2%) 2 (4%)	1 (20/)
				1 (2%)
Cervix, hydrometra			1 (2%)	1 (20/)
Cervix, hyperplasia	1 (20/)			1 (2%)
Cervix, hypertrophy	1 (2%)			1 (20/)
Cervix, epithelium, cyst				1 (2%)
Hematopoietic System				
Bone marrow	(50)	(50)	(50)	(50)
Hyperplasia			1 (2%)	
Myelofibrosis			1 (2%)	
Lymph node	(2)	(1)	(2)	(1)
Ectasia				1 (100%)
Lymph node, mandibular	(49)	(49)	(50)	(50)
Hyperplasia	1 (2%)	1 (2%)	× /	2 (4%)
Lymph node, mesenteric	(50)	(50)	(50)	(50)
Pigmentation, lipofuscin	()	1 (2%)	1 (2%)	()
Spleen	(50)	(50)	(50)	(50)
Fibrosis	1 (2%)		(20)	(00)
Hematopoietic cell proliferation	1 (2%)	1 (2%)	1 (2%)	4 (8%)
Necrosis	1 (270)	1 (270)	1 (2%)	1 (0/0)
Pigmentation, hemosiderin	1 (2%)	3 (6%)	1 (2%) 1 (2%)	1 (2%)
Vacuolization cytoplasmic	1 (2%) 1 (2%)	5 (070)	1 (2/0)	1 (2/0)
Lymphoid follicle, depletion cellular	1 (2/0)			1 (2%)
Thymus	(49)	(17)	(40)	(48)
Atrophy	(49)	(47)	(49) (2%)	(40)
Atropny Cyst	1 (2%) 1 (2%)		1 (2%)	
Integumentary System	(50)	(50)	(50)	(50)
Mammary gland	(50)	(50)	(50)	(50)
Galactocele	14 (28%)	10 (20%)	12 (24%)	10 (20%)
Hyperplasia	10 (20%)	5 (10%)	3 (6%)	9 (18%)
Skin	(50)	(50)	(50)	(50)
Ulcer				2 (4%)
Musculoskeletal System				
Bone	(50)	(50)	(50)	(50)
Osteosclerosis	1 (2%)			. ,

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Nervous System				
Brain	(50)	(50)	(50)	(50)
Hemorrhage	1 (2%)			
Hydrocephalus			1 (2%)	1 (2%)
Mineralization				1 (2%)
Respiratory System				
Lung	(50)	(50)	(50)	(50)
Congestion		1 (2%)	2 (4%)	
Inflammation, chronic active	16 (32%)	13 (26%)	14 (28%)	17 (34%)
Pigmentation	1 (2%)			
Alveolar epithelium, hyperplasia	10 (20%)	10 (20%)	8 (16%)	3 (6%)
Bronchiole, epithelium, hyperplasia	1 (2%)	(10)	1 (2%)	(50)
Nose	(50)	(49)	(50)	(50)
Inflammation, chronic active Olfactory epithelium, metaplasia	1 (2%)			3 (6%)
onactory epimenum, metapiasia	1 (2/0)			
Special Senses System				
Eye		(1)	(1)	(3)
Inflammation, chronic active		1 (100%)		1 (220/)
Cornea, inflammation, chronic active				1 (33%)
Lens, mineralization			1 (1000/)	1 (33%)
Retina, degeneration Harderian gland			1 (100%)	3 (100%)
Inflammation, chronic active				(1) 1 (100%)
infammation, enfonce active				1 (10076)
Urinary System				
Kidney	(50)	(50)	(50)	(50)
Accumulation, hyaline droplet		1 (2%)		
Casts protein				1 (2%)
Cyst			2 (4%)	4 (8%)
Infarct	1 (2%)		1 (2%)	1 (2%)
Inflammation, chronic active	1 (2%)	5 (10%)	4 (8%)	5 (10%)
Mineralization	1 (2%)	1 (2%)	2 (4%)	
Necrosis	1 (2%)			
Nephropathy	14 (28%)	16 (32%)	20 (40%)	23 (46%)
Pigmentation	2 (4%)	3 (6%)	1 (2%)	
Renal tubule, regeneration		1 (2%)		
Urinary bladder	(50)	(50)	(50)	(50)
Inflammation, chronic active	3 (6%)	2 (4%)	2 (4%)	5 (10%)

TABLE B5 Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite

APPENDIX C SUMMARY OF LESIONS IN MALE MICE IN THE 2-YEAR DRINKING WATER STUDY OF SODIUM NITRITE

TABLE C1	Summary of the Incidence of Neoplasms in Male Mice	
	in the 2-Year Drinking Water Study of Sodium Nitrite	146
TABLE C2	Individual Animal Tumor Pathology of Male Mice	
	in the 2-Year Drinking Water Study of Sodium Nitrite	150
TABLE C3	Statistical Analysis of Primary Neoplasms in Male Mice	
	in the 2-Year Drinking Water Study of Sodium Nitrite	170
TABLE C4	Summary of the Incidence of Nonneoplastic Lesions in Male Mice	
	in the 2-Year Drinking Water Study of Sodium Nitrite	174

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite^a

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Disposition Summary Animals initially in study Early deaths	50	50	50	50
Moribund Natural deaths	3 8	2 3	3 5	1 10
Survivors Terminal sacrifice	39	45	42	39
Animals examined microscopically	50	50	50	50
Alimentary System				
Intestine small, duodenum	(49)	(50)	(48)	(49)
Carcinoma	X - 7	1 (2%)	X 77	
Carcinoma, metastatic, intestine small,		- (-/*)		
jejunum			1 (2%)	
Polyp adenomatous	2 (4%)	3 6%)	1 (2%)	
Intestine small, jejunum	(50)	(50)	(50)	(50)
Carcinoma	5 (10%)	1 (2%)	1 (2%)	
Leiomyosarcoma	. ,	· /	1 (2%)	
Polyp adenomatous				1 (2%)
Liver	(50)	(50)	(50)	(50)
Alveolar/bronchiolar carcinoma, metastatic,			· · ·	
lung				1 (2%)
Carcinoma, metastatic, islets, pancreatic		1 (2%)		
Cholangiocarcinoma		· · ·		1 (2%)
Hemangiosarcoma	2 (4%)	2 (4%)	1 (2%)	2 (4%)
Hemangiosarcoma, metastatic, spleen	2 (4%)			
Hepatoblastoma	5 (10%)	1 (2%)	2 (4%)	
Hepatocellular carcinoma	9 (18%)	10 (20%)	6 (12%)	6 (12%)
Hepatocellular carcinoma, multiple				3 (6%)
Hepatocellular adenoma	10 (20%)	15 (30%)	8 (16%)	13 (26%)
Hepatocellular adenoma, multiple	9 (18%)	2 (4%)	5 (10%)	5 (10%)
Sarcoma			1 (2%)	
Mesentery	(7)	(6)	(7)	(5)
Alveolar/bronchiolar carcinoma, metastatic,				
lung				1 (20%)
Cholangiocarcinoma, metastatic, liver				1 (20%)
Hepatoblastoma, metastatic, liver			1 (14%)	
Sarcoma, metastatic, liver	(10)	(= 0)	1 (14%)	(= 0)
Pancreas	(49)	(50)	(50)	(50)
Alveolar/bronchiolar carcinoma, metastatic,				
lung				1 (2%)
Cholangiocarcinoma, metastatic, liver	1 (201)			1 (2%)
Hepatoblastoma, metastatic, liver	1 (2%)	(50)	(50)	(50)
Salivary glands	(50)	(50)	(50)	(50)
Stomach, forestomach	(50)	(50)	(50)	(50)
Squamous cell papilloma	1 (2%)	1 (2%)	(50)	1 (2%)
Stomach, glandular	(50)	(50)	(50)	(50)
Sarcoma, metastatic, liver	(5)	(5)	1 (2%)	(1)
Tooth	(5)	(5)	(4)	(1)
Odontoma		2 (40%)	1 (25%)	

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Cardiovascular System				
Heart Alveolar/bronchiolar carcinoma, metastatic,	(50)	(50)	(50)	(50)
lung Fibrosarcoma, metastatic, uncertain primary site		1 (2%)		1 (2%)
Endocrine System				
Adrenal cortex	(50)	(50)	(50)	(50) (50)
Cholangiocarcinoma, metastatic, liver (slets, pancreatic	(50)	(50)	(50)	1 (2%) (50)
Adenoma Carcinoma	3 (6%)	2 (4%) 1 (2%)	2 (4%)	(30)
General Body System None				
Genital System				
Epididymis	(50)	(50)	(50)	(50)
Prostate Cholangiocarcinoma, metastatic, liver	(50)	(50)	(49)	(50) 1 (2%)
Seminal vesicle	(50)	(50)	(50)	(50)
Cholangiocarcinoma, metastatic, liver	(50)	(30)	(30)	1 (2%)
Festes	(50)	(50)	(50)	(50)
Hemangiosarcoma, metastatic, liver Interstitial cell, adenoma		2 (4%)		1 (2%)
Hematopoietic System				
Bone marrow	(50)	(50)	(49)	(50)
Hemangiosarcoma	2 (4%)			
Lymph node Mediastinal, alveolar/bronchiolar carcinoma,	(1)	(1)	(3)	(5)
metastatic, lung Pancreatic, cholangiocarcinoma, metastatic,				1 (20%)
liver				1 (20%)
Renal, cholangiocarcinoma, metastatic, liver	(47)	(50)	(47)	1 (20%) (48)
Carcinoma, metastatic, harderian gland	(**)	(50)	(47) 1 (2%)	(01)
Lymph node, mesenteric	(49)	(49)	(48)	(49)
Hemangiosarcoma, metastatic, liver				1 (2%)
Spleen	(50)	(50)	(50)	(50)
Hemangiosarcoma Hemangiosarcoma, metastatic, bone marrow	3 (6%) 1 (2%)		2 (4%)	
Hemangiosarcoma, metastatic, bone marrow Hemangiosarcoma, metastatic, liver	1 (270)		1 (2%)	1 (2%)
Hemangiosarcoma, metastatic, skin	1 (2%)		1 (2/0)	1 (270)
Thymus	(37)	(39)	(38)	(42)
Alveolar/bronchiolar carcinoma, metastatic,				
lung				1 (2%)

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Integumentary System				
Skin	(50)	(50)	(50)	(50)
Subcutaneous tissue, hemangiosarcoma	1 (2%)			
Subcutaneous tissue, sarcoma, metastatic,	1 (20/)			
brain Subcutaneous tissue, pinna, melanoma	1 (2%)			
malignant				1 (2%)
Musculoskeletal System None				
Nervous System				
Brain	(50)	(50)	(50)	(50)
Sarcoma	1 (2%)			
Respiratory System				
Lung	(50)	(50)	(50)	(50)
Alveolar/bronchiolar adenoma	10 (20%)	5 (10%)	8 (16%)	10 (20%)
Alveolar/bronchiolar adenoma, multiple			1 (2%)	
Alveolar/bronchiolar carcinoma	4 (8%)	1 (2%)	3 (6%)	7 (14%)
Alveolar/bronchiolar carcinoma, metastatic, lung			1 (2%)	1 (2%)
Carcinoma, metastatic, harderian gland			1 (2%)	
Carcinoma, metastatic, intestine small, jejunum	1 (2%)			
Cholangiocarcinoma, metastatic, liver				1 (2%)
Fibrosarcoma, metastatic, uncertain primary site	1 (20)	1 (2%)		
Hemangiosarcoma, metastatic, liver	1 (2%)			
Hepatoblastoma, metastatic, liver	2(4%)	2 (10/)	2 (49/)	0 (40/)
Hepatocellular carcinoma, metastatic, liver	3 (6%)	2(4%)	2 (4%)	2 (4%)
Hepatocholangiocarcinoma, metastatic, liver Sarcoma, metastatic, brain	1 (2%)	1 (2%)		
Sarcoma, metastatic, brain Sarcoma, metastatic, liver	1 (2/0)		1 (2%)	
Mediastinum, alveolar/bronchiolar carcinoma,			1 (270)	
metastatic, lung	1 (2%)			2 (4%)
Mediastinum, fibrosarcoma, metastatic,				- ()
uncertain primary site		1 (2%)		
Mediastinum, hemangiosarcoma, metastatic,		× /		
bone marrow	1 (2%)			
Mediastinum, sarcoma, metastatic, brain	1 (2%)			
Special Senses System Harderian gland	(5)	(4)	(6)	(1)
Adenoma	4 (80%)	3 (75%)	4 (67%)	1 (100%)
Carcinoma	. /	· /	2 (33%)	. ,
Sarcoma, metastatic, brain	1 (20%)			

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Urinary System				
Kidney	(50)	(50)	(50)	(50)
Alveolar/bronchiolar carcinoma, metastatic,				2 (40/)
lung Renal tubule, adenoma		1 (2%)		2 (4%)
Systemic Lesions Multiple organs ^b Lymphoma malignant	(50) 1 (2%)	(50) 1 (2%)	(50) 4 (8%)	(50) 1 (2%)
Neoplasm Summary				
Total animals with primary neoplasms ^c	40	35	36	38
Total primary neoplasms	72	54	53	52
Total animals with benign neoplasms	28	28	26	29
Total benign neoplasms	39	36	30	31
Total animals with malignant neoplasms	27	15	20	20
Total malignant neoplasms	33	18	23	21
Total animals with metastatic neoplasms	13	4	7	7
Total metastatic neoplasms	18	7	11	24
Total animals with malignant neoplasms		1		
of uncertain primary site		1		

Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms а b

c

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm 5 5 7 7 7 7 7 7 7 7 7 7 6 6 6 6 6 6 7 7 7 7 7 7 7 Number of Days on Study 0 2 1 4 4 5 6 8 0 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 7 7 7 7 7 7 7 1 6 7 3 7 2 1 7 1 5 3 7 7 7 7 7 0 0 0 **Carcass ID Number** 2 1 3 2 0 1 0 0 4 3 0 0 0 0 1 1 1 2 2 2 3 3 3 4 4 2 3 4 9 3 6 1 2 8 6 8 5 7 9 1 2 5 1 4 6 0 5 7 4 5 **Alimentary System** Esophagus + + + Gallbladder + Intestine large, colon + ++ Intestine large, rectum Intestine large, cecum + Intestine small, duodenum + ++Polyp adenomatous X X Intestine small, jejunum + + + + + + Carcinoma Х Intestine small, ileum + + + ++ Liver + ++ + + ++ ++Hemangiosarcoma Х X Hemangiosarcoma, metastatic, spleen Х Х Hepatoblastoma Х Х Х Hepatocellular carcinoma Х Х Hepatocellular adenoma X X Х Х Hepatocellular adenoma, multiple Х Х Х Х Mesentery + + + Oral mucosa Pancreas Hepatoblastoma, metastatic, liver Salivary glands Stomach, forestomach Squamous cell papilloma Stomach, glandular Tooth ++**Cardiovascular System** Blood vessel + + + + Heart ++ + + +++ + ++ + ++ ++ **Endocrine System** Adrenal cortex Adrenal medulla + ++ + ++++ + Islets, pancreatic + + + + + + + + + + + + + + +Adenoma Х Х Х Parathyroid gland Μ + + + Μ +M M + + + M M+М Μ + + + + + Pituitary gland + + + + + + + $^+$ + + + $^+$ $^+$ + $^{+}$ $^+$ + + + + Thyroid gland ++ ++++++++ $^+$ $^{+}$ +++ $^+$ +++ + + + + + +**General Body System** None **Genital System** Epididymis Preputial gland + ++ + ++ + + + Prostate + + + + + Seminal vesicle $^+$ ++ ++ ++ +++++++ ++ Testes ++++ ++ ++++ + ++++ ++++ ++++++

+: Tissue examined microscopically

A: Autolysis precludes examination

M: Missing tissue I: Insufficient tissue X: Lesion present Blank: Not examined

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm

Individual Annual Tumor Tathology	or mar	• 11	-		-	-					0					v									
Number of Days on Study	7 2 7	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	7 7 2 2 8 8	2 2	2 2	7 2 8	7 2 8	7 2 8	2	2	2	-	2	2	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	2	
Carcass ID Number	0 4 6	0 0 4	0 1 0	0 1 4	0 1 8	2	0 (2 2 3 5	2 3		0 3 3	0 3 8	0 4 0		5	0		1	2	0 2 8		0 4 1	0 4 3	0 4 7	4	Total Tissues/ Tumors
Alimentary System																									
Esophagus	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, rectum	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Polyp adenomatous																									2
Intestine small, jejunum	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	+	+	50
Carcinoma	Х					Х					Х					Х									5
Intestine small, ileum	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Liver	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma Hemangiosarcoma, metastatic, spleen																									2 2
Hepatoblastoma				Х														Х						Х	5
Hepatocellular carcinoma							Х		Х	Х				Х		Х								Х	9
Hepatocellular adenoma				Х	Х	Х							Х				Х					Х			10
Hepatocellular adenoma, multiple			Х				2	Κ	Х							Х								Х	9
Mesentery	+									+													+		7
Oral mucosa	+	+		+	+		+		+	+	+	+	+			+	+	+	+	+	+		$^+$		26
Pancreas	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	+	+	49
Hepatoblastoma, metastatic, liver																		Х							1
Salivary glands	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Squamous cell papilloma											Х														1
Stomach, glandular	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Tooth																	+	+				+			5
Cardiovascular System																									
Blood vessel	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Heart	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal medulla	+ +	+	+	+	+	+	+ -	, , + 4		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Islets, pancreatic	+ +	+	+	+	+	+	+ -	, , + 4		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma	1	'									'										'				3
Parathyroid gland	+	М	+	+	+	+	+ -	+ +	+ +	+	+	м	+	+	м	+	+ 1	м	+	+	+	м	м	+	36
Pituitary gland	+		М		+	+			 	+	+	+	+	+	+	+	· . +	+	+	+	+	+	+	+	30 49
Thyroid gland	+	+	+	+	+	+	+ -	 	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
	1					•	•								•	•	•	•	•	•					50
General Body System None																									
Genital System																									
Epididymis	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Preputial gland	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Prostate	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Seminal vesicle	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Seminar vestere																									50

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm 7 7 7 7 7 7 7 7 7 5 5 6 6 6 6 6 6 7 7 7 7 7 7 7 7 Number of Days on Study 0 2 1 4 4 5 6 8 0 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 77 1 6 7 3 7 2 1 7 1 5 3 7 7 7 7 7 7 7 7 7 7 **Carcass ID Number** 2 1 3 2 0 1 0 0 4 3 0 0 0 0 1 1 1 2 2 2 3 3 3 4 4 2 3 4 9 3 6 1 2 8 6 8 5 7 9 1 2 5 1 4 6 0 5 7 4 5 Hematopoietic System + $^+$ + + + Bone marrow Hemangiosarcoma Х Lymph node Lymph node, mandibular + + M + M + M +++ Lymph node, mesenteric + + + $^{+}$ $^{+}$ $^+$ Μ + + $^{+}$ $^+$ + + + + + + Spleen +++ + ++Hemangiosarcoma X Х Hemangiosarcoma, metastatic, bone marrow Hemangiosarcoma, metastatic, skin Thymus + + + + M + M M M + + + + + + M + + M + + + + M +**Integumentary System** Mammary gland Skin + + + Subcutaneous tissue, hemangiosarcoma Subcutaneous tissue, sarcoma, metastatic, brain Х Musculoskeletal System Bone + + + + + + + + ++ + + + + + + + + + + + + + + **Nervous System** Brain Sarcoma Х **Respiratory System** $^{+}$ + Lung +++++++ +++Alveolar/bronchiolar adenoma Х Х ХХ X X Alveolar/bronchiolar carcinoma Х Х Carcinoma, metastatic, intestine small, jejunum Hemangiosarcoma, metastatic, liver Х Hepatoblastoma, metastatic, liver Х Hepatocellular carcinoma, metastatic, liver Х Sarcoma, metastatic, brain Х Mediastinum, alveolar/bronchiolar carcinoma, Х metastatic, lung Mediastinum, hemangiosarcoma, metastatic, bone marrow Mediastinum, sarcoma, metastatic, brain Х Nose $^{+}$ + Trachea + + + + + **Special Senses System** Eye + Harderian gland + + + Adenoma Х Х Х Sarcoma, metastatic, brain Х

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm

Number of Days on Study	7 2 7	7 2 8	7 7 2 2 8 8	77 22 88		7 2 8	7 2 8	7 2 9																	
Carcass ID Number	0 4 6	0 0 4	0 1 0	0 1 4	0 1	0 2	0	0 2	0	0 () 3 3) () 3 3	0 0	0 4 2	0 5	0 0 6	0 1 7	0 1 9	0 2 7	0 2 8	0 3 9	0 4 1	0 4 3		0 4 9	Total Tissues/ Tumors
Hematopoietic System																									
Bone marrow	+	+	+	+	+	+	+	+	+	+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma			Х																						2
Lymph node																									1
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	47
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	49
Spleen	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma			v																						3
Hemangiosarcoma, metastatic, bone marrow Hemangiosarcoma, metastatic, skin			Х																Х						1
Thymus	<u>т</u>	+	-	-	м	<u>т</u>	м	т	+	Ц. Ц.	L _		М	-	м	м	+	-		т.	-	-	м	+	37
Thymus	Т	Ŧ	Ŧ	т	IVI	Ŧ	IVI	т	т	T 1		- T	IVI	т	IVI	IVI	Ŧ	т	Ŧ	т	т	т	IVI	т	37
Integumentary System																									
Mammary gland	Μ											1 M													
Skin	+	+	+	+	+	+	+	+	+	+ +	+ +	- +	+	+	+	+	+	+		+	+	+	+	+	50
Subcutaneous tissue, hemangiosarcoma																			Х						1
Subcutaneous tissue, sarcoma,																									
metastatic, brain																									1
Musculoskeletal System																									
Bone	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	50
No																									
Nervous System																									50
Brain Sarcoma	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Sarcollia																									1
Respiratory System																									
Lung	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma					Х										Х		Х							Х	10
Alveolar/bronchiolar carcinoma			Х												Х										4
Carcinoma, metastatic, intestine small,																									
jejunum	Х																								1
Hemangiosarcoma, metastatic, liver																									1
Hepatoblastoma, metastatic, liver																		Х							2
Hepatocellular carcinoma, metastatic, liver							Х									Х									3
Sarcoma, metastatic, brain																									1
Mediastinum, alveolar/bronchiolar carcinoma,																									
metastatic, lung																									1
Mediastinum, hemangiosarcoma,			**																						
metastatic, bone marrow			Х																						1
Mediastinum, sarcoma, metastatic, brain																									1
Nose	+	+	+	+	+	+	+	+	+	+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	50
Trachea	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	50
Special Senses System																									
Eye																									1
Harderian gland										+															5
										Χ															4
Adenoma Sarcoma, metastatic, brain									-																1

154

TABLE C2

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm
--

	5 5	6	6 6	6	6	6	7	7	7	7	7	7 '	7 1	77	7	7	7	7	7	7	7	7		
Number of Days on Study	0 2	1	4 4	5	6	8	0	0	1	2	2	2 3	2 2	2 2	2	2	2	2	2	2	2	2		
	1 6	7	3 7	2	1	7	1	5	3	7	7	7	7 7	7 7	7	7	7	7	7	7	7	7		
	0 0	0	0 0	0 (0	0	0	0	0	0	0	0	0 () 0	0	0	0	0	0	0	0	0		
Carcass ID Number	2 1	3	2 () 1	0	0	4	3	0	0	0	0	1	l 1	2	2	2	3	3	3	4	4		
	2 3	4	93	6	1	2	8	6	8	5	7	9	1 2	2 5	1	4	6	0	5	7	4	5		
Urinary System																								
Kidney	+ +	+	+ +	- +	$^+$	+	+	+	+	+	+	+ •	+ -	+ +	+	+	+	+	$^+$	$^+$	+	+		
Urinary bladder	+ +	+	+ +	- +	+	+	+	+	+	+	+	+ ·	+ -	+ +	+	+	+	+	+	+	+	+		
Systemic Lesions																								
Multiple organs	+ +	+	+ +	- +	+	+	+	+	+	+	+	+ •	+ -	+ +	+	+	+	+	+	+	+	+		
Lymphoma malignant																	Х							

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm

Number of Days on Study	7 2 7	7 2 7	7 2 8	7 2 9																							
Carcass ID Number	0 4 6	4	0 0 4	0 1 0	0 1 4	0 1 8	0 2 0	0 2 3	0 2 5	0 3 1	0 3 2	0 3 3	0 3 8	0 4 0	0 4 2	0 5 0	0 0 6	0 1 7	0 1 9	0 2 7	0 2 8	0 3 9	0 4 1	0 4 3	0 4 7	4	Total Tissues/ Tumors
Urinary System Kidney Urinary bladder	+	+	+ +	++	+++	+++	+ +	+++	+ +	+++	+ +	+++	+ +	+ +	++	+++	+++	+ +	+ +	+++	+++	+ +	+++	+++	+++	+ +	50 50
Systemic Lesions Multiple organs Lymphoma malignant	+	ł	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm

Number of Days on Study	4 4 4	6 0 1	6 1 2	6 3 7	6 4 4	7 2 7	2	2	2	7 2 7	7 2 8	7 2 8													
Carcass ID Number	0 8 7	0 9 9	0 8 5	0 9 7	0 7 2		5	0 5 6	6	0 6 5	0 6 6	0 6 8	0 6 9		8	8	0 8 9	0 9 1	0 9 3	0 9 5	0 9 6	0 9 8	1 0 0	5	
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine argeç olon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine arger ectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Carcinoma																									
Polyp adenomatous																									
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	+	+	+
Carcinoma												Х													
Intestines malli leum	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	+	+	$^+$	+	+	+
Liver	+	+	$^+$	$^+$	+	+	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	$^+$	$^+$	$^+$	+	$^+$	+
Carcinoma, metastatic, islets, pancreatic Hemangiosarcoma Hepatoblastoma																								Х	
Hepatocellular carcinoma		Х			Х									Х		Х			Х					Х	
Hepatocellular adenoma				Х					Х								Х	x							
Hepatocellular adenoma, multiple								Х									11								
Mesentery	+				+							+							+	+					
Oral mucosa						+				+	+		+	+	+	+	+	+		+	+			+	
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Salivaryg lands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomachf orestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Squamous cell papilloma										x															
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Tooth	'				'	'	'	+	'		'			+		'	'				'	'	+		1
Odontoma								'						'									X		
Odomolila																							Л		
Cardiovascular System																									
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Fibrosarcoma, metastatic, uncertain primary site					Х																				
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	+	+	$^+$	+	+	+
Adenoma																				Х					
Carcinoma																								Х	
	+	+	$^+$	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	$^+$	$^+$	$^+$	$^+$	+
Parathyroid gland																		+	-	NЛ					
Parathyroid gland Pituitary gland	+	+	+	$^+$	+	+	+	+	+	+	+	+	+	+	+	Ŧ	Ŧ	Ŧ	T	Μ	-	+	+	+	+

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm

Number of Days on Study	7 2 8	7 2 9	2																							
Carcass ID Number	0 6 7	0 7 3	0 7 4	0 7 5	0 7 6	0 7 7	0 7 8	0 7 9	8	0 8 1	0 8 6	9	0 9 4	5	0 5 2	0 5 3	0 5 7	0 5 8	0 6 0	0 6 2	0 6 4	0 7 1	0 8 3	0 8 4	9	Total Tissues/ Tumors
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	+	+	+	50
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	+	50
Intestine argeç olon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	+	+	+	$^+$	$^+$	+	+	50
Intestine arger ectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	+	+	+	$^+$	$^+$	+	+	50
Intestine large, cecum	+	+	$^+$	$^+$	+	+	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	+	50
Intestine small, duodenum	+	+	$^+$	$^+$	+	+	+	+	+	+	+	+	$^+$	+	+	+	+	+	$^+$	$^+$	$^+$	$^+$	$^+$	$^+$	+	50
Carcinoma																				Х						1
Polyp adenomatous				Х								Х											Х			3
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	$^+$	+	+	$^+$	$^+$	+	+	50
Carcinoma																										1
Intestines malli leum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	$^+$	+	+	50
Carcinoma, metastatic, islets, pancreatic																										1
Hemangiosarcoma																					Х		Х			2
Hepatoblastoma				Х																						1
Hepatocellular carcinoma					Х										Х		Х						Х			10
Hepatocellulan denoma								Х		Х	Х			Х				х	х	Х	Х		Х			15
Hepatocellular adenoma, multiple							Х																			2
Mesentery											+															6
Oral mucosa		+		+	+	+			+	+	+	+	+	+		+	+				+	+	+			27
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivaryg lands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomachf orestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Squamous cell papilloma																										1
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Tooth	'		+	+	'	'	'				'	'			'						'	'			'	5
Odontoma			x																							2
Cardiovascular System																										
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Fibrosarcoma, metastatic, uncertain primary site																										1
Endocrine System																										
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma																								Х		2
Carcinoma																										1
Parathyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	48
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
																									+	50

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm 7 7 7 7 7 7 7 7 7 7 7 7 4 6 6 6 6 7 7 7 7 7 7 7 7 Number of Days on Study 0 1 3 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 4 2 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 8 4 1 2 7 4 7 7 7 8 0 1 0 0 **Carcass ID Number** 6 6 6 6 6 7 8 9 8 9 7 5 5 5 8 8 8 9 9 9 9 9 0 5 6 7 9 5 7 2 4 5 6 3 5 6 8 9 0 2 8 9 1 3 5 6 8 0 9 1 **Genital System** Coagulating gland Epididymis + Preputial gland + + + + Prostate Seminal vesicle Testes + Interstitial cell, adenoma Х X Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Thymus + ++МММ ++ ++ +М +++Μ ++ +Μ ++ **Integumentary System** Mammary gland Skin + + + + + ++ + + + + +Musculoskeletal System Bone + ++ ++ + ++++++++++**Nervous System** Brain + ++++++++++++++++++++ **Respiratory System** Lung ++ Alveolar/bronchiolar adenoma Х Alveolar/bronchiolar carcinoma Х X X Fibrosarcoma, metastatic, uncertain primary site Hepatocellular carcinoma, metastatic, liver Х Hepatocholangiocarcinoma, metastatic, liver Х Mediastinum, fibrosarcoma, metastatic, uncertain primary site Х Nose + Trachea + + + **Special Senses System** Harderian gland + + Х Х Adenoma **Urinary System** Kidney Renal tubule, adenoma Urinary bladder + + + + + ++ + + + ++ + ++ + + + + + + + +++ Systemic Lesions Multiple organs + Lymphoma malignant Х

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm

	7	7	7	7	7	7	7	7	7	7	7	7	7		7	7	7	7	7	7	7	7	7	7		
Number of Days on Study	2 8	2 8	2 8	2 8	2 8	2 8	2 9	2 9	2 9	2 9	2 9	2 9	2 9	2 9	2 9	2 9	2 9									
Carcass ID Number	0 6 7	0 7 3	0 7 4	0 7 5	0 7 6	0 7 7	0 7 8	0 7 9	8	0 8 1	8	0 9 2	0 9 4	0 5 1	5	0 5 3	0 5 7	0 5 8	0 6 0	0 6 2	0 6 4	0 7 1	0 8 3	0 8 4	9	Total Tissues/ Tumors
Genital System																										1
Coagulating gland Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	1 50
Preputiag land	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Seminaly esicle Testes	+	+	+	++	+	+	+	++	+	+	+	+	+	+	++	+	+	+	+	+	++	+	++	++	+++	50 50
Interstitial cell, adenoma					'	'	'			,	'	'			'	'	1	'		'	'	1			1	2
Hematopoietic System																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	1 50
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Thymus	М	М	+	+	+	+	+	+	М	+	+	+	+	М	+	+	+	М	+	+	+	+	+	+	+	39
ntegumentary System	м	м	м	м	м	м	м	м	м	м	м	м	м	М	м	м	м	м	м	м	м	м	м	м	м	
Латтагу gland Skin		+		+		+			+		+			+					+					+		50
Musculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Vervous System Brain	<u>т</u>	-	-	-	-	-	<u>т</u>	1	-	<u>т</u>	-	-	+	-	-	_	1	т.	т	+	т.	<u>т</u>	-	т	+	50
	1				'					'		'				'		'				'			1	50
Respiratory System Lung		+	+	т.	Т	+	<u>т</u>	+	т.	_	+	-	+	т.	+	<u>т</u>	+	+	+	+	+	_	+	+	+	50
Alveolar/bronchiolar adenoma	T	Ŧ	T	т	т	Ŧ	-	т	т	т	т	X	X	т	т	Ŧ	т	т	Х		т	Ŧ	т	т	т	5
Alveolar/bronchiolar carcinoma																										1
Fibrosarcoma, metastatic, uncertain primary site																										1
Hepatocellular carcinoma, metastatic, liver																										2
Hepatocholangiocarcinoma, metastatic, liver Mediastinum, fibrosarcoma, metastatic,																										1
uncertain primary site																										1
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Frachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Special Senses System Harderian gland				+																	+					4
Adenoma				'																	x					4
Urinary System																										
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Renal tubule, adenoma Jrinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	X +	+	+	+	+	+	+	+	+	+	+	1 50
																										50
Systemic Lesions Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymphoma malignant																										1

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm

		5	6	6	6		-	-	77	-	-	7	7	7	7	7	7	7	7	7	7	7	7	7
Number of Days on Study	7 7	9 6	4 1	4 3	4 3	6 4			22 77	2 7	2 8	2 8												
	1	1	1	1	1	1	1	1	1 1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Carcass ID Number	0 3	4 4	4 7	0 1	3 5	3 2	1 9	0 8	$\begin{array}{ccc} 0 & 0 \\ 2 & 6 \end{array}$	1 5	1 7	2 8	3 0	3 1	3 3	3 4	3 8	4 0	4 3	4 6	4 8	5 0	0 4	
Alimentary System	_		-		-		-	-	-	-		-	-		-		-	-	-	-	-	-		-
Esophagus	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Gallbladder	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, colon	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, rectum	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, cecum	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, duodenum	+	М	+	+	+	+	+	+	+ +	Μ	+	+	+	+	+	+	+	+	+	+	+	$^+$	+	+
Carcinoma, metastatic, intestine small, jejunum																								
Polyp adenomatous														Х										
Intestine small, jejunum	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Carcinoma																								
Leiomyosarcoma			Х																					
Intestine small, ileum	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Liver	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Hemangiosarcoma						Х																		
Hepatoblastoma																								
Hepatocellular carcinoma		Х											Х				Х							Х
Hepatocellular adenoma											Х							Х			Х	Х		
Hepatocellular adenoma, multiple																	Х		Х					
Sarcoma				Х																				
Mesentery				+																+			+	
Hepatoblastoma, metastatic, liver																								
Sarcoma, metastatic, liver				Х																				
Oral mucosa					+			+ ·	+ +				+	+		+		+	+				+	+
Pancreas	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Salivary glands	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, forestomach	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, glandular	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Sarcoma, metastatic, liver				Х																				
Tooth										+											+			+
Odontoma																								
Cardiovascular System																								
Blood vessel	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Heart	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Endocrine System																								
Adrenal cortex	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adrenal medulla	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Islets, pancreatic	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adenoma																								
Parathyroid gland	+	М	+	+	М	+	+]	M	+ +	+	+	+	+	+	М	+	+	+	М	+	М	+	+	+
Pituitary gland	+	+	+	+	Ι	+	+	+	+ +	+	+	+	+	М		+	+	+	+	+	+	+	+	+
Thyroid gland	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
General Body System None																								
Genital System																								
Epididymis	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Preputial gland	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Prostate	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Seminal vesicle	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm

	7	7	7	7	7	7	7	7	7	7	7	7	7	<u> </u>	7	7	7	7	7	7	7	7	7		7	
Number of Days on Study	2 8	2 8	2 8	2 8	2 8	2 9																				
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Total
Carcass ID Number	0 7	1 0	1 1	1 3	1 4	1 6	1 8	2 1	2 4	2 5	2 6	2 7	3 6	3 9	4 1	4 2	4 5	4 9	0 9	1 2	2 0	2 2	2 3	2 9	3 7	Tissues/ Tumors
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Carcinoma, metastatic, intestine small, jejunum			Х																							1
Polyp adenomatous																										1
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Carcinoma			Х																							1
Leiomyosarcoma																,										1
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma		v			v																					1
Hepatoblastoma		Х			X X													v								2
Hepatocellular carcinoma				v	л Х							v				Х		Х								6
Hepatocellular adenoma				Λ	л							Х				л	Х	v							v	8
Hepatocellular adenoma, multiple Sarcoma																	л	л							Х	5 1
Mesentery			+																		+	+				1
Hepatoblastoma, metastatic, liver			Ŧ		+ X																Ŧ	Ŧ				1
Sarcoma, metastatic, liver					л																					1
Oral mucosa	+	+													+		+	+							+	17
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Sarcoma, metastatic, liver		·																								1
Tooth														+												4
Odontoma														X												1
Cardiovascular System																										
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																										
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma						Х								Х												2
Parathyroid gland	Μ	+	+	+	+		+	М	+	+	+	+	+	+	+	М	+	+	М	М	+	+	+	+	+	38
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	Ι	+	+	+	+	+	+	+	+	+	+	+	47
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
General Body System None																										
Genital System																										
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Preputial gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	+	+	+	+	49
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	49
Prostate																										
Seminal vesicle	+	$^+$	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm 7 7 7 7 7 7 7 7 7 7 7 5 5 6 6 6 6 6 7 7 7 7 7 7 7 Number of Days on Study 7 9 4 4 4 6 6 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 7 7 7 7 7 7 7 7 6 1 3 3 4 7 7 7 7 7 7 7 7 8 8 1 **Carcass ID Number** 0 4 4 0 3 3 1 0 0 0 1 1 2 3 3 3 3 3 4 4 4 4 5 0 0 3 4 7 1 5 29 8 2 6 5 7 8 0 1 3 4 8 0 3 6 8 0 4 5 Hematopoietic System Bone marrow + + + Lymph node Lymph node, mandibular M M + M Carcinoma, metastatic, harderian gland Х Lymph node, mesenteric + Spleen +++ Hemangiosarcoma Х Hemangiosarcoma, metastatic, liver Х Thymus M + + + M $^+$ + M + M + + ++ + + M M M + M + + + M**Integumentary System** Mammary gland Skin Musculoskeletal System Bone + + + + + ++ + + ++ + + $^{+}$ ++++ + ++++ ++**Nervous System** Brain + + $^{+}$ + + + + + + + + + + + $^{+}$ ++ $^{+}$ + + **Respiratory System** Lung + + Alveolar/bronchiolar adenoma Х Х Х Х Alveolar/bronchiolar adenoma, multiple Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma, metastatic, lung Х Carcinoma, metastatic, harderian gland Hepatocellular carcinoma, metastatic, liver Sarcoma, metastatic, liver Х Nose + + + + + + + + +++ + Trachea + ++ + + + + + + + +++ + + ++++++ ++ +Special Senses System Harderian gland + Adenoma Х Carcinoma **Urinary System** Kidney + + + + + + + + + ++ + + + ++ ++ +++++ ++Urinary bladder + + + + + + + + + + $^+$ + + + + + + + + + + + + + + Systemic Lesions Multiple organs + + + + + + + + + + ++ + + + + + + + + + + + + +Lymphoma malignant Х

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm

																	-						_			eee ppii
Number of Days on Study	7 2 8	2	7 2 8	7 2 8	2	7 2 8	7 2 8	7 2 8	7 2 8	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	2										
Carcass ID Number	1 0 7	1 1 0	1 1 1	1	1 1 4	1 1 6	1 1 8	2	2	2	2	1 2 7	3		4	4	4	1 4 9	0	1 1 2	2	2	1 2 3	1 2 9	3	Total Tissues/ Tumors
Hematopoietic System																										
Bone marrow Lymph node	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49 3
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	3 47
Carcinoma, metastatic, harderian gland												·			'						·					1
Lymph node, mesenteric	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma									Х																	2
Hemangiosarcoma, metastatic, liver Thymus	-	-	-	-	+	-	+	_	-	-	-	+	+	м	м	_	_	+	-	_	+	т.	+	-	м	1 38
Thymus	т	т	Ŧ	Ŧ	т	т	т	Τ	т	Ŧ	Ŧ	т	т	IVI	IVI	Ŧ	Τ	т	т	Ŧ	т	Ŧ	т	т	IVI	38
Integumentary System																										
Mammary gland	M						М																			1
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Musculoskeletal System Bone	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
							-					-	-	_				-							-	
Nervous System																										50
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System																										
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma								Х	Х		Х										Х	Х				8
Alveolar/bronchiolar adenoma, multiple				Х						х						v										1
Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma, metastatic, lung				л						л						X X										3
Carcinoma, metastatic, harderian gland																Λ										1
Hepatocellular carcinoma, metastatic, liver					Х													Х								2
Sarcoma, metastatic, liver																										1
Nose	+	+	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Special Senses System																										
Harderian gland			+					+		+	+									+						6
Adenoma			Х					Х			Х									Х						4
Carcinoma								Х																		2
Urinary System																										
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
	+																									
Urinary bladder	+																									
Urinary bladder Systemic Lesions Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm 4 5 5 7 7 7 7 7 7 7 5 5 5 6 6 6 6 6 7 7 7 7 7 7 7 Number of Days on Study 7 0 4 5 8 9 2 5 6 8 9 2 2 2 2 2 2 2 2 2 2 2 2 2 2 7 7 7 7 7 7 7 7 7 7 7 2 2 9 6 3 4 9 4 5 5 8 7 7 7 1 **Carcass ID Number** 9 7 8 8 8 5 5 6 7 89 5 5 5 6 6 6 7 7 7 8 8 8 9 9 7 7 8 5 1 9 5 2 5 0 1 1 3 7 1 4 7 1 2 8 4 6 9 3 4 **Alimentary System** Esophagus + Gallbladder Intestine argeç olon Intestine arger ectum Intestine large, cecum + + Intestine small, duodenum + + Μ Intestine small, jejunum Polyp adenomatous Intestines malli leum Liver + Х Alveolar/bronchiolar carcinoma, metastatic, lung Cholangiocarcinoma Х Hemangiosarcoma Х Х Hepatocellular carcinoma ХХ Х Х Х Х Х Hepatocellular carcinoma, multiple ххх Hepatocellulan denoma Х Х Х Х Х Hepatocellular adenoma, multiple Х + Mesentery + + Alveolar/bronchiolar carcinoma, metastatic, lung Х Х Cholangiocarcinoma, metastatic, liver Oral mucosa Pancreas + Alveolar/bronchiolar carcinoma, metastatic, lung Х Х Cholangiocarcinoma, metastatic, liver Salivaryg lands + + Stomachf orestomach Squamous cell papilloma Stomach, glandular + Tooth **Cardiovascular System** Blood vessel Heart Alveolar/bronchiolar carcinoma, metastatic, lung Х **Endocrine System** Adrenal cortex + + Cholangiocarcinoma, metastatic, liver Х Adrenal medulla + Islets, pancreatic + + + + + + Parathyroid gland + + Μ Μ + + + + + Μ + + + + + + + + Pituitary gland + +++ M ++ ++++ ++ Μ ++++++ + Thyroid gland + + + + + + + **General Body System**

None

164

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm

Number of Days on Study	7 2 7	7 2 7	7 2 7	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	2	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	7 2 9	7 2 9	7 2 9	7 2 9	2	7 2 9	
Carcass ID Number	1 9 8	1 9 9	2 0 0	1 5 2	1 5 6	1 5 8	1 6 0	1 6 3	1 6 5	6	1 6 9	1 7 0	1 7 3	7	1 7 6	1 8 3	1 8 7	1 9 2	1 9 5	1 5 4	1 6 8	1 7 9	1 8 2	1 9 0	9	Total Tissues/ Tumors
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	49
Intestine argeç olon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine arger ectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small, jejunum Polyp adenomatous	+	+	+	+	+	+	$^+_{\rm X}$	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Intestinos mallį leum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Liver Alveolar/bronchiolar carcinoma, metastatic, lung Cholangiocarcinoma Hemangiosarcoma Hepatocellular carcinoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1 1 2 6
Hepatocellular carcinoma, multiple							Х			Х																3
Hepatocellular adenoma			Х						Х		Х								Х					Х		13
Hepatocellular adenoma, multiple														Х				х		Х			Х			5
Mesentery Alveolar/bronchiolar carcinoma, metastatic, lung Cholangiocarcinoma, metastatic, liver																				+						5 1 1
Orah ucosa				+		+	+		+			+	+		+	+			+			+			+	19
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar carcinoma, metastatic, lung											'															1
Cholangiocarcinoma, metastatic, liver																										1
Salivaryg lands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomachf orestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Squamous cell papilloma	'				'	x	'	'			'	'		'				'		'						1
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Footh	1	'	1	1	1	1				1	1		1								1	'	1		I	1
Cardiovascular System																										
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar carcinoma, metastatic, lung																										1
E ndocrine System Adrenal cortex	1	-			-	-	-	-		-	-	-	-	т	+	-	-	_	-	-	-	-	-	-	-	50
Cholangiocarcinoma, metastatic, liver	Τ'	Т	Г	Г	F	Г	ſ	1-	r	1-	17	17	17	1.	1	1-	17	1-	1.	1	F	г	т	т	1.	50 1
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
slets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Parathyroid gland	Ń	+	+	+	+	+	+	+	+	M	M	+	M	+	+	+	+	+	+	+	Ń	+	+	+	M	41
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	47
Thyroid gland							÷			+	+	+	+	+			+				÷	÷		-	+	50

		5	5	5	5	5	6			6	6	7	/	7	7	1	1	1	1	/	/	/	/	/	/
Number of Days on Study	7 2	0 2	4 9	5 6	8 3	9 4	2 9	5 4		8 5	9 8	2 7	2 7	2 7	2 7	2 7	2 7	2 7	2 7	2 7	2 7	2 7	2 7	2 7	2 7
Carcass ID Number	1 9 7	1 7 7	1 8 8	8	8	5	5	1 6 2	7	8	9	5	1 5 3	1 5 7	6	1 6 4	1 6 7	1 7 1	1 7 2	1 7 8	1 8 4	8	8	1 9 3	9
Genital System																									
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Preputial gland Prostate	+	+	+	+	+	+	++	++	++	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ +
Cholangiocarcinoma, metastatic, liver	Ŧ	Ŧ	т	т	Ŧ	Ŧ	Ŧ	Х	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	т	Ŧ	т	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ
Seminal vesicle	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Cholangiocarcinoma, metastatic, liver								Х																	
l'estes	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Hemangiosarcoma, metastatic, liver			Х																						
Hematopoietic System																									
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
_ymph node		+				+		+			+												+		
Mediastinal, alveolar/bronchiolar carcinoma,		v																							
metastatic, lung		Х						Х																	
Pancreatic, cholangiocarcinoma, metastatic, liver Renal, cholangiocarcinoma, metastatic, liver								Л																	
.ymph node, mandibular	+	+	+	+	М	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Jymph node, mesenteric	+	+	+	+	+	+		+			+			+	+	+	+	+	+	+	+	+	+	+	+
Hemangiosarcoma, metastatic, liver											Х														
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Hemangiosarcoma, metastatic, liver			Х																						
Chymus Alveolar/bronchiolar carcinoma, metastatic, lung	+	+ X	+	+	+	+	+	+	+	+	М	+	М	+	+	+	М	+	+	+	М	+	+	+	+
Aiveolai/oronemolai caremonia, meastatic, lung		71																							
ntegumentary System																									
Mammary gland																								М	
Skin Subautanaana tianna malanama malianant	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Subcutaneous tissue, pinna, melanoma, malignant																									
Musculoskeletal System																									
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Nervous System																									
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Respiratory System																									
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+
Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma		х					Х						Å		Х				Х	А				Х	
Alveolar/bronchiolar carcinoma, metastatic, lung		Λ					Х																	Λ	
Cholangiocarcinoma, metastatic, liver								Х																	
Hepatocellular carcinoma, metastatic, liver					Х																				
Mediastinum, alveolar/bronchiolar carcinoma,																									
metastatic, lung		Х					Х																		
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

166

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm 7 Number of Days on Study 2 9 7 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 9 9 9 9 9 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 Total 1 1 1 1 **Carcass ID Number** 9 9 0 5 5 5 6 6 6 6 6 7 7 7 7 8 8 9 9 5 6 8 9 9 7 Tissues/ 8 9 0 2 6 8 0 3 5 6 9 0 3 4 6 3 7 2 5 4 8 9 2 0 6 Tumors **Genital System** Epididymis + + + + ++ + + + + + + + + + 50 + + + ++ +++++Preputial gland + 50 Prostate + 50 + +++ + + Cholangiocarcinoma, metastatic, liver 1 Seminal vesicle 50 Cholangiocarcinoma, metastatic, liver 1 Testes 50 Hemangiosarcoma, metastatic, liver 1 **Hematopoietic System** 50 Bone marrow + + Lymph node 5 Mediastinal, alveolar/bronchiolar, carcinoma, metastatic, lung 1 Pancreatic, cholangiocarcinoma, metastatic, liver 1 Renal, cholangiocarcinoma, metastatic, liver 1 Lymph node, mandibular 48 49 Lymph node, mesenteric + ++ + Μ ++ Hemangiosarcoma, metastatic, liver 1 Spleen 50 Hemangiosarcoma, metastatic, liver 1 Thymus + M 42 Μ + M + + + + Μ + + Alveolar/bronchiolar carcinoma, metastatic, lung 1 **Integumentary System** Mammary gland 50 Skin + + + + ++ + + + ++ + + + + + ++ +++ + + + Subcutaneous tissue, pinna, melanoma, malignant Х 1 Musculoskeletal System Bone 50 + + $^{+}$ ++++ $^{+}$ + $^+$ $^{+}$ $^{+}$ $^{+}$ + $^{+}$ $^{+}$ $^{+}$ $^{+}$ + $^+$ ++ $^{+}$ **Nervous System** 50 Brain ++ +++++ ++ ++ +++++ ++ + + **Respiratory System** Lung + + + + 50 $^{+}$ + + ++ +++ Х Х ХХХ Alveolar/bronchiolar adenoma Х 10 Alveolar/bronchiolar carcinoma Х Х Х Х 7 Alveolar/bronchiolar carcinoma, metastatic, lung 1 Cholangiocarcinoma, metastatic, liver 1 Hepatocellular carcinoma, metastatic, liver Х 2 Mediastinum, alveolar/bronchiolar carcinoma, 2 metastatic, lung Nose 50 ++++++++++ +++++++Trachea + ++ + ++ ++ + + + +++ + +++++ + ++ + + 50 **Special Senses System** Harderian gland 1 Adenoma 1

168

TABLE C2

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm

Number of Days on Study	7	5 0 2	5 4 9	5 5 6	5 8 3	5 9 4	6 2 9	6 5 4	6 6 5	6 8 5	6 9 8	7 2 7														
Carcass ID Number	1 9 7	1 7 7	1 8 8	1 8 5	1 8 1	1 5 9	1 5 5	1 6 2	1 7 5	1 8 0	1 9 1	1 5 1	1 5 3	1 5 7	1 6 1	1 6 4	1 6 7	1 7 1	1 7 2	1 7 8	1 8 4	1 8 6	1 8 9	1 9 3	1 9 4	
Urinary System Kidney Alveolar/bronchiolar carcinoma, metastatic, lung Urinary bladder	++	+ X +	++	+	+	++	+ X +	+	++	++	+	+	+	++	+	++	+	+	+	+	+	+	+		+ +	
Systemic Lesions Multiple organs Lymphoma malignant	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	

Individual Animal Tumor Pathology of Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm

Number of Days on Study	7 2 7	7 2 7	7 2 7	7 2 8	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9																
Carcass ID Number	1 9 8		2 0 0	1 5 2	1 5 6	1 5 8	1 6 0	1 6 3	1 6 5	1 6 6	1 6 9	1 7 0	1 7 3	1 7 4	1 7 6	1 8 3	1 8 7	1 9 2	1 9 5	1 5 4	1 6 8	1 7 9	1 8 2		1 9 6	Total Tissues/ Tumors
Urinary System Kidney Alveolar/bronchiolar carcinoma, metastatic, lung Urinary bladder	++	++	++	++	++	++	++	++	++	+	++	++	++	++	++	+ M	++	++	+	+	++	++	++		++	50 2 49
Systemic Lesions Multiple organs Lymphoma malignant	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1

Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Harderian Gland: Adenoma				
Overall rate ^a	4/50 (8%)	3/50 (6%)	4/50 (8%)	1/50 (2%)
Adjusted rate	8.5%	6.2%	8.4%	2.2%
rerminal rate	2/39 (5%)	2/45 (4%)	4/42 (10%)	1/39 (3%)
First incidence (days)	661	612	4/42 (1078) 727 (T)	727 (T)
Poly-3 test	P=0.173N	P=0.488N	P=0.637N	P=0.190N
019-5 1051	1-0.175N	1-0.4881	1-0.037N	1-0.1901
Harderian Gland: Adenoma or Carcinoma	4/50 (89/)	2/50 (69/)	5/50 (10%)	1/50 (29/)
	4/50 (8%)	3/50 (6%)	5/50 (10%)	1/50 (2%)
Adjusted rate	8.5%	6.2%	10.5%	2.2%
Cerminal rate	2/39 (5%)	2/45 (4%)	5/42 (12%)	1/39 (3%)
First incidence (days)	661 D-0 109N	612 D-0 489NI	727 (T) P=0.506	727 (T) P=0.100N
oly-3 test	P=0.198N	P=0.488N	P=0.506	P=0.190N
mall Intestine (Duodenum): Adenomatous Polyp				
Overall rate	2/50 (4%)	3/50 (6%)	1/50 (2%)	0/50 (0%)
djusted rate	4.3%	6.3%	2.1%	0.0%
erminal rate	2/39 (5%)	3/45 (7%)	1/42 (2%)	0/ <u>39</u> (0%)
irst incidence (days)	727 (T)	727 (T)	727 (T)	_
bly-3 test	P=0.108N	P=0.509	P=0.494N	P=0.244N
Small Intestine (Duodenum and Jejunum): Adenomatous	s Polvp			
Overall rate	2/50 (4%)	3/50 (6%)	1/50 (2%)	1/50 (2%)
djusted rate	4.3%	6.3%	2.1%	2.2%
erminal rate	2/39 (5%)	3/45 (9%)	1/42 (2%)	1/39 (3%)
irst incidence (days)	727 (T)	727 (T)	727 (T)	727 (T)
oly-3 test	P=0288N	P=0.509	P=0.494N	P=0.510N
mall Intestine (Jejunum): Carcinoma	5/50 (10%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
		2.1%	2.1%	0.0%
djusted rate erminal rate	10.6% 4/39 (10%)	1/45 (2%)	2.1% 1/42 (2%)	0/39 (0%)
		· /	. ,	0/39 (0%)
irst incidence (days) oly-3 test	643 P=0.016N	727 (T) P=0.098N	727 (T) P=0.099N	 P=0.034N
11y-3 (CSL	r=0.0101N	r-0.0981N	r=0.0991N	r=0.034m
mall Intestine (Duodenum and Jejunum): Carcinoma				0.000
Overall rate	5/50 (10%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
adjusted rate	10.6%	4.2%	2.1%	0.0%
erminal rate	4/39 (10%)	2/45 (4%)	1/42 (2%)	0/39 (0%)
irst incidence (days)	643	727 (T)	727 (T)	—
bly-3 test	P=0.014N	P=0.211N	P=0.099N	P=0.034N
iver: Hepatocellular Adenoma				
Overall rate	19/50 (38%)	17/50 (34%)	13/50 (26%)	18/50 (36%)
djusted rate	40.1%	35.4%	27.3%	38.5%
erminal rate	16/39 (41%)	16/45 (36%)	13/42 (31%)	14/39 (36%)
irst incidence (days)	643	637	727 (T)	472
Poly-3 test	P=0.473N	P=0.395N	P=0.134N	P=0.521N

Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite

v v I	0 v			
	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Liver: Hepatocellular Carcinoma				
Dverall rate	9/50 (18%)	10/50 (20%)	6/50 (12%)	9/50 (18%)
Adjusted rate	19.1%	20.6%	12.5%	19.3%
erminal rate	8/39 (21%)	8/45 (18%)	5/42 (12%)	5/39 (13%)
irst incidence (days)	617	601	596	583
oly-3 test	P=0.490N	P=0.527	P=0.275N	P=0.591
iver: Hepatocellular Adenoma or Carcinoma				
verall rate	24/50 (48%)	24/50 (48%)	16/50 (32%)	25/50 (50%)
djusted rate	50.2%	49.2%	33.3%	52.4%
erminal rate	20/39 (51%)	21/45 (47%)	15/42 (36%)	18/39 (46%)
irst incidence (days)	617	601	596	472
oly-3 test	P=0.516	P=0.539N	P=0.068N	P=0.499
iver: Hepatoblastoma				
overall rate	5/50 (10%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
djusted rate	10.6%	2.1%	4.2%	0.0%
erminal rate	3/39 (8%)	1/45 (2%)	2/42 (5%)	0/39 (0%)
irst incidence (days)	617	727 (T)	727 (T)	_ ` ´
oly-3 test	P=0.027N	P=0.099N	P=0.214N	P=0.034N
iver: Hepatocellular Carcinoma or Hepatoblastoma				
verall rate	12/50 (24%)	11/50 (22%)	7/50 (14%)	9/50 (18%)
djusted rate	25.4%	22.7%	14.6%	19.3%
erminal rate	10/39 (26%)	9/45 (20%)	6/42 (14%)	5/39 (13%)
irst incidence (days)	617	601	596	583
oly-3 test	P=0.239N	P=0.472N	P=0.143N	P=0.325N
iver: Hepatocellular Adenoma, Hepatocellular Carcino	oma, or Hepatobla	stoma		
Overall rate	26/50 (52%)	25/50 (50%)	17/50 (34%)	25/50 (50%)
djusted rate	54.3%	51.2%	35.4%	52.4%
erminal rate	21/39 (54%)	22/45 (49%)	16/42 (38%)	18/39 (46%)
irst incidence (days)	617	601	596	472
ly-3 test	P=0.410N	P=0.460N	P=0.046N	P=0.506N
ung: Alveolar/bronchiolar Adenoma				
overall rate	10/50 (20%)	5/50 (10%)	9/50 (18%)	10/50 (20%)
djusted rate	21.2%	10.4%	18.9%	22.0%
erminal rate	9/39 (23%)	4/45 (9%)	8/42 (19%)	10/39 (26%)
irst incidence (days)	617	644	707	727 (T)
oly-3 test	P=0.335	P=0.121N	P=0.490N	P=0.562
ung: Alveolar/bronchiolar Carcinoma				
verall rate	4/50 (8%)	1/50 (2%)	3/50 (6%)	7/50 (14%)
djusted rate	8.4%	2.1%	6.3%	15.1%
erminal rate	3/39 (8%)	1/45 (2%)	3/42 (7%)	5/39 (13%)
irst incidence (days)	526	727 (T)	727 (T)	502
Poly-3 test	P=0.074	P=0.177N	P=0.498N	P=0.249

Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Lung: Alveolar/bronchiolar Adenoma or Carcinoma				
Overall rate	13/50 (26%)	6/50 (12%)	12/50 (24%)	17/50 (34%)
Adjusted rate	27.2%	12.5%	25.2%	36.6%
Terminal rate	11/39 (28%)	5/45 (11%)	11/42 (26%)	15/39 (39%)
First incidence (days)	526	644	707	502
Poly-3 test	P=0.057	P=0.059N	P=0.503N	P=0.223
Pancreatic Islets: Adenoma				
Overall rate	3/50 (6%)	2/50 (4%)	2/50 (4%)	0/50 (0%)
Adjusted rate	6.4%	4.2%	4.2%	0.0%
erminal rate	1/39 (3%)	2/45 (4%)	2/42 (5%)	0/39 (0%)
irst incidence (days)	652	727 (T)	727 (T)	_ `
oly-3 test	P=0.093N	P=0.495N	P=0.497N	P=0.126N
Pancreatic Islets: Adenoma or Carcinoma				
Overall rate	3/50 (6%)	3/50 (6%)	2/50 (4%)	0/50 (0%)
Adjusted rate	6.4%	6.3%	4.2%	0.0%
erminal rate	1/39 (3%)	3/45 (7%)	2/42 (5%)	0/39 (0%)
irst incidence (days)	652	727 (T)	727 (T)	_ ` `
oly-3 test	P=0.078N	P=0.657N	P=0.497N	P=0.126N
Spleen: Hemangiosarcoma				
Overall rate	3/50 (6%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
djusted rate	6.4%	0.0%	4.2%	0.0%
erminal rate	2/39 (5%)	0/45 (0%)	1/42 (2%)	0/39 (0%)
irst incidence (days)	661	_	707	_
oly-3 test	P=0.131N	P=0.116N	P=0.494N	P=0.125N
All Organs: Hemangiosarcoma				
Dverall rate	7/50 (14%)	2/50 (4%)	3/50 (6%)	2/50 (4%)
djusted rate	14.9%	4.2%	6.3%	4.3%
erminal rate	5/39 (13%)	2/45 (4%)	1/42 (2%)	0/39 (0%)
irst incidence (days)	661	727 (T)	664	549
oly-3 test	P=0.083N	P=0.076N	P=0.151N	P=0.084N
All Organs: Malignant Lymphoma				
Overall rate	1/50 (2%)	1/50 (2%)	4/50 (8%)	1/50 (2%)
Adjusted rate	2.1%	2.1%	8.4%	2.2%
erminal rate	1/39 (3%)	1/45 (2%)	3/42 (7%)	0/39 (0%)
irst incidence (days)	727 (T)	727 (T)	664	594
oly-3 test	P=0.508	P=0.756N	P=0.186	P=0.756
ll Organs: Benign Neoplasms				
Overall rate	28/50 (56%)	28/50 (56%)	26/50 (52%)	29/50 (58%)
djusted rate	58.1%	57.4%	54.6%	62.0%
erminal rate	22/39 (56%)	25/45 (56%)	25/42 (60%)	25/39 (64%)
Tirst incidence (days)	617	612	707	472
Poly-3 test	P=0.385	P=0.555N	P=0.444N	P=0.427

Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm 750 ppm		1,500 ppm	3,000 ppm	
All Organs: Malignant Neoplasms					
Overall rate	27/50 (54%)	15/50 (30%)	20/50 (40%)	20/50 (40%)	
Adjusted rate	54.9%	30.9%	40.8%	41.1%	
Terminal rate	20/39 (51%)	13/45 (29%)	15/42 (36%)	11/39 (28%)	
First incidence (days)	501	601	596	502	
Poly-3 test	P=0.234N	P=0.013N	P=0.116N	P=0.121N	
All Organs: Benign or Malignant Neoplasms					
Overall rate	40/50 (80%)	35/50 (70%)	36/50 (72%)	38/50 (76%)	
Adjusted rate	80.5%	71.1%	73.5%	76.8%	
Terminal rate	30/39 (77%)	31/45 (69%)	31/42 (74%)	28/39 (72%)	
First incidence (days)	501	601	596	472	
Poly-3 test	P=0.479N	P=0.196N	P=0.279N	P=0.423N	

(T)Terminal sacrifice

⁴ Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for liver, lung, pancreatic islets, and spleen; for other tissues, denominator is number of animals necropsied.

b Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

c Observed incidence at terminal kill

^a Beneath the control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposure group is indicated by **N**.

e Not applicable; no neoplasms in animal group

Summary of the Incidence of Nonneop	lastic Lesions in Male Mice in the 2-Year Di	rinking Water Study of Sodium Nitrite ^a

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths				
Moribund	3	2	3	1
Natural deaths	8	3	5	10
Survivors				
Terminal sacrifice	39	45	42	39
Animals examined microscopically	50	50	50	50
Alimentary System				
Gallbladder	(50)	(50)	(49)	(49)
Cyst	1 (2%)	(20)	()	()
Intestine small, duodenum	(49)	(50)	(48)	(49)
Ectasia	()	2 (4%)	()	2 (4%)
Hyperplasia		1 (2%)	2 (4%)	= ()
Intestine small, jejunum	(50)	(50)	(50)	(50)
Inflammation, chronic active	()	()	1 (2%)	()
Intussusception			1 (2%)	
Peyer's patch, hyperplasia, lymphoid		2 (4%)		
Peyer's patch, inflammation, granulomatous		2 ()		1 (2%)
Intestine small, ileum	(50)	(49)	(50)	(50)
Parasite metazoan	()	()	1 (2%)	()
Liver	(50)	(50)	(50)	(50)
Basophilic focus	3 (6%)	3 (6%)	()	1 (2%)
Clear cell focus	4 (8%)	6 (12%)	10 (20%)	7 (14%)
Eosinophilic focus	12 (24%)	14 (28%)	14 (28%)	7 (14%)
Fibrosis	1 (2%)			, (-,,,)
Hematopoietic cell proliferation	1 (2/0)		1 (2%)	1 (2%)
Infarct	2 (4%)		- (-,-)	- (-,-)
Infiltration cellular, mononuclear cell	2 (4%)		3 (6%)	1 (2%)
Inflammation, chronic active	25 (50%)	25 (50%)	31 (62%)	19 (38%)
Mineralization	1 (2%)	1 (2%)		2 (4%)
Mixed cell focus	6 (12%)	2(4%)	7 (14%)	9 (18%)
Necrosis	12 (24%)	4 (8%)	6 (12%)	2 (4%)
Pigmentation	2 (4%)	(0,0)	2(4%)	1 (2%)
Vacuolization cytoplasmic	3 (6%)		3 (6%)	1 (2%)
Bile duct, cyst	- (0,0)		2 (0,0)	1 (2%)
Bile duct, hyperplasia	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Hepatocyte, karyomegaly	. (=/0)	. (2/0)	1 (2%)	- (1/0)
Mesentery	(7)	(6)	(7)	(5)
Infiltration cellular, mononuclear cell	2 (29%)	X-7	X-7	X- 7
Inflammation, granulomatous	2 (29%)		2 (29%)	
Mineralization	1 (14%)	1 (17%)	- (->>)	
Pigmentation	- ()	1 (17%)	1 (14%)	
Artery, inflammation, chronic active		1 (17%)	. (11/0)	
Fat, necrosis	4 (57%)	4 (67%)	3 (43%)	2 (40%)
Dral mucosa	(26)	(27)	(17)	(19)
Gingival, foreign body	26 (100%)	27 (100%)	17 (100%)	19 (100%)
Gingival, inflammation, chronic active	21 (81%)	22 (81%)	14 (82%)	11 (58%)
Pancreas	(49)	(50)	(50)	(50)
Fibrosis	1 (2%)	(20)		
Infiltration cellular, mononuclear cell	2 (4%)	2 (4%)	3 (6%)	2 (4%)
Inflammation, chronic active	1 (2%)	- (1/0)	5 (0/0)	- (170)
Acinus, atrophy	1 (2%) 1 (2%)	1 (2%)		
romas, au opiny	1 (270)	1 (270)		

^a Number of animals examined microscopically at the site and the number of animals with lesion

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Alimentary System (continued)				
Pancreas (continued)	(49)	(50)	(50)	(50)
Acinus, hypertrophy	(47)	(50)	1 (2%)	(50)
Artery, inflammation, chronic active		1 (2%)	1 (270)	
Salivary glands	(50)	(50)	(50)	(50)
Atrophy	1 (2%)	(23)	(23)	(20)
Infiltration cellular, mononuclear cell	27 (54%)	28 (56%)	33 (66%)	32 (64%)
Mineralization	1 (2%)	20 (3070)	55 (0070)	1 (2%)
tomach, forestomach	(50)	(50)	(50)	(50)
Ulcer	3 (6%)	(50)	1 (2%)	1 (2%)
Epithelium, hyperplasia	6 (12%)	1 (2%)	2 (4%)	3 (6%)
Epithelium, inflammation, chronic active	2 (4%)	1 (270)	2 (4%)	1 (2%)
tomach, glandular	(50)	(50)	(50)	(50)
Mineralization	(50)	(50)	1 (2%)	(50)
Epithelium, erosion			1 (2%) 1 (2%)	
Epithelium, hyperplasia			2 (4%)	10 (20%)
Epithelium, necrosis			2 (478)	1 (2%)
Glands, ectasia	12 (24%)	18 (36%)	16 (32%)	1 (2%) 14 (28%)
Sooth	(5)	(5)		
Malformation	5 (100%)	4 (80%)	(4) 3 (75%)	(1) 1 (100%)
Wanonnation	5 (10076)	4 (8076)	3 (7376)	1 (10076)
Cardiovascular System				
Blood vessel	(50)	(50)	(50)	(50)
Aorta, inflammation, chronic active		1 (2%)		
eart	(50)	(50)	(50)	(50)
Cardiomyopathy		(())		1 (2%)
Inflammation, chronic active		1 (2%)		- (-, -, -)
Mineralization	3 (6%)	- (-/-)	1 (2%)	
Artery, inflammation, chronic active		2 (4%)		
Atrium, thrombosis	1 (2%)	- (113)		
Endocrine System	(50)	(50)	(50)	(50)
Adrenal cortex Accessory adrenal cortical nodule	(50)	(50)	(50) 6 (12%)	(50)
	2 (4%)			4 (8%)
Degeneration, fatty Pigmentation	1 (2%)	1 (2%)	1 (2%)	
Capsule, hyperplasia	46 (92%)	42 (84%)	40 (80%)	40 (80%)
	40 (9276)	42 (84%) 1 (2%)	40 (8078)	
Zona fasciculata, hyperplasia	19 (2(0/)	1(270)	14 (280/)	1 (2%)
Zona fasciculata, hypertrophy	18 (36%)	24 (48%)	14 (28%)	21 (42%)
drenal medulla	(50)	(50)	(50)	(50)
Hyperplasia	(50)	1 (2%)	(50)	(50)
lets, pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	46 (92%)	47 (94%)	49 (98%)	44 (88%)
arathyroid gland	(36)	(48)	(38)	(41)
Cyst	(10)	(10)	1 (3%)	(47)
ituitary gland	(49)	(49)	(47)	(47)
Pars distalis, cyst	3 (6%)	2 (4%)	2 (4%)	4 (9%)
Pars distalis, hyperplasia		1 (2%)		
hyroid gland	(50)	(50)	(50)	(50)
Inflammation, chronic active		1 (2%)		
Follicle, cyst	4 (8%)	1 (2%)	1 (2%)	2 (4%)
Follicular cell, hyperplasia		1 (2%)		

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
General Body System None				
Genital System				
Coagulating gland		(1)		
Inflammation, chronic active		1 (100%)		
Epididymis	(50)	(50)	(50)	(50)
Granuloma sperm	1 (2%)	1 (2%)		1 (2%)
Infiltration cellular, mononuclear cell	21 (42%)	22 (44%)	25 (50%)	25 (50%)
Infiltration cellular, mixed cell				1 (2%)
Inflammation, chronic active			1 (2%)	
Preputial gland	(50)	(50)	(49)	(50)
Atrophy	1 (2%)		1 (2%)	
Infiltration cellular, mononuclear cell	27 (54%)	28 (56%)	29 (59%)	25 (50%)
Inflammation, chronic active	7 (14%)	8 (16%)	4 (8%)	4 (8%)
Inflammation, suppurative	22 (660/)	22 (640/)	2 (4%)	20 (700/)
Duct, cyst	33 (66%)	32 (64%)	33 (67%)	39 (78%)
Prostate Infiltration cellular, mononuclear cell	(50) 15 (30%)	(50) 22 (44%)	(49) 29 (59%)	(50)
Inflammation, chronic active	13 (30%) 1 (2%)	22 (44%) 2 (4%)	29 (39%) 3 (6%)	28 (56%)
Inflammation, suppurative	1 (2%) 1 (2%)	2 (4/0)	1 (2%)	
Artery, inflammation, chronic active	1 (270)	2 (4%)	1 (270)	
Seminal vesicle	(50)	(50)	(50)	(50)
Congestion	(30)	(30)	(50)	1 (2%)
Dilatation	2 (4%)	2 (4%)		1 (270)
Infiltration cellular, mononuclear cell	= (1/0)	1 (2%)	1 (2%)	1 (2%)
Inflammation, chronic active	2 (4%)			
Inflammation, suppurative	()		1 (2%)	
Bilateral, dilatation	1 (2%)	1 (2%)	1 (2%)	
Testes	(50)	(50)	(50)	(50)
Mineralization				2 (4%)
Germinal epithelium, atrophy		1 (2%)		1 (2%)
Germinal epithelium, necrosis			1 (2%)	
Interstitial cell, hyperplasia			2 (4%)	
Hematopoietic System	(50)	(50)	(10)	(50)
Bone marrow	(50)	(50)	(49)	(50)
Hemorrhage			1 (2%)	
Thrombosis Myalaid call hymorphysic			1 (2%)	2 (40/)
Myeloid cell, hyperplasia	(1)	(1)	(2%)	2 (4%)
Lymph node Lumbar, hyperplasia, plasma cell	(1)	(1)	(3) 1 (33%)	(5)
Mediastinal, hemorrhage			1 (3370)	1 (20%)
Mediastinal, inflammation, granulomatous				1 (20%)
Renal, hyperplasia, lymphoid		1 (100%)		1 (2070)
Renal, hyperplasia, plasma cell		1 (10070)	1 (33%)	
Lymph node, mandibular	(47)	(50)	(47)	(48)
Hyperplasia, lymphoid	2 (4%)	1 (2%)	1 (2%)	()

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Hematopoietic System (continued)				
Lymph node, mesenteric Ectasia	(49)	(49) 1 (2%)	(48)	(49)
Hematopoietic cell proliferation Hyperplasia, plasma cell		2 (4%)	1 (2%)	1 (2%)
Hyperplasia, lymphocyte Infiltration cellular, eosinophil	1 (2%)	1 (2%)	1 (2%)	1 (20/)
Inflammation, chronic active Inflammation, granulomatous	(- 0)		1 (2%)	1 (2%) 2 (4%)
Spleen Hematopoietic cell proliferation	(50) 22 (44%)	(50) 11 (22%)	(50) 14 (28%)	(50) 20 (40%)
Hyperplasia, lymphoid	1 (2%)		1 (2%)	
Thymus	(37) (249()	(39)	(38)	(42) (219()
Cyst Hemorrhage	9 (24%) 1 (3%)	14 (36%)	16 (42%)	9 (21%)
Inflammation, granulomatous	1 (3%)			
Necrosis	1 (3%)			
Integumentary System				
Skin Court anithalial inclusion	(50)	(50)	(50)	(50)
Cyst epithelial inclusion Inflammation, chronic active	1 (2%) 4 (8%)	1 (2%)	1 (2%)	2 (4%)
Ulcer	3 (6%)	1 (2%)	1 (2%) 1 (2%)	2 (4%)
Epidermis, hyperplasia	2 (4%)	1 (2%)	1 (2%)	
Subcutaneous tissue, infiltration cellular, mononuclear cell			1 (2%)	
Musculoskeletal System				
Bone	(50)	(50)	(49)	(50)
Cranium, hyperostosis	1 (2%)			
Nervous System	(50)	(50)	(50)	(50)
Brain Neuron, necrosis	(50) 2 (4%)	(50)	(50)	(50)
	2 (470)			
Respiratory System	(50)	(50)	(50)	(50)
Hemorrhage	(30)	(50)	(50)	1 (2%)
Inflammation, chronic	1 (2%)			(-,-)
Inflammation, chronic active	1 (2%)	1 (2%)	1 (2%)	
Mineralization	4 (8%)		3 (6%)	,
Necrosis	2 ((0/)	2 (40/)	((100/)	2 (4%)
Alveolar epithelium, hyperplasia Alveolus, infiltration cellular, histiocyte	3 (6%) 3 (6%)	2 (4%) 1 (2%)	6 (12%) 2 (4%)	9 (18%) 3 (6%)
Interstitium, inflammation, chronic active	5 (070)	1 (2/0)	2 (4%) 1 (2%)	5 (070)
Mediastinum, inflammation, chronic active		1 (2%)	- (-,,)	
Mediastinum, inflammation, suppurative			1 (2%)	
Mediastinum, pigmentation		1 (2%)		

TABLE C4

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Respiratory System (continued)				
Nose	(50)	(50)	(49)	(50)
Foreign body	2 (4%)	1 (2%)	3 (6%)	1 (2%)
Inflammation, chronic active	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Inflammation, suppurative	1 (2%)		1 (2%)	()
Nasolacrimal duct, inflammation, suppurative		1 (2%)		
Special Senses System				
Eye	(1)			
Atrophy	1 (100%)			
Harderian gland	(5)	(4)	(6)	(1)
Hyperplasia	<- /	1 (25%)	(-)	× /
Inflammation, chronic		1 (25%)		
Urinary System Kidney	(50)	(50)	(50)	(50)
Hydronephrosis			1 (2%)	1 (2%)
Infarct	11 (22%)	10 (20%)	9 (18%)	13 (26%)
Infiltration cellular, mononuclear cell	42 (84%)	41 (82%)	41 (82%)	45 (90%)
Infiltration cellular, plasma cell	2 (40/)	1 (20/)	1 (2%)	1 (20/)
Inflammation, chronic active	2(4%)	1 (2%)	1 (20/)	1 (2%)
Inflammation, suppurative	1 (2%)	2(60/)	1 (2%)	
Metaplasia, osseous Mineralization	2 (4%) 48 (96%)	3 (6%) 50 (100%)	18 (06%)	46 (020/)
Necrosis	48 (96%) 1 (2%)	50 (100%) 1 (2%)	48 (96%)	46 (92%)
	44 (88%)	49 (98%)	45 (90%)	12 (840/)
Nephropathy Pigmentation	44 (88%) 1 (2%)	49 (9070)	43 (90%)	42 (84%)
Artery, inflammation, chronic active	1 (270)	2 (4%)	1 (2%)	
Cortex, cyst	5 (10%)	2 (4%) 9 (18%)	6 (12%)	4 (8%)
Renal tubule, hypertrophy, focal	5 (1070)	7 (10/0)	0 (1270)	4 (8%) 1 (2%)
Urinary bladder	(50)	(50)	(50)	(49)
Infiltration cellular, mononuclear cell	6 (12%)	(30)	16 (32%)	10 (20%)
Inflammation, suppurative	0 (12/0)	1 (2%)	10 (3270)	10 (20%)

APPENDIX D SUMMARY OF LESIONS IN FEMALE MICE IN THE 2-YEAR DRINKING WATER STUDY OF SODIUM NITRITE

TABLE D1	Summary of the Incidence of Neoplasms in Female Mice	
	in the 2-Year Drinking Water Study of Sodium Nitrite	180
TABLE D2	Individual Animal Tumor Pathology of Female Mice	
	in the 2-Year Drinking Water Study of Sodium Nitrite	184
TABLE D3	Statistical Analysis of Primary Neoplasms in Female Mice	
	in the 2-Year Drinking Water Study of Sodium Nitrite	202
TABLE D4	Historical Incidence of Forestomach Neoplasms in Control Female B6C3F ₁ Mice	206
TABLE D5	Summary of the Incidence of Nonneoplastic Lesions in Female Mice	
	in the 2-Year Drinking Water Study of Sodium Nitrite	207

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite^a

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Dismosition Cummour				
Disposition Summary Animals initially in study	50	50	50	50
Early deaths	50	50	50	50
Moribund	1	7	2	4
Natural deaths	9	9	11	5
Survivors				
Terminal sacrifice	40	34	37	41
Animals examined microscopically	50	50	50	50
Alimentary System				
Gallbladder	(48)	(50)	(50)	(49)
Intestine large, rectum	(49)	(50)	(50)	(50)
Fibrosarcoma, metastatic, skin			1 (2%)	
Intestine small, jejunum	(50)	(50)	(50)	(50)
Intestine small, ileum	(49)	(49)	(50)	(50)
Leiomyosarcoma, metastatic, uterus			1 (2%)	
Liver	(50)	(50)	(50)	(50)
Carcinoma, metastatic, islets, pancreatic		1 (2%)		
Fibrosarcoma, metastatic, skin			1 (2%)	
Hemangiosarcoma			1 (2%)	
Hepatocellular carcinoma	2 (4%)	2 (4%)	4 (8%)	1 (2%)
Hepatocellular adenoma	9 (18%)	6 (12%)	2 (4%)	5 (10%)
Hepatocellular adenoma, multiple		1 (2%)	1 (2%)	1 (2%)
Hepatocholangiocarcinoma	1 (2%)	1 (2%)		
Mesentery	(14)	(19)	(17)	(13)
Carcinoma, metastatic, islets, pancreatic		1 (5%)	1 ((0))	
Fibrosarcoma, metastatic, skin	1 (50.1)	1 (5%)	1 (6%)	
Hepatocholangiocarcinoma, metastatic, liver	1 (7%)	1 (5%)	1 ((0))	
Osteosarcoma, metastatic, bone			1 (6%)	
Sarcoma	(50)	(50)	1 (6%)	(50)
Pancreas	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, metastatic, liver	1 (2%)	1 (2%)	(49)	(50)
Salivary glands Schwannoma malignant, metastatic, skin	(49)	(49)	(48)	(50) (50)
Schwannoma malignant, metastatic, skin Stomach, forestomach	(50)	(50)	(50)	1 (2%)
Stomacn, forestomacn Squamous cell carcinoma	(50)	(50)	(50)	(50) 2 (4%)
Squamous cell papilloma	1 (2%)		1 (2%)	2 (476) 3 (6%)
Stomach, glandular	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, metastatic, liver		1 (2%)		(00)
Cardiovacaular System				
Cardiovascular System Heart	(50)	(50)	(50)	(50)
.10411	(50)	(30)	(50)	(50)
Endocrine System				
Adrenal cortex	(50)	(50)	(49)	(50)
Fibrosarcoma, metastatic, skin			1 (2%)	
Hepatocholangiocarcinoma, metastatic, liver	1 (2%)			
Osteosarcoma, metastatic, bone			1 (2%)	
Adrenal medulla	(50)	(50)	(48)	(49)
Pheochromocytoma benign		1 (2%)	1 (2%)	

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Endocrine System (continued)				
Islets, pancreatic	(50)	(50)	(50)	(50)
Adenoma	(50)	(50)	3 (6%)	(50)
Carcinoma		1 (2%)	5 (070)	
Pituitary gland	(48)	(47)	(43)	(48)
Pars distalis, adenoma	1 (2%)	3 (6%)	()	1 (2%)
Thyroid gland	(49)	(49)	(48)	(49)
Bilateral, follicular cell, adenoma		1 (2%)		
Follicular cell, carcinoma				1 (2%)
General Body System				
Peritoneum		(1)		(1)
Hepatocholangiocarcinoma, metastatic, liver		1 (100%)		. /
		~ /		
Genital System				
Clitoral gland	(50)	(49)	(50)	(48)
Ovary	(47)	(49)	(50)	(49)
Cystadenoma		2 (4%)	1 (2%)	3 (6%)
Granulosa cell tumor benign			1 (2%)	
Hemangioma		2 (4%)	1 (2%)	1 (2%)
Hepatocholangiocarcinoma, metastatic, liver	1 (2%)			1 (20)
Luteoma			1 (20())	1 (2%)
Osteosarcoma, metastatic, bone		1 (20()	1 (2%)	
Teratoma benign	(50)	1 (2%)	(50)	(50)
Jterus	(50)	(50)	(50)	(50)
Leiomyosarcoma Polyp stromal		3 (6%)	1 (2%)	1 (2%)
		5 (070)		1 (270)
Hematopoietic System				
Bone marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)		
Lymph node	(7)	(7)	(8)	(4)
Mediastinal, hepatocholangiocarcinoma,				
metastatic, liver	1 (14%)	1 (14%)		
Mediastinal, sarcoma, metastatic, skin	1 (14%)			
Lymph node, mandibular	(47)	(46)	(48)	(48)
ymph node, mesenteric	(50)	(49)	(47)	(49)
Spleen	(49)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)	2 (4%)	
Thymus	(46)	(47)	(44)	(46)
Hepatocholangiocarcinoma, metastatic, liver	1 (2%)			
Thymoma benign	1 (2%)			
Integumentary System				
Skin	(50)	(50)	(50)	(50)
Subcutaneous tissue, fibrosarcoma	(50)	5 (10%)	1 (2%)	2 (4%)
Subcutaneous tissue, hemangiosarcoma	1 (2%)	5 (10/0)	1 (270)	- (170)
Subcutaneous tissue, sarcoma	1 (2%)			
Subcutaneous tissue, schwannoma malignant	1 (2/0)			2 (4%)
Saccadineous dissue, sellwannonna manghant				∠ (¬/0)

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Musculoskeletal System				
Bone	(50)	(50)	(50)	(50)
Femur, osteosarcoma			1 (2%)	1 (20/)
Vertebra, osteosarcoma Skeletal muscle	(3)	(2)	(1)	1 (2%) (3)
Carcinoma, metastatic, islets, pancreatic	(3)	1 (50%)	(1)	(3)
Hepatocholangiocarcinoma, metastatic, liver	1 (33%)			
Osteosarcoma, metastatic, bone			1 (100%)	
Nervous System				
Brain	(50)	(50)	(49)	(50)
Spinal cord				(2)
Meninges, meningioma malignant				1 (50%)
Respiratory System				
Lung	(50)	(50)	(50) (40()	(50)
Alveolar/bronchiolar adenoma Alveolar/bronchiolar adenoma, multiple	1 (2%)	4 (8%)	2 (4%) 1 (2%)	5 (10%)
Alveolar/bronchiolar carcinoma		3 (6%)	2 (4%)	1 (2%)
Carcinoma, metastatic, uncertain primary site		1 (2%)	2 (470)	1 (270)
Fibrosarcoma, metastatic, skin		2 (4%)	1 (2%)	
Hepatocellular carcinoma, metastatic, liver	1 (2%)	. ,	1 (2%)	1 (2%)
Hepatocholangiocarcinoma, metastatic, liver	1 (2%)	1 (2%)		
Osteosarcoma, metastatic, bone			1 (2%)	1 (2%)
Sarcoma, metastatic, skin	1 (2%)			1 (29/)
Schwannoma malignant, metastatic, skin				1 (2%)
Special Senses System Harderian gland		(1)	(1)	(2)
Adenoma		1 (100%)	(1)	2 (100%)
Carcinoma			1 (100%)	
Urinary System				
Kidney	(50)	(50)	(50)	(50)
Fibrosarcoma, metastatic, skin			1 (2%)	
Hepatocholangiocarcinoma, metastatic, liver		1 (2%)		
Jrinary bladder	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, metastatic, liver		1 (2%)		
Systemic Lesions	(50)	(50)	(70)	(50)
Multiple organs ^b	(50)	(50) 10 (20%)	(50)	(50)
Lymphoma malignant	7 (14%)	10 (20%)	8 (16%)	6 (12%)

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Neoplasm Summary				
Total animals with primary neoplasms ^c	21	32	31	32
Total primary neoplasms	25	49	36	41
Total animals with benign neoplasms	13	22	14	20
Total benign neoplasms	13	25	14	24
Total animals with malignant neoplasms	12	20	19	17
Total malignant neoplasms	12	24	22	17
Total animals with metastatic neoplasms	3	6	4	3
Total metastatic neoplasms	11	15	13	4
Total animals with malignant neoplasms				
of uncertain primary site		1		

Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms а b

c

	4	5	5	5	5	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	5	4	6	8	8	1	2	3	6	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
	6	7	5	0	6	5	2	1	3	6	8	8	8	9	9	9	9	9	9	9	9	9	9	9	9	
	2	2	2	2	2	2	2	2	2	r	2	2	2	2	r	2	2	2	2	2	2	2	2	2	r	
Carcass ID Number	2	1	1	0	1	2	2	2		0	0	2	4		0		0	1	1	1	2	2	2	2		
	2	3	0						9																	
Alimontowy System																										
Alimentary System Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Ň	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, rectum	Ń	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	111	, ,				' -	' +							- -	- -	- -	- -	- -		- -		- -	- -	- -	+	
	- -	+ +	- -	+ +	+	+ +	+ +	- -	+ +	+	+	+	+	+ +	+	+ +	+	+	- -	+ +	+	+	+	+ +	т _	
Intestine small, jejunum	T M	- -	- -	- -	-	- -	т	-	- -	-	- -	+	- -	- -	+	- -	- -	- -	- -	-	- -	-	- -	- -	+	
Intestine small, ileum	IVI	+	+	+	+	++	++	++	+	++	++	++	++	- -	++	++	++	++	+	+	+	+	+		++	
Liver	+	+	+	+	+	+	Ŧ	Ŧ	+	+	+	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	+	+	+	+	Ŧ	
Hepatocellular carcinoma					v						v						v				v					
Hepatocellular adenoma					Х				v		Х						Х				Х					
Hepatocholangiocarcinoma									X																	
Mesentery		+					+	+	+			+		+					+			+		+		
Hepatocholangiocarcinoma, metastatic, liver									Х																	
Oral mucosa																										
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Hepatocholangiocarcinoma, metastatic, liver									Х																	
Salivary glands	+	+	+	+	+	+			М			+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Squamous cell papilloma																										
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Tongue									М																	
Cardiovascular System		_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_		
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Endocrine System Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Hepatocholangiocarcinoma, metastatic, liver		'			'	'		•	x	ŕ	'									'	'	'	'			
Adrenal medulla	ـــ	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Islets, pancreatic	т с	T' 	т _	т 	т -	г -	+	+	r T	Ļ	г -	+	+	- +	+	+	+	+	+	+	т 	т -	⊤ ⊥	т .⊥	+	
	+	T M	т 	т 	-T _!	 J	+		+ M	M	-			т M							-T _!	т .!	т			
Parathyroid gland	+	M	- 	- 	- -	Ţ	+	++	+	+	+	+				+	+	M +		++		++	M +			
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	
Pars distalis, adenoma						,			14		,						+			,				X		
Thyroid gland	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
General Body System																										
None																										
Genital System																										
Clitoral gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Ovary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Hepatocholangiocarcinoma, metastatic, liver	F	1.							X	1		1	1		'	'				'						
Oviduct									Λ																	
Uterus	J	1	<u>т</u>	<i>т</i>	+	+	+	+	+	-	1	+	+	+	+	+	+	+	+	+	<u>_</u> _	<u> </u>	<u> </u>	<u>ـــ</u>	+	
Oterus	+	+	+	+	+	+	T	T	+	+	+	T	T	-	T	T	-	T	-	-	+	+	+	+	-	

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm

+: Tissue examined microscopically A: Autolysis precludes examination M: Missing tissue I: Insufficient tissue X: Lesion present Blank: Not examined

7 Number of Days on Study 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 9 9 9 9 9 9 9 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 Total **Carcass ID Number** 3 3 3 4 4 4 4 4 0 1 1 $1\quad 2\quad 2\quad 2\quad 2\quad 2$ 3 3 3 3 4 4 4 4 5 Tissues/ 9 3 4 0 4 6 7 8 6 2 4 5 0 3 6 7 0 5 7 8 1 2 3 5 0 Tumors **Alimentary System** Esophagus + + 50 + + + + + + + Gallbladder Μ 48 Intestine argeç olon 50 + ++ + + Intestine arger ectum 49 Intestine large, cecum + 49 50 Intestine small, duodenum + +Intestine small, jejunum 50 + + + 49 Intestines malli leum + + + + + + + + ++ ++ + + + Liver + + 50 Х Hepatocellular carcinoma Х 2 9 Hepatocellular adenoma Х Х Х Х Х Hepatocholangiocarcinoma 1 Mesentery ++ 14 Hepatocholangiocarcinoma, metastatic, liver 1 Oral mucosa 1 Pancreas 50 Hepatocholangiocarcinoma, metastatic, liver 1 + 49 Salivaryg lands Stomachf orestomach + + 50 Squamous cell papilloma Х 1 Stomach, glandular + 50 ++ + +Tongue **Cardiovascular System** Blood vessel + 50 + + ++ + + + Heart + + 50 + + + + + + **Endocrine System** Adrenal cortex 50 Hepatocholangiocarcinoma, metastatic, liver 1 Adrenal medulla 50 Islets, pancreatic 50 ++ +++ + +++ Parathyroid gland + + + + 33 + + М + МММ + М Μ + Μ + М Μ Pituitary gland + +М 48 Pars distalis, adenoma 1 Thyroid gland 49 + + +++ + ++ $^+$ + $^{+}$ + + $^+$ +++ + + ++ + **General Body System** None **Genital System** Clitoral gland 50 Ovary 47 + M M Μ Hepatocholangiocarcinoma, metastatic, liver 1 Oviduct 1 Uterus + + + + + + + $^+$ + $^+$ $^+$ $^+$ + + $^+$ + + + ++ + + + + 50

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm

185

Individual Animal Tumor Pathology o	f Fen	nal	e M	lice	e in	th	e 2	-Y	ear	·D	rin	iki	ng	Wa	ate	r S	tu	dy	of	So	diu	m	Ni	tri	te: 0	ррт	
Number of Days on Study	4 5 6	5 4 7	5 6 5	8	5 8 6	6 1 5	2	3	6 6 3	1	7 2 8	7 2 8	7 2 8	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9									
Carcass ID Number	2 3 2	2 1 3	2 1 0	2 0 2	2 1 8	2 3 6		2 1 7		2 0 1	2 0 3	2 2 4	2 4 9	2 0 4	2 0 5	2 0 7		2 1 1	2 1 6	2 1 9	2 2 2	2 2 5	2 2 8	2 2 9			
Hematopoietic System Bone marrow Lymph node Mediastinal, hepatocholangiocarcinoma,	+	+	+	+ +	+ +	+	+	+ +	+ + X	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+		
metastatic, liver Mediastinal, sarcoma, metastatic, skin Lymph node, mandibular Lymph node, mesenteric Spleen Thymus Hepatocholangiocarcinoma, metastatic, liver Thymoma benign	+ + + +	+ + M +	+ + + +	+ + + +	X H + M	+ +		+ + +	M +	+ +	+ +	+ + +	+ + +	+ + +	++++++	+++++++	+ + +	+ + +	+ + +	+ + +	+ + H M	++++++	++++++	+ + + +	+ + +		
Integumentary System Mammarg land Skin Subcutaneous tissue, hemangiosarcoma Subcutaneous tissue, sarcoma	+ +	++	+++	+ +	+ + X	+ +	+ +	M +	+++	+ +	+ +	+++	+++	+ +	+ +	+ +	+++	+++	+++	+++	+ +	+++	+ +	++	+ +		
Musculoskeletal System Bone Skeletal muscle Hepatocholangiocarcinoma, metastatic, liver	+	+	+	+++	+	+	+	+	+ + X	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Respiratory System Lung Alveolar/bronchiolar adenoma Hepatocellular carcinoma, metastatic, liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+		
Hepatocholangiocarcinoma, metastatic, liver Sarcoma, metastatic, skin Nose Trachea	+ +	+ +	+++	+++	X + +	+++	+++	+++	X + M	+++	+++	+++	+++	+++	+ +	+ +	+++	+++	+++	+++	++	+++	+++	+++	+ +		
Special Senses System None																											
Urinary System Kidney Urinary bladder	+++	+++	+++	+++	+ +	+++	+++	+++	++++	+ +	+++	+++	+++	+++	+ +	+ +	+++	+++	+++	+++	+++	++	+++	+++	+ +		
Systemic Lesions Multiple organs Lymphoma malignant	+	+	+	+ X	+	+	+ X	+ X	+	+	+ X	+	+	+ X	+	+	+	+	+	+	+	+	+	+ X	+		

 TABLE D2

 Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 0 ppm

						-	_	_	_	_	_		_	_					-					_	
	7	7	7	7	7	7	7	7	7	7	7 ′	7 '	77	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	2	2	2	2	2	2 9	2 9	2 9			3 1 0 (33 00		3	3	3	3	3	3	3	3	3	3 0	
	-					-	-	-	-	-				-	-	-			-	-	-		-		
Carcass ID Number	2	2	2	2	2	2							22					2	2		2	2	2		Total Tissues/
Carcass ID Number	3	3 4	3 9	4 0	4 4	4 6	4 7		-				22 03				3 5	3 7	3 8	4 1	4 2	4 3	4 5		Tumors
Hematopoietic System																									
Bone marrow	+	+	+	+	+	+	+	+	+	+	+ -	+ •	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Lymph node															+			+							7
Mediastinal, hepatocholangiocarcinoma, metastatic, liver																									1
Mediastinal, sarcoma, metastatic, skin																									1
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+ -	+ •	+ +	- +	+	+	+	+	+	+	+	+	+	+	47
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+ -	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Spleen	+	+	+	+	+	+	+	+	+	+	+ -	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	49
Thymus	+	М	+	+	+	+	+	М	+	+	+ -	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	46
Hepatocholangiocarcinoma, metastatic, liver Thymoma benign														Х											1 1
Integumentary System																									
Mammaryg land	+	+	+	+	+	+	+	+	+	+	+ -	+ .	+ +	- +	+	+	+	+	+	+	+	+	+	+	49
Skin	+	+	+	+	+	+	+	+	+	+	+ .	+ .	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Subcutaneous tissue, hemangiosarcoma							Х																		1
Subcutaneous tissue, sarcoma																									1
Musculoskeletal System																									
Bone	+	+	+	+	+	+	+	+	+	+	+ -	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Skeletal muscle																									3
Hepatocholangiocarcinoma, metastatic, liver																									1
Nervous System																									50
Brain	+	+	+	+	+	+	+	+	+	+	+ •	+ •	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Respiratory System																									-
Lung	+	+	+	+	+	+	+	+	+	+	+ -	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma Hepatocellular carcinoma, metastatic, liver																			Х						1
Hepatocholangiocarcinoma, metastatic, liver																			л						1
Sarcoma, metastatic, skin																									1
Nose	+	+	+	+	+	+	+	+	+	+	+ -	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	50
Trachea	+	+	+	+	+	+	+	+	+	+	+ •	+ •	+ +	- +	+	+	+	+	+	+	+	+	+	+	49
Special Senses System																									
None																									
U rinary System Kidney					J	J	ч	-	_L	-		L	L .			. 1	.1			.1	.1	. 1		-	50
Urinary bladder	+	+ +	+ +	+ +	+ +	+ +	+ +	+	+	+	+ -	+ ·	 + -	- +	+	+ +	+ +	+	+ +	+	+	+ +	+ +	+ +	50 50
	7"	Τ'	Τ'	т	Г	Г	I.	17	1.	1			. 7	-1	Τ.	Τ'	т	г	Г	Т	т	Τ'	Τ'	1-	50
Systemic Lesions Multiple organs					J	J	ч	-	_L	-		L	L .			+	+	+	+		.1			-	50
viulupie organs	+	+	+	+	+	+	τ	Ŧ	Ŧ	-	- ·	- ·	r 1	- +	+	+	+	+	+	+	+	+	+	Ŧ	50 7

	1	6	6	6	6	6	6	6 (66	5 6	5 6	6	6	7	7	7	7	7	7	7	7	7	7	7	
Noushan of David on Study.	4	0	4	6									_		0	2	2	2	2	2	2	2	2	2	
Number of Days on Study	8 4	0 5	4	5 0	5	5 1		5 :		56 47	57 73	3	8	0 6	0 9	2	2 8	2 8	2	28	2	2	2 9	2	
	т	5	5	0	1	1	2	<i>)</i>	/ -	Ŧ /	/)	5	5	0	,	0	0	0	0	0	0	0	,	,	
	2	2	2	2	2	2	2	2 2	2 2	2 2	2 2	2	2	2	2	2	2	2	2	2	2	2	2	2	
Carcass ID Number	5	6	7	7	5	8	6	7 3	86	5 7	76	9	7	9	8	5	5	5	7	8	9	9	5	5	
	7	9	7	4	4	8	4	2	9 7	7 5	58	3	1	4	0	5	8	9	9	2	1	6	2	6	
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+ -	+ -	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder	+	+	+	+	+	+	+	+ -	+ -	+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon	+	+	+	+	+	+	+	+ -	+ +	+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, rectum	+	+	+	+	+	+	+	+ -	+ +	+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	+	+	+	+	+	+	+	+ -	+ +	+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	M	+	+	+	+	+	M	+ -		+ +	 		+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum	111	+ +	+ +	- -	+ +	+ +	1VI	т - 			г т ц ц	- T	- T	+ +	+	+	+ +	+ +							
		т 1	т 1	т 1	- -	T	т 1	- -	T 7			- T	- T	- T	т 1	- -	- -	т 1	т 1	т 1	т 1	- -	т 1	+	
intestine small, ileum	- -	- -	- -	- -	- -	- -	-	- -	+ -	+ +	 + +	- +	+	+	+	+	+	- -	- -	- -	-	- -	- -	- -	
Liver	+	+	+	+	+	+	+	+ -			+ +	- +	+	+	+	+	+	+	+	+	+	+	+	÷	
Carcinoma, metastatic, islets, pancreatic									2	X						37									
Hepatocellular carcinoma											7	X				Х									
Hepatocellular adenoma										У	X	Х													
Hepatocellular adenoma, multiple																									
Hepatocholangiocarcinoma									X																
Mesentery			+	+	+			-		+ +	+		+	+			+			+					
Carcinoma, metastatic, islets, pancreatic									2	X															
Fibrosarcoma, metastatic, skin													Х												
Hepatocholangiocarcinoma, metastatic, liver								2	X																
Pancreas	+	+	$^+$	+	+	+	+	+ -	+ -	+ +	+ +	- +	+	+	$^+$	$^+$	$^+$	$^+$	+	+	+	+	+	+	
Hepatocholangiocarcinoma, metastatic, liver								2	X																
Salivary glands	+	$^+$	$^+$	М	+	+	+	+ •	+ +	+ +	+ +	+	+	$^+$	$^+$	$^+$	$^+$	$^+$	+	$^+$	+	$^+$	+	+	
Stomach, forestomach	+	+	+	+	+	+	+	+ -	+ -	+ +	+ +	+	+	+	+	$^+$	$^+$	+	+	+	+	+	+	+	
Stomach, glandular	+	+	+	+	+	+	+	+ -	+ +	+ +	+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	
Hepatocholangiocarcinoma, metastatic, liver								2	X																
Cardiovascular System																									
Blood vessel	+	+	+	+	+	+	+	+ -	+ -	+ -	+ +		+	+	+	+	+	+	+	+	+	+	+	+	
Heart		т 1	т 1	т 1	- -	T	т 1	- -	T 7			- +	- T	+	+	- -	+	т 1	т 1	т 1	т 1	- -	т 1	- -	
neart	т	т	т	Ŧ	Ŧ	Ŧ	Ŧ	Τ .	Τ -			· +	т	Ŧ	т	Ŧ	Τ	т	т	т	т	Ŧ	т	т	
Endocrine System																									
Adrenal cortex	+	$^+$	$^+$	$^+$	+	+	+	+ -	+ +	+ +	+ +	- +	+	$^+$	$^+$	$^+$	$^+$	$^+$	+	+	+	$^+$	+	+	
Adrenal medulla	+	+	+	+	+	+	+	+ -	+ +	+ +	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	
Pheochromocytoma benign																					Х				
Islets, pancreatic	+	+	+	+	+	+	+	+ -	+ +	+ +	+ +	+ +	+	+	+	+	+	+	+	+		+	+	+	
Carcinoma										X															
Parathyroid gland	+	+	+	М	М	М	М	м -			A +	. +	М	+	+	+	М	+	М	+	М	+	+	+	
Pituitary gland								+ -			+ +					+	+		+			+			
Pars distalis, adenoma	111		X			•															•				
Thyroid gland	+	+	л +	+	+	+	+	+ -	+ -	+ -	+ -+		+	+	+	+	+	+	+	+	+	+	+	+	
Bilateral, follicular cell, adenoma	1-		'	'	1	'					, т		1.	1	1	1	'	'	'	'	'	1	'		
Communal Barder Secretaria																									
General Body System Peritoneum									L																
									+ v																
Hepatocholangiocarcinoma, metastatic, liver								2	X																
Genital System																									
Clitoral gland	+	+	+	+	+	+	+	+ 1	- N	+ +	+ +	+	+	+	+	+	$^+$	+	+	+	+	+	+	+	
Ovary	+	+	+	+	+	+	+	+ -	+ +	+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	
Cystadenoma																									
Hemangioma																									
Teratoma benign			Х																						
															+	+		+							
Uterus	+	+	+	+	+	+	+	T 7	+ -	+ -	+ +	- +	- +	-	+	-	+	+	+	+	+	+	+	+	

7 Number of Days on Study 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 2 2 3 3 3 3 9 9 9 9 9 9 9 9 9 9 9 9 0 0 0 0 0 0 0 0 0 0 0 0 0 2 Total **Carcass ID Number** 6 6 6 6 7 8 9 9 9 9 0 5 56 7 7 7 8 8 8 8 8 9 9 Tissues/ 6 1 2 3 5 6 0 4 0 2 8 9 0 1 3 0 3 6 8 1 3 5 6 7 5 7 Tumors **Alimentary System** 50 Esophagus Gallbladder 50 Intestine large, colon 50 Intestine large, rectum 50 Intestine large, cecum 50 Intestine small, duodenum 48 + 50 Intestine small, jejunum Intestine small, ileum 49 + Liver 50 Carcinoma, metastatic, islets, pancreatic 1 Hepatocellular carcinoma 2 Hepatocellular adenoma Х Х Х 6 Х Х Hepatocellular adenoma, multiple 1 Hepatocholangiocarcinoma 1 Mesentery 19 Carcinoma, metastatic, islets, pancreatic 1 Fibrosarcoma, metastatic, skin 1 Hepatocholangiocarcinoma, metastatic, liver 1 Pancreas 50 Hepatocholangiocarcinoma, metastatic, liver 1 49 Salivary glands + Stomach, forestomach 50 + Stomach, glandular 50 Hepatocholangiocarcinoma, metastatic, liver 1 **Cardiovascular System** Blood vessel + 50 + Heart + + ++50 + +**Endocrine System** Adrenal cortex 50 Adrenal medulla + 50 Pheochromocytoma benign 1 Islets, pancreatic 50 Carcinoma 1 Parathyroid gland 31 MM M Μ M Pituitary gland + +I Μ 47 ++Pars distalis, adenoma 3 Х Х Thyroid gland + + $^+$ М $^{+}$ + 49 Bilateral, follicular cell, adenoma Х 1 **General Body System** Peritoneum 1 Hepatocholangiocarcinoma, metastatic, liver 1 **Genital System** Clitoral gland 49 + 49 Ovary + +Μ + Х 2 Cystadenoma Hemangioma Х Х 2 Teratoma benign 1 $^+$ + + + 50 Uterus ++Polyp stromal Х 3

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm

	4	1	1	1	1	1	(6	1	1	6	<i>(</i>	<i>c</i>	<i>c</i> ,	, ,		, ,	, -	, ,	7	7	7	7	7	7	
	4	6	6	6	6				6					6						/	7	1	7	1	1	
Number of Days on Study	8 4	0 5	4	5	5 1	5 1		5 9				7 3) (02 98		2 2 8 8		2	2 8	2 8	2 8	2 9		
	4	5	3	0	1	1	Z	9	9	4	/	3	5	5) ;	9 (b	• •)	0	0	0	0	7	9	
	2	2	2	2	2	2	2	2	2	2			2	2								2				
Carcass ID Number	5 7	6 9	7 7	7 4	5 4	8 8				6 7				7 9) 8 4 (5 5	5			9 1		5 2		
Hematopoietic System																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ -	+ -	+ -	+ -	+	+	+	+	+	+	
Hemangiosarcoma		Х																								
Lymph node			+	+	+				+	+																
Mediastinal, hepatocholangiocarcinoma, metastatic, liver									Х																	
Lymph node, mandibular	+	+	+	М	+	+	+			+	+	+	+	м·	+ -	+ -	+ -	+ -	+ -	+	+	+	+	+	+	
Lymph node, mesenteric	+	+	+	+	+	+	+	+	М	+	+	+	+			+ -	+ -	+ -	+ -	+	+	+	+	+	+	
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ -	+ -	+ -	+ -	+	+	+	+	+	+	
Hemangiosarcoma		Х	_												_											
Thymus	+	+	М	+	+	+	+	+	+	+	+	+	+	+ 1	Л-	+ -	+ -	+ -	+ ·	+	+	+	+	+	+	
Integumentary System																										
Mammary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+ •	+ -	+ -	+ -	+ -	+ -	+	+	+	+	+	+	
Skin	+	+	+	+	+	+	+	+	+	+		+	+		+ -	+ -	+ -	+ -	+ -	+	+	+	+	+	+	
Subcutaneous tissue, fibrosarcoma						Х					Х	Х		Х												
Musculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ -	+ -	+ -	+ -	+	+	+	+	+	+	
Skeletal muscle						+				+																
Carcinoma, metastatic, islets, pancreatic										Х																
Nervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ -	+ -	+ -	+ -	+	+	+	+	+	+	
Respiratory System																										
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+ •	+ -	+ -	+ -	+ -	+ -	+	+	+	+	+	+	
Alveolar/bronchiolar adenoma								Х				Х														
Alveolar/bronchiolar carcinoma																										
Carcinoma, metastatic, uncertain primary site						17						v														
Fibrosarcoma, metastatic, skin Hepatocholangiocarcinoma, metastatic, liver						Х			Х			Х														
Nose	+	+	+	М	+	+	+	+	л +	+	+	+	+	+ •	+ -	+ -	+ -		+ -	+	+	+	+	+	+	
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+ •	+ -	+ -	+ -	+ -	+ •	+	+	+	+	+	+	
Spacial Sansas System																										
Special Senses System Harderian gland																										
Adenoma																										
Urinary System																										
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ -	+ -	+ -	+ -	+ ·	+	+	+	+	+	+	
Hepatocholangiocarcinoma, metastatic, liver					,	,			X		+															
Urinary bladder Hepatocholangiocarcinoma, metastatic, liver	+	+	+	+	+	Ŧ	Ŧ		+ X	+	Ŧ	Τ	Ŧ	Τ.	τ	T	r' -	r -	τ	T	т	Ŧ	Ŧ	+	+	
Systemic Lesions Multiple organs					J	L	+	-	+	-	-	+	-	+	L	L	L	L	L	-	-	Ц	_	J	+	

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 750 ppm 7 Number of Days on Study 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 2 2 3 3 3 9 9 9 9 9 9 9 9 9 9 9 9 0 0 0 0 0 0 0 0 0 0 0 0 0 2 Total **Carcass ID Number** 6 7 8 9 9 9 9 0 5 5 6 7 7 7 8 8 8 8 8 9 9 Tissues/ 6 6 6 6 1 2 3 5 6 0 4 0 2 8 9 0 1 3 0 3 6 8 1 3 5 6 7 5 7 Tumors Hematopoietic System + + + + + + 50 Bone marrow + Hemangiosarcoma 1 7 Lymph node Mediastinal, hepatocholangiocarcinoma, metastatic, liver 1 Lymph node, mandibular M 46 +M Lymph node, mesenteric 49 Spleen + 50 + + + Hemangiosarcoma 1 Thymus 47 + + + + + + + $^{+}$ $^+$ $^{+}$ $^{+}$ ++ + $^{+}$ + + $^{+}$ + $^+$ $^{+}$ + M + **Integumentary System** 50 Mammary gland + 50 Skin + Subcutaneous tissue, fibrosarcoma 5 Х Musculoskeletal System 50 Bone + Skeletal muscle 2 Carcinoma, metastatic, islets, pancreatic 1 **Nervous System** 50 Brain **Respiratory System** Lung + + + + + 50 Х Alveolar/bronchiolar adenoma Х 4 Х Alveolar/bronchiolar carcinoma Х Х 3 Carcinoma, metastatic, uncertain primary site Х 1 2 Fibrosarcoma, metastatic, skin Hepatocholangiocarcinoma, metastatic, liver 1 49 Nose Trachea + + + + 50 **Special Senses System** Harderian gland + 1 Adenoma Х 1 **Urinary System** Kidney 50 Hepatocholangiocarcinoma, metastatic, liver 1 50 Urinary bladder Hepatocholangiocarcinoma, metastatic, liver 1 Systemic Lesions + 50 Multiple organs + + + + + + ++ + + Lymphoma malignant Х Х ХХХ 10

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm

Number of Days on Study	4 7 7	5 2 4	6 1 0	6 1 7	6 2 1	6 7 7	8	9	7 0 6	1 6	1	2	2	2	2	2	2		2	7 2 8	7 2 8	7 2 8	7 2 9	7 2 9	2	
Carcass ID Number	3 1 0	3 1 3	3 0 7	3 3 8	3 4 7	3 0 2	0	3 1 5		1	1		0	3 1 0 1	0		1	2	2	3 3 3	3 4 6	3 5 0	3 0 6	3 1 6	1	
Alimentary System		-		÷		_	-	-	-	_	-	-	-	-		-	-	-	-	-	-	÷	-			
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ .	+ -	+	+	+	+	+	+	+	+	+	
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ •	+ -	+	+	+	+	+	+	+	+	+	
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ .	+ -	+	+	+	+	+	+	+	+	+	
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ •	+ -	+	+	+	+	+	+	+	+	+	
Fibrosarcoma, metastatic, skin	X		·																				·			
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ .	+ -	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+ .	+ .	+ -	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+ .	+ .	+ .	+	+	+	+	+	+	+	+	+	
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ .	+ -	+	+	+	+	+	+	+	+	+	
Leiomyosarcoma, metastatic, uterus	1	'		X	'	'				'		'	'	·							'					
Liver	+	+	+	л +	+	+	+	+	+	+	+	+	+	+ -	+ .	+	+	+	+	+	+	+	+	+	+	
Fibrosarcoma, metastatic, skin	X				'						'	1		1					1	1	1	1.	1.		'	
Hemangiosarcoma	Л																Х									
Hepatocellular carcinoma								Х								x	~		Х							
Hepatocellular adenoma								Λ						,	x	n.		-	A				Х			
Hepatocellular adenoma, multiple														-	Δ								л			
Mesentery	+	+	+	-					+	<u>т</u>		+	+			+		L			+					
Fibrosarcoma, metastatic, skin	X								1				'								'					
Osteosarcoma, metastatic, skin	Λ								х																	
Sarcoma									Л				Х													
Oral mucosa												+	Λ													
Pancreas	+	+	+	+	+	+	+	+	+	+	+		+	+ -	+ .	+	+	+	+	+	+	+	+	+	+	
Salivary glands	+	+	+	+	+	+	+	+	M	+	+			+ •	+ •	+	+	+ -	+	+	+	+	+	+	+	
Stomach, forestomach	, T	- -		- -		, ,	- -	- -	1V1	, ,	, ,	' -	+			+ -		+		+	+	- -			, ,	
Squamous cell papilloma	т	Ŧ	т	Ŧ	т	т	т	Ŧ	Ŧ	т	т	т	Ŧ	-	Т	T		×	-	Ŧ	Ŧ	T	т	Ŧ	т	
Stomach, glandular	+	-	+	-	+	+	+	+	Т	-	т	т	т	т.	+ -	+		Λ +	-	+	-	-	-	-	+	
	т	Ŧ	т	Ŧ	т	т	т		M	т	т	т	т	-	Т	T	т	T	-	Ŧ	Ŧ	T	т	Ŧ	т	
Tongue									IVI																	
Cardiovascular System																										
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+ ·	+ ·	+	+	+	+	+	$^+$	+	+	+	+	
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ ·	+	+	+	+	+	+	+	+	+	+	
Endocrine System																										
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	м	± .	÷.	+ .	+	+	+	+	+	+	+	+	+	
Fibrosarcoma, metastatic, skin	X	1.			'						'	1	141	1					1	1	1	1.	1.		'	
Osteosarcoma, metastatic, skin	Л								Х																	
Adrenal medulla	+	+	+	М	+	+	+		л +	+	+	+	м	+ -	÷ .	+	+	+	+	+	+	+	+	+	+	
	+	Ŧ	Ŧ	111	-	7	Τ'	т	Τ'	Τ'	Τ.	Τ'	111	Γ,	г ·	с ,	Г	C I	Г	Τ'	-	Ŧ	Ŧ	-	Τ'	
Pheochromocytoma benign (slets, pancreatic	.1	<u> </u>	_L	<u>ـــ</u>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷		<u>т</u>	+	+	
Adenoma	+	Ŧ	Ŧ	T	-	7	Τ'	т		+ X	Τ.	Τ'	т	τ,	с ,	r i	Г	r.	Г	Τ'	T	Ŧ	т	-	Τ'	
Parathyroid gland	м	.1		J	м	-	+	<u>т</u>			-	+	м	יא	л	L	т,		M.	M	L	5		+	<u>т</u>	
																								++		
Pituitary gland														+ 1										++		

None

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm

Number of Dave on Study	7	7	7	7	7	7	7					77	7	7	7	7	7	7	7	7	7	7	7		
Number of Days on Study	2 9	2 9	2 9	2 9	2 9	2 9	3 0					3 3 0 0	3 0												
	3	3	3	3	3	3	3	3	3	3	3 3	3 3	3	3	3	3	3	3	3	3	3	3	3	3	Total
Carcass ID Number	2 1	3 2	3 7	4 0	4 4	4 9	0 8	1 8			2 2 3 5	22 56		2 8	2 9	3 0	3 1	3 4	3 5	3 6	3 9	4 2	4 3		Tissues/ Tumors
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	$^+$	+	+	50
Gallbladder	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine argeç olon	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine arger ectum	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	50
Fibrosarcoma, metastatic, skin																									1
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestines malli, leum	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	$^+$	+	+	50
Leiomyosarcoma, metastatic, uterus																									1
Liver Fibrosarcoma, metastatic, skin Hemangiosarcoma	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	50 1 1
Hepatocellular carcinoma									Х																4
Hepatocellular adenoma									Л																4
Hepatocellular adenoma, multiple					Х																				1
Mesentery	+				Λ									+			+		+	+	+				17
Fibrosarcoma, metastatic, skin	1													'											1
Osteosarcoma, metastatic, bone																									1
Sarcoma																									1
Oral mucosa																	+								2
Pancreas	+	+	+	+	+	+	+	+	+	+	+ -	+ +	. +	+	+	+	+	+	+	+	+	+	+	+	50
Salivaryg lands	+	+	+	+	+	+	+	+	+	+	, + -	· ·	+	+	+	+	+	+	+	+	+	+	+	+	48
Stomachf orestomach	+	+	+	+	+	+	+	+	+	+	+ -	 + +	+	+	+	+	+	+	+	+	+	+	+	+	50
Squamous cell papilloma					,																				1
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	50
Fongue					,			·												'					50
Cardiovascular System																									
Blood vessel	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	$^+$	+	+	50
Heart	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	49
Fibrosarcoma, metastatic, skin																									1
Osteosarcoma, metastatic, bone																									1
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	48
Pheochromocytoma benign															Х										1
slets, pancreatic	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+		+	+	+	+	+	50
Adenoma																			Х					Х	3
Parathyroid gland	+	М	М	М	+	+		М	+	+		M +		М	М				Ι	+		М		+	31
Pituitary gland	+	+	+	+	+	+	+	+	-			+ +		+	+	+	+	+	+	+	+	+		М	43
Thyroid gland	+	+	+	+	$^+$	+	+	+	+	+	+ -	+ +	+	+	+	$^+$	+	$^+$	+	+	+	$^+$	$^+$	+	48

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm 4 5 7 7 7 7 7 7 7 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 7 2 1 2 7 8 9 0 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 99 7 4 0 7 1 771 6 6 6 3 6 8 8 8 8 8 8 8 8 8 9 3 **Carcass ID Number** 1 1 0 3 4 0 0 1 4 1 1 4 0 0 0 0 1 2 2 3 4 5 0 1 1 0 3 7 8 7 2 5 5 5 2 4 1 4 1 39 1 0 4 3 6 0 6 6 7 **Genital System** Clitoral gland + + ++ + + ++ + ++ + + + + + + + + + ++Ovary + + + + + + Х Cystadenoma Granulosa cell tumor benign Х Hemangioma Osteosarcoma, metastatic, bone + Uterus Х Leiomyosarcoma **Hematopoietic System** Bone marrow + + Lymph node + + Lymph node, mandibular + +M ++M + + Lymph node, mesenteric М + + М + + Μ Spleen + ++ + + + + + + + + + ++ + + Hemangiosarcoma Х Thymus Μ + + + + + + + $^{+}$ $^{+}$ + + + + M M M + $^+$ $^+$ M + M**Integumentary System** Mammary gland + Μ + + + ++ +++ +++ +++Skin + + + Subcutaneous tissue, fibrosarcoma Х Musculoskeletal System Bone + Femur, osteosarcoma Х + Skeletal muscle Х Osteosarcoma, metastatic, bone **Nervous System** Brain + + + + + + M + + + + $^{+}$ + ++ + **Respiratory System** Larynx M Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar adenoma, multiple Alveolar/bronchiolar carcinoma Х Fibrosarcoma, metastatic, skin Х Hepatocellular carcinoma, metastatic, liver Х Osteosarcoma, metastatic, bone Х Nose Trachea + **Special Senses System** Eye + Harderian gland + Carcinoma Х

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm 7 Number of Days on Study 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 99 9 9 9 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 Total **Carcass ID Number** 2 3 3 4 4 4 0 1 1 2 2 2 2 2 2 2 3 3 3 3 3 3 4 4 4 Tissues/ 1 2 7 0 4 9 8 8 9 2 3 5 6 7 8 9 0 1 4 5 6 9 2 3 8 Tumors **Genital System** Clitoral gland + + + + + + + + + + + + + + + + + + + 50 + +++++Ovary + + + + + + + + + + + + + + + + + 50 Cystadenoma 1 Granulosa cell tumor benign 1 Hemangioma Х 1 Osteosarcoma, metastatic, bone 1 + + + + 50 Uterus + + + + Leiomyosarcoma 1 **Hematopoietic System** 50 Bone marrow + Lymph node + 8 Lymph node, mandibular + +48 + + + +Lymph node, mesenteric 47 + Spleen + + + + + + + + + + + 50 2 Hemangiosarcoma X Thymus + + + + + + ++ + $^+$ $^{+}$ $^+$ + + $^+$ + $^+$ $^{+}$ + $^{+}$ $^{+}$ $^{+}$ $^{+}$ + 44 **Integumentary System** 49 Mammary gland + ++++++++++++++++ ++ ++ + ++50 Skin + Subcutaneous tissue, fibrosarcoma 1 Musculoskeletal System 50 Bone + + + + Femur, osteosarcoma 1 Skeletal muscle 1 Osteosarcoma, metastatic, bone 1 **Nervous System** Brain 49 ++ + +**Respiratory System** Larynx Lung + + $^+$ + + 50 + Alveolar/bronchiolar adenoma Х Х 2 Alveolar/bronchiolar adenoma, multiple Х 1 2 Alveolar/bronchiolar carcinoma Х 1 Fibrosarcoma, metastatic, skin Hepatocellular carcinoma, metastatic, liver 1 Osteosarcoma, metastatic, bone 1 Nose 50 +Trachea + + + + + + + + + + +++ + + + + + + + + + + 50 + +**Special Senses System** Eye 1 Harderian gland 1 Carcinoma 1

196

TABLE D2

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm

Number of Days on Study	4 5 6 6 6 6 7
Carcass ID Number	3 3
Urinary System Kidney Fibrosarcoma, metastatic, skin Urinary bladder	+ + + + + + + + + + + + + + + + + + +
Systemic Lesions Multiple organs Lymphoma malignant	+ + + + + + + + + + + + + + + + + + +

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 1,500 ppm

Number of Days on Study	7 2 9	7 3 0	2	7 3 0																							
Carcass ID Number	3 2 1	3 2 1	3 3 2	3 3 7	3 4 0	3 4 4	3 4 9	3 0 8	3 1 8	3 1 9	3 2 2	3 2 3	3 2 5	3 2 6	3 2 7	3 2 8	3 2 9	3 3 0	3 3 1	3 3 4	3 3 5	3 3 6	3 3 9	3 4 2	4	3 4 8	Total Tissues/ Tumors
Urinary System Kidney Fibrosarcoma, metastatic, skin Urinary bladder	+	+	+	++	+	+	+	+	+	+	+	+	+	+	++	+	+	+	+	+	+	++	++	++	++	++	50 1 50
Systemic Lesions Multiple organs Lymphoma malignant	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+ X	+	+	+	+	50 8

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm 4 4 5 5 6 7 7 7 7 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 0 8 2 6 5 7 8 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 9 9 9 1 4 0 7 9 3 7 5 8 8 8 8 8 8 8 8 8 8 9 9 9 9 3 **Carcass ID Number** 9 5 5 8 6 6 5 9 0 5 5 6 6 6 7 7 8 9 5 55 5 6 6 7 4 1 9 0 6 4 8 2 0 6 7 1 3 8 1 6 2 6 2 3 4 5 0 9 4 **Alimentary System** Esophagus + + + + Gallbladder M Intestine large, colon + ++ + + Intestine large, rectum Intestine large, cecum + Intestine small, duodenum ++ + M Intestine small, jejunum + + Intestine small, ileum + + + + + + + + + Liver +Hepatocellular carcinoma Х Х Hepatocellular adenoma Х Hepatocellular adenoma, multiple Mesentery + +Oral mucosa Pancreas + Salivary glands + Schwannoma malignant, metastatic, skin Х Stomach, forestomach + + + + Squamous cell carcinoma Squamous cell papilloma Х Stomach, glandular + ++ + ++++++++++++++++++++ **Cardiovascular System** Blood vessel Heart + + **Endocrine System** Adrenal cortex + Adrenal medulla М + + + + + + + + Islets, pancreatic + ++ +++ + + ++ + ++++ + ++ + ++ ++ ++Parathyroid gland М + + + + + М + + + М + М + + + + М + М + $^{+}$ М Μ Pituitary gland М + T + Pars distalis, adenoma Thyroid gland +Follicular cell, carcinoma **General Body System** Peritoneum **Genital System** Clitoral gland + M + ++Μ Ovary + + Cystadenoma Х Hemangioma Luteoma Uterus + +++ + + ++ ++Polyp stromal Х

7 Number of Days on Study 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 9 9 9 9 9 9 9 9 9 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 Total **Carcass ID Number** 7 7 8 8 8 9 9 9 9 9 6 6 6 7 7 7 7 7 8 8 8 8 8 9 9 Tissues/ 7 9 1 5 8 0 3 5 8 9 2 5 7 0 2 3 5 8 3 4 6 7 9 1 7 Tumors **Alimentary System** Esophagus 50 + Gallbladder 49 Intestine large, colon 50 Intestine large, rectum 50 Intestine large, cecum 50 Intestine small, duodenum 49 4 Intestine small, jejunum 50 50 Intestine small, ileum + + Liver 50 Hepatocellular carcinoma 1 Х Hepatocellular adenoma Х 5 Х Hepatocellular adenoma, multiple Х 1 Mesentery + + + 13 + Oral mucosa 3 Pancreas 50 Salivary glands 50 Schwannoma malignant, metastatic, skin 1 50 Stomach, forestomach + + + Squamous cell carcinoma Х Х 2 Х 3 Squamous cell papilloma Х Stomach, glandular + 50 +++ +++ +++ +++++++++++++++ **Cardiovascular System** Blood vessel 50 Heart 50 + **Endocrine System** Adrenal cortex 50 Adrenal medulla 49 + + 50 Islets, pancreatic + + + + + + + + + + + ++ Parathyroid gland 37 + М М + + + + + + M M М Pituitary gland 48 + + + + Pars distalis, adenoma Х 1 Thyroid gland +Μ + ++ 49 Follicular cell, carcinoma Х 1 **General Body System** Peritoneum 1 + **Genital System** Clitoral gland 48 ++49 Ovary + + + + Μ + + Cystadenoma Х Х 3 Hemangioma Х 1 Luteoma Х 1 Uterus + + 50 Polyp stromal 1

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm

			~	~	1	1	1	7	7	7	7	7	7	7	7	7	7	7	7	7	7	-	-	-	7	
	4	4	5	5	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	0	8	2	6	5	7	8	0	0	2	2	2	2				2	2	2	2	2	2	2	2	2	
	1	4	0	7	9	3	7	5	8	8	8	8	8	8	8	8	8	8	9	9	9	9	9	9	9	
	3	3	3	3	3	3	3	3	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
Carcass ID Number	9	5	5	8	6	6	5	9	0	5	5	6	6	6	7	7	8	9	5	5	5	5	6	6	7	
	4	1	9	0	6	4	8	2	0	6	7	1	3	8	1	6	2	6	2	3	4	5	0	9	4	
Hematopoietic System																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node							+			+								+								
Lymph node, mandibular	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node, mesenteric	+	+	+	М		+		+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Thymus	+	+	+	+	M	+	+				+	+	+	+	+	+	+			+	+	+	+	+		
I																										
Integumentary System Mammary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Subcutaneous tissue, fibrosarcoma	1							x		'	1	'			'	'	'	'		'	'				'	
Subcutaneous tissue, schwannoma malignant			Х					Λ				Х														
Subcutaneous tissue, pinna, fibroma			л									л											Х			
Subcutaneous fissue, pinita, fibronia																							л			
Musculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Vertebra, osteosarcoma																										
Skeletal muscle	+			+																						
Nervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Peripheral nerve	+			+																						
Spinal cord	+			+																						
Meninges, meningioma malignant	x			'																						
Respiratory System																										
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Alveolar/bronchiolar adenoma																										
Alveolar/bronchiolar carcinoma																							Х			
Hepatocellular carcinoma, metastatic, liver																			Х							
Osteosarcoma, metastatic, bone																										
Schwannoma malignant, metastatic, skin			Х																							
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Special Senses System																										
Harderian gland																										
Adenoma																										
Urinary System																										
Urinary System						,																				
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Systemic Lesions																										
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	
Lymphoma malignant						Х	X											Х								

Individual Animal Tumor Pathology of Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite: 3,000 ppm 7 Number of Days on Study 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 9 9 9 9 9 9 9 9 9 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 3 3 Total **Carcass ID Number** 7 7 8 8 8 9 9 9 9 9 6 6 6 7 7 7 7 7 8 8 8 8 89 9 Tissues/ 7 9 1 5 8 0 3 5 89 2 5 7 0 2 3 5 8 3 4 6 7 9 1 7 Tumors **Hematopoietic System** Bone marrow 50 Lymph node 4 Lymph node, mandibular 48 Lymph node, mesenteric 49 Spleen + + 50 Thymus 46 + M +++ + +++ **Integumentary System** 50 Mammaryg land 50 Skin +Subcutaneous tissue, fibrosarcoma x 2 Subcutaneous tissue, schwannoma malignant 2 Subcutaneous tissue, pinna, fibroma 1 Musculoskeletal System 50 Bone ++Х Vertebra, osteosarcoma 1 Skeletal muscle 3 **Nervous System** 50 Brain Peripheral nerve 2 Spinal cord 2 Meninges, meningioma malignant 1 **Respiratory System** 50 Lung + +++ Х Alveolar/bronchiolar adenoma Х ХХХ 5 Alveolar/bronchiolar carcinoma 1 Hepatocellular carcinoma, metastatic, liver 1 Osteosarcoma, metastatic, bone Х 1 Schwannoma malignant, metastatic, skin 1 Nose 50 50 Trachea + ++++++++++ ++++++++++++++ **Special Senses System** Harderian gland + + 2 Adenoma Х Х 2 **Urinary System** 50 Kidney + 50 Urinary bladder Systemic Lesions 50 Multiple organs $^+$ + + + + + + + + + + ++ Lymphoma malignant Х Х Х 6

Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite

		5	-	
	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Liver: Hepatocellular Adenoma				
Overall rate ^a	9/50 (18%)	7/50 (14%)	3/50 (6%)	6/50 (12%)
Adjusted rate ^b	19.5%	15.2%	6.4%	12.9%
Ferminal rate ^c	8/40 (20%)	5/34 (15%)	3/37 (8%)	6/41 (15%)
First incidence (days)	586	667	728 (T)	728 (T)
oly-3 test ^d	P=0.197N	P=0.394N	P=0.057N	P=0.283N
iver: Hepatocellular Carcinoma				
Overall rate	2/50 (4%)	2/50 (4%)	4/50 (8%)	1/50 (2%)
djusted rate	4.4%	4.4%	8.5%	2.2%
erminal rate	2/40 (5%)	1/34 (3%)	3/37 (8%)	1/41 (2%)
irst incidence (days)	728 (T)	673	691	728 (T)
oly-3 test	P=0.422N	P=0.693N	P=0.349	P=0.494N
Liver: Hepatocellular Adenoma or Carcinoma	10/50 (200/)	8/50 (160/)	7/50 (140/)	7/50 (140/)
	10/50 (20%)	8/50 (16%)	7/50 (14%)	7/50 (14%)
adjusted rate	21.6%	17.3%	14.9%	15.1%
erminal rate	9/40 (23%)	6/34 (18%)	6/37 (16%)	7/41 (17%)
irst incidence (days)	586 D=0.250N	667 D=0.200N	691 D=0.285N	728 (T) P=0 202N
bly-3 test	P=0.250N	P=0.399N	P=0.285N	P=0.292N
ung: Alveolar/bronchiolar Adenoma				
Overall rate	1/50 (2%)	4/50 (8%)	3/50 (6%)	5/50 (10%)
djusted rate	2.2%	8.7%	6.4%	10.8%
erminal rate	1/40 (3%)	2/34 (6%)	3/37 (8%)	5/41 (12%)
irst incidence (days)	728 (T)	659	728 (T)	728 (T)
oly-3 test	P=0.118	P=0.181	P=0.313	P=0.105
ung: Alveolar/bronchiolar Carcinoma				
Overall rate	0/50 (0%)	3/50 (6%)	2/50 (4%)	1/50 (2%)
djusted rate	0.0%	6.6%	4.3%	2.2%
erminal rate	0/40 (0%)	3/34 (9%)	2/37 (5%)	1/41 (2%)
irst incidence (days)	e	728 (T)	728 (T)	728 (T)
bly-3 test	P=0.566	P=0.118	P=0.242	P=0.503
ung: Alveolar/bronchiolar Adenoma or Carcinoma				
Overall rate	1/50 (2%)	6/50 (12%)	5/50 (10%)	6/50 (12%)
djusted rate	2.2%	13.0%	10.7%	12.9%
erminal rate	1/40 (3%)	4/34 (12%)	5/37 (14%)	6/41 (15%)
irst incidence (days)	728 (T)	659	728 (T)	728 (T)
bly-3 test	P=0.110	P=0.057	P=0.106	P=0.059
Ovary: Cystadenoma				
overall rate	0/47 (0%)	2/49 (4%)	1/50 (2%)	3/49 (6%)
djusted rate	0.0%	4.5%	2.1%	6.6%
erminal rate	0/37 (0%)	2/33 (6%)	1/37 (3%)	3/40 (8%)
irst incidence (days)		728 (T)	728 (T)	728 (T)
Poly-3 test	P=0.113	P=0.247	P=0.518	P=0.130

Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Pancreatic Islets: Adenoma				
Overall rate	0/50 (0%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
Adjusted rate	0.0%	0.0%	6.4%	0.0%
erminal rate	0/40 (0%)	0/34 (0%)	2/37 (5%)	0/41 (0%)
irst incidence (days)		_ ``	716	
sly-3 test	P=0.550	f	P=0.123	—
ancreatic Islets: Adenoma or Carcinoma				
overall rate	0/50 (0%)	1/50 (2%)	3/50 (6%)	0/50 (0%)
Adjusted rate	0.0%	2.2%	6.4%	0.0%
erminal rate	0/40 (0%)	0/34 (0%)	2/37 (5%)	0/41 (0%)
first incidence (days)		664	716	
oly-3 test	P=0.627N	P=0.501	P=0.123	_
twitten Cland (Dave Distalia). A davage				
ituitary Gland (Pars Distalis): Adenoma verall rate	1/48 (2%)	3/47 (6%)	0/43 (0%)	1/48 (2%)
djusted rate	2.3%	3/47 (0%) 6.9%	0.0%	2.2%
5				
erminal rate	1/38 (3%) 728 (T)	2/32 (6%)	0/33 (0%)	1/40 (3%)
irst incidence (days)	728 (T)	643 D=0.205	— D=0.515N	728 (T)
ly-3 test	P=0.401N	P=0.305	P=0.515N	P=0.754N
kin (Subcutaneous Tissue): Fibrosarcoma				
verall rate	0/50 (0%)	5/50 (10%)	1/50 (2%)	2/50 (4%)
djusted rate	0.0%	10.7%	2.1%	4.3%
erminal rate	0/40 (0%)	1/34 (3%)	0/37 (0%)	1/41 (2%)
irst incidence (days)	_	651	477	705
bly-3 test	P=0.514	P=0.032	P=0.507	P=0.241
kin (Subcutaneous Tissue): Fibrosarcoma or Sar	coma			
Overall rate	1/50 (2%)	5/50 (10%)	1/50 (2%)	2/50 (4%)
djusted rate	2.2%	10.7%	2.1%	4.3%
erminal rate	0/40 (0%)	1/34 (3%)	0/37 (0%)	1/41 (2%)
irst incidence (days)	586	651	477	705
bly-3 test	P=0.517N	P=0.103	P=0.755N	P=0.503
kin (Subcutaneous Tissue): Fibroma, Fibrosarco	ma or Sarcoma			
verall rate	1/50 (2%)	5/50 (10%)	1/50 (2%)	3/50 (6%)
djusted rate	2.2%	10.7%	2.1%	6.4%
erminal rate	0/40 (0%)	1/34 (3%)	0/37 (0%)	2/41 (5%)
rst incidence (days)	586 D. 0.462	651 D. 0.102	477 D. 0.7550	705 D. 0.200
ly-3 test	P=0.462	P=0.103	P=0.755N	P=0.308
tomach (Forestomach): Squamous Cell Papillom				
verall rate	1/50 (2%)	0/50 (0%)	1/50 (2%)	3/50 (6%)
djusted rate	2.2%	0.0%	2.1%	6.4%
erminal rate	1/40 (3%)	0/34 (0%)	1/37 (3%)	2/41 (5%)
First incidence (days)	728 (T)	_ `´	728 (T)	708
Poly-3 test	P=0.099	P=0.500N	P=0.756N	P=0.312

TABLE I)3
---------	----

Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
stomach (Forestomach): Squamous Cell Papil	loma or Carcinoma			
Overall rate	1/50 (2%)	0/50 (0%)	1/50 (2%)	5/50 (10%)
Adjusted rate	2.2%	0.0%	2.1%	10.7%
erminal rate	1/40 (3%)	0/34 (0%)	1/37 (3%)	4/41 (10%)
First incidence (days)	728 (T)		728 (T)	708
oly-3 test	P=0.011	P=0.500N	P=0.756N	P=0.106
Jterus: Stromal Polyp				
Overall rate	0/50 (0%)	3/50 (6%)	0/50 (0%)	1/50 (2%)
djusted rate	0.0%	6.5%	0.0%	2.1%
erminal rate	0/40 (0%)	1/34 (3%)	0/37 (0%)	0/41 (0%)
irst incidence (days)	_ ``	664	_ `	659
oly-3 test	P=0.627N	P=0.120	—	P=0.504
ll Organs: Hemangiosarcoma				
overall rate	1/50 (2%)	1/50 (2%)	3/50 (6%)	0/50 (0%)
djusted rate	2.2%	2.2%	6.4%	0.0%
erminal rate	1/40 (3%)	0/34 (0%)	3/37 (8%)	0/41 (0%)
irst incidence (days)	728 (T)	605	728 (T)	_
bly-3 test	P=0.402N	P=0.759N	P=0.313	P=0.497N
ll Organs: Hemangioma or Hemangiosarcon				
verall rate	1/50 (2%)	3/50 (6%)	4/50 (8%)	1/50 (2%)
djusted rate	2.2%	6.5%	8.6%	2.2%
erminal rate	1/40 (3%)	2/34 (6%)	4/37 (11%)	1/41 (2%)
irst incidence (days)	728 (T)	605 D. 0.200	728 (T)	728 (T)
oly-3 test	P=0.513N	P=0.308	P=0.185	P=0.757N
ll Organs: Malignant Lymphoma		10/50 (000/)		
overall rate	7/50 (14%)	10/50 (20%)	8/50 (16%)	6/50 (12%)
djusted rate	14.9%	21.5%	16.7%	12.8%
erminal rate irst incidence (days)	4/40 (10%) 580	7/34 (21%) 650	4/37 (11%) 524	4/41 (10%)
bly-3 test	580 P=0.331N	650 P=0.288	524 P=0.515	673 P=0.502N
JIY-5 1081	P=0.331N	P=0.288	P=0.515	r=0.3021N
Il Organs: Benign Neoplasms	12/50 (2/0/)	22/50 (440/)	14/50 (200/)	20/50 (409/)
verall rate	13/50 (26%)	22/50 (44%)	14/50 (28%)	20/50 (40%)
djusted rate	28.1%	46.6%	29.6%	42.7%
erminal rate	12/40 (30%)	15/34 (44%)	12/37 (32%)	18/41 (44%)
irst incidence (days)	586 D=0.208	643 P=0.048	610 P=0.526	659 P=0 102
oly-3 test	P=0.208	P=0.048	P=0.526	P=0.103
ll Organs: Malignant Neoplasms				
overall rate	12/50 (24%)	21/50 (42%)	19/50 (38%)	17/50 (34%)
djusted rate	25.2%	43.5%	38.6%	35.1%
erminal rate	7/40 (18%)	11/34 (32%)	11/37 (30%)	12/41 (29%)
irst incidence (days)	580	605	477	401
oly-3 test	P=0.320	P=0.045	P=0.113	P=0.201

Statistical Analysis of	f Primary Neoplasms	in Female Mice in the 2-	Year Drinking Water Stu	lv of Sodium Nitrite

0 ppm	750 ppm	1,500 ppm	3,000 ppm
21/50 (42%)	33/50 (66%)	31/50 (62%)	32/50 (64%)
44.0%	67.4%	63.0%	65.6%
16/40 (40%)	20/34 (59%)	22/37 (60%)	25/41 (61%)
580	605	477	401
P=0.054	P=0.015	P=0.045	P=0.024
	21/50 (42%) 44.0% 16/40 (40%) 580	21/50 (42%) 33/50 (66%) 44.0% 67.4% 16/40 (40%) 20/34 (59%) 580 605	21/50 (42%) 33/50 (66%) 31/50 (62%) 44.0% 67.4% 63.0% 16/40 (40%) 20/34 (59%) 22/37 (60%) 580 605 477

(T)Terminal sacrifice

Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for liver, lung, ovary, pancreatic islets, and pituitary gland; for other tissues, denominator is number of animals necropsied.

b Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality

с Observed incidence at terminal kill d

Beneath the control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The Poly-3 test accounts for differential mortality in animals that do not reach terminal sacrifice. A negative trend or a lower incidence in an exposure group is indicated by N.

e Not applicable; no neoplasms in animal group

f

Value of statistic cannot be computed.

		Incidence in Contro	ols
Study	Squamous Cell Papilloma	Squamous Cell Carcinoma	Squamous Cell Papilloma or Carcinoma
Historical Incidence in Controls Given NTP-2	2000 Diet ^a		
<i>p,p</i> ′-Dichlorodiphenyl sulfone (feed)	0/50	0/50	0/50
Indium phosphide (inhalation)	0/50	1/50	1/50
Methacrylonitrile (gavage)	0/50	0/50	0/50
p-Nitrotoluene (feed)	0/50	0/50	0/50
Sodium nitrite (drinking water)	1/50	0/50	1/50
Overall Historical Incidence in Controls Give	en NTP-2000 Diet		
Total (%)	1/250 (0.4%)	1/250 (0.4%)	2/250 (0.8%)
Mean \pm standard deviation	$0.4\% \pm 0.9\%$	$0.4\% \pm 0.9\%$	$0.8\% \pm 1.1\%$
Range	0%-2%	0%-2%	0%-2%
Historical Incidence in Drinking Water Cont	rols Given NIH-07 Diet at Batt	elle Columbus Labor	ratories ^b
Sodium fluoride	3/80	0/80	3/80
Overall Historical Incidence in Drinking Wa	ter Controls Given NIH-07 Die	t	
Total (%)	5/340 (1.5%)	0/340	5/340 (1.5%)
Mean \pm standard deviation	$1.3\% \pm 1.6\%$		$1.3\% \pm 1.6\%$
Range	0%-4%		0%-4%
Overall Historical Incidence in Feed Controls	s Given NIH-07 Diet		
Total (%)	15/953 (1.6%)	1/953 (0.1%)	16/953 (1.7%)
Mean \pm standard deviation	$1.6\% \pm 2.0\%$	$0.1\% \pm 0.5\%$	$1.7\% \pm 2.0\%$
Range	0%-6%	0%-2%	0%-6%
Overall Historical Incidence in Gavage (Corr	o Oil) Controls Given NIH-07 I	Diet	
Total (%)	19/463 (4.1%)	0/463	19/463 (4.1%)
Mean \pm standard deviation	$4.1\% \pm 3.5\%$		$4.1\% \pm 3.5\%$
Range	0%-10%		0%-10%
Overall Historical Incidence in Gavage (Wate	er) Controls Given NIH-07 Die	t	
Total	0/51	0/51	0/51
Overall Historical Incidence in Inhalation (A	ir) Controls Given NIH-07 Die	t	
Total (%)	8/1,077 (0.7%)	2/1,077 (0.2%)	10/1,077 (0.9%)
Mean \pm standard deviation	$0.7\% \pm 1.0\%$	$0.2\% \pm 0.6\%$	$0.9\% \pm 1.1\%$
Range	0%-2%	0%-2%	0%-3%

TABLE D4 Historical Incidence of Forestomach Neoplasms in Control Female B6C3F1 Mice

a Data as of 14 March 2000 Data as of 23 December 1999

TABLE D5 Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite^a

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths				
Moribund	1	7	2	4
Natural deaths	9	9	11	5
Survivors				
Terminal sacrifice	40	34	37	41
Animals examined microscopically	50	50	50	50
Alimentary System				
Gallbladder	(48)	(50)	(50)	(49)
Cyst	1 (2%)	1 (2%)	× /	. /
Infiltration cellular, mononuclear cell	× /	3 (6%)	1 (2%)	4 (8%)
Epithelium, cytoplasmic alteration		1 (2%)	× /	× /
Epithelium, hyperplasia		1 (2%)		
ntestine small, duodenum	(50)	(48)	(50)	(49)
Epithelium, inflammation, chronic active	1 (2%)		· ·	. /
Epithelium, ulcer	1 (2%)			
ntestine small, jejunum	(50)	(50)	(50)	(50)
Necrosis	1 (2%)			× /
Peyer's patch, hyperplasia, lymphoid	× ,			1 (2%)
ntestine small, ileum	(49)	(49)	(50)	(50)
Inflammation, chronic active	. /	× /		1 (2%)
Liver	(50)	(50)	(50)	(50)
Angiectasis				2 (4%)
Basophilic focus	3 (6%)	4 (8%)	3 (6%)	1 (2%)
Clear cell focus	2 (4%)	3 (6%)	3 (6%)	2 (4%)
Congestion				1 (2%)
Eosinophilic focus	7 (14%)	3 (6%)	4 (8%)	5 (10%)
Hematopoietic cell proliferation	2 (4%)	5 (10%)	3 (6%)	4 (8%)
Hemorrhage	1 (2%)	· · ·		
Infiltration cellular, mononuclear cell	30 (60%)	32 (64%)	29 (58%)	35 (70%)
Inflammation, chronic active	36 (72%)	35 (70%)	30 (60%)	35 (70%)
Mineralization	1 (2%)	1 (2%)	1 (2%)	. /
Mixed cell focus	3 (6%)	1 (2%)		
Necrosis	5 (10%)	4 (8%)	3 (6%)	2 (4%)
Pigmentation	12 (24%)	17 (34%)	16 (32%)	18 (36%)
Thrombosis		1 (2%)		
Vacuolization cytoplasmic	10 (20%)	17 (34%)	12 (24%)	13 (26%)
Bile duct, cyst			1 (2%)	
Bile duct, hyperplasia	1 (2%)	1 (2%)		1 (2%)
Centrilobular, necrosis				2 (4%)
Centrilobular, vacuolization cytoplasmic				1 (2%)
Hepatocyte, centrilobular, hypertrophy	1 (2%)			

^a Number of animals examined microscopically at the site and the number of animals with lesion

TABLE D5 Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Alimentary System (continued)				
Mesentery	(14)	(19)	(17)	(13)
Congestion		1 (5%)		
Hemorrhage			1 (6%)	
Infiltration cellular, mononuclear cell				1 (8%)
Inflammation, chronic active		1 (5%)		
Inflammation, granulomatous	1 (7%)			
Pigmentation, hemosiderin	()		1 (6%)	
Thrombosis		1 (5%)		
Artery, inflammation, chronic active				1 (8%)
Fat, necrosis	10 (71%)	7 (37%)	10 (59%)	11 (85%)
Dral mucosa	(1)		(2)	(3)
Gingival, foreign body	1 (100%)		2 (100%)	3 (100%)
Gingival, inflammation, chronic active	1 (100%)		2 (100%)	2 (67%)
Pancreas	(50)	(50)	(50)	(50)
Infiltration cellular, mononuclear cell	14 (28%)	10 (20%)	7 (14%)	13 (26%)
Inflammation, chronic active		1 (2%)	()	- ()
Acinus, atrophy	1 (2%)	(-, -,		1 (2%)
Acinus, hyperplasia	× · · ·		1 (2%)	
Acinus, hypertrophy				1 (2%)
Artery, inflammation, chronic active			1 (2%)	1 (2%)
Duct, cyst	1 (2%)	1 (2%)		
Salivary glands	(49)	(49)	(48)	(50)
Atrophy				2 (4%)
Infiltration cellular, mononuclear cell	34 (69%)	36 (73%)	40 (83%)	35 (70%)
Stomach, forestomach	(50)	(50)	(50)	(50)
Infiltration cellular, mononuclear cell	(••)	1 (2%)	((**))	
Ulcer	1 (2%)	2(4%)	2 (4%)	
Epithelium, hyperkeratosis	1 (270)	= ()	= ()	1 (2%)
Epithelium, hyperplasia	2 (4%)	3 (6%)	3 (6%)	6 (12%)
Epithelium, inflammation, chronic active	2 (4%)	3 (6%)	3 (6%)	1 (2%)
Stomach, glandular	(50)	(50)	(50)	(50)
Mineralization	1 (2%)	(50)	(20)	(00)
Epithelium, hyperplasia	1 (270)		1 (2%)	1 (2%)
Epithelium, necrosis			1 (2%)	1 (270)
Glands, ectasia	19 (38%)	16 (32%)	10 (20%)	21 (42%)
Glands, necrosis	13 (2070)	10 (0270)	1 (2%)	(/)
Cardiovascular System				
Blood vessel	(50)	(50)	(50)	(50)
Infiltration cellular, mononuclear cell			1 (2%)	
Aorta, inflammation, chronic active			· /	1 (2%)
Aorta, mineralization	2 (4%)			
Pulmonary artery, mineralization	1 (2%)			
Ieart	(50)	(50)	(50)	(50)
Cardiomyopathy		1 (2%)		
Inflammation, chronic active		1 (2%)	1 (2%)	
Infiltration cellular, mononuclear cell	1 (2%)		× /	
Mineralization	1 (2%)	2 (4%)		1 (2%)
Artery, inflammation, chronic active	× /			1 (2%)
Artery, mineralization		1 (2%)		
Valve, inflammation, chronic active	2 (4%)			

TABLE D5 Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite

(50) 1 (2%) 1 (2%) 49 (98%) 1 (2%)	(50) 2 (4%) 2 (4%) 1 (2%) 50 (100%)	(49) 1 (2%) 1 (2%) 49 (100%)	(50) 1 (2%) 2 (4%) 2 (4%)
1 (2%) 1 (2%) 49 (98%)	2 (4%) 2 (4%) 1 (2%)	1 (2%) 1 (2%)	1 (2%) 2 (4%)
1 (2%) 1 (2%) 49 (98%)	2 (4%) 2 (4%) 1 (2%)	1 (2%) 1 (2%)	1 (2%) 2 (4%)
1 (2%) 49 (98%)	2 (4%) 1 (2%)	1 (2%)	2 (4%)
49 (98%)	1 (2%)		
49 (98%)		49 (100%)	
		49 (100%)	
1 (2%)	× ,		49 (98%)
1 (2%)		1 (2%)	1 (2%)
	1 (2%)		
	1 (2%)		1 (2%)
(50)	(50)	(50)	(50)
45 (90%)	44 (88%)	40 (80%)	42 (84%)
		1 (2%)	
(33)	(31)	(31)	(37)
· ·		1 (3%)	
(48)	(47)	(43)	(48)
1 (2%)	3 (6%)	· ·	3 (6%)
. /		2 (5%)	2 (4%)
2 (4%)	3 (6%)	4 (9%)	6 (13%)
(49)	(49)		(49)
2 (4%)			1 (2%)
			1 (2%)
	. ,	1 (2%)	
	(1)		(1) 1 (100%)
(50)	(40)	(50)	(40)
			(48)
	4 (8%)	13 (26%)	3 (6%)
1 (2%)	2(49/)	2(49/)	1 (2%)
1 (29/)	2 (470)	2 (4%)	
	(40)	(50)	(40)
(47)	(49)	(30)	(49) 1 (2%)
6 (120/)	0 (100/)	0 (100/)	7 (14%)
			1 (2%)
2 (4/0)		1 (2/0)	1 (2/0)
3 (6%)	1 (2/0)		1 (2%)
5 (0/0)			1 (2%) 1 (2%)
2 (10/2)		1 (2%)	1 (2%) 1 (2%)
	(50)		(50)
(30)		(30)	(50)
32 (64%)	. ,	33 (66%)	37 (74%)
. ,	51 (0270)	55 (0070)	57 (777)
		2(4%)	
	10 (20%)		18 (36%)
13 (2070)	10 (2070)		10 (3070)
	(48) 1 (2%) 2 (4%)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Hematopoietic System				
Bone marrow	(50)	(50)	(50)	(50)
Atrophy	()	()	()	2 (4%)
Hyperplasia				1 (2%)
Myelofibrosis			2 (4%)	- (-, -,)
Myeloid cell, hyperplasia	2 (4%)	3 (6%)	1 (2%)	3 (6%)
Lymph node	(7)	(7)	(8)	(4)
Inflammation, granulomatous	()	(i)	(6)	1 (25%)
Inguinal, hyperplasia, lymphoid			1 (13%)	1 (2576)
			1 (1376)	1 (25%)
Lumbar, hyperplasia, lymphoid				
Mediastinal, hematopoietic cell proliferation			2 (280/)	1 (25%)
Mediastinal, hyperplasia, lymphoid			3 (38%)	1 (25%)
Mediastinal, pigmentation, hemosiderin		1 (14%)		
Renal, ectasia	1 (14%)		1 (13%)	
Renal, hemorrhage	1 (14%)		1 (13%)	
Lymph node, mandibular	(47)	(46)	(48)	(48)
Hematopoietic cell proliferation				1 (2%)
Hyperplasia, lymphoid	1 (2%)		5 (10%)	5 (10%)
Hyperplasia, plasma cell		1 (2%)	1 (2%)	
Lymph node, mesenteric	(50)	(49)	(47)	(49)
Ectasia	1 (2%)	1 (2%)	2 (4%)	
Fibrosis			1 (2%)	
Hematopoietic cell proliferation			(),	1 (2%)
Hyperplasia, lymphoid		1 (2%)	2 (4%)	
Inflammation, granulomatous		- (-, -,)	_ (())	1 (2%)
Spleen	(49)	(50)	(50)	(50)
Hematopoietic cell proliferation	37 (76%)	39 (78%)	35 (70%)	39 (78%)
Hyperplasia, lymphoid	4 (8%)	3 (6%)	4 (8%)	1 (2%)
Metaplasia, osseous	4 (070)	1 (2%)	4 (878)	1 (270)
Capsule, inflammation, chronic active		1 (270)		1 (2%)
	(40)	(47)	(4.4)	
Thymus	(46)	(47)	(44)	(46)
Cyst	10 (22%)	12 (26%)	17 (39%)	16 (35%)
Ectopic parathyroid gland	1 (2%)	5 (11%)	3 (7%)	2 (4%)
Hyperplasia, lymphoid			1 (2%)	
Integumentary System				
Mammary gland	(49)	(50)	(49)	(50)
Hyperplasia, cystic	1 (2%)	3 (6%)	(27)	1 (2%)
Skin	(50)	(50)	(50)	(50)
Inflammation, chronic active	· · ·	3 (6%)		(50)
,	1 (2%)		2 (4%)	
Ulcer Enidormia hyperplasia	1 (2%)	1 (2%)	1 (2%)	
Epidermis, hyperplasia	2 (40/)	1 (2%)	1 (2%)	
Subcutaneous tissue, fibrosis	2 (4%)			
Subcutaneous tissue, infiltration cellular,				2 (40/)
mononuclear cell				2 (4%)
Musculoskeletal System				
Bone	(50)	(50)	(50)	(50)
Periosteum, synovial tissue, inflammation,	(30)	(50)	(50)	(30)
chronic active				1 (2%)
Skeletal muscle	(3)	(2)	(1)	
	(3)	(2)	(1)	(3) (2294)
Artery, inflammation, chronic active				1 (33%)

TABLE D5 Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
Nervous System				
Brain	(50)	(50)	(49)	(50)
Degeneration	1 (2%)		(13)	(00)
Hemorrhage	1 (2%)	1 (2%)		
Peripheral nerve		()		(2)
Sciatic, inflammation, chronic active				1 (50%)
Spinal cord				(2)
Demyelination				2 (100%)
Respiratory System				
Lung	(50)	(50)	(50)	(50)
Hemorrhage			1 (2%)	× /
Infiltration cellular, mononuclear cell	1 (2%)	2 (4%)	X · 9	1 (2%)
Inflammation, chronic active	2 (4%)	3 (6%)	2 (4%)	× /
Metaplasia, osseous	× /	× /	× /	1 (2%)
Mineralization		1 (2%)	1 (2%)	· · ·
Alveolar epithelium, hyperplasia		1 (2%)	4 (8%)	3 (6%)
Alveolus, infiltration cellular, histiocyte		3 (6%)	2 (4%)	2 (4%)
Bronchus, mineralization	1 (2%)			
Interstitium, inflammation, chronic active				1 (2%)
Vein, mineralization	1 (2%)	1 (2%)	1 (2%)	
Nose	(50)	(49)	(50)	(50)
Foreign body			1 (2%)	
Inflammation, chronic active			1 (2%)	
Nasolacrimal duct, inflammation, suppurative		1 (2%)	1 (2%)	1 (2%)
Special Senses System				
Eye			(1)	
Cataract			1 (100%)	
Urinary System				
Xidney	(50)	(50)	(50)	(50)
Accumulation, hyaline droplet	()	1 (2%)	()	()
Infarct	2 (4%)	4 (8%)	3 (6%)	6 (12%)
Infiltration cellular, mononuclear cell	35 (70%)	37 (74%)	34 (68%)	40 (80%)
Infiltration cellular, plasma cell	× /	× ,	× /	1 (2%)
Inflammation, suppurative	1 (2%)			× ,
Mineralization	5 (10%)	8 (16%)	6 (12%)	4 (8%)
Nephropathy	20 (40%)	17 (34%)	13 (26%)	20 (40%)
Cortex, cyst				1 (2%)
Vein, inflammation, chronic active				1 (2%)
Jrinary bladder	(50)	(50)	(50)	(50)
Infiltration cellular, mononuclear cell	25 (50%)	29 (58%)	24 (48%)	25 (50%)
Inflammation, chronic active Mineralization	1 (2%) 1 (2%)			1 (2%)

APPENDIX E GENETIC TOXICOLOGY

SALMONELLA TYPHIMURIUM MUTAGENICITY TEST PROTOCOL	214
RAT AND MOUSE BONE MARROW MICRONUCLEUS TEST PROTOCOL	214
MOUSE PERIPHERAL BLOOD MICRONUCLEUS TEST PROTOCOL	215
EVALUATION PROTOCOL	215
Results	215
TABLE E1 Mutagenicity of Sodium Nitrite in Salmonella typhimurium	216
TABLE E2 Induction of Micronuclei in Bone Marrow Polychromatic Erythrocytes of Male Rats	
Treated with Sodium Nitrite by Intraperitoneal Injection	217
TABLE E3 Induction of Micronuclei in Bone Marrow Polychromatic Erythrocytes of Male Mice	
Treated with Sodium Nitrite by Intraperitoneal Injection	218
TABLE E4 Frequency of Micronuclei in Peripheral Blood Erythrocytes of Mice	
Following Administration of Sodium Nitrite in Drinking Water	
for 14 Weeks	219

GENETIC TOXICOLOGY

SALMONELLA TYPHIMURIUM MUTAGENICITY TEST PROTOCOL

Testing was performed as reported by Zeiger *et al.* (1992). Sodium nitrite was sent to the laboratory as a coded aliquot from Radian Corporation (Austin, TX). It was incubated with the *Salmonella typhimurium* tester strains TA98 and TA100 either in buffer or S9 mix (metabolic activation enzymes and cofactors from Aroclor 1254-induced male Sprague-Dawley rat or Syrian hamster liver) for 20 minutes at 37° C. Top agar supplemented with L-histidine and d-biotin was added, and the contents of the tubes were mixed and poured onto the surfaces of minimal glucose agar plates. Histidine-independent mutant colonies arising on these plates were counted following incubation for 2 days at 37° C.

Each trial consisted of triplicate plates of concurrent positive and negative controls and five doses of sodium nitrite. The high dose was limited to 10,000 μ g/plate. All positive trials were repeated under the conditions that elicited the positive response.

In this assay, a positive response is defined as a reproducible, dose-related increase in histidine-independent (revertant) colonies in any one strain/activation combination. An equivocal response is defined as an increase in revertants that is not dose related, is not reproducible, or is not of sufficient magnitude to support a determination of mutagenicity. A negative response is obtained when no increase in revertant colonies is observed following chemical treatment. There is no minimum percentage or fold increase required for a chemical to be judged positive or weakly positive.

RAT AND MOUSE BONE MARROW MICRONUCLEUS TEST PROTOCOL

The standard three-exposure protocol is described in detail by Shelby *et al.* (1993). Male F344/N rats and $B6C3F_1$ mice were injected intraperitoneally (three times at 24-hour intervals) with sodium nitrite dissolved in phosphate-buffered saline. Solvent control animals were injected with phosphate-buffered saline only. The positive control animals received injections of cyclophosphamide. The animals were killed 24 hours after the third injection, and blood smears were prepared from bone marrow cells obtained from the femurs. Air-dried smears were fixed and stained; 2,000 polychromatic erythrocytes (PCEs) were scored for the frequency of micronucleated cells in up to five animals per dose group.

The results were tabulated as the mean of the pooled results from all animals within a treatment group plus or minus the standard error of the mean. The frequency of micronucleated cells among PCEs was analyzed by a statistical software package that tested for increasing trend over dose groups with a one-tailed Cochran-Armitage trend test, followed by pairwise comparisons between each dosed group and the control group (ILS, 1990). In the presence of excess binomial variation, as detected by a binomial dispersion test, the binomial variance of the Cochran-Armitage test was adjusted upward in proportion to the excess variation. In the micronucleus test, an individual trial is considered positive if the trend test P value is less than or equal to 0.025 or if the P value for any single dosed group is less than or equal to 0.025 divided by the number of dosed groups. A final call of positive for micronucleus induction is preferably based on reproducibly positive trials (as noted above). Ultimately, the final call is determined by the scientific staff after considering the results of statistical analyses, the reproducibility of any effects observed, and the magnitudes of those effects.

MOUSE PERIPHERAL BLOOD MICRONUCLEUS TEST PROTOCOL

A detailed discussion of this assay is presented by MacGregor *et al.* (1990). At the end of the 14-week toxicity study, peripheral blood samples were obtained from male and female mice. Smears were immediately prepared and fixed in absolute methanol. The methanol-fixed slides were stained with acridine orange and coded. Slides were scanned to determine the frequency of micronuclei in 2,000 normochromatic erythrocytes (NCEs) in each of 10 animals per exposure group.

The results for NCEs in mouse peripheral blood were tabulated as described for PCEs in the rat and mouse bone marrow micronucleus test protocol.

EVALUATION PROTOCOL

These are the basic guidelines for arriving at an overall assay result for assays performed by the National Toxicology Program. Statistical as well as biological factors are considered. For an individual assay, the statistical procedures for data analysis have been described in the preceding protocols. There have been instances, however, in which multiple aliquots of a chemical were tested in the same assay, and differing results were obtained among aliquots and/or among laboratories. Results from more than one aliquot or from more than one laboratory are not simply combined into an overall result. Rather, all the data are critically evaluated, particularly with regard to pertinent protocol variations, in determining the weight of evidence for an overall conclusion of chemical activity in an assay. In addition to multiple aliquots, the *in vitro* assays have another variable that must be considered in arriving at an overall test result. *In vitro* assays are conducted with and without exogenous metabolic activation. Results obtained in the absence of activation are not combined with results obtained in the presence of activation; each testing condition is evaluated separately. The summary table in the Abstract of this Technical Report presents a result that represents a scientific judgement of the overall evidence for activity of the chemical in an assay.

RESULTS

Sodium nitrite (100-10,000 µg/plate) was mutagenic in *S. typhimurium* strain TA100, with and without Aroclor 1254-induced hamster and rat liver S9 enzymes; no mutagenicity was observed in strain TA98 (Table E1; Zeiger *et al.*, 1992). When sodium nitrite was administered by intraperitoneal injection at 6.25 to 200 mg/kg to male rats three times at 24-hour intervals, no significant increase in the frequency of micronucleated PCEs was observed in any of the dose groups (Table E2). The initial trial was judged to be positive, based on the trend test (P=0.001); however, results of a repeat trial, in which 50 mg/kg was the highest nonlethal dose tested, were negative, and the rat bone marrow micronucleus test with sodium nitrite was judged to be negative overall. A similar study in which male mice were administered 7.81 to 250 mg/kg also gave negative results (Table E3). A third *in vivo* study, a peripheral blood micronucleus test in mice administered sodium nitrite (375-5,000 ppm) for 14 weeks, showed no significant increase in the frequency of micronucleated NCEs in either males or females (Table E4). Thus, sodium nitrite demonstrated mutagenic activity in a strain of *S. typhimurium* that mutates via base-pair substitution, but no indication of chromosomal damage was observed in three micronucleus studies conducted in rats and mice *in vivo*.

Strain	Dose	-S	9	+30% ha	+30% hamster S9		+30% rat S9	
	(µg/plate)	Trial 1	Trial 2	Trial 1	Trial 2	Trial 1	Trial 2	
TA100	0	139 ± 19.4	171 ± 5.5	150 ± 0.7	158 ± 12.0	160 ± 0.6	173 ± 6.2	
	100	143 ± 14.1		148 ± 8.5	187 ± 5.6	201 ± 13.3	199 ± 14.7	
	333	126 ± 8.7		165 ± 4.4	182 ± 13.5	197 ± 9.2	233 ± 6.4	
	1,000	142 ± 7.5	211 ± 19.9	223 ± 4.6	220 ± 4.7	237 ± 12.5	230 ± 11.8	
	1,666		224 ± 10.6					
	3,333	195 ± 6.9	274 ± 21.4	341 ± 6.4	309 ± 11.7	259 ± 36.8	312 ± 10.4	
	6,666		376 ± 7.5					
	10,000	280 ± 9.9	443 ± 12.0	508 ± 29.5	451 ± 20.1	390 ± 38.8	353 ± 5.4	
						Weakly		
Trial sum	imary	Positive	Positive	Positive	Positive	Positive	Positive	
Positive	control	$1,036 \pm 10.2$	878 ± 22.7	832 ± 34.1	894 ± 24.1	568 ± 22.5	555 ± 18.3	
TA98	0	31 ± 0.9		42 ± 1.7		40 ± 4.8		
	100	27 ± 0.6		40 ± 4.6		33 ± 3.6		
	333	26 ± 4.2		39 ± 3.1		41 ± 3.8		
	1,000	30 ± 3.5		47 ± 4.2		29 ± 1.0		
	3,333	25 ± 2.6		42 ± 2.1		33 ± 2.8		
	10,000	26 ± 2.8		30 ± 5.2		21 ± 5.0		
Trial sun	nmary	Negative		Negative		Negative		
Positive	control	432 ± 19.0		539 ± 6.1		155 ± 14.3		

TABLE E1 Mutagenicity of Sodium Nitrite in Salmonella typhimurium^a

а Study was performed at SRI International. The detailed protocol and these data are presented by Zeiger et al. (1992). 0 µg/plate was the solvent control. Revertants are presented as mean \pm standard error from three plates. b

с

The positive controls in the absence of metabolic activation were sodium azide (TA100) and 4-nitro-o-phenylenediamine (TA98). The positive control for metabolic activation with both strains was 2-aminoanthracene.

Dose (mg/kg)	Number of Rats with Erythrocytes Scored	Micronucleated PCEs/ 1,000 PCEs ^b	P Value ^c
0	5	1.10 ± 0.24	
25	5	26.20 ± 2.95	0.0000
6.25 12.5 25 50 100 200	5 5 5 5 5 Lethal	$\begin{array}{c} 0.90 \pm 0.33 \\ 0.80 \pm 0.30 \\ 1.10 \pm 0.48 \\ 1.30 \pm 0.60 \\ 2.70 \pm 0.60 \end{array}$ P=0.001 ^f	0.6411 0.7109 0.5000 0.3707 0.0180
0	5	1.10 ± 0.51	
25	3	24.83 ± 2.52	0.0000
25 50	5 5	1.00 ± 0.45 1.10 ± 0.37	0.5635 0.5000
	(mg/kg) 0 25 6.25 12.5 25 50 100 200 0 25 25	Dose (mg/kg) with Erythrocytes Scored 0 5 25 5 6.25 5 12.5 5 25 5 12.5 5 20 5 100 5 200 Lethal 0 5 25 3 25 5	Dose (mg/kg)with Erythrocytes ScoredMicronucleated PCEs/ 1,000 PCEsb05 1.10 ± 0.24 255 26.20 ± 2.95 6.25 5 0.90 ± 0.33 12.5 5 0.80 ± 0.30 25 5 1.10 ± 0.48 505 1.30 ± 0.60 1005 2.70 ± 0.60 200LethalP= 0.001^{f} 05 1.10 ± 0.51 253 24.83 ± 2.52 255 1.00 ± 0.45

TABLE E2Induction of Micronuclei in Bone Marrow Polychromatic Erythrocytes of Male RatsTreated with Sodium Nitrite by Intraperitoneal Injection^a

^a Study was performed at Integrated Laboratory Systems, Inc. The detailed protocol is presented by Shelby *et al.* (1993). PCE=polychromatic
 ^b PCE=polychromatic

^b Mean \pm standard error

^c Pairwise comparison with the solvent control; significant at $P \le 0.005$ for trial 1 and at $P \le 0.012$ for trial 2 (ILS, 1990) d Solvent control.

d Solvent control

f Positive control

Significance of micronucleated PCEs/1,000 PCEs tested by the one-tailed trend test; significant at $P \le 0.025$ (ILS, 1990)

Compound	Dose (mg/kg)	Number of Mice with Erythrocytes Scored	Micronucleated PCEs/ 1,000 PCEs ^b	P Value ^c	
Phosphate-buffered saline ^d	0	5	1.10 ± 0.51		
Cyclophosphamide ^e	50	5	28.60 ± 4.24	0.0000	
Sodium nitrite	7.81	5	1.80 ± 0.34	0.1933	
	15.63	5	1.80 ± 0.60	0.1933	
	31.25	5	1.60 ± 0.78	0.2608	
	62.5	5	1.60 ± 0.73	0.2608	
	125	5	1.80 ± 0.49	0.1933	
	250	Lethal			
			P=0.343 ^f		

TABLE E3Induction of Micronuclei in Bone Marrow Polychromatic Erythrocytes of Male MiceTreated with Sodium Nitrite by Intraperitoneal Injection^a

^a Study was performed at Integrated Laboratory Systems, Inc. The detailed protocol is presented by Shelby *et al.* (1993). PCE=polychromatic erythrocyte

^b Mean \pm standard error

^c Pairwise comparison with the solvent control; significant at $P \le 0.005$ (ILS, 1990) d Column control

^d Solvent control

e Positive control

Significance of micronucleated PCEs/1,000 PCEs tested by the one-tailed trend test; significant at P≤0.025 (ILS, 1990)

TABLE E4 Frequency of Micronuclei in Peripheral Blood Erythrocytes of Mice Following Administration of Sodium Nitrite in Drinking Water for 14 Weeks^a

	Concentration (ppm)	Number of Mice with Erythrocytes Scored	Micronucleated NCEs/ 1,000 NCEs ^b	P Value ^c
Male				
	0	10	0.65 ± 0.17	
	375	10	0.80 ± 0.15	0.2887
	750	10	0.50 ± 0.13	0.7343
	1,500	10	0.85 ± 0.22	0.2325
	3,000	10	0.90 ± 0.12	0.1845
	5,000	10	0.80 ± 0.08	0.2887
			P=0.204 ^d	
Female				
	0	10	0.50 ± 0.17	
	375	10	0.70 ± 0.20	0.2070
	750	10	0.55 ± 0.16	0.4136
	1,500	10	0.55 ± 0.14	0.4136
	3,000	10	0.60 ± 0.16	0.3349
	5,000	10	0.45 ± 0.12	0.5907
			P=0.704	

а Study was performed at SITEK Research Laboratories, Inc. The detailed protocol is presented by MacGregor *et al.* (1990). NCE=normochromatic erythrocyte

b

c d

Mean \pm standard error Pairwise comparison with the control; significant at P<0.005 (ILS, 1990) Significance of micronucleated NCEs/1,000 NCEs tested by the one-tailed trend test; significant at P<0.025 (ILS, 1990)

APPENDIX F CLINICAL PATHOLOGY RESULTS

TABLE F1	Hematology and Clinical Chemistry Data for Rats	
	in the 14-Week Drinking Water Study of Sodium Nitrite	222
TABLE F2	Hemoglobin, Methemoglobin, and Serum and Gastric Nitrosamine Data for Rats	
	on Days 70 and 71 in the 14-Week Drinking Water Study of Sodium Nitrite	228

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
Male						
Hematology						
n						
Day 5	9	6	10	7	8	9
Day 19	10	10	9	10	10	9
Week 14	10	10	10	9	10	10
Hematocrit (%)						
Day 5	41.6 ± 0.5^{b}	41.1 ± 0.6^{c}	$39.2 \pm 0.6*$	40.0 ± 0.4^{d}	41.0 ± 0.7^{b}	39.5 ± 0.6^{b}
Day 19	43.5 ± 0.2	43.9 ± 0.4	44.3 ± 0.4^{b}	42.8 ± 1.0	46.3 ± 1.1	37.7 ± 1.3^{b}
Week 14	43.8 ± 0.6	44.1 ± 0.5	42.0 ± 0.6	42.2 ± 0.6	45.5 ± 0.5	$46.5 \pm 0.7*$
Hemoglobin (g/dL)	15.0 = 0.0	11.1 = 0.5	12.0 = 0.0	12.2 = 0.0	10.0 = 0.0	10.5 = 0.7
Day 5	14.5 ± 0.2^{b}	14.2 ± 0.2^{c}	$13.6 \pm 0.2*$	13.8 ± 0.1^{d}	14.2 ± 0.2^{b}	13.8 ± 0.2^{b}
Day 19	14.3 ± 0.2 14.9 ± 0.1	14.2 ± 0.2 15.0 ± 0.1	$15.0 \pm 0.2^{\circ}$ $15.1 \pm 0.1^{\circ}$	13.8 ± 0.1 14.7 ± 0.3	14.2 ± 0.2 15.3 ± 0.3	15.8 ± 0.2 $12.5 \pm 0.4^{**b}$
Week 14	14.9 ± 0.1 15.0 ± 0.2	15.0 ± 0.1 15.2 ± 0.1	13.1 ± 0.1 14.7 ± 0.2	14.7 ± 0.3 14.7 ± 0.2	15.5 ± 0.5 $15.7 \pm 0.1*$	12.3 ± 0.4 16.0 ± 0.3 **
	15.0 ± 0.2	15.2 ± 0.1	14.7 ± 0.2	14.7 ± 0.2	$15.7 \pm 0.1^{\circ}$	10.0 ± 0.3
Erythrocytes $(10^6/\mu L)$,			,	,	,
Day 5	7.08 ± 0.08^{b}	$6.95 \pm 0.13^{\circ}$	6.90 ± 0.10	6.79 ± 0.08^{d}	6.94 ± 0.13^{b}	6.89 ± 0.12^{b}
Day 19	7.61 ± 0.05	7.65 ± 0.10	$7.90 \pm 0.08 *^{b}$	7.54 ± 0.17	$8.44 \pm 0.15 **$	$8.10 \pm 0.21 **^{b}$
Week 14	8.30 ± 0.12	8.39 ± 0.08	7.97 ± 0.13	7.91 ± 0.10	8.29 ± 0.08	8.92 ± 0.25
Reticulocytes $(10^6/\mu L)$						
Day 5	0.45 ± 0.03	0.47 ± 0.05	$0.72 \pm 0.05 **$	0.51 ± 0.05	$0.67 \pm 0.06 **$	$0.69 \pm 0.03^{**d}$
Day 19	0.21 ± 0.02	0.19 ± 0.01	0.21 ± 0.02	0.23 ± 0.03	$0.37 \pm 0.02 **$	$0.58 \pm 0.05 **$
Week 14	0.22 ± 0.02	0.22 ± 0.03	0.26 ± 0.02	0.18 ± 0.02	$0.30 \pm 0.03*$	$0.37 \pm 0.04 **$
Nucleated erythrocytes $(10^3/\mu L)$	0.22 - 0.02	0.22 - 0.05	0.20 - 0.02	0.10 - 0.02	0.50 - 0.05	0.07 = 0.01
Day 5	1.00 ± 0.33	3.00 ± 0.45	2.80 ± 0.65	1.57 ± 0.69	2.75 ± 1.03	2.78 ± 0.49
Day 19	0.60 ± 0.22	0.90 ± 0.23	0.89 ± 0.35	1.20 ± 0.44	$2.70 \pm 0.52^{**}$	$5.33 \pm 1.12^{**}$
Week 14	0.70 ± 0.30	0.70 ± 0.21	0.60 ± 0.27	0.89 ± 0.20	1.10 ± 0.41	1.70 ± 0.50
Mean cell volume (fL)	0.70 ± 0.50	0.70 ± 0.21	0.00 ± 0.27	0.09 ± 0.20	1.10 ± 0.41	1.70 ± 0.50
Day 5	58.8 ± 0.3^{b}	59.2 ± 0.3^{c}	$56.9 \pm 0.2 **$	59.0 ± 0.4^{d}	59.1 ± 0.4^{b}	57.4 ± 0.3^{b}
Day 19	57.1 ± 0.4	57.2 ± 0.5 57.4 ± 0.5	56.2 ± 0.5^{b}	59.0 ± 0.4 56.9 ± 0.5	59.1 ± 0.4 54.9 ± 0.9	$46.4 \pm 0.5^{**b}$
Week 14	57.1 ± 0.4 52.8 ± 0.2	57.4 ± 0.3 52.5 ± 0.2	50.2 ± 0.3 52.8 ± 0.1	50.9 ± 0.3 53.3 ± 0.3	54.9 ± 0.9 55.0 ± 0.2 **	$52.4 \pm 1.2^{**}$
Mean cell hemoglobin (pg)	52.6 ± 0.2	52.5 ± 0.2	52.6 ± 0.1	55.5 ± 0.5	55.0 ± 0.2	52.4 ± 1.2
Day 5	20.4 ± 0.1^{b}	$20.5 \pm 0.1^{\circ}$	$19.8 \pm 0.1*$	$20.3\pm0.1^{\text{d}}$	20.5 ± 0.2^{b}	20.0 ± 0.1^{b}
	20.4 ± 0.1 19.6 ± 0.1	19.6 ± 0.2	$19.8 \pm 0.1^{+1}$ $19.1 \pm 0.2^{+b}$	20.3 ± 0.1 19.6 ± 0.2	20.3 ± 0.2 $18.1 \pm 0.3 **$	20.0 ± 0.1 15.4 ± 0.2 **
Day 19 Week 14	19.0 ± 0.1 18.1 ± 0.1	19.0 ± 0.2 18.1 ± 0.1	$19.1 \pm 0.2^{\circ}$ $18.5 \pm 0.1^{\circ}$	19.0 ± 0.2 $18.5 \pm 0.1*$	$18.1 \pm 0.3^{++}$ $18.9 \pm 0.1^{**}$	$15.4 \pm 0.2^{++}$ $18.1 \pm 0.5^{**}$
		18.1 ± 0.1	$18.5 \pm 0.1^{+1}$	$18.5 \pm 0.1^{+1}$	18.9 ± 0.1 **	18.1 ± 0.5
Mean cell hemoglobin concentration	$\frac{247}{247}$	24.010	24.7 ± 0.1	245 L 0 2d	247 L 0 2b	34.9 ± 0.2^{b}
Day 5	34.7 ± 0.2^{b}	$34.6 \pm 0.1^{\circ}$	34.7 ± 0.1	34.5 ± 0.2^{d}	34.7 ± 0.2^{b}	34.9 ± 0.2^{-5}
Day 19	34.3 ± 0.2	34.1 ± 0.2	34.0 ± 0.2^{b}	34.4 ± 0.3	$33.0 \pm 0.2 **$	$33.1 \pm 0.3^{**b}$
Week 14 Platelets $(10^3/\mu L)$	34.4 ± 0.2	34.4 ± 0.2	35.1 ± 0.2	34.8 ± 0.1	34.5 ± 0.1	34.4 ± 0.3
• •	h			b	h	h
Day 5	999.9 ± 23.9^{b}	$1,028.6 \pm 43.3^{\circ}$	$1,140.8 \pm 31.1*$	966.3 ± 51.6^{d}	$1,008.7 \pm 23.2^{b}$	$1,166.4 \pm 42.0^{*b}$
Day 19	763.6 ± 17.9	753.9 ± 24.5	827.4 ± 23.7^{b}	777.3 ± 45.5	759.1 ± 30.6	$1,815.2 \pm 129.0^{**b}$
Week 14	577.7 ± 21.4	608.0 ± 13.0	597.9 ± 15.1	588.3 ± 18.3	606.1 ± 16.3	673.4 ± 56.4
Leukocytes $(10^3/\mu L)$	h	-		A	h	h
Day 5	7.39 ± 0.79^{b}	$5.78 \pm 0.55^{\circ}$	7.81 ± 0.75	6.34 ± 0.43^{d}	7.79 ± 0.62^{b}	$8.33 \pm 0.68^{b}_{b}$
Day 19	8.11 ± 0.26	7.22 ± 0.58	8.47 ± 0.41^{b}	8.40 ± 0.60	7.66 ± 0.27	9.03 ± 0.49^{b}
Week 14	9.68 ± 0.78	9.55 ± 0.54	9.67 ± 0.59	8.88 ± 0.73	8.91 ± 0.64	9.44 ± 0.57
Segmented neutrophils $(10^3/\mu L)$						
Day 5	0.93 ± 0.11	0.73 ± 0.15	0.90 ± 0.15	0.71 ± 0.09	1.14 ± 0.22	1.09 ± 0.10
Day 19	0.85 ± 0.11	0.80 ± 0.10	1.07 ± 0.19	1.09 ± 0.22	0.85 ± 0.08	1.20 ± 0.16
Week 14	1.62 ± 0.16	1.57 ± 0.22	1.45 ± 0.14	1.11 ± 0.20	1.38 ± 0.22	$1.01 \pm 0.13*$

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
Male (continued)						
Hematology (continued)						
n						
Day 5	9	6	10	7	8	9
Day 19	10	10	9	10	10	9
Week 14	10	10	10	9	10	10
Immature neutrophils $(10^3/\mu L)$						
Day 5	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.014 ± 0.014	0.000 ± 0.000	0.000 ± 0.000
Day 19	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.011 ± 0.011
Week 14	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Metamyelocytes $(10^3/\mu L)$	0.000 - 0.000	0.000 - 0.000	0.000 - 0.000	0.000 ± 0.000	0.000 - 0.000	0.000 - 0.000
Day 5	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Day 19	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000
Week 14	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000
Myelocytes $(10^3/\mu L)$	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Day 5	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
					0.000 ± 0.000 0.000 ± 0.000	
Day 19	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000		0.000 ± 0.000
Week 14 Promyelocytes (10 ³ /µL)	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
				0.000 + 0.000	0.000 + 0.000	
Day 5	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Day 19	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Week 14	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Lymphocytes $(10^3/\mu L)$	6.00 . 0.60		(00 · 0 (0	5 00 × 0 05	6.00 . 0.54	
Day 5	6.80 ± 0.68	4.77 ± 0.57	6.88 ± 0.63	5.83 ± 0.37	6.89 ± 0.54	7.56 ± 0.54
Day 19	6.99 ± 0.22	6.24 ± 0.53	7.17 ± 0.40	7.14 ± 0.52	6.63 ± 0.23	7.76 ± 0.47
Week 14	8.02 ± 0.66	7.96 ± 0.47	8.16 ± 0.53	7.73 ± 0.61	7.43 ± 0.47	8.41 ± 0.50
Monocytes $(10^3/\mu L)$						
Day 5	0.08 ± 0.03	0.05 ± 0.02	0.04 ± 0.02	0.03 ± 0.02	0.08 ± 0.03	0.07 ± 0.02
Day 19	0.21 ± 0.03	0.15 ± 0.03	0.20 ± 0.03	0.13 ± 0.03	0.20 ± 0.05	0.18 ± 0.04
Week 14	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00 .
Basophils $(10^3/\mu L)$						
Day 5	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Day 19	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Week 14	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Eosinophils $(10^3/\mu L)$						
Day 5	0.01 ± 0.01	0.03 ± 0.03	0.01 ± 0.01	0.03 ± 0.02	0.05 ± 0.04	0.01 ± 0.01
Day 19	0.10 ± 0.04	0.06 ± 0.02	0.03 ± 0.02	0.03 ± 0.02	0.02 ± 0.01	$0.01 \pm 0.01*$
Week 14	0.04 ± 0.02	0.02 ± 0.01	0.02 ± 0.01	0.03 ± 0.02	0.09 ± 0.04	0.02 ± 0.01
Methemoglobin (g/dL)						
Day 5	0.03 ± 0.02	0.04 ± 0.02	$4.36 \pm 0.78^{**^{c}}$	$0.08 \pm 0.03 **$	$1.37 \pm 0.41^{**e}$	$3.97 \pm 0.75 **$
Day 19	0.09 ± 0.05	0.06 ± 0.02	$0.28 \pm 0.12*$	0.38 ± 0.12 **	$1.25 \pm 0.37 **$	$3.26 \pm 0.36^{**}$
Week 14	0.03 ± 0.01	$0.08 \pm 0.01 **$	$0.12 \pm 0.02 **$	$0.25 \pm 0.07 **$	$0.71 \pm 0.20 **$	$3.38 \pm 0.80 **$
Glutathione, erythrocyte (mg/dL e						
Day 5	89.6 ± 5.5	89.7 ± 3.7^{e}	$98.3 \pm 5.0^{\circ}$	86.9 ± 6.6	98.3 ± 5.4	101.7 ± 9.6^{b}
Day 19	$90.3 \pm 4.2^{\circ}$	$95.1 \pm 6.4^{\rm d}$	98.1 ± 6.5^{b}	94.1 ± 4.3	104.5 ± 4.9	$116.0 \pm 8.6^{*c}$
Week 14	63.7 ± 1.9^{e}	$67.5 \pm 3.6^{\rm d}$	$72.5 \pm 3.4^{\rm d}$	70.7 ± 2.3	$72.1 \pm 2.5^{*c}$	$73.8 \pm 1.9^{**}$
Heinz bodies $(10^6/\mu L)^f$	05.7 ± 1.7	07.5 - 5.0	12.5 - 5.7	10.1 - 2.5	12.1 - 2.5	10.0 - 1.7
Day 5	0.002 ± 0.001	0.005 ± 0.001	$0.009 \pm 0.002*$	0.010 ± 0.004	0.007 ± 0.002	0.013 ± 0.004**
Day 19	0.002 ± 0.001 0.004 ± 0.002	0.003 ± 0.001 0.004 ± 0.002	$0.009 \pm 0.002^{\circ}$ 0.003 ± 0.001	0.010 ± 0.004 0.004 ± 0.002	0.007 ± 0.002 0.006 ± 0.002	0.013 ± 0.004
Week 14	0.170 ± 0.114	0.170 ± 0.114	0.470 ± 0.128	0.267 ± 0.133	0.240 ± 0.122	0.350 ± 0.144

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
Male (continued)						
Clinical Chemistry						
n						
Day 5	10	10	10	9	10	10
Day 19	10	10	10	9	10	10
Week 14	10	10	10	10	10	10
Urea nitrogen (mg/dL)						
Day 5	20.4 ± 0.5	18.3 ± 0.7	21.7 ± 0.5	19.7 ± 1.0	19.9 ± 0.6	21.3 ± 0.6
Day 19	21.0 ± 0.7	21.4 ± 0.4	20.8 ± 0.5	22.3 ± 0.5	22.0 ± 0.3	$24.9 \pm 0.7^{**}$
Week 14	17.8 ± 0.5	$20.5 \pm 0.9^*$	20.0 ± 0.0 21.2 ± 0.7 **	$20.4 \pm 0.8^*$	22.0 ± 0.5 22.3 ± 1.4 **	$22.0 \pm 0.8^{**}$
Creatinine (mg/dL)	17.0 - 0.0	-0.0 - 0.9		-0.1 = 0.0		
Day 5	0.62 ± 0.01	0.66 ± 0.02	$0.72 \pm 0.03*$	0.62 ± 0.03	0.71 ± 0.04	0.69 ± 0.02
Day 19	0.66 ± 0.03	0.60 ± 0.02 0.63 ± 0.02	0.64 ± 0.03	0.02 ± 0.03 0.70 ± 0.03	0.69 ± 0.03	0.05 ± 0.02 0.76 ± 0.03
Week 14	0.68 ± 0.02	$0.70 \pm 0.02^{\circ}$	0.69 ± 0.02	0.70 ± 0.00 0.71 ± 0.01	0.69 ± 0.01	0.69 ± 0.02
Total protein (g/dL)	0.00 - 0.02	0.70 - 0.02	0.09 - 0.02	0.71 - 0.01	0.07 - 0.01	0.09 - 0.02
Day 5	6.5 ± 0.1	6.4 ± 0.1	6.0 ± 0.1 **	$6.3 \pm 0.1 **$	$6.2 \pm 0.1*$	$6.1 \pm 0.1 **$
Day 19	6.7 ± 0.2	7.0 ± 0.1	6.9 ± 0.1	6.7 ± 0.1	6.6 ± 0.1	6.4 ± 0.1
Week 14	6.7 ± 0.1	7.0 ± 0.1	7.0 ± 0.1	7.0 ± 0.1	7.0 ± 0.1	6.5 ± 0.1
Albumin (g/dL)						
Day 5	4.3 ± 0.1	4.3 ± 0.0	4.1 ± 0.0	4.2 ± 0.0	4.2 ± 0.0	4.2 ± 0.0
Day 19	4.4 ± 0.1	4.5 ± 0.0	4.5 ± 0.0	4.4 ± 0.1	4.4 ± 0.1	4.3 ± 0.0
Week 14	4.4 ± 0.0	4.5 ± 0.1	4.6 ± 0.1	4.5 ± 0.1	4.6 ± 0.1	4.4 ± 0.1
Alanine aminotransferase (IU/L)						
Day 5	45 ± 2	44 ± 2	40 ± 2	42 ± 2	45 ± 3	38 ± 2
Day 19	48 ± 3	42 ± 2	46 ± 3	55 ± 6	46 ± 1	45 ± 3
Week 14	52 ± 3	50 ± 3	57 ± 7	51 ± 3	56 ± 6	46 ± 2
Alkaline phosphatase (IU/L)						
Day 5	570 ± 12	586 ± 14	$445 \pm 8^{**}$	$544 \pm 11*$	$504 \pm 8**$	$441 \pm 5**$
Day 19	448 ± 8	455 ± 8	450 ± 8	423 ± 13^{b}	$402 \pm 6^{**}$	$333 \pm 11**$
Week 14	216 ± 6	233 ± 9	231 ± 9	209 ± 6	213 ± 6	210 ± 7
Creatine kinase (IU/L)						
Day 5	302 ± 45^{c}	397 ± 50	192 ± 32	245 ± 33	295 ± 34	199 ± 18
Day 19	$295 \pm 80^{\circ}$	274 ± 49	221 ± 38^{c}	279 ± 79	234 ± 34	337 ± 60
Week 14	120 ± 32	132 ± 40	135 ± 28	184 ± 86	143 ± 27	131 ± 19
Sorbitol dehyrogenase (IU/L)						
Day 5	9 ± 1	13 ± 1	12 ± 2	11 ± 2	12 ± 3	12 ± 1
Day 19	12 ± 1	11 ± 1	11 ± 0	13 ± 2^{b}	12 ± 1	14 ± 1
Week 14	14 ± 3	11 ± 4	17 ± 2	17 ± 4	19 ± 4	19 ± 4
Bile acids (µmol/L)						
Day 5	13.8 ± 2.9	$24.6 \pm 5.0*$	12.9 ± 1.7	16.3 ± 3.9	14.0 ± 2.7	8.8 ± 1.3
Day 19	15.3 ± 4.6	14.2 ± 4.7	$13.6 \pm 2.1^{\circ}$	13.4 ± 2.3	7.9 ± 0.6	12.5 ± 1.9
Week 14	5.7 ± 0.7^{c}	6.3 ± 0.5^{g}	13.6 ± 4.7^{d}	$13.9 \pm 1.8 **$	9.7 ± 2.6^{e}	5.8 ± 0.5^{g}

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
Female						
Hematology						
n						
Day 5	9	8	9	9	8	9
Day 19	10	10	10	10	10	10
Week 14	10	10	10	10	9	10
Hematocrit (%)						
Day 5	45.6 ± 1.4	44.3 ± 1.2	46.0 ± 0.9^{b}	46.0 ± 0.7	$45.1 \pm 1.0^{\circ}$	44.8 ± 0.6
Day 19	46.8 ± 0.5	46.0 ± 0.6	45.2 ± 0.5	46.6 ± 0.8	48.5 ± 1.3	42.7 ± 1.8
Week 14	43.8 ± 0.4	40.0 ± 0.0 43.5 ± 0.4	43.2 ± 0.3 42.1 ± 0.4	43.0 ± 0.0	$47.1 \pm 0.4^{**}$	42.7 ± 1.0 51.3 ± 0.6 **
Hemoglobin (g/dL)	15.0 = 0.1	15.5 = 0.1	12.1 = 0.1	15.0 = 0.1	17.1 = 0.1	51.5 = 0.0
Day 5	15.3 ± 0.4	14.8 ± 0.3	15.4 ± 0.2^{b}	15.4 ± 0.2	15.3 ± 0.2^{c}	15.2 ± 0.1
Day 19	15.7 ± 0.4 15.7 ± 0.1	14.8 ± 0.3 15.3 ± 0.1	15.4 ± 0.2 15.2 ± 0.2	15.4 ± 0.2 15.6 ± 0.2	15.9 ± 0.2 15.9 ± 0.4	13.2 ± 0.1 $13.9 \pm 0.6*$
Week 14	15.7 ± 0.1 15.2 ± 0.1	15.0 ± 0.1 15.0 ± 0.1	13.2 ± 0.2 14.7 ± 0.1	15.0 ± 0.2 15.0 ± 0.1	16.2 ± 0.1 **	15.5 ± 0.0 17.5 ± 0.1 **
Erythrocytes $(10^6/\mu L)$	15.2 = 0.1	10.0 = 0.1	11.7 = 0.1	15.0 = 0.1	10.2 = 0.1	17.5 = 0.1
Day 5	7.62 ± 0.26	7.27 ± 0.21	7.64 ± 0.13^{b}	7.56 ± 0.13	$7.44 \pm 0.20^{\circ}$	7.49 ± 0.09
Day 19	7.82 ± 0.20 7.87 ± 0.12	7.72 ± 0.13	7.54 ± 0.08	7.83 ± 0.17	$8.36 \pm 0.11*$	8.71 ± 0.20 **
Week 14	7.64 ± 0.07	7.61 ± 0.05	7.34 ± 0.08 7.31 ± 0.06	7.35 ± 0.07	7.74 ± 0.05	$8.49 \pm 0.15^{**}$
Reticulocytes $(10^6/\mu L)$	/.04 ± 0.07	7.01 ± 0.05	7.51 ± 0.00	7.55 ± 0.07	7.74 ± 0.05	8.49 ± 0.15
Day 5	0.29 ± 0.03	0.34 ± 0.02	0.36 ± 0.03	$0.44 \pm 0.05*$	$0.63 \pm 0.03 **$	$0.73 \pm 0.07 **$
Day 19	0.29 ± 0.03 0.14 ± 0.01	0.34 ± 0.02 $0.17 \pm 0.01*$	0.30 ± 0.03 0.14 ± 0.01	0.44 ± 0.03 $0.20 \pm 0.02^{**}$	0.03 ± 0.03 $0.41 \pm 0.05^{**}$	0.75 ± 0.07 0.65 ± 0.07 **
Week 14	0.14 ± 0.01 0.21 ± 0.02	0.17 ± 0.01 0.15 ± 0.02	0.14 ± 0.01 0.18 ± 0.02	0.20 ± 0.02 0.23 ± 0.03	0.41 ± 0.03 0.28 ± 0.03	0.03 ± 0.07 $0.40 \pm 0.03^{**}$
Nucleated erythrocytes $(10^3/\mu L)$	0.21 ± 0.02	0.13 ± 0.02	0.18 ± 0.02	0.23 ± 0.03	0.28 ± 0.05	0.40 ± 0.03
	1.80 ± 0.44^{b}	1.13 ± 0.35	1.44 ± 0.48	1.56 ± 0.53	2.40 ± 0.43^{b}	2.22 ± 0.36
Day 5	1.80 ± 0.44 0.60 ± 0.22				2.40 ± 0.43 0.60 ± 0.27	
Day 19		0.40 ± 0.16	0.90 ± 0.48	1.10 ± 0.38		$3.00 \pm 0.78*$
Week 14 Mean cell volume (fL)	1.00 ± 0.30	0.60 ± 0.22	0.80 ± 0.25	1.60 ± 0.34	1.00 ± 0.37	1.70 ± 0.42
	59.9 ± 0.4	60.9 ± 0.3	60.3 ± 0.4^{b}	60.8 ± 0.3	$60.7 \pm 0.5^{\circ}$	59.8 ± 0.3
Day 5						39.8 ± 0.3 $48.9 \pm 1.0**$
Day 19 Wash 14	59.5 ± 0.5	59.6 ± 0.6	60.0 ± 0.4	59.5 ± 0.5	58.0 ± 1.0	48.9 ± 1.0^{44} $60.5 \pm 0.7^{**}$.
Week 14	57.2 ± 0.1	57.2 ± 0.3	57.6 ± 0.2	$58.6 \pm 0.2 **$	$60.8 \pm 0.2 **$	$60.5 \pm 0.7^{\text{mm}}$.
Mean cell hemoglobin (pg)	20.1 ± 0.2	20.2 + 0.2	20.1 ± 0.2^{b}	20.2 ± 0.1	$20.7 \pm 0.2^{\circ}$	20.2 ± 0.1
Day 5	20.1 ± 0.2	20.3 ± 0.2		20.3 ± 0.1	$20.7 \pm 0.3^{\circ}$	20.3 ± 0.1
Day 19	19.9 ± 0.2	19.9 ± 0.2	20.1 ± 0.1	19.9 ± 0.3	19.0 ± 0.4	$15.8 \pm 0.3 **$
Week 14	19.9 ± 0.1	19.7 ± 0.1	20.1 ± 0.1	$20.5 \pm 0.1 **$	$20.9 \pm 0.1 **$	$20.7 \pm 0.3 **$
Mean cell hemoglobin concentrati	(U)	22.2 + 0.2	22 4 L 0 2b	22.4 + 0.2	24.0 + 0.20	22.0 + 0.2
Day 5	33.6 ± 0.3	33.3 ± 0.2	33.4 ± 0.3^{b}	33.4 ± 0.2	$34.0 \pm 0.3^{\circ}$	33.9 ± 0.3
Day 19	33.5 ± 0.2	33.4 ± 0.2	33.6 ± 0.1	33.4 ± 0.3	$32.9 \pm 0.2*$	32.4 ± 0.2 **
Week 14	34.7 ± 0.2	34.4 ± 0.1	34.9 ± 0.2	34.9 ± 0.2	34.3 ± 0.2	34.2 ± 0.2
Platelets $(10^3/\mu L)$	704 () 11 0	001.1 . 07.6	out a sar ib		005.2 + 24.5+**	001 0 10 01
Day 5	794.6 ± 41.0	891.1 ± 27.6	847.3 ± 35.4^{b}	866.9 ± 16.3	$995.3 \pm 34.5^{**c}$	931.8 ± 43.9**
Day 19	701.8 ± 24.7	703.4 ± 22.4	698.4 ± 30.7	709.4 ± 16.3	726.7 ± 61.2	$1,631.0 \pm 171.7 **$
Week 14	656.6 ± 17.0	611.5 ± 10.8	668.7 ± 21.3	613.6 ± 11.3	645.3 ± 21.9	617.5 ± 14.9
Leukocytes $(10^3/\mu L)$			1000b		o 40C	
Day 5	9.16 ± 0.76	9.41 ± 1.06	10.03 ± 0.68^{b}	8.16 ± 0.98	$9.19 \pm 0.60^{\circ}$	9.34 ± 0.93
Day 19	10.55 ± 0.54	9.55 ± 0.67	9.28 ± 0.48	9.18 ± 0.44	8.86 ± 0.56	10.72 ± 0.63
Week 14	9.61 ± 0.20	10.03 ± 0.46	8.60 ± 0.50	8.63 ± 0.48	11.29 ± 0.63	9.72 ± 0.41
Segmented neutrophils $(10^3/\mu L)$						
Day 5	0.98 ± 0.16	1.03 ± 0.15	0.90 ± 0.15	1.06 ± 0.14	1.04 ± 0.19	0.97 ± 0.17
Day 19	0.85 ± 0.10	0.75 ± 0.11	1.13 ± 0.14	0.95 ± 0.08	0.73 ± 0.11	0.93 ± 0.11
Week 14	1.53 ± 0.21	1.56 ± 0.22	1.61 ± 0.16	1.54 ± 0.11	1.86 ± 0.28	1.42 ± 0.10

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
Female (continued)						
Hematology (continued)						
n						
Day 5	9	8	9	9	8	9
Day 19	10	10	10	10	10	10
Week 14	10	10	10	10	9	10
Immature neutrophils $(10^3/\mu L)$						
Day 5	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.011 ± 0.011	0.000 ± 0.000	0.000 ± 0.000
Day 19	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.001 ± 0.001	0.000 ± 0.000 0.010 ± 0.010	0.000 ± 0.000 0.000 ± 0.000
Week 14	0.000 ± 0.000 0.000 ± 0.000	0.010 ± 0.010 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000			
	0.000 ± 0.000					
Metamyelocytes (10 ³ /µL)	0.000 ± 0.000	0.000 ± 0.000	0.000 + 0.000	0.000 + 0.000	0.000 + 0.000	0.000 ± 0.000
Day 5	0.000 ± 0.000					
Day 19	0.000 ± 0.000					
Week 14	0.000 ± 0.000	0.000 ± 0.000				
Myelocytes $(10^3/\mu L)$						
Day 5	0.000 ± 0.000					
Day 19	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Week 14	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Promyelocytes $(10^3/\mu L)$						
Day 5	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Day 19	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Week 14	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Lymphocytes $(10^3/\mu L)$						
Day 5	8.11 ± 0.68	8.23 ± 0.94	9.00 ± 0.73	7.00 ± 0.90	8.18 ± 0.53	8.28 ± 0.78
Day 19	9.33 ± 0.46	8.52 ± 0.62	7.82 ± 0.48	7.98 ± 0.42	7.86 ± 0.51	9.59 ± 0.63
Week 14	7.93 ± 0.21	8.32 ± 0.52	6.93 ± 0.41	6.92 ± 0.38	9.30 ± 0.50	8.16 ± 0.48
Monocytes $(10^3/\mu L)$						
Day 5	0.03 ± 0.02	0.01 ± 0.01	0.02 ± 0.02	0.04 ± 0.02	0.10 ± 0.02	0.07 ± 0.04
Day 19	0.29 ± 0.06	0.22 ± 0.07	0.29 ± 0.06	0.22 ± 0.05	0.22 ± 0.04	0.18 ± 0.04
Week 14	0.09 ± 0.03	0.03 ± 0.02	0.02 ± 0.01	0.06 ± 0.04	0.02 ± 0.02	0.08 ± 0.03
Basophils $(10^3/\mu L)$						
Day 5	0.000 ± 0.000					
Day 19	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000	0.000 ± 0.000 0.000 ± 0.000
Week 14	0.000 ± 0.000 0.000 ± 0.000					
Eosinophils $(10^3/\mu L)$	0.000 ± 0.000					
	0.04 ± 0.02	0.14 ± 0.04	0.06 ± 0.02	0.04 ± 0.02	0.03 ± 0.02	0.06 ± 0.03
Day 5			0.08 ± 0.02 0.08 ± 0.04			
Day 19	0.06 ± 0.02	0.05 ± 0.02		0.05 ± 0.02	0.06 ± 0.02	0.01 ± 0.01
Week 14	0.08 ± 0.03	0.13 ± 0.04	0.07 ± 0.03	0.11 ± 0.03	0.11 ± 0.04	0.09 ± 0.04
Methemoglobin (g/dL)	0.02 + 0.01	0.10 . 0.05*	0.05 + 0.01	0.01 . 0.00**	0.41 . 0.7(**	4.05 + 0.00**
Day 5	0.02 ± 0.01	$0.10 \pm 0.05^{*}$	0.05 ± 0.01	$0.21 \pm 0.08 **$	$2.41 \pm 0.76 **$	$4.95 \pm 0.92^{**}$
Day 19	0.03 ± 0.01	$0.11 \pm 0.03^*$	$0.18 \pm 0.04 **$	$2.01 \pm 0.49^{**}$	$3.78 \pm 0.79 * *$	$6.66 \pm 0.36^{**}$
Week 14	0.06 ± 0.02	$0.14 \pm 0.02 **$	$0.16 \pm 0.02 **$	$0.48 \pm 0.05^{**c}$	$0.99 \pm 0.20 **$	$2.27 \pm 0.54 **$
Glutathione, erythrocyte (mg/dL e	erythrocytes)	o c o0	d a d	a - c - d	o	
Day 5	83.4 ± 6.6^{d}	$86.8 \pm 6.7^{g}_{d}$	81.5 ± 6.2^{d}	$87.6 \pm 4.3^{d}_{d}$	$91.1 \pm 4.9^{\circ}$	105.0 ± 5.5^{d}
Day 19	88.3 ± 5.4	83.0 ± 4.8^{d}	$79.6 \pm 5.5^{c}_{d}$	89.8 ± 4.2^{d}	84.0 ± 1.7^{e}	98.3 ± 3.8
Week 14	$77.9 \pm 4.2^{\text{d}}$	$79.2 \pm 2.1^{\circ}$	85.4 ± 2.4^{d}	88.3 ± 1.6	84.2 ± 3.4	77.3 ± 2.6^{d}
Heinz bodies $(10^6/\mu L)^f$						
Day 5	0.002 ± 0.001	0.001 ± 0.001	0.002 ± 0.001	0.002 ± 0.001	0.006 ± 0.002	0.010 ± 0.002 **
Day 19	0.002 ± 0.001	0.002 ± 0.001	0.001 ± 0.001	0.003 ± 0.002	0.002 ± 0.002	0.002 ± 0.001
Duy 1						

Hematology and Clinical Chemistry Data for Rats in the 14-Week Drinking Water Study of Sodium Nitrite

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
Female (continued)						
Clinical Chemistry						
n						
Day 5	10	9	9	9	10	10
Day 19	10	10	10	10	10	10
Week 14	10	10	10	10	9	10
Urea nitrogen (mg/dL)						
Day 5	22.1 ± 1.1	21.2 ± 0.6	21.3 ± 0.6	20.3 ± 0.7^{d}	21.0 ± 0.5	22.5 ± 0.6 .
Day 19	$24.4 \pm 1.0^{\circ}$	24.2 ± 0.7	23.2 ± 0.5	23.9 ± 0.5	24.1 ± 0.6	$30.6 \pm 0.8 **$
Week 14	17.8 ± 0.6	19.0 ± 0.4	19.0 ± 0.7	$21.7 \pm 0.4 **$	$22.3 \pm 0.7 **$	$21.5 \pm 0.5 **$
Creatinine (mg/dL)						
Day 5	$0.63 \pm 0.03^{\circ}$	0.62 ± 0.03	0.70 ± 0.04	0.65 ± 0.02^{d}	$0.71 \pm 0.01 *^{c}$	$0.73 \pm 0.03 *^{c}$
Day 19	0.58 ± 0.04^{d}	$0.65 \pm 0.03*$	0.60 ± 0.02	$0.69 \pm 0.03 **$	$0.73 \pm 0.04 **$	$0.81 \pm 0.03 **$
Week 14	0.66 ± 0.02	0.68 ± 0.03	0.67 ± 0.02	0.68 ± 0.03	0.68 ± 0.03	0.69 ± 0.02
Total protein (g/dL)						
Day 5	6.1 ± 0.1	6.2 ± 0.1	6.2 ± 0.1	6.3 ± 0.1	6.2 ± 0.1	6.1 ± 0.1
Day 19	6.1 ± 0.1	6.2 ± 0.1	6.2 ± 0.1	6.3 ± 0.2	6.1 ± 0.1	6.2 ± 0.1
Week 14	6.8 ± 0.1	7.2 ± 0.1	7.0 ± 0.1	7.1 ± 0.1	7.0 ± 0.1	6.7 ± 0.1
Albumin (g/dL)			,			
Day 5	4.2 ± 0.1	4.4 ± 0.1	4.4 ± 0.1	$4.5 \pm 0.1 *^{d}$	4.5 ± 0.1	4.4 ± 0.1
Day 19	4.3 ± 0.1	4.5 ± 0.0	4.5 ± 0.0	4.5 ± 0.1	4.4 ± 0.1	4.5 ± 0.1
Week 14	4.5 ± 0.0	4.8 ± 0.1	4.8 ± 0.1	$4.8 \pm 0.1*$	4.7 ± 0.1	4.8 ± 0.1
Alanine aminotransferase (IU/L)						
Day 5	41 ± 4	37 ± 1	40 ± 2^{b}	38 ± 2	37 ± 1	44 ± 3
Day 19	38 ± 2	35 ± 1	33 ± 2	37 ± 2	38 ± 2	40 ± 1
Week 14	45 ± 2	42 ± 2	43 ± 2	57 = 2 53 ± 3	$53 \pm 2^{*}$	48 ± 3
Alkaline phosphatase (IU/L)						
Day 5	424 ± 21	423 ± 15	415 ± 14^{b}	377 ± 13	$345 \pm 11 * *$	$315 \pm 12**$
Day 19	350 ± 10	$299 \pm 22*$	340 ± 5	$315 \pm 16*$	$288 \pm 16^{**}$	257 ± 4**
Week 14	178 ± 5	176 ± 8	180 ± 5	167 ± 3	164 ± 3	$142 \pm 5**$
Creatine kinase (IU/L)						
Day 5	$344 \pm 60^{\circ}$	396 ± 94	398 ± 71^{d}	397 ± 62	321 ± 54^{c}	468 ± 75^{d}
Day 19	288 ± 67^{e}	267 ± 28	292 ± 40	229 ± 21	383 ± 52	391 ± 42^{c}
Week 14	99 ± 22	71 ± 14	67 ± 10	69 ± 14	60 ± 9	109 ± 11
Sorbitol dehydrogenase (IU/L)						
Day 5	11 ± 1	9 ± 1	11 ± 0^{b}	10 ± 1	10 ± 1	13 ± 2
Day 19	13 ± 0	13 ± 0	12 ± 1	13 ± 1	14 ± 1	14 ± 1
Week 14	12 ± 5	7 ± 1	6 ± 1	8 ± 1	7 ± 1	10 ± 1
Bile acids (µmol/L)						
Day 5	12.7 ± 2.5^{c}	12.4 ± 2.1	21.0 ± 5.9^{d}	16.3 ± 5.0^{d}	13.6 ± 2.2^{c}	17.4 ± 3.5^{d}
Day 19	$21.1 \pm 5.8^{\circ}$	15.4 ± 2.3	16.8 ± 3.0	12.9 ± 1.4	14.8 ± 2.5	15.8 ± 3.0
Week 14	17.6 ± 2.2	20.2 ± 3.6	25.1 ± 4.2	30.0 ± 8.6	25.0 ± 3.4	32.0 ± 7.7

* Significantly different (P \leq 0.05) from the control group by Dunn's or Shirley's test

** P≤0.01

^a Mean \pm standard error. Statistical tests were performed on unrounded data.

Total number of erythrocytes with Heinz bodies

^g n=6

^b n=10

c n=9

 $[\]begin{array}{c} d \\ n=8 \\ e \\ n=7 \end{array}$

e n=7 f Tota

Hemoglobin, Methemoglobin, and Serum and Gastric Nitrosamine Data for Rats on Days 70 and 71 in the 14-Week Drinking Water Study of Sodium Nitrite^a

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
n	5	5	5	5	5	5
Male						
Hemoglobin (g/dL) Day 70 (at 2000 hours) Day 70 (at 2200 hours) Day 71 (at 0900 hours)	$14.0 \pm 0.8 \\ 15.2 \pm 0.2 \\ 15.4 \pm 0.2$	$14.4 \pm 0.7^{b} \\ 15.4 \pm 0.3 \\ 15.4 \pm 0.2$	$\begin{array}{c} 14.9 \pm 0.2 \\ 15.1 \pm 0.2 \\ 15.3 \pm 0.1 \end{array}$	15.0 ± 0.2 15.3 ± 0.4^{c} 15.0 ± 0.2	$\begin{array}{c} 16.1 \pm 0.4 \\ 16.7 \pm 0.6 \\ 15.9 \pm 0.2 \end{array}$	$\begin{array}{c} 14.6 \pm 0.8 \\ 15.2 \pm 0.5 \\ 14.4 \pm 0.1 * \end{array}$
Methemoglobin (g/dL) Day 70 (at 2000 hours) Day 70 (at 2200 hours) Day 71 (at 0900 hours)	$\begin{array}{c} 0.05 \pm 0.02 \\ 0.02 \pm 0.01 \\ 0.03 \pm 0.01 \end{array}$	$\begin{array}{c} 0.09 \pm 0.02^b \\ 0.05 \pm 0.01 \\ 0.09 \pm 0.01^{**} \end{array}$	$0.12 \pm 0.02*$ $0.07 \pm 0.01**$ $0.10 \pm 0.03*$	$0.44 \pm 0.17^{**}$ $0.14 \pm 0.00^{**^{c}}$ $0.54 \pm 0.23^{**}$	$\begin{array}{c} 0.47 \pm 0.27^{**} \\ 0.70 \pm 0.48^{**} \\ 3.50 \pm 0.68^{**} \end{array}$	$0.54 \pm 0.09^{**}$ $0.64 \pm 0.23^{**}$ $5.13 \pm 1.40^{**}$
Serum nitrosamine Day 70 (at 2000 hours) Day 70 (at 2200 hours) Day 71 (at 0900 hours)	d 	 		 	 	
Gastric nitrosamine Day 70 (at 2000 hours) Day 70 (at 2200 hours) Day 71 (at 0900 hours)	 	 	 	 	 	
Female						
Hemoglobin (g/dL) Day 70 (at 2000 hours) Day 70 (at 2200 hours) Day 71 (at 0900 hours)	16.2 ± 0.3 15.7 ± 0.4 15.7 ± 0.2	$15.4 \pm 0.2 \\ 15.5 \pm 0.3^{b} \\ 15.2 \pm 0.2$	15.1 ± 0.1 15.4 ± 0.2 15.8 ± 0.1	$\begin{array}{c} 15.8 \pm 0.4 \\ 15.8 \pm 0.3 \\ 15.2 \pm 0.2 \end{array}$	17.5 ± 0.2 $16.8 \pm 0.2*$ $16.5 \pm 0.1*$	$\begin{array}{c} 15.5 \pm 0.5^{b} \\ 16.7 \pm 0.0^{c} \\ 17.2 \pm 0.8^{b} \end{array}$
Methemoglobin (g/dL) Day 70 (at 2000 hours) Day 70 (at 2200 hours) Day 71 (at 0900 hours)	$\begin{array}{c} 0.04 \pm 0.02 \\ 0.27 \pm 0.09 \\ 0.09 \pm 0.02 \end{array}$	$\begin{array}{c} 0.21 \pm 0.08 * \\ 0.12 \pm 0.02 \\ 0.19 \pm 0.05 * \end{array}$	$\begin{array}{c} 0.39 \pm 0.12^{**} \\ 0.26 \pm 0.06 \\ 1.16 \pm 0.30^{**} \end{array}$	$0.60 \pm 0.11 **$ 0.26 ± 0.05 $1.06 \pm 0.09 **$	$0.57 \pm 0.20^{**}$ 0.50 ± 0.10 $4.39 \pm 0.79^{**}$	$2.76 \pm 0.75^{**b}$ 0.44 ± 0.07^{c} $3.32 \pm 1.78^{**b}$
Serum nitrosamine Day 70 (at 2000 hours) Day 70 (at 2200 hours) Day 71 (at 0900 hours) Contrio nitrogening		 				
Gastric nitrosamine Day 70 (at 2000 hours) Day 70 (at 2200 hours) Day 71 (at 0900 hours)				 	 	

* Significantly different (P≤0.05) from the control group by Dunn's or Shirley's test

^a Mean ± standard error. Statistical tests were performed on unrounded data.

^d Undetectable by thermal energy analyzer. Nitrosamine includes N-nitrosodimethylamine, N-nitrosodiethylamine, N-nitrosodipropylamine, N-nitrosodiporpylamine, N-nitrosod

^{**} P≤0.01

b n=4

c n=3 d Und

APPENDIX G ORGAN WEIGHTS AND ORGAN-WEIGHT-TO-BODY-WEIGHT RATIOS

TABLE G1	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats	
	in the 14-Week Drinking Water Study of Sodium Nitrite	. 230
TABLE G2	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice	
	in the 14-Week Drinking Water Study of Sodium Nitrite	232

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
Male						
n	10	10	10	10	10	10
Necropsy body wt	372 ± 5	357 ± 7	360 ± 9	366 ± 4	$347 \pm 6*$	316 ± 8**
Heart						
Absolute	1.109 ± 0.014	1.056 ± 0.023	1.106 ± 0.034	1.123 ± 0.019	1.113 ± 0.021	1.078 ± 0.039
Relative R. Kidney	0.298 ± 0.004	0.296 ± 0.005	0.307 ± 0.006	0.307 ± 0.005	$0.321 \pm 0.004 **$	$0.340 \pm 0.006 **$
Absolute	1.273 ± 0.016	1.293 ± 0.036	1.276 ± 0.033	1.319 ± 0.021	1.328 ± 0.030	1.250 ± 0.029
Relative	0.342 ± 0.003	$0.362 \pm 0.007*$	$0.354 \pm 0.003*$	$0.360 \pm 0.004^*$	$0.382 \pm 0.005^{**}$	$0.396 \pm 0.006 **$
Liver						
Absolute	13.140 ± 0.412^{b}	13.252 ± 0.394	13.098 ± 0.351	13.222 ± 0.187	12.593 ± 0.367	11.086 ± 0.343**
Relative	3.522 ± 0.066^{b}	3.712 ± 0.085	3.638 ± 0.051	3.610 ± 0.048	3.622 ± 0.066	3.509 ± 0.075
Lung						
Absolute	1.796 ± 0.051	1.785 ± 0.075	1.675 ± 0.069	1.756 ± 0.082	1.746 ± 0.057	1.575 ± 0.056
Relative	0.483 ± 0.016	0.499 ± 0.016	0.465 ± 0.014	0.479 ± 0.022	0.502 ± 0.010	0.497 ± 0.008
Spleen						
Absolute	0.822 ± 0.006	0.793 ± 0.019	0.829 ± 0.018	0.849 ± 0.015	0.881 ± 0.019	0.818 ± 0.025
Relative	0.221 ± 0.003	0.222 ± 0.003	0.230 ± 0.003	$0.232 \pm 0.003 *$	$0.254 \pm 0.004 \text{**}$	$0.259 \pm 0.004 **$
R. Testis						
Absolute	1.686 ± 0.127	1.515 ± 0.024	1.539 ± 0.022	1.575 ± 0.016	1.553 ± 0.018	1.497 ± 0.019
Relative	0.452 ± 0.032	0.425 ± 0.005	0.429 ± 0.009	0.430 ± 0.006	0.448 ± 0.009	0.476 ± 0.009
Thymus						
Absolute	0.366 ± 0.018	0.363 ± 0.013	0.367 ± 0.011	0.396 ± 0.010	0.385 ± 0.019	0.328 ± 0.015
Relative	0.098 ± 0.005	0.102 ± 0.003	0.102 ± 0.004	0.108 ± 0.003	0.111 ± 0.006	0.104 ± 0.006

TABLE G1 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats in the 14-Week Drinking Water Study of Sodium Nitrite^a

	0 ppm	375 ppm	750 ppm	1,500 ppm	3,000 ppm	5,000 ppm
Female						
n	10	10	10	10	9	10
Necropsy body wt	207 ± 4	207 ± 2	200 ± 3	207 ± 3	194 ± 3*	185 ± 6**
Heart						
Absolute	0.711 ± 0.018	0.716 ± 0.013	0.700 ± 0.020	0.734 ± 0.015	0.713 ± 0.009	0.742 ± 0.009
Relative	0.344 ± 0.004	0.345 ± 0.005	0.350 ± 0.006	0.355 ± 0.005	$0.369 \pm 0.006 *$	0.406 ± 0.014 **
R. Kidney						
Absolute	0.778 ± 0.017	0.758 ± 0.017	0.768 ± 0.012	0.793 ± 0.013	0.819 ± 0.022	0.841 ± 0.017 **
Relative	0.376 ± 0.003	0.365 ± 0.006	0.385 ± 0.003	0.383 ± 0.005	$0.423 \pm 0.008 **$	$0.460 \pm 0.017 **$
Liver						
Absolute	6.376 ± 0.178	6.814 ± 0.164	6.730 ± 0.200	6.730 ± 0.119	6.324 ± 0.133	6.155 ± 0.167
Relative	3.086 ± 0.061	3.286 ± 0.073	3.371 ± 0.078	3.256 ± 0.041	3.268 ± 0.063	3.364 ± 0.141
Lung						
Absolute	1.281 ± 0.066	1.214 ± 0.043	1.273 ± 0.054	1.301 ± 0.044	1.284 ± 0.063	1.160 ± 0.024
Relative	0.621 ± 0.032	0.585 ± 0.020	0.636 ± 0.020	0.628 ± 0.014	0.662 ± 0.028	0.633 ± 0.021
Spleen						
Absolute	0.532 ± 0.009	0.523 ± 0.006	0.514 ± 0.007	0.552 ± 0.014	$0.612 \pm 0.013 **$	$0.654 \pm 0.013 **$
Relative	0.258 ± 0.004	0.252 ± 0.003	0.258 ± 0.003	0.267 ± 0.005	$0.317 \pm 0.006 **$	$0.357 \pm 0.013 **$
Thymus						
Absolute	0.276 ± 0.011	0.276 ± 0.011	0.272 ± 0.008	0.284 ± 0.006	0.279 ± 0.014	0.270 ± 0.006
Relative	0.134 ± 0.006	0.133 ± 0.005	0.137 ± 0.004	0.138 ± 0.002	0.144 ± 0.007	0.148 ± 0.006

TABLE G1 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats in the 14-Week Drinking Water Study of Sodium Nitrite

* Significantly different (P≤0.05) from the control group by Williams' or Dunnett's test

** P≤0.01

a Organ weights (absolute weights) and body weights are given in grams; organ-weight-to-body-weight ratios (relative weights) are given as g organ weight/
 g body weight as a percentage (mean ± standard error).

b n=9

750 ppm 3,000 ppm 0 ppm 375 ppm 1,500 ppm 5,000 ppm 10 10 n 10 10 10 10 Male Necropsy body wt 34.4 ± 0.8 33.5 ± 0.7 33.4 ± 1.0 $31.7 \pm 1.0*$ $30.7 \pm 0.8 **$ 34.6 ± 0.8 Heart 0.166 ± 0.006 0.173 ± 0.005 0.168 ± 0.007 0.166 ± 0.007 0.162 ± 0.003 0.169 ± 0.008 Absolute Relative 0.480 ± 0.019 0.502 ± 0.012 0.502 ± 0.014 0.499 ± 0.017 0.515 ± 0.018 $0.552 \pm 0.030*$ R. Kidney Absolute 0.296 ± 0.007 0.291 ± 0.004 0.284 ± 0.008 0.285 ± 0.008 0.288 ± 0.007 0.291 ± 0.008 Relative 0.859 ± 0.023 0.851 ± 0.024 0.850 ± 0.017 0.856 ± 0.019 0.912 ± 0.026 $0.952 \pm 0.018 **$ Liver Absolute 1.630 ± 0.042 1.530 ± 0.142 1.652 ± 0.041 1.450 ± 0.046 1.648 ± 0.058 1.616 ± 0.075 Relative 4.718 ± 0.107 4.400 ± 0.388 4.944 ± 0.114 4.349 ± 0.079 5.200 ± 0.108 5.257 ± 0.168 Lung 0.295 ± 0.013 0.267 ± 0.020 0.273 ± 0.013 0.277 ± 0.014 0.269 ± 0.011 0.276 ± 0.017 Absolute 0.852 ± 0.031 0.772 ± 0.049 0.815 ± 0.030 0.836 ± 0.047 0.860 ± 0.052 0.898 ± 0.043 Relative Spleen Absolute 0.071 ± 0.003 0.071 ± 0.002 0.072 ± 0.002 0.074 ± 0.002 0.080 ± 0.003 $0.106 \pm 0.005 **$ Relative 0.206 ± 0.007 0.209 ± 0.007 0.221 ± 0.007 $0.253 \pm 0.009 **$ $0.344 \pm 0.013 **$ 0.217 ± 0.006 R. Testis 0.124 ± 0.003 0.123 ± 0.002 0.117 ± 0.002 0.121 ± 0.002 0.117 ± 0.003 0.122 ± 0.002 Absolute 0.372 ± 0.011 $0.398 \pm 0.008 **$ Relative 0.358 ± 0.010 0.358 ± 0.007 0.350 ± 0.004 0.364 ± 0.010 Thymus Absolute 0.062 ± 0.003 0.060 ± 0.004 0.051 ± 0.005 0.050 ± 0.003 0.050 ± 0.004 0.052 ± 0.003 Relative 0.181 ± 0.010 0.174 ± 0.012 0.152 ± 0.015 0.150 ± 0.005 0.158 ± 0.014 0.170 ± 0.009 Female Necropsy body wt 30.1 ± 0.9 31.4 ± 1.0 31.8 ± 1.2 31.3 ± 1.0 31.7 ± 1.1 28.2 ± 0.6 Heart 0.143 ± 0.005 0.139 ± 0.006 0.159 ± 0.006 0.156 ± 0.005 $0.164 \pm 0.006*$ $0.168 \pm 0.006 **$ Absolute 0.502 ± 0.022 0.501 ± 0.020 $0.598 \pm 0.021 \texttt{**}$ Relative 0.477 ± 0.021 0.443 ± 0.017 0.521 ± 0.020 R. Kidney Absolute 0.198 ± 0.004 0.196 ± 0.005 0.208 ± 0.005 0.201 ± 0.004 $0.214 \pm 0.005*$ $0.212 \pm 0.004*$ 0.627 ± 0.012 0.657 ± 0.014 0.644 ± 0.013 $0.753 \pm 0.006 **$ Relative 0.659 ± 0.014 0.677 ± 0.016 Liver Absolute 1.454 ± 0.030 1.504 ± 0.031 1.617 ± 0.053 1.487 ± 0.035 $1.682 \pm 0.041 **$ $1.575 \pm 0.042 **$ Relative 4.853 ± 0.112 4.822 ± 0.120 5.096 ± 0.091 4.785 ± 0.143 $5.328 \pm 0.096 **$ $5.597 \pm 0.137 **$ Lung Absolute 0.296 ± 0.009 0.293 ± 0.017 0.311 ± 0.013 0.289 ± 0.014 0.274 ± 0.018 0.254 ± 0.019 Relative 0.989 ± 0.037 0.938 ± 0.050 0.986 ± 0.049 0.934 ± 0.053 0.871 ± 0.061 0.899 ± 0.061 Spleen 0.098 ± 0.002 0.125 ± 0.004 ** $0.149 \pm 0.008 **$ Absolute 0.090 ± 0.003 0.090 ± 0.003 0.096 ± 0.003 Relative 0.300 ± 0.010 0.290 ± 0.012 0.312 ± 0.012 0.311 ± 0.015 $0.396 \pm 0.014 \texttt{**}$ $0.531 \pm 0.028 **$ Thymus Absolute 0.061 ± 0.004 0.064 ± 0.004 0.065 ± 0.004 0.066 ± 0.003 0.065 ± 0.003 0.056 ± 0.003 Relative 0.204 ± 0.012 0.204 ± 0.009 0.206 ± 0.013 0.211 ± 0.006 0.208 ± 0.012 0.198 ± 0.011

TABLE G2 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice in the 14-Week Drinking Water Study of Sodium Nitrite^a

* Significantly different (P≤0.05) from the control group by Williams' or Dunnett's test

** P≤0.01

^a Organ weights (absolute weights) and body weights are given in grams; organ-weight-to-body-weight ratios (relative weights) are given as g organ weight/ g body weight as a percentage (mean ± standard error).

APPENDIX H REPRODUCTIVE TISSUE EVALUATIONS AND ESTROUS CYCLE CHARACTERIZATION

TABLE H1	Summary of Reproductive Tissue Evaluations for Male Rats	
	in the 14-Week Drinking Water Study of Sodium Nitrite	
TABLE H2	Estrous Cycle Characterization for Female Rats	
	in the 14-Week Drinking Water Study of Sodium Nitrite	
TABLE H3	Summary of Reproductive Tissue Evaluations for Male Mice	
	in the 14-Week Drinking Water Study of Sodium Nitrite	
TABLE H4	Estrous Cycle Characterization for Female Mice	
	in the 14-Week Drinking Water Study of Sodium Nitrite	

	0 ppm	375 ppm	1,500 ppm	5,000 ppm
1	10	10	10	10
Weights (g)				
Necropsy body wt	372 ± 5	357 ± 7	366 ± 4	$316 \pm 8 * *$
L. Cauda epididymis	0.2030 ± 0.0066	0.1976 ± 0.0044	0.1860 ± 0.0042	0.1900 ± 0.0050
L. Epididymis	0.5110 ± 0.0133	0.5017 ± 0.0067	0.4922 ± 0.0090	$0.4745 \pm 0.0072*$
L. Testis	1.5359 ± 0.0609	1.4418 ± 0.0719	1.6062 ± 0.0145	1.5386 ± 0.0249
Spermatid measurements_				
Spermatid heads $(10^7_7/\text{g testis})$	9.471 ± 0.562	10.722 ± 1.046	10.268 ± 0.733	9.309 ± 0.488
Spermatid heads (10 ⁷ /testis) Spermatid count	14.310 ± 0.540	14.865 ± 0.645	16.560 ± 1.282	14.325 ± 0.773
(mean/10 ⁻⁴ mL suspension)	71.550 ± 2.702	74.325 ± 3.227	82.800 ± 6.412	71.625 ± 3.863
Epididymal spermatozoal measurements				
Motility (%)	89.45 ± 1.85	91.09 ± 1.38	$83.18 \pm 2.15*$	$73.42 \pm 4.15 **$
Concentration $(10^{6}/\text{g cauda epididymal tissue})$	366 ± 15^{b}	370 ± 14	366 ± 14	391 ± 15

TABLE H1 Summary of Reproductive Tissue Evaluations for Male Rats in the 14-Week Drinking Water Study of Sodium Nitrite^a

Significantly different (P<0.05) from the control group by Williams' test (epididymis weight) or Shirley's test (motility)

** Significantly different (P≤0.01) from the control group by Williams' test (body weight) or Shirley's test (motility) а

Data are presented as mean ± standard error. Differences from the control group are not significant by Dunnett's test (cauda epididymis and testis weights) or Dunn's test (spermatid measurements, epididymal spermatozoal concentration). b

n=9

TABLE H2 Estrous Cycle Characterization for Female Rats in the 14-Week Drinking Water Study of Sodium Nitrite^a

	0 ppm	375 ppm	750 ppm	3,000 ppm
n	10	10	10	9
Necropsy body wt (g)	205 ± 4	207 ± 2	200 ± 3	194 ± 3*
Estrous cycle length (days)	5.100 ± 0.125	4.850 ± 0.076	5.050 ± 0.117	5.278 ± 0.121
Estrous stages (% of cycle)				
Diestrus	40.8	40.0	42.5	42.6
Proestrus	15.0	15.0	12.5	15.7
Estrus	23.3	25.0	25.8	21.3
Metestrus	20.8	20.0	18.3	20.4
Uncertain diagnoses	0.0	0.0	0.8	0.0

Significantly different (P \leq 0.05) from the control group by Williams' test а

Necropsy body weight and estrous cycle length data are presented as mean ± standard error. Differences from the control group for estrous cycle length are not significant by Dunn's test. By multivariate analysis of variance, exposed females do not differ significantly from the control females in the relative length of time spent in the estrous stages.

	0 ppm	375 ppm	1,500 ppm	5,000 ppm
n	10	10	10	10
Weights (g)				
Necropsy body wt	34.6 ± 0.8	34.4 ± 0.8	33.4 ± 0.9	$30.7 \pm 0.8 **$
L. Cauda epididymis	0.0287 ± 0.0035	0.0254 ± 0.0032	0.0273 ± 0.0038	0.0256 ± 0.0032
L. Epididymis	0.0613 ± 0.0060	0.0549 ± 0.0027	0.0587 ± 0.0040	0.0601 ± 0.0074
L. Testis	0.1222 ± 0.0039	0.1216 ± 0.0049	0.1236 ± 0.0034	0.1167 ± 0.0027
Spermatid measurements_				
Spermatid heads $(10^7/\text{g testis})$	18.274 ± 0.635	17.016 ± 0.891	18.566 ± 0.702	18.012 ± 1.017
Spermatid heads (10 ⁷ /testis) Spermatid count	2.228 ± 0.092	2.060 ± 0.111	2.287 ± 0.091	2.094 ± 0.112
$(\text{mean}/10^{-4} \text{ mL suspension})$	69.625 ± 2.864	64.350 ± 3.485	71.500 ± 2.853	65.425 ± 3.519
Epididymal spermatozoal measurements				
Motility (%)	73.89 ± 4.14	71.74 ± 3.63	67.86 ± 1.57	39.23 ± 7.41 **
Concentration $(10^6/\text{g cauda epididymal tissue})$	527 ± 93	685 ± 74	457 ± 106	717 ± 99

TABLE H3 Summary of Reproductive Tissue Evaluations for Male Mice in the 14-Week Drinking Water Study of Sodium Nitrite^a

** Significantly different ($P \le 0.01$) from the control group by Williams' test (body weight) or Shirley's test (motility)

^a Data are presented as mean ± standard error. Differences from the control group are not significant by Dunnett's test (tissue weights) or Dunn's test (spermatid measurements, epididymal spermatozoal concentration).

TABLE H4
Estrous Cycle Characterization for Female Mice in the 14-Week Drinking Water Study of Sodium Nitrite ^a

	0 ppm	375 ppm	1,500 ppm	5,000 ppm
n	10	10	10	10
Necropsy body wt (g) Estrous cycle length (days) Estrous stages (% of cycle)	$\begin{array}{c} 30.1 \pm 0.9 \\ 4.188 \pm 0.132^{b} \end{array}$	31.4 ± 1.0 4.400 ± 0.125	31.3 ± 1.0 $4.667 \pm 0.118*^{c}$	$28.2 \pm 0.6 \\ 4.813 \pm 0.091 **^{b}$
Diestrus	37.5	29.2	30.8	32.5
Proestrus	20.8	20.8	19.2	18.3
Estrus	25.0	30.8	35.8	33.3
Metestrus	16.7	19.2	14.2	15.8

* Significantly different (P≤0.05) from the control group by Shirley's test

** P≤0.01

^a Necropsy body weight and estrous cycle length data are presented as mean ± standard error. Differences from the control group for necropsy cycle length are not significant by Dunn's test. By multivariate analysis of variance, exposed females do not differ significantly from the control females in the relative length of time spent in the estrous stages.

b Estrous cycle was longer than 12 days or unclear in 2 of 10 animals.

c Estrous cycle was longer than 12 days of unclear in 2 of 10 animals. Estrous cycle was longer than 12 days or unclear in 1 of 10 animals.

APPENDIX I DETERMINATIONS OF PLASMA NITRITE AND BLOOD METHEMOGLOBIN CONCENTRATIONS

TABLE I1	Plasma Nitrite and Blood Methemoglobin Concentrations at 2 Weeks	
	in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite	238
TABLE I2	Plasma Nitrite and Blood Methemoglobin Concentrations at 2 Weeks	
	in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite	239
TABLE I3	Plasma Nitrite and Blood Methemoglobin Concentrations at 3 Months	
	in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite	240
TABLE I4	Plasma Nitrite and Blood Methemoglobin Concentrations at 3 Months	
	in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite	241
FIGURE I1	Blood Methemoglobin Concentrations at 2 Weeks in Male and Female Rats	
	in the 2-Year Drinking Water Study of Sodium Nitrite	242
FIGURE I2	Blood Methemoglobin Concentrations at 3 Months in Male and Female Rats	
	in the 2-Year Drinking Water Study of Sodium Nitrite	243
TABLE I5	Plasma Nitrite and Blood Methemoglobin Concentrations at 18 Months	
	in Aged Male Rats after a Single Gavage Dose of 40 mg/kg Sodium Nitrite	244
TABLE I6	Plasma Nitrite and Blood Methemoglobin Concentrations at 18 Months	
	in Aged Female Rats after a Single Gavage Dose of 40 mg/kg Sodium Nitrite	244
TABLE I7	Plasma Nitrite and Blood Methemoglobin Concentrations at 12 Months	
	in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite	245
TABLE I8	Blood Methemoglobin Concentrations at 12 Months in Female Mice	
	in the 2-Year Drinking Water Study of Sodium Nitrite	245
TABLE I9	Plasma Nitrite and Blood Methemoglobin Concentrations at 18 Months	
	in Aged Male Mice after a Single Gavage Dose of 62.5 mg/kg Sodium Nitrite	246
TABLE I10	Plasma Nitrite and Blood Methemoglobin Concentrations at 18 Months	
	in Aged Female Mice after a Single Gavage Dose of 62.5 mg/kg Sodium Nitrite	246
FIGURE I3	Plasma Nitrite Concentrations at 18 Months in Aged Male Mice	
	after a Single Gavage Dose of 62.5 mg/kg Sodium Nitrite	247
FIGURE I4	Plasma Nitrite Concentrations at 18 Months in Aged Female Mice	
	after a Single Gavage Dose of 62.5 mg/kg Sodium Nitrite	247

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
n	2	2	2	2
Plasma Nitrite (µg/mL)				
Time of collection 0600 1200 2100 2400 0300	b 	2.000 ^c		4.500^{c} 9.000 ± 2.000 8.100 ± 2.900
Blood Methemoglobin (g/dL)				
Time of collection 0600 1200 2100 2400 0300	$\begin{array}{c} 0.250 \pm 0.050 \\ 0.150 \pm 0.050 \\ 0.350 \pm 0.050 \\ 0.400 \pm 0.100 \\ 0.400 \pm 0.000 \end{array}$	$\begin{array}{c} 0.150 \pm 0.050 \\ 0.250 \pm 0.050 \\ 0.550 \pm 0.050 \\ 0.700 \pm 0.000 \\ 0.500 \pm 0.100 \end{array}$	$\begin{array}{c} 1.200 \pm 0.400 \\ 0.400 \pm 0.100 \\ 1.650 \pm 0.250 * \\ 2.350 \pm 0.550 \\ 0.800 \pm 0.200 \end{array}$	$\begin{array}{c} 2.750 \pm 1.150 \\ 0.650 \pm 0.150 * \\ 3.850 \pm 0.550 * \\ 0.500 \pm 0.000 \\ 2.300 \pm 0.700 * \end{array}$

TABLE I1 Plasma Nitrite and Blood Methemoglobin Concentrations at 2 Weeks in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite^a

Significantly different from the control group ($P \le 0.05$) by Shirley's test *

а

Mean \pm standard error Both samples in this group were below the estimated limit of quantitation (1.7 μ g/mL). b c

n=1

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
n	2	2	2	2
Plasma Nitrite (µg/mL)				
Time of collection 0600 1200 2100 2400 0300	b 	 	7.400° 3.500 $^{\circ}$ 2.900 $^{\circ}$	9.700 ± 2.300 3.450 \pm 1.350 4.086 ± 0.079 6.600 ^c
Blood Methemoglobin (g/dL)				
Time of collection 0600 1200 2100 2400 0300	$\begin{array}{c} 0.250 \pm 0.050 \\ 0.250 \pm 0.050 \\ 0.350 \pm 0.050 \\ 0.500 \pm 0.000 \\ 0.400 \pm 0.100 \end{array}$	$\begin{array}{c} 0.250 \pm 0.150 \\ 0.200 \pm 0.100 \\ 0.600 \pm 0.200 \\ 0.500 \pm 0.000 \\ 0.700 \pm 0.100 \end{array}$	$\begin{array}{c} 1.650 \pm 0.050 \\ 0.200 \pm 0.100 \\ 2.650 \pm 0.150 * \\ 1.900 \pm 0.400 \\ 2.250 \pm 0.450 \end{array}$	$\begin{array}{c} 6.350 \pm 1.550 \\ 0.600 \pm 0.200 \\ 3.850 \pm 0.750* \\ 4.350 \pm 1.050* \\ 3.850 \pm 2.550 \end{array}$

TABLE I2 Plasma Nitrite and Blood Methemoglobin Concentrations at 2 Weeks in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite^a

* Significantly different from the control group ($P \le 0.05$) by Shirley's test

 $Mean \pm standard \ error$ b

Both samples in this group were below the estimated limit of quantitation (1.7 μ g/mL). c

n=1

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
n	2	2	2	2
Plasma Nitrite (µg/mL)				
Time of collection 0600 1200 2100 2400 0300	b 	 	2.000 ^c	$ \begin{array}{r} 1.800^{c} \\ 4.200^{c} \\ 3.000^{c} \\ 4.500 \pm 1.100 \\ \end{array} $
Blood Methemoglobin (g/dL)				
Time of collection 0600 1200 2100 2400 0300	$\begin{array}{c} 0.700 \pm 0.000 \\ 0.300 \pm 0.000 \\ 0.350 \pm 0.050 \\ 0.450 \pm 0.050 \\ 0.300 \pm 0.000 \end{array}$	$\begin{array}{c} 0.750 \pm 0.050 \\ 0.300 \pm 0.000 \\ 0.600 \pm 0.000 \\ 0.600 \pm 0.000 \\ 0.400 \pm 0.000 \end{array}$	$\begin{array}{c} 2.100 \pm 0.700 \\ 0.400 \pm 0.000 \\ 1.450 \pm 0.250 \\ 0.900 \pm 0.100^* \\ 0.650 \pm 0.350 \end{array}$	$\begin{array}{l} 4.400 \pm 1.900 * \\ 2.450 \pm 0.050 * \\ 1.350 \pm 0.750 \\ 3.400 \pm 0.600 * \\ 1.150 \pm 0.750 \end{array}$

TABLE I3 Plasma Nitrite and Blood Methemoglobin Concentrations at 3 Months in Male Rats in the 2-Year Drinking Water Study of Sodium Nitrite

* Significantly different from the control group c_{r} = $\frac{1}{2}$ Mean \pm standard error b Both samples in this group were below the estimated limit of quantitation (1.7 µg/mL). c n=1

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
n	2	2	2	2
Plasma Nitrite (µg/mL)				
Time of collection				
0600	b	_	_	2.400°
1200		_	_	_
2100		_	_	3.000 ^c
1200	—	—	—	_
0300	—	—	—	2.700 ^c
Blood Methemoglobin (g/dL)				
Time of collection				
0600	0.450 ± 0.050	0.500 ± 0.100	0.550 ± 0.050	3.550 ± 1.050
1200	0.150 ± 0.050	0.300 ± 0.000	0.400 ± 0.000 *	$0.900 \pm 0.400 *$
2100	0.200 ± 0.000	0.650 ± 0.250	$3.650 \pm 0.550 *$	2.250 ± 0.050
2400	0.350 ± 0.150	0.450 ± 0.150	1.150 ± 0.550	2.400 ± 1.200
0300	0.300 ± 0.100	0.450 ± 0.050	1.600 ± 0.300	3.000 ± 2.300

TABLE I4 Plasma Nitrite and Blood Methemoglobin Concentrations at 3 Months in Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite

* a Significantly different from the control group (P≤0.05) by Dunn's or Shirley's test

Mean \pm standard error b

Both samples in this group were below the estimated limit of quantitation (1.7 μ g/mL). n=1 c





FIGURE II

Blood Methemoglobin Concentrations at 2 Weeks in Male and Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite (0% = 0 ppm, 0.075% = 750 ppm, 0.15% = 1,500 ppm, 0.30% = 3,000 ppm)






FIGURE 12

Blood Methemoglobin Concentrations at 3 Months in Male and Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite (0% = 0 ppm, 0.075% = 750 ppm, 0.15% = 1,500 ppm, 0.30% = 3,000 ppm)

TABLE I5 Plasma Nitrite and Blood Methemoglobin Concentrations at 18 Months in Aged Male Rats after a Single Gavage Dose of 40 mg/kg Sodium Nitrite^a

Time after Dosing (minutes)	Concentration	
Plasma Nitrite (µg/mL)	b	
5	2.500 ^c	
10	8.000	
30	8.950 ± 2.050	
60	6.300	
Methemoglobin (g/dL)		
2	1.333 ± 0.176	
5	2.167 ± 0.328	
10	2.700 ± 0.208	
30	4.200 ± 0.300	
60	5.100 ± 1.100	

а Mean ± standard error. Three animals were bled at 2, 5, and 10 minutes and two animals were bled at 30 and 60 minutes for blood methemoglobin measurements. b

All samples in this group were below the estimated limit of quantitation (1.7 μ g/mL). Two samples in this group were below the estimated limit of quantitation (1.7 μ g/mL). c

TABLE I6 Plasma Nitrite and Blood Methemoglobin Concentrations at 18 Months in Aged Female Rats after a Single Gavage Dose of 40 mg/kg Sodium Nitrite^a

Time after Dosing (minutes)	Concentration	
Plasma Nitrite (µg/mL)		
2	b	
5	3.500 ± 0.200	
10	6.067 ± 0.578	
30	8.133 ± 0.561	
60	6.350 ± 0.550	
Methemoglobin (g/dL)		
2	1.333 ± 0.203	
5	2.933 ± 0.145	
10	2.700 ± 0.265	
30	5.200 ± 0.058	
60	5.650 ± 0.150	

а Mean ± standard error. Three animals were bled at 2, 5, 10, and 30 minutes and two animals were bled at 60 minutes for blood methemoglobin measurements.

b All samples in this group were below the estimated limit of quantitation (1.7 µg/mL).

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
n	2	2	2	2
Plasma Nitrite (µg/mL)				
Time of collection 0600 1200 2100 2400 0300	b 	 	2.140 ^c 2.329 ^c 2.515 ^c	4.251 ± 1.095 $$
Blood Methemoglobin (g/dL)				
Time of collection 0600 1200 2100 2400 0300	$\begin{array}{c} 0.200 \pm 0.000 \\ 0.200 \pm 0.000 \\ 0.100 \pm 0.000 \\ 0.300 \pm 0.000 \\ 0.250 \pm 0.050 \end{array}$	$\begin{array}{c} 0.200 \pm 0.000 \\ 0.200 \pm 0.000 \\ 0.150 \pm 0.050 \\ 0.300 \pm 0.100 \\ 0.200 \pm 0.000 \end{array}$	$\begin{array}{c} 0.300 \pm 0.000 \\ 0.200 \pm 0.000 \\ 0.250 \pm 0.050 \\ 0.200 \pm 0.000 \\ 0.200 \pm 0.000 \end{array}$	$\begin{array}{c} 0.750 \pm 0.050 \\ 0.250 \pm 0.050 \\ 0.200 \pm 0.000 \\ 0.450 \pm 0.050 \\ 0.300 \pm 0.100 \end{array}$

TABLE I7 Plasma Nitrite and Blood Methemoglobin Concentrations at 12 Months in Male Mice in the 2-Year Drinking Water Study of Sodium Nitrite^a

а Mean \pm standard error

b Both samples in this group were below the estimated limit of quantitation (1.7 μ g/mL). c

n=1

TABLE I8 Blood Methemoglobin Concentrations at 12 Months in Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite^a

	0 ppm	750 ppm	1,500 ppm	3,000 ppm
n	2	2	2	2
Time of collection				
0600	0.200 ± 0.000	0.200 ± 0.000	0.200 ± 0.100	0.250 ± 0.050
1200	0.400^{b}	0.300 ± 0.000	0.300 ± 0.000	0.300 ± 0.000
2100	0.200 ± 0.000	0.200 ± 0.000	0.200 ± 0.000	0.200 ± 0.000
2400	0.150 ± 0.050	0.250 ± 0.050	0.250 ± 0.050	0.250 ± 0.050
0300	0.200 ± 0.000	0.300 ± 0.100	0.200 ± 0.000	0.250 ± 0.050

^a b Data are given in g/dL as mean \pm standard error. All plasma nitrite samples were below the estimated limit of quantitation (1.7 µg/mL). n=1

TABLE I9Plasma Nitrite and Blood Methemoglobin Concentrations at 18 Months in Aged Male Miceafter a Single Gavage Dose of 62.5 mg/kg Sodium Nitrite^a


Time after Dosing (minutes)	Concentration
Plasma Nitrite (µg/mL)	
2 5 10 30 60	22.233 ± 6.082 23.967 ± 5.206 32.267 ± 4.018 13.533 ± 0.717 8.933 ± 0.921
Methemoglobin (g/dL) 2 5 10 30 60	$\begin{array}{l} 1.100 \pm 0.208 \\ 1.833 \pm 0.088 \\ 2.000 \pm 0.289 \\ 1.600 \pm 0.058 \\ 0.800 \pm 0.153 \end{array}$


^a Mean \pm standard error. Three animals were bled at each time point.


TABLE I10 Plasma Nitrite and Blood Methemoglobin Concentrations at 18 Months in Aged Female Mice after a Single Gavage Dose of 62.5 mg/kg of Sodium Nitrite^a


Time after Dosing (minutes)	Concentration	
Plasma Nitrite (µg/mL)		
2	27.100 ± 4.637	
5	64.933 ± 6.199	
10	50.800 ± 3.293	
30	45.933 ± 6.583	
60	43.967 ± 11.737	
Methemoglobin (g/dL)		
2	1.533 ± 0.376	
5	2.900 ± 0.361	
10	3.433 ± 0.393	
30	3.833 ± 0.857	
60	5.000 ± 0.231	

^a Mean ± standard error. Three animals were bled at each time point.









APPENDIX J CHEMICAL CHARACTERIZATION AND DOSE FORMULATION STUDIES

PROCUREM	ENT AND CHARACTERIZATION OF SODIUM NITRITE	250
PREPARATIO	ON AND ANALYSIS OF DOSE FORMULATIONS	251
FIGURE J1	Infrared Absorption Spectrum of Sodium Nitrite	252
TABLE J1	High-Performance Liquid Chromatography Systems Used	
	in the Drinking Water Studies of Sodium Nitrite	253
TABLE J2	Preparation and Storage of Dose Formulations	
	in the Drinking Water Studies of Sodium Nitrite	253
TABLE J3	Results of Analyses of Dose Formulations Administered to Rats and Mice	
	in the 14-Week Drinking Water Study of Sodium Nitrite	254
TABLE J4	Results of Analyses of Dose Formulations Administered to Rats and Mice	
	in the 2-Year Drinking Water Study of Sodium Nitrite	257
TABLE J5	Results of Referee Analyses of Dose Formulations Administered to Rats and Mice	
	in the 14-Week Drinking Water Studies of Sodium Nitrite	260

CHEMICAL CHARACTERIZATION AND DOSE FORMULATION STUDIES

PROCUREMENT AND CHARACTERIZATION OF SODIUM NITRITE

Sodium nitrite was obtained from J.T. Baker, Inc. (Phillipsburg, NJ), in two lots (A42340 and H05714). Lot A42340 was used during the 14-week and 2-year studies and lot H05714 was used during the 2-year studies. Identity, purity, and stability analyses were conducted by the analytical chemistry laboratory, Midwest Research Institute (Kansas City, MO). Reports on analyses performed in support of the sodium nitrite studies are on file at the National Institute of Environmental Health Sciences.

Both lots of the chemical, a white crystalline solid, were identified as sodium nitrite by infrared and ultraviolet/visible spectroscopy. The infrared spectra were consistent with the literature spectra (*Sadtler Standard Spectra*; *Aldrich*, 1985) of sodium nitrite; the ultraviolet/visible spectra were consistent with the structure of sodium nitrite. The infrared spectrum is presented in Figure J1. The melting point ranges of 281.2° to 282.7° C determined for lot A42340 and 281.1° to 281.6° C for lot H05714 were in agreement with a value of 281° C cited in the literature (Klein and McDonald, 1982).

The purity of both lots was determined by elemental analyses, weight loss on drying, spark source mass spectrometry, and high-performance liquid chromatography (HPLC). The purity of lot A42340 was also analyzed by differential scanning calorimetry, a United States Pharmacopeia (USP) XXI titrimetric assay, and American Chemical Society (ACS) tests for chloride and sulfate. Elemental analyses of lot A42340 were performed by the analytical chemistry laboratory and Lancaster Laboratories (Lancaster, PA); elemental analyses of lot H05714 were performed by Galbraith Laboratories, Inc. (Knoxville, TN). Spark source mass spectrometry was performed by the analytical chemistry laboratory for lot A42340 and by Accu-Labs Research, Inc. (Golden, CO), for lot H05714. Lot A42340 was analyzed with HPLC by system A, and lot H05714 was analyzed with HPLC by system B (Table J1).

For lot A42340, elemental analyses for sodium and nitrogen were in agreement with the theoretical values for sodium nitrite. Weight loss on drying indicated $0.006\% \pm 0.002\%$ water. Differential scanning calorimetry determined a melting point of 280.8° C and indicated that the purity was greater than 99 molar percent. Spark source mass spectrometry identified sodium as the major component; the concentration of impurities was less than 87 ppm. The USP method of titration with potassium permanganate to a colorimetric endpoint indicated a purity of $100.4\% \pm 0.4\%$. ACS tests on lot A42340 for chloride and sulfate produced less turbidity than tests on a standard solution, indicating less than 0.005% chloride ion and less than 0.01% sulfate ion. HPLC indicated a major peak and a single impurity with an area of 0.2% relative to the major peak area (system A). The cumulative data indicated a purity greater than 99%.

For lot H05714, elemental analyses for sodium and nitrogen were in agreement with the theoretical values for sodium nitrite. There was no weight loss on drying. HPLC by system B indicated one major peak and one impurity with an area of 0.15% relative to the major peak area. Spark source mass spectrometry identified sodium as the major component and no major contaminants; traces of calcium, fluorine, potassium, phosphorus, and iron were detected. The overall purity of lot H05714 was determined to be 99% or greater.

Stability studies of the bulk chemical were performed by the analytical chemistry laboratory. Permanganate titration was performed by reacting sodium nitrite with an excess of standard potassium permanganate (USP XIX). These studies indicated that sodium nitrite was stable as a bulk chemical for 2 weeks when stored protected from light at temperatures up to 60° C.

To ensure stability, the bulk chemical was stored at 5° C, protected from light, in closed containers under an inert atmospere during the 14-week study and in Nalgene[®] containers at room temperature, protected from light, during the 2-year studies. Stability was monitored by the study laboratory with infrared and ultraviolet/visible spectroscopy and HPLC by system C (14-week studies) and with ultraviolet spectroscopy (2-year studies). No degradation of the bulk chemical was detected.

PREPARATION AND ANALYSIS OF DOSE FORMULATIONS

The dose formulations were prepared every 2 weeks (14-week studies) or approximately every 4 weeks (2-year studies) by mixing sodium nitrite with water (Table J2). Formulations were stored in glass carboys at room temperature for up to 3 weeks for the 14-week studies and in Nalgene[®] tanks at room temperature for up to 35 days for the 2-year studies.

Stability studies of a 0.075 mg/mL dose formulation were performed by the analytical chemistry laboratory using ultraviolet/visible spectrophotometry by measuring absorbance at 347 nm of an aliquot of the sample treated with a salt solution (sodium sulfate and sodium acetate) and a color reagent (hydrochloric acid, resorcinol and zinconyl chloride). Stability was confirmed for at least 35 days for dose formulations stored at 5° C or at room temperature in the dark.

Periodic analyses of the dose formulations of sodium nitrite were conducted by the study laboratory using ultraviolet/visible spectroscopy as described for the stability study. During the 14-week studies, the dose formulations were analyzed at the beginning, midpoint, and end of the studies; animal room samples of these dose formulations were also analyzed (Table J3). All 32 dose formulations analyzed were within 10% of the target concentrations; all 30 animal room samples for rats and 22 of 25 for mice were also within 10% of the target concentrations. During the 2-year studies, the dose formulations were analyzed approximately every 8 to 12 weeks; animal room samples were also analyzed periodically (Table J4). All 39 of the 2-year dose formulations analyzed were within 10% of the target concentrations. All 12 animal room samples for rats and for mice were within 10% of the target concentrations. Results of periodic referee analyses performed by the analytical chemistry laboratory agreed with the results obtained by the study laboratory (Table J5).




FIGURE J1 Infrared Absorption Spectrum of Sodium Nitrite

TABLE J1

High-Performance Liquid Chromatography Systems Used in the Drinking Water Studies of Sodium Nitrite^a

Detection System	Column	Solvent System
System A		
Ultraviolet (230 nm)	Whatman Partisil 10 SAX, 250 mm × 4.6 mm (Whatman, Inc., Clifton, NJ)	0.0125 M potassium dihydrogen phosphate, pH 4.5; flow rate 1.0 mL/minute
System B		
Dionex CDM-3 Conductivity Detector (300 µS)	Dionex AS4A-SC, 250 mm \times 4.0 mm, 13 μ m (Dionex Corp., Sunnyvale, CA)	1.5 mM sodium carbonate/1.2 mM sodium bicarbonate, in water; flow rate 2 mL/minute
System C		
Waters Model 430 Conductivity Detector	Waters IC-PAK Anion, 5 cm × 4.6 mm (Waters-Millipore, Milford, MA)	Water containing (in 1 L) approximately 4.3 mL glycerin, 20 mL n-butanol, 120 mL acetonitrile, 0.3 g sodium gluconate, 0.3 g boric acid, and 0.4 g sodium tetraborate decahydrate; flow rate 0.9 mL/minute

^a Chromatographs were manufactured by Waters-Millipore (Milford, MA) and Dionex Corp. (Sunnyvale, CA).

TABLE J2 Preparation and Storage of Dose Formulations in the Drinking Water Studies of Sodium Nitrite

14-Week Studies	2-Year Studies
Preparation Sodium nitrite was mixed with charcoal-filtered deionized water (pH 6.8-7.0) with a stir-bar and then further diluted with water. Dose formulations were prepared every 2 weeks.	Sodium nitrite was mixed with tap water with an automatic stirrer, then further diluted and stirred for an additional 5 minutes. A 2-L portion was removed from the bottom of the preparation and returned to the top; the formulation was then stirred for 5 minutes. Dose formulations were prepared approximately every 4 weeks.
Chemical Lot Number Lot A42340	Lots A42340 and H05714
Maximum Storage Time 3 weeks	35 days
Storage Conditions Stored in glass carboys at room temperature	Stored in Nalgene [®] tanks at room temperature
Study Laboratory Microbiological Associates, Inc. (Bethesda, MD)	Battelle Columbus Laboratories (Columbus, OH)
Referee Laboratory Midwest Research Institute (Kansas City, MO)	None

Date Prepared	Date Analyzed	Target Concentration (%)	Determined Concentration ^a (%)	Difference from Target (%)
Rats				
1 August 1989	3 August 1989	0.0375	0.0361	-4
	2	0.0375	0.0358	-5
		0.075	0.0726	-3
		0.075	0.0724	-3
		0.15	0.139	-7
		0.15	0.159	+6
		0.15	0.137	-9
		0.30	0.286	-5
		0.30	0.295	-2
		0.50	0.532	+6
		0.50	0.541	+8
		0.50	0.534	+7
	24 August 1989 ^b	0.0375	0.0349	-7
	24 August 1989			- 7 -9
		0.0375 0.075	0.0342	-7
			0.0698	
		0.075	0.0708	-6
		0.15	0.139	-7 -7
		0.15	0.139	- 7 -9
		0.30	0.273	
		0.30 0.50	0.291 0.500	-3 0
		0.50	0.300	-2
2 September 1989	13 September 1989	0.0375	0.0384	+2
1	1	0.0375	0.0378	+1
		0.075	0.0768	+2
		0.075	0.0770	+3
		0.15	0.153	+2
		0.15	0.155	+3
		0.30	0.310	+3
		0.30	0.311	+4
		0.50	0.524	+5
		0.50	0.513	+3
	5 October 1989 ^b	0.0375	0.0389	+4
		0.0375	0.0386	+3
		0.075	0.0776	+3
		0.075	0.0763	+2
		0.15	0.155	+3
		0.15	0.164	+9
		0.30	0.307	+2
		0.30	0.316	+5
		0.50	0.523	+5
		0.50	0.523	+5

Table J3Results of Analyses of Dose Formulations Administered to Rats and Micein the 14-Week Drinking Water Studies of Sodium Nitrite

TABLE J3Results of Analyses of Dose Formulations Administered to Rats and Micein the 14-Week Drinking Water Studies of Sodium Nitrite

Date Prepared	Date Analyzed	Target Concentration (%)	Determined Concentration (%)	Difference from Target (%)
24 October 1989	25 October 1989	0.0375	0.0403	+7
21 000001 1909	20 000000 1909	0.0375	0.0405	+8
		0.075	0.0828	+10
		0.075	0.0779	+4
		0.15	0.162	+8
		0.15	0.162	+8
		0.30	0.330	+10
		0.30	0.327	+9
		0.50	0.528	+6
		0.50	0.525	+5
	15 November 1989 ^b	0.0375	0.0397	+6
		0.0375	0.0403	+7
		0.075	0.0763	+2
		0.075	0.0786	+5
		0.15	0.162	+8
		0.15	0.159	+6
		0.30	0.318	+6
		0.30	0.307	+2
		0.50	0.520	+4
		0.50	0.512	+2
Mice				
1 August 1989	3 August 1989	0.0375	0.0361	-4
		0.0375	0.0358	-5
		0.075	0.0726	-3
		0.075	0.0724	-3
		0.15	0.139	-7
		0.15	0.159	+6
		0.15	0.137	-9
		0.30	0.286	- 5
		0.30	0.295	-2
		0.50	0.532	+6
		0.50	0.541	+8
		0.50	0.534	+7
	24 August 1989 ^b	0.0375	0.0348	-7
		0.0375	0.0340	-9
		0.075	0.0714	-5
		0.075	0.0710	-5
		0.15	0.138	- 8
		0.15	0.156	+4
		0.30	0.282	-6
		0.30	0.282	-6
		0.50	0.478	-4
		0.50	0.500	0

Date Prepared	Date Analyzed	Target Concentration (%)	Determined Concentration (%)	Difference from Target (%)
12 September 1989	13 September 1989	0.0375	0.0384	+2
12 September 1969	15 September 1969	0.0375	0.0378	+1
		0.075	0.0768	+2
		0.075	0.0770	+3
		0.15	0.153	+2
		0.15	0.155	+3
		0.30	0.310	+3
		0.30	0.311	+4
		0.50	0.524	+4
		0.50	0.513	+3
		0.50	0.513	+3
	5 October 1989 ^b	0.0375	0.0303	-19
	5 October 1989	0.0375	0.0556	+48
		0.0375	0.0530	-21
		0.075	0.0390	-21 +3
				+3 +7
		0.15	0.160	
		0.15	0.161	+7
		0.30	0.280	-7
		0.30	0.307	+2
		0.50	0.535	+7
		0.50	0.516	+3
	11 October 1989 ^b	0.0375	0.0282	-25
	11 October 1989	0.0375	0.0282	+43
		0.075	0.0598	-20
24 October 1989	25 October 1989	0.0375	0.0403	+7
24 OCIOUCI 1989	25 October 1989	0.0375	0.0405	+8
		0.075	0.0828	$+10^{+10}$
		0.075	0.0779	+4
		0.15	0.162	+4 +8
		0.15	0.162	+8 +8
		0.13	0.102	+8 +10
		0.30	0.330	+10 +9
		0.50	0.527	+9 +6
		0.50	0.525	+5
	15 November 1989 ^b	0.0375	0.0376	0
	15 INOVERIDER 1989	0.0375	0.0378	0 +4
		0.15	0.160	+7
		0.30	0.318	+6
		0.50	0.471	-6

TABLE J3 Results of Analyses of Dose Formulations Administered to Rats and Mice in the 14-Week Drinking Water Studies of Sodium Nitrite

а Results of duplicate analyses Animal room samples b

TABLE J4Results of Analyses of Dose Formulations Administered to Rats and Micein the 2-Year Drinking Water Studies of Sodium Nitrite

Date Prepared	Date Analyzed	Target Concentration (%)	Determined Concentration ^a (%)	Difference from Target (%)	
Rats					
1 August 1995	3 August 1995	0.075	0.07639	+2	
1 Hugust 1995	5 Hugust 1995	0.15	0.1534	+2	
		0.30	0.3062	+2	
	22 August 1995 ^b	0.075	0.07438	- 1	
	22 Mugust 1995	0.15	0.1530	+2	
		0.30	0.3047	+2	
20 September 1995	21-22 September 1995	0.075	0.07480	0	
20 September 1995	21 22 September 1795	0.15	0.1548	+3	
		0.30	0.2928	-2	
13 December 1995	14 December 1995	0.075	0.07819	+4	
15 December 1775		0.075	0.1577	+4+5	
		0.30	0.3154	+5	
7 February 1996	7 February 1996	0.075	0.07550	+1	
, 1 coruly 1990	/ i contairy 1770	0.15	0.1524	+2	
		0.30	0.3027	+1	
	15 March 1996 ^b	0.075	0.07495	0	
		0.15	0.1484	- 1	
		0.30	0.2951	-2	
3 April 1996	3 April 1996	0.075	0.07803	+4	
r r	- F	0.15	0.1578	+5	
		0.30	0.3148	+5	
26 June 1996	26 June 1996	0.075	0.07964	+6	
		0.15	0.1572	+5	
		0.30	0.3057	+2	
21 August 1996	22 August 1996	0.075	0.07635	+2	
-	-	0.15	0.1518	+1	
		0.30	0.3049	+2	
	30 September 1996 ^b	0.075	0.07991	+7	
	1	0.15	0.1563	+4	
		0.30	0.3127	+4	
16 October 1996	16 October 1996	0.075	0.07684	+2	
		0.15	0.1491	- 1	
		0.30	0.3125	+4	
8 January 1997	9 January 1997	0.075	0.07751	+3	
	,	0.15	0.1546	+3	
		0.30	0.3083	+3	

Date Prepared	Date Analyzed	Target Concentration (%)	Determined Concentration (%)	Difference from Target (%)
March 1997	6 March 1997	0.075	0.07682	+2
		0.15	0.1535	+2
		0.30	0.3057	+2
	15 April 1997 ^b	0.075	0.08139	+9
	•	0.15	0.1547	+3
		0.30	0.3112	+4
0 April 1997	1 May 1997	0.075	0.07732	+3
1	2	0.15	0.1537	+2
		0.30	0.3031	+1
3 July 1997	23 July 1997	0.075	0.07385	-2
-	-	0.15	0.1561	+4
		0.30	0.2984	-1
Mice				
25 July 1995	26 July 1995	0.075	0.07694	+3
, ,	5	0.15	0.1551	+3
		0.30	0.3035	+1
	9 August 1995 ^b	0.075	0.07705	+3
	-	0.15	0.1550	+3
		0.30	0.3040	+1
August 1995	3 August 1995	0.075	0.07639	+2
C	e	0.15	0.1534	+2
		0.30	0.3062	+2
0 September 1995	21-22 September 1995	0.075	0.07480	0
-	-	0.15	0.1548	+3
		0.30	0.2928	-2
3 December 1995	14 December 1995	0.075	0.07819	+4
		0.15	0.1577	+5
		0.30	0.3154	+5
February 1996	7 February 1996	0.075	0.07550	+1
		0.15	0.1524	+2
		0.30	0.3027	+1
	15 March 1996 ^b	0.075	0.07319	-2
		0.15	0.1450	-3
		0.30	0.2891	-4

TABLE J4Results of Analyses of Dose Formulations Administered to Rats and Micein the 2-Year Drinking Water Studies of Sodium Nitrite

TABLE J4 Results of Analyses of Dose Formulations Administered to Rats and Mice in the 2-Year Drinking Water Studies of Sodium Nitrite

Date Prepared	Date Analyzed	Target Concentration (%)	Determined Concentration (%)	Difference from Target (%)
April 1996	3 April 1996	0.075	0.07803	+4
r	- F	0.15	0.1578	+5
		0.30	0.3148	+5
6 June 1996	26 June 1996	0.075	0.07964	+6
		0.15	0.1572	+5
		0.30	0.3057	+2
1 August 1996	22 August 1996	0.075	0.07635	+2
č	č	0.15	0.1518	+1
		0.30	0.3049	+2
	30 September 1996 ^b	0.075	0.08076	+8
	1	0.15	0.1583	+6
		0.30	0.3081	+3
6 October 1996	16 October 1996	0.075	0.07684	+2
		0.15	0.1491	-1
		0.30	0.3125	+4
January 1997	9 January 1997	0.075	0.07751	+3
	,	0.15	0.1546	+3
		0.30	0.3083	+3
March 1997	6 March 1997	0.075	0.07682	+2
		0.15	0.1535	+2
		0.30	0.3057	+2
	15 April 1997 ^b	0.075	0.07688	+3
	-	0.15	0.1534	+2
		0.30	0.3109	+4
0 April 1997	1 May 1997	0.075	0.07732	+3
		0.15	0.1537	+2
		0.30	0.3031	+1
3 July 1997	23 July 1997	0.075	0.07385	-2
		0.15	0.1561	+4
		0.30	0.2984	-1

a b Results of duplicate analyses Animal room samples

		Determined Co	ncentration (%)
Date Prepared	Target Concentration (%)	Study Laboratory ^a	Referee Laboratory ^b
1 August 1989	0.3	0.286	0.282 ± 0.000
12 September 1989	0.075	0.0768	0.0788 ± 0.0002

TABLE J5 Results of Referee Analyses of Dose Formulations Administered to Rats and Mice in the 14-Week Drinking Water Studies of Sodium Nitrite

a b

Results of duplicate analyses Results of triplicate analyses (mean ± standard error)

APPENDIX K WATER AND COMPOUND CONSUMPTION IN THE 2-YEAR DRINKING WATER STUDIES OF SODIUM NITRITE

TABLE K1	Water and Compound Consumption by Male Rats	
	in the 2-Year Drinking Water Study of Sodium Nitrite	262
TABLE K2	Water and Compound Consumption by Female Rats	
	in the 2-Year Drinking Water Study of Sodium Nitrite	263
TABLE K3	Water and Compound Consumption by Male Mice	
	in the 2-Year Drinking Water Study of Sodium Nitrite	264
TABLE K4	Water and Compound Consumption by Female Mice	
	in the 2-Year Drinking Water Study of Sodium Nitrite	265

Water and Compound Consum	ption by Male Rats in the 2	2-Year Drinking Water Stud	ly of Sodium Nitrite

	0 p	pm		750 ppm			1,500 ppm	l		3,000 ppm	I
Week	Water (g/day) ^a	Body Weight (g)	Water (g/day)	Body Weight (g)	Dose (mg/kg) ^b	Water (g/day)	Body Weight (g)	Dose (mg/kg)	Water (g/day)	Body Weight (g)	Dose (mg/kg)
1	16.4	107	17.8	107	125	18.1	107	256	13.4	107	375
2	17.0	144	17.7	144	92	18.2	143	192	14.7	134	329
6	19.3	259	18.9	254	56	18.0	254	106	15.9	242	197
10	18.9	314	17.7	307	43	16.9	304	84	13.6	288	142
14	19.5	354	18.0	348	39	16.3	341	72	14.2	322	133
18	18.3	381	16.7	376	33	15.3	367	63	13.5	349	116
22	18.0	406	17.6	399	33	17.1	392	66	14.9	369	121
26	17.9	426	17.5	416	32	16.9	410	62	15.1	385	118
30	17.4	438	17.2	435	30	16.2	423	57	15.0	400	112
34	18.9	450	17.5	446	29	17.9	435	62	16.0	412	116
38	18.5	458	17.0	460	28	16.8	443	57	15.7	418	113
42	17.4	466	16.6	462	27	16.5	450	55	15.4	422	109
46	17.2	478	16.1	474	26	16.1	463	52	15.2	433	105
50	17.2	487	16.3	486	25	16.5	470	53	14.9	437	102
54	17.5	492	16.2	487	25	16.7	473	53	14.5	441	98
58	16.9	491	16.6	495	25	16.6	477	52	14.9	445	101
62	17.7	499	16.8	495	25	17.0	481	53	15.2	448	102
66	17.7	499	16.6	494	25	16.9	480	53	15.9	444	107
70	17.9	499	17.0	499	25	16.9	481	53	16.3	452	108
74	18.4	501	17.8	498	27	17.6	477	55	16.2	449	109
78	18.1	501	17.7	497	27	18.0	481	56	15.5	446	104
82	18.5	502	17.5	493	27	17.5	479	55	16.1	445	108
86	17.5	497	17.3	495	26	17.5	481	55	15.4	445	104
90	17.7	494	16.8	499	25	17.1	480	54	14.5	441	98
94	17.6	495	16.8	496	25	17.2	481	54	14.6	440	100
98	17.5	492	16.2	488	25	16.8	480	52	14.4	442	98
102	17.9	496	16.7	485	26	18.0	483	56	15.0	441	102
	or weeks										
1-13	17.9	206	18.0	203	79	17.8	202	159	14.4	193	261
14-52	18.0	435	17.1	430	30	16.6	420	60	15.0	395	115
53-102	17.8	497	16.9	494	26	17.2	480	54	15.3	445	103

Water and Compound Consumption by Female Rats in the 2-Year Drinking Water Study of Sodium Nitrite

	0 p	pm		750 ppm			1,500 ppm	l <u> </u>	3,000 ppm							
Week	Water (g/day) ^a	Body Weight (g)	Water (g/day)	Body Weight (g)	Dose (mg/kg) ^b	Water (g/day)	Body Weight (g)	Dose (mg/kg)	Water (g/day)	Body Weight (g)	Dose (mg/kg)					
1	13.1	96	13.0	95	103	13.7	96	215	12.0	95	377					
2	14.9	118	14.4	116	94	14.3	115	186	11.9	111	324					
6	14.7	168	15.0	164	68	13.4	164	123	11.0	159	207					
10	13.9	187	13.2	182	55	12.2	183	101	10.0	177	169					
14	12.8	201	12.2	196	46	11.4	195	88	9.3	188	148					
18	13.0	212	12.2	206	45	11.4	204	84	9.7	197	147					
22	13.6	220	12.7	214	45	11.7	212	83	10.5	204	155					
26	13.5	227	12.2	221	41	12.0	218	83	10.2	211	145					
30	12.2	238	11.3	231	37	11.0	227	73	9.6							
34	12.7	245	11.9	236	38	11.5	234	74	10.1	224	136					
38	12.6	254	11.8	245	36	11.2	241	70	10.2	231	132					
42	12.6	260	11.6	251	35	11.2	246	68	10.1	235	129					
46	12.1	271	11.4	259	33	10.8	252	65	9.8	241	122					
50	11.9	281	11.2	269	31	11.1	264	63	10.2	250	122					
54	12.0	286	11.2	276	31	11.2	270	62	10.1	256	119					
58	11.8	293	11.8	284	31	11.4	276	62	10.1	261	116					
62	11.9	302	11.8	291	30	11.5	287	60	11.7	265	132					
66	12.9	307	12.1	293	31	12.0	288	63	11.3	269	126					
70	13.1	315	12.8	305	31	12.5	299	63	11.7	276	127					
74	13.4	319	13.1	312	31	13.0	305	64	11.6	279	125					
78	13.5	329	13.5	319	32	13.4	313	64	12.0	285	126					
82	13.6	332	12.9	320	30	12.8	314	61	11.6	287	121					
86	13.5	333	13.7	325	32	13.3	319	62	12.1	291	125					
90	13.5	339	13.1	327	30	12.6	323	58	11.3	290	117					
94	14.1	346	13.4	330	31	12.7	326	58	12.2	302	121					
98	14.8	350	13.6	333	31	13.2	332	60	12.1	308	118					
102	14.4	344	14.4	337	32	13.6	332	61	12.6	312	121					
Mean f	or weeks															
1-13	14.1	142	13.9	139	80	13.4	139	156	11.2	135	269					
14-52	12.7	241	11.8	233	39	11.3	229	75	10.0	220	137					
53-102	13.3	323	12.9	312	31	12.5	307	61	11.6	283	123					

Water and Compound Consum	ption by Male Mi	ice in the 2-Year Drinking	Water Study of Sodium Nitrite

	0 p	pm		750 ppm			1,500 ppm	1	3,000 ppm								
Week	Water (g/day) ^a	Body Weight (g)	Water (g/day)	Body Weight (g)	Dose (mg/kg) ^b	Water (g/day)	Body Weight (g)	Dose (mg/kg)	Water (g/day)	Body Weight (g)	Dose (mg/kg)						
2	3.2	23.7	3.4	23.7	106	3.3	23.6	211	2.9	23.4	368						
6	3.1	29.5	3.1	29.6	78	3.2	29.1	164	2.7	28.3 288							
10	3.1	34.9	3.2	34.5	69	3.0	33.7	133	2.7	32.7	247						
14	3.2	39.1	3.1	38.9	60	3.1	37.7	124	2.9	36.2	244						
18	3.8	43.2	3.5	42.9	62	3.4	41.9	123	3.3	40.2	247						
22	3.3	45.6	3.1	44.9	52	3.1	44.0	106	2.9	42.1	209						
26	3.6	47.5	3.3	46.6	53	3.1	45.7	102	3.0	44.6	203						
30	3.3	49.6	3.2	48.9	48	3.1	48.3	96	3.0								
34	3.4	50.8	3.1	50.1	47	3.1	49.2	95	3.0	48.4	188						
38	3.6	50.6	3.2	49.7	49	3.3	48.7	101	3.1	48.1	193						
42	3.7	50.9	3.4	49.9	51	3.2	48.4	101	3.1	48.6	191						
46	3.8	50.8	3.3	49.4	50	3.3	48.3	102	3.0	48.6	186						
50	3.9	50.3	3.7	49.0	57	3.4	48.0	107	3.1	48.3	195						
54	3.8	51.3	3.4	50.5	50	3.3	49.2	102	3.0	49.5	180						
58	3.7	51.1	3.3	49.6	50	3.5	49.3	105	3.2	49.8	194						
62	3.7	51.4	3.5	50.4	52	3.4	49.4	103	3.1	49.5	189						
66	3.8	50.7	3.5	49.8	53	3.6	49.0	109	3.2	48.8	200						
70	3.9	50.0	3.6	49.7	55	3.6	48.8	110	3.3	48.7	206						
73	3.8	49.4	3.6	49.5	54	3.7	48.8	114	3.3	48.1	207						
78	4.1	49.4	3.8	49.1	58	3.9	48.2	120	3.5	47.6	222						
82	4.0	48.7	3.8	48.4	59	4.0	48.2	125	3.5	46.6	223						
86	4.1	47.2	3.9	46.9	63	3.9	46.8	124	3.6	45.4	235						
90	3.8	46.4	3.5	46.4	57	3.7	46.1	120	3.2	44.7	216						
94	4.0	44.7	3.4	44.4	57	3.7	44.5	123	3.3	44.1	221						
98	3.7	43.0	3.5	43.7	61	3.6	43.6	126	3.1	42.8	221						
102	4.0	40.2	3.6	41.3	65	3.6	41.4	131	3.3	41.0	244						
Mean	for weeks																
2-13	3.1	29.4	3.2	29.3	84	3.2	28.8	169	2.8	28.1	301						
14-52	3.6	47.8	3.3	47.0	53	3.2	46.0	106	3.1	45.2	205						
53-102	3.9	48.0	3.6	47.7	56	3.6	47.2	116	3.3	46.7	212						

Water and Compound Consumption by Female Mice in the 2-Year Drinking Water Study of Sodium Nitrite

	0 p	pm		750 ppm			1,500 ppm	L	3,000 ppm								
Week	Water (g/day) ^a	Body Weight (g)	Water (g/day)	Body Weight (g)	Dose (mg/kg) ^b	Water (g/day)	Body Weight (g)	Dose (mg/kg)	Water (g/day)	Body Weight (g)	Dose (mg/kg)						
1	2.9	18.9	2.8	18.9	113	2.7	18.8	211	2.3	18.9	370						
2	3.0	19.4	3.0	19.7	114	3.0	19.5	227	2.3	19.4 364							
6	2.9	23.7	3.0	23.9	93	2.8	23.9	174	2.5	23.2	325						
10	3.1	28.2	2.8	28.4	74	2.8	28.2	149	2.5	26.9	281						
14	2.9	31.4	3.0	32.6	69	2.7	31.5	129	2.9	30.3	282						
18	3.1	35.6	2.8	37.8	55	2.7	36.5	110	2.4	34.4	208						
22	2.8	40.0	2.4	41.7	44	2.4	40.6	88	2.2	38.2	177						
26	2.5	43.2	2.4	44.9	40	2.3	43.7	80	2.2	41.1	163						
30	2.6	46.6	2.3	47.4	36	2.3	46.2	74	2.3	43.3 158							
34	2.4	49.2	2.2	49.6	34	2.3	48.8	71	2.3	45.4	151						
38	2.6	51.1	2.5	51.1	36	2.4	50.0	73	2.4	46.9	153						
42	2.6	53.4	2.4	53.3	34	2.3	52.3	65	2.3	48.8	139						
46	2.4	54.2	2.2	54.6	30	2.1	54.0	59	2.1	50.8	125						
50	2.5	55.3	2.2	55.6	30	2.2	54.8	61	2.1	52.5	120						
54	2.2	56.1	2.2	55.3	30	2.2	55.2	59	2.0	53.0	111						
58	2.6	56.7	2.6	57.0	34	2.5	56.6	67	2.3	54.2	126						
62	2.3	58.8	2.2	58.2	28	2.1	58.4	54	2.0	56.1	106						
66	2.4	58.3	2.3	57.5	31	2.3	57.4	61	2.0	55.4	111						
70	2.7	57.7	2.3	56.8	30	2.3	56.5	62	2.1	54.4	117						
73	2.5	56.1	2.3	56.1	30	2.3	55.0	62	2.1	53.7	116						
78	2.8	55.5	2.6	56.3	35	2.6	55.0	71	2.3	53.8	131						
82	2.8	55.0	2.6	55.6	35	2.4	54.2	67	2.3	54.2	126						
86	2.8	53.5	2.5	53.7	35	2.5	53.5	71	2.2	53.2	123						
90	3.2	52.6	2.6	52.8	37	2.7	53.1	75	2.2	51.2	127						
94	3.1	52.1	2.5	52.1	36	2.6	52.3	76	2.1	49.6	128						
98	2.8	52.0	2.4	51.4	36	2.5	51.4	72	2.1	49.3	129						
02	2.8	51.1	2.3	50.7	34	2.6	50.7	77	2.0	48.9	124						
	or weeks																
1-13	3.0	22.5	2.9	22.7	98	2.8	22.6	190	2.4	22.1	335						
14-52	2.6	46.0	2.4	46.9	41	2.4	45.8	81	2.3	43.2	168						
53-102	2.7	55.0	2.4	54.9	33	2.4	54.6	67	2.1	52.8	121						

APPENDIX L INGREDIENTS, NUTRIENT COMPOSITION, AND CONTAMINANT LEVELS IN NTP-2000 RAT AND MOUSE RATION

TABLE L1	Ingredients of NTP-2000 Rat and Mouse Ration	268
TABLE L2	Vitamins and Minerals in NTP-2000 Rat and Mouse Ration	268
TABLE L3	Nutrient Composition of NTP-2000 Rat and Mouse Ration	269
TABLE L4	Contaminant Levels in NTP-2000 Rat and Mouse Ration	270

Ingredients	Percent by Weight	
Ground hard winter wheat	22.26	
Ground #2 yellow shelled corn	22.18	
Wheat middlings	15.0	
Oat hulls	8.5	
Alfalfa meal (dehydrated, 17% protein)	7.5	
Purified cellulose	5.5	
Soybean meal (49% protein)	5.0	
Fish meal (60% protein)	4.0	
Corn oil (without preservatives)	3.0	
Soy oil (without preservatives)	3.0	
Dried brewer's yeast	1.0	
Calcium carbonate (USP)	0.9	
Vitamin premix ^a	0.5	
Mineral premix ^b	0.5	
Calcium phosphate, dibasic (USP)	0.4	
Sodium chloride	0.3	
Choline chloride (70% choline)	0.26	
Methionine	0.2	

TABLE L1 Ingredients of NTP-2000 Rat and Mouse Ration

а

Wheat middlings as carrier Calcium carbonate as carrier b

	Amount	Source
Vitamins		
A	4,000 IU	Stabilized vitamin A palmitate or acetate
)	1,000 IU	D-activated animal sterol
X	1.0 mg	Menadione sodium bisulfite complex
x-Tocopheryl acetate	100 IU	•
Niacin	23 mg	
Folic acid	1.1 mg	
<i>l</i> -Pantothenic acid	10 mg	d-Calcium pantothenate
Riboflavin	3.3 mg	-
Thiamine	4 mg	Thiamine mononitrate
B ₁₂	52 µg	
Pyridoxine	6.3 mg	Pyridoxine hydrochloride
Biotin	0.2 mg	<i>d</i> -Biotin
Minerals		
Magnesium	514 mg	Magnesium oxide
ron	35 mg	Iron sulfate
Zinc	12 mg	Zinc oxide
Manganese	10 mg	Manganese oxide
Copper	2.0 mg	Copper sulfate
odine	0.2 mg	Calcium iodate
Chromium	0.2 mg	Chromium acetate

TABLE L2 Vitamins and Minerals in NTP-2000 Rat and Mouse Ration^a

^a Per kg of finished product

TABLE L3 Nutrient Composition of NTP-2000 Rat and Mouse Ration

Nutrient	Mean ± Standard Deviation	Range	Number of Samples
Protein (% by weight)	13.8 ± 0.72	12.7 - 16.2	23
Crude fat (% by weight)	8.1 ± 0.33	7.5 - 8.7	23
Crude fiber (% by weight)	9.5 ± 0.59	7.8 - 10.3	23
Ash (% by weight)	5.0 ± 0.16	4.8 - 5.4	23
Amino Acids (% of total diet)			
Arginine	0.732 ± 0.050	0.670 - 0.800	6
Cystine	0.220 ± 0.011	0.210 - 0.240	6
Glycine	0.683 ± 0.048	0.620 - 0.740	6
Histidine	0.333 ± 0.020	0.310 - 0.350	6
Isoleucine	0.522 ± 0.054	0.430 - 0.590	6
Leucine	1.065 ± 0.070	0.960 - 1.130	6
Lysine	0.705 ± 0.066	0.620 - 0.790	6
Methionine	0.402 ± 0.042	0.350 - 0.460	6
Phenylalanine	0.600 ± 0.042	0.540 - 0.640	6
Threonine	0.000 ± 0.042 0.512 ± 0.056	0.430 - 0.590	6
Tryptophan	0.512 ± 0.050 0.125 ± 0.015	0.430 = 0.350 0.110 = 0.150	6
Tyrosine	0.125 ± 0.015 0.410 ± 0.037	0.110 - 0.150 0.360 - 0.460	6
Valine	0.410 ± 0.057 0.628 ± 0.052	0.550 - 0.690	6
Essential Fatty Acids (% of total diet)			
Linoleic	3.98 ± 0.325	3.59 - 4.54	6
Linolenic	0.30 ± 0.048	0.21 - 0.35	6
Vitamins			
Vitamin A (IU/kg)	$5,018 \pm 1,421$	2,780 - 8,140	23
Vitamin D (IU/kg)	1,000 ^a	_,,,.,	
α-Tocopherol (ppm)	77.2 ± 10.94	62.2 - 87.1	6
Thiamine (ppm)	9.4 ± 2.19	6.0 - 15.0	23
Riboflavin (ppm)	5.6 ± 1.24	4.20 - 7.70	6
Niacin (ppm)	73.1 ± 4.13	66.4 - 78.8	6
Pantothenic acid (ppm)	24.2 ± 2.92	21.4 - 29.1	6
Pyridoxine (ppm)	9.37 ± 2.50	6.7 - 12.4	6
			6
Folic acid (ppm) Biotin (ppm)	1.70 ± 0.43 0.349 ± 0.18	1.26 - 2.32 0.225 0.704	6
Biotin (ppm) Vitomin B. (nnh)	0.349 ± 0.18	0.225 - 0.704	
Vitamin B ₁₂ (ppb)	83.4 ± 67.1	30.0 - 174.0	6
Choline (ppm)	$3,082 \pm 232$	2,700 - 3,400	6
Minerals Calcium (%)	0.958 ± 0.051	0.858 1.050	23
		0.858 - 1.050 0.548 - 0.640	
Phosphorus (%)	0.577 ± 0.022	0.548 - 0.640	23
Potassium (%)	6.660 ± 0.026	0.627 - 0.691	6
Chloride (%)	0.356 ± 0.031	0.300 - 0.392	6
Sodium (%)	0.193 ± 0.020	0.160 - 0.212	6
Magnesium (%)	0.197 ± 0.010	0.185 - 0.213	6
Sulfur (%)	0.182 ± 0.023	0.153 - 0.209	6
Iron (ppm)	158 ± 15.2	135 – 173	6
Manganese (ppm)	51.8 ± 4.05	46.2 - 56.0	6
Zinc (ppm)	53.2 ± 5.68	45.0 - 61.1	6
Copper (ppm)	6.49 ± 0.786	5.38 - 7.59	6
Iodine (ppm)	0.487 ± 0.204	0.233 - 0.843	6
Chromium (ppm)	0.763 ± 0.620	0.330 - 2.000	6
Cobalt (ppm)	0.53 ± 0.720	0.20 - 2.0	6

^a b From formulation As hydrochloride

	Mean ± Standard Deviation ^b	Range	Number of Samples
a , . .			
Contaminants	0.26 + 0.11	0.10 - 0.50	22
Arsenic (ppm)	0.26 ± 0.11		23
Cadmium (ppm)	0.05 ± 0.01	0.04 - 0.10	23
Lead (ppm)	0.14 ± 0.10	0.06 - 0.4	23
Mercury (ppm)	<0.02	0.10 0.40	23
Selenium (ppm)	0.18 ± 0.68	0.10 - 0.40	23
Aflatoxins (ppb)	<5.00	4.00 01.00	23
Vitrate nitrogen (ppm) ^c _c	13.2 ± 5.79	4.80 - 31.90	23
Nitrite nitrogen (ppm) ^c 3HA (ppm) ^d 2HT (npm) ^d	0.85 ± 0.672	0.30 - 3.20	23
3HA (ppm) ^a	1.3 ± 1.04	0.01 - 5.00	23
	1.2 ± 0.96	0.01 - 5.00	23
Aerobic plate count (CFU/g) ^e	$156,770 \pm 306,635$	7,700 - 1,000,000	10
Coliform (MPN/g)	17 ± 20	3 - 70	10
Escherichia coli (MPN/g)	<10		23
Salmonella (MPN/g)	Negative		23
Fotal nitrosoamines (ppb) ¹	6.5 ± 4.10	2.1 - 20.9	23
V-Nitrosodimethylamine (ppb) ^f	3.5 ± 2.50	1.0 - 9.4	23
V-Nitrosopyrrolidine (ppb)	2.9 ± 2.70	1.0 - 14.5	23
Pesticides (ppm)			
x-BHC	< 0.01		23
3-BHC	<0.02		23
-BHC	< 0.01		23
S-BHC	< 0.01		23
Heptachlor	< 0.01		23
Aldrin	<0.01		23
Heptachlor epoxide	<0.01		23
DDE	<0.01		23
DDD	<0.01		23
DDT	<0.01		23
ICB	<0.01		23
Airex	<0.01		23
	<0.01 <0.05		23
Methoxychlor			23
Dieldrin	<0.01		
Endrin	< 0.01		23
felodrin	<0.01		23
Chlordane	<0.05		23
foxaphene	<0.10		23
Estimated PCBs	<0.20		23
Ronnel	<0.01		23
Ethion	<0.02		23
Trithion	<0.05		23
Diazinon	<0.10		23
Methyl chlorpyrifos	0.053 ± 0.051	0.010 - 0.160	22
Methyl parathion	< 0.02		23
Ethyl parathion	< 0.02		23
Aalathion	0.138 ± 0.195	0.020 - 0.830	23
Endosulfan I	< 0.01		23
Endosulfan II	< 0.01		23
Endosulfan sulfate	< 0.03		23

TABLE L4 Contaminant Levels in NTP-2000 Rat and Mouse Ration^a

а CFU=colony-forming units; MPN=most probable number; BHC=hexachlorocyclohexane or benzene hexachloride

b с

d

e

For values less than the limit of detection, the detection limit is given as the mean. Sources of contamination: alfalfa, grains, and fish meal Sources of contamination: soy oil and fish meal Nonirradiated samples; microbial counts for irradiated samples were below the detection limit. All values were corrected for percent recovery. f

APPENDIX M SENTINEL ANIMAL PROGRAM

RESULTS	• • •		••		•••	• • •		•••	••	••	••	••	••	•••	••	•••	 •••	••		 •••	• •	 •••	••		 •••	••		•••	••	• • •	•••	272
METHODS	••	• • •	••	• • •	•••	• • •	•••	••	••	••	••	••	••	••	••	•••	 •••	••	•••	 ••	••	 •••	••	•••	 •••	••	•••	•••	••	• • •	•••	272

SENTINEL ANIMAL PROGRAM

METHODS

Rodents used in the Carcinogenesis Program of the National Toxicology Program are produced in optimally clean facilities to eliminate potential pathogens that may affect study results. The Sentinel Animal Program is part of the periodic monitoring of animal health that occurs during the toxicologic evaluation of chemical compounds. Under this program, the disease state of the rodents is monitored via serology on sera from extra (sentinel) animals in the study rooms. These animals and the study animals are subject to identical environmental conditions. The sentinel animals come from the same production source and weanling groups as the animals used for the studies of chemical compounds.

Serum samples were collected from randomly selected rats and mice during the 14-week and 2-year studies. Blood from each animal was collected and allowed to clot, and the serum was separated. The samples were processed appropriately and sent to Microbiological Associates, Inc. (Bethesda, MD), for determination of antibody titers. The laboratory serology methods and viral agents for which testing was performed are tabulated below; the times at which blood was collected during the studies are also listed.

<u>Method and Test</u> RATS 14-Week Study	<u>Time of Analysis</u>
ELISA	
PVM (pneumonia virus of mice) RCV/SDA (rat coronavirus/sialodacryoadenitis virus)	Study termination Study termination
Sendai	Study termination
Hemagglutination Inhibition	
H-1 (Toolan's H-1 virus)	Study termination
KRV (Kilham rat virus)	Study termination
2-Year Study	
ELISA	
Mycoplasma arthritidis	Study termination
Mycoplasma pulmonis	Study termination
PVM DCN/GDA	1, 6, 12, and 18 months, study termination
RCV/SDA Sendai	1, 6, 12, and 18 months, study termination
Sendar	1, 6, 12, and 18 months, study termination
Immunofluorescence Assay	
M. arthritidis	Study termination
Hemagglutination Inhibition	
H-1	1, 6, 12, and 18 months, study termination
KRV	1, 6, 12, and 18 months, study termination

MICE

14-Week Study

ELISA

Ectromelia virus GDVII (mouse encephalomyelitis virus) LCM (lymphocytic choriomeningitis virus) Mouse adenoma virus MHV (mouse hepatitis virus) PVM Reovirus 3 Sendai

Immunofluorescence Assay EDIM (epizootic diarrhea of infant mice) MVM (minute virus of mice)

Hemagglutination Inhibition K (papovavirus)

Polyoma virus

2-Year Study

ELISA

Ectromelia virus EDIM GDVII LCM Mouse adenoma virus-FL MHV *M. arthritidis M. pulmonis* PVM Reovirus 3 Sendai

Immunofluorescence Assay Ectromelia virus EDIM GDVII LCM Mouse adenoma virus-FL MCMV (mouse cytomegalovirus) MHV PVM

Hemagglutination Inhibition K MVM Polyoma virus

RESULTS

All test results were negative.

Study termination Study termination Study termination Study termination Study termination Study termination Study termination

Study termination Study termination

Study termination Study termination

1, 6, 12, and 18 months, study termination 1, 6, 12, and 18 months, study termination 1, 6, 12, and 18 months, study termination 1, 6, 12, and 18 months, study termination 1, 6, 12, and 18 months, study termination 1, 6, 12, and 18 months, study termination Study termination 1, 6, 12, and 18 months, study termination

Study termination 6 months Study termination Study termination Study termination 6 months, study termination 1 month, study termination

1, 6, 12, and 18 months, study termination 1, 6, 12, and 18 months, study termination 1, 6, 12, and 18 months, study termination



National Toxicology Program National Institute of Environmental Health Sciences

National Institute of Environmental Health Sciences National Institutes of Health P.O. Box 12233, MD K2-05 Durham, NC 27709 Tel: 984-287-3211 ntpwebrequest@niehs.nih.gov

https://ntp.niehs.nih.gov

ISSN 2378-8925